



13.09.2024

10:15 - 11:45 **Type: Industry Satellite Symposium** **Santander Auditorium - Hall 5**
Title: Bristol Myers Squibb - Therapeutic Advances in GI Cancers: Immuno-Oncology and Beyond
 Chair(s): Sara Lonardi, IT

10:15 - 10:20 **Welcome and Introduction**
S. Lonardi, IOV - Istituto Oncologico Veneto IRCCS, Padova, IT

10:20 - 10:47 **Colorectal Cancer: Novel Combination Therapies**
S. Lonardi, IOV - Istituto Oncologico Veneto IRCCS, Padova, IT

10:47 - 11:14 **Gastroesophageal Cancers: the Role of Immunotherapy**
T. Fleitas, Hospital Clinico Universitario de Valencia, Valencia, ES

11:14 - 11:41 **Hepatocellular Carcinoma: First-line Treatment Options in the Metastatic Setting**
T. Decaens, CHU Grenoble-Alpes - Le site nord à La Tronche - Hopital Michallon, La Tronche, FR

11:41 - 11:45 **Summary and Close**
S. Lonardi, IOV - Istituto Oncologico Veneto IRCCS, Padova, IT

10:15 - 11:45 **Type: Industry Satellite Symposium** **Valencia Auditorium - Hall 5**
Title: Johnson & Johnson and Thermo Fisher Scientific - Maximising the synergy of tumour tissue and liquid biopsy testing in oncology clinical practice
 Chair(s): Christian Rolfo, US

10:15 - 10:25 **The state of the art of liquid biopsy for solid tumour molecular testing**
C. Rolfo, Icahn School of Medicine at Mount Sinai, New York, US

10:25 - 10:40 **Molecular testing in GU oncology: Addressing challenges and unmet needs**
G. Roubaud, Institute Bergonié, Bordeaux, FR

10:40 - 10:55 **Molecular testing in NSCLC: The role of liquid biopsy**
F. Cappuzzo, IRCCS Istituto Nazionale Tumori Regina Elena (IRE), Rome, IT

10:55 - 11:00 **Q&A - Oncologist perspective**
C. Rolfo¹, G. Roubaud², F. Cappuzzo³, S. Pilotto⁴, B. Sipos⁵, ¹Icahn School of Medicine at Mount Sinai, New York, US, ²Institute Bergonié, Bordeaux, FR, ³IRCCS Istituto Nazionale Tumori Regina Elena (IRE), Rome, IT, ⁴UNIVR - Università di Verona, Verona, IT, ⁵BAG für Pathologie und Molekularpathologie Stuttgart, Stuttgart, DE

11:00 - 11:15 **Practical insights on NGS implementation in clinical routine**
B. Sipos, BAG für Pathologie und Molekularpathologie Stuttgart, Stuttgart, DE



11:15 - 11:40 **Navigating real-world challenges: Case studies in oncology practice**

S. Pilotto, UNIVR - Università di Verona, Verona, IT

11:40 - 11:45 **Conclusion**

C. Rolfo, Icahn School of Medicine at Mount Sinai, New York, US

10:15 - 11:45 **Type: Industry Satellite Symposium** **Alicante Auditorium - Hall 3**
Title: ImmunoGen - Platinum resistance in ovarian cancer – is this the end of the line?
 Chair(s): Ana Oaknin, ES

10:15 - 10:40 **The unmet need in relapsed ovarian cancer: what do we need to do now?**

A. Oaknin, Vall d'Hebron University Hospital, Barcelona, ES

10:40 - 11:00 **Exploring FRa-targeted therapeutics in PROC**

P. Harter, KEM | Evang. Kliniken Essen-Mitte gGmbH, Essen, DE

11:00 - 11:20 **Exploring ADC development beyond FRa in PROC**

K. Moore, Stephenson Cancer Center/University of Oklahoma, Oklahoma City, US

11:20 - 11:45 **Digesting the data: reflections on ADCs**

A. Oaknin¹, K. Moore², P. Harter³, ¹Vall d'Hebron University Hospital, Barcelona, ES, ²Stephenson Cancer Center/University of Oklahoma, Oklahoma City, US, ³KEM | Evang. Kliniken Essen-Mitte gGmbH, Essen, DE

10:15 - 11:45 **Type: Industry Satellite Symposium** **Pamplona Auditorium - Hall 3**
Title: Astellas - Guiding the future of mG/GEJ adenocarcinoma: Emerging biomarkers in the evolving treatment paradigm
 Chair(s): Javier Sastre Varela, ES

10:15 - 10:20 **Welcome and introduction**

J. Sastre Varela, Hospital Clinico Universitario San Carlos, Madrid, ES

10:20 - 10:40 **Scanning the horizon of biomarker-driven treatment for advanced G/GEJ adenocarcinoma**

J. Sastre Varela, Hospital Clinico Universitario San Carlos, Madrid, ES

10:40 - 10:55 **Shining a light on the potential challenges and solutions to integrating new biomarker tests**

F. Penault-Llorca, Jean Perrin Center, Clermont-Ferrand, FR

10:55 - 11:15 **A look ahead into the practicalities of an evolving treatment paradigm**

N. Fazio, IEO - Istituto Europeo di Oncologia IRCCS, Milan, IT



11:15 - 11:40 **Preparing for smooth sailing: panel discussion and Q&A**
J. Sastre Varela¹, F. Penault-Llorca², N. Fazio³, ¹Hospital Clinico Universitario San Carlos, Madrid, ES, ²Jean Perrin Center, Clermont-Ferrand, FR, ³IEO - Istituto Europeo di Oncologia IRCCS, Milan, IT

11:40 - 11:45 **Summary and close**
J. Sastre Varela, Hospital Clinico Universitario San Carlos, Madrid, ES

10:15 - 11:45 **Type: Industry Satellite Symposium** **Oviedo Auditorium - Hall 3**
Title: Servier - Precision Medicine: From Early Detection to Improved Outcomes in Patients with IDH Mutations
 Chair(s): John Bridgewater, GB; Teresa Macarulla Mercade, ES

10:15 - 10:35 **Role of IDH mutations in cancers**
J. Bridgewater, UCL Cancer Institute - Paul O'Gorman Building, London, GB

10:35 - 10:50 **IDH: A common mutation in a rare cancer: Focus on Glioma**
G. Tabatabai, Crona Kliniken - Universitätsklinikum Tübingen, Tübingen, DE

10:50 - 11:00 **IDH: A common mutation in a rare cancer: Focus on Chondrosarcoma**
S. Stacchiotti, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT

11:00 - 11:25 **IDH: A rare mutation in common cancers: Focus on AML and CCA**
T. Macarulla Mercade, Vall d'Hebron Institute of Oncology - Cellex Center, Barcelona, ES

11:25 - 11:40 **Panel Discussion**
J. Bridgewater¹, T. Macarulla Mercade², G. Tabatabai³, S. Stacchiotti⁴, ¹UCL Cancer Institute - Paul O'Gorman Building, London, GB, ²Vall d'Hebron Institute of Oncology - Cellex Center, Barcelona, ES, ³Crona Kliniken - Universitätsklinikum Tübingen, Tübingen, DE, ⁴Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT

11:40 - 11:45 **Conclusion**
T. Macarulla Mercade, Vall d'Hebron Institute of Oncology - Cellex Center, Barcelona, ES

10:15 - 11:45 **Type: Industry Satellite Symposium** **Toledo Auditorium - Hall 3**
Title: Eisai Inc. - Charting the Path: Cutting Through the Mysteries of Patient Characteristics for Precision in Endometrial Cancer Treatment
 Chair(s): Christian Marth, AT

10:15 - 10:20 **Welcome**
C. Marth, Innsbruck Medical University, Innsbruck, AT

10:20 - 10:40 **Endometrial Cancer: The Current Treatment Landscape**
C. Marth, Innsbruck Medical University, Innsbruck, AT

10:40 - 11:00 **Evolving Molecular Considerations in Endometrial Cancer**
X. Matias-Guiu, IDIBELL - Bellvitge Biomedical Research Institute, Hospitalet de Llobregat, ES

11:00 - 11:25 **Patient Characteristics and Optimized Sequencing**
C. Marth, Innsbruck Medical University, Innsbruck, AT

11:25 - 11:45 **Regional Specific Treatment Approaches**
R. Eskander, University of California San Diego - UCSD, La Jolla, US

12:00 - 13:45 **Type: Opening session** **Barcelona Auditorium - Hall 2**
Title: ESMO 2024 Opening session
 Chair(s): Andres Cervantes, ES

12:00 - 12:15 **ESMO Award: Addressing the unintended consequences of cancer care**
A.H. Partridge, Dana Farber Cancer Institute, Boston, US

12:15 - 12:30 **ESMO Award for Translational Research: From bytes to bedside using mutational signatures in cancer**
S. Nik-Zainal, University of Cambridge-Wellcome Trust Centre for Stem Cell Research, Cambridge, GB

12:30 - 12:45 **ESMO Women for Oncology Award: Bridging gaps in lung cancer research and gender equity**
M.-J. Ahn, Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR

12:45 - 13:00 **ESMO Lifetime Achievement Award: Empowering T cells to fight cancer**
J. Haanen, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL

14:00 - 15:30 **Type: Educational session** **Madrid Auditorium - Hall 2**
Title: Treating KRAS-mutated NSCLC
 Chair(s): Natasha Leighl, CA; Roberto Ferrara, IT

14:00 - 14:20 **G12C targeted therapies**
N. Leighl, UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA

14:20 - 14:40 **Non-G12C mutations: Future perspectives**
C. Lindsay, The Christie NHS Foundation Trust, Manchester, GB

14:40 - 15:00 **Resistance and sequencing**
M. Awad, Dana Farber Cancer Institute, Boston, US

15:00 - 15:20 **Combinations with IO**
J. Naidoo, Beaumont Hospital, Dublin, IE

15:20 - 15:30 **Q&A and discussion**

14:00 - 15:30 **Type: Educational session** **Sevilla Auditorium - Hall 2**
Title: Metastatic colorectal cancer: Changing paradigms and the relevance for patient care
 Chair(s): Thierry Landre, FR; Claire Gallois, FR

14:00 - 14:20 **Profiling the biology of CRC: Actionability and implementability**
R. Corcoran, MGH - Massachusetts General Hospital, Boston, US

14:20 - 14:40 **Optimal sequencing of therapeutic strategies in immunogenic CRC**
T. André, Hopital Saint-Antoine, Paris, FR

14:40 - 15:00 **Optimal sequencing of therapeutic strategies in molecularly-driven CRC**
L. Weiss, Uniklinikum Salzburg - Landeskrankenhaus, Salzburg, AT

15:00 - 15:20 **Optimal sequencing of therapeutic strategies in biomarker unselected MSS CRC**
C. Cremolini, AOU Pisana - Stabilimento di Santa Chiara, Pisa, IT

15:20 - 15:30 **Q&A and discussion**



14:00 - 15:30	Type: Proffered Paper session Title: Proffered Paper session: Non-metastatic NSCLC Chair(s): Stephen Liu, US; Fiona Blackhall, GB	Bilbao Auditorium - Hall 2
14:00 - 14:10	LBA48 - CCTG BR.31: A global, double-blind placebo-controlled, randomized phase III study of adjuvant durvalumab in completely resected non-small cell lung cancer (NSCLC) <u>G. Goss</u>¹, G. Darling², V. Westeel³, K. Nakagawa⁴, B. Massuti Sureda⁵, F. Perrone⁶, S.-A. Mclachlan⁷, J.H. Kang⁸, Y.-L. Wu⁹, A.-M. Dingemans¹⁰, R. Dziadziuszko¹¹, M. Okada¹², L. Greillier¹³, C. Audigier-Valette¹⁴, S. Sugawara¹⁵, E. Nadal¹⁶, A. Catino¹⁷, M. Stockler¹⁸, K. Ding¹⁹, C. O'Callaghan¹⁹, ¹Ottawa Hospital Research Institute, University of Ottawa, Ottawa, CA, ²Department of Surgery Dalhousie University, Halifax, CA, ³CHRU Besancon - Hopital Jean Minjoz, Besancon, FR, ⁴Kindai University School of Medicine - Main Campus, Osaka, JP, ⁵Hospital General Universitario de Alicante, Alicante, ES, ⁶Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Napoli, IT, ⁷Australasian Lung Cancer Trials Group, Melbourne, AU, ⁸The Korean Cancer Study Group St. Mary's Hospital - Catholic Medical Center, Seoul, KR, ⁹Guangdong Lung Cancer Institute, Guangdong Province People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, CN, ¹⁰Erasmus MC Cancer Institute- University Medical Center, Rotterdam, NL, ¹¹Medical University of Gdansk, Gdansk, PL, ¹²Hiroshima University Hospital, Hiroshima, JP, ¹³Hopital Nord, Marseille, FR, ¹⁴Hospital Sainte Musse, Toulon, FR, ¹⁵West Japan Oncology Group, Sendai Kousei Hospital, Sendai, JP, ¹⁶ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), L'Hospitalet de Llobregat, ES, ¹⁷Istituto Tumori Giovanni Paolo II, Bari, IT, ¹⁸NHMRC Clinical Trials Centre, Camperdown, AU, ¹⁹Canadian Cancer Trials Group, Kingston, CA	
14:10 - 14:20	Invited Discussant LBA48 <u>P. Garrido Lopez</u>, Hospital Universitario Ramon y Cajal, Madrid, ES	
14:20 - 14:25	Q&A	



14:25 - 14:35

LBA81 - Durvalumab (D) as consolidation therapy in limited-stage SCLC (LS-SCLC): Outcomes by prior concurrent chemoradiotherapy (cCRT) regimen and prophylactic cranial irradiation (PCI) use in the ADRIATIC trial

S. Senan¹, D.R. Spigel², B.C. Cho³, K. Laktionov⁴, Y. Zenke⁵, K.H. Lee⁶, Q. Wang⁷, A. Navarro Mendivil⁸, E.L. Buchmeier⁹, S. Sezgin Goksu¹⁰, A. Badzio¹¹, A. Shi¹², D. Daniel¹³, M. Zemanova¹⁴, P. Iyengar¹⁵, L. Paz-Ares¹⁶, L. Szadkowski¹⁷, P. Chugh¹⁸, W.C. Lai¹⁹, Y. Cheng²⁰, ¹Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, NL, ²Sarah Cannon Research Institute, Nashville, US, ³Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, KR, ⁴Federal State Budgetary Institution "N.N. Blokhin National Medical Research Center of Oncology" of the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO), Moscow, RU, ⁵National Cancer Center Hospital East, Kashiwa, JP, ⁶Chungbuk National University Hospital, Cheongju, KR, ⁷The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, CN, ⁸Hospital Vall d'Hebron and Vall d'Hebron Institute of Oncology, Barcelona, ES, ⁹Hospitals of the City of Cologne gGmbH, Cologne, DE, ¹⁰Akdeniz University Medical Faculty, Antalya, TR, ¹¹Medical University of Gdansk, Gdańsk, PL, ¹²Peking University Cancer Hospital & Institute, Beijing, CN, ¹³Tennessee Oncology PLLC, Nashville, US, ¹⁴Charles University, and General University Hospital, Prague, CZ, ¹⁵Memorial Sloan Kettering Cancer Center, New York, US, ¹⁶Hospital Universitario 12 de Octubre, CNIO-H120 Lung Cancer Unit, Ciberonc and Universidad Complutense, Madrid, ES, ¹⁷AstraZeneca, Mississauga, CA, ¹⁸AstraZeneca, Waltham, US, ¹⁹AstraZeneca, New York, US, ²⁰Jilin Cancer Hospital, Changchun, CN

14:35 - 14:45

1786O - BMS-986012 (anti-fucosyl-monosialoganglioside-1 [fuc-GM1]) with carboplatin & etoposide; nivolumab (CE/NIVO) as first-line (1L) therapy in extensive-stage small cell lung cancer (ES-SCLC): Interim analysis (IA) of a randomized phase II study

E. Kalinka¹, I. Bahce², A. Navarro Mendivil³, N. Ready⁴, Q.S.-C. Chu⁵, S. Sugawara⁶, A. Sibille⁷, M. Provencio Pulla⁸, M. Johnson⁹, J. Hiltermann¹⁰, T.-E. Ciuleanu¹¹, R. Dziadziuszko¹², A. Santo¹³, Y. Zhang¹⁴, Y. Liu¹⁴, R. Sarmiento¹⁴, S. Tannenbaum-Dvir¹⁴, L. Ojalvo¹⁴, J. Wu¹⁵, K. O'Byrne¹⁶, ¹Polish Mother's Memorial Hospital-research Institute, Łódź, PL, ²Amsterdam UMC - Vrije University Medical Centre (VUMC), Amsterdam, NL, ³Vall d'Hebron University Hospital, Barcelona, ES, ⁴Duke Cancer Institute, Durham, US, ⁵Cross Cancer Institute, Edmonton, CA, ⁶Sendai Kousei Hospital, Sendai, JP, ⁷Centre Hospitalier Universitaire Sart Tilman, Liège, BE, ⁸University Hospital Puerta de Hierro Majadahonda, Majadahonda, ES, ⁹Tennessee Oncology Nashville, Nashville, US, ¹⁰UMCG - University Medical Center Groningen, Groningen, NL, ¹¹Institutul Oncologic, Bucharest, RO, ¹²Medical University of Gdańsk, Gdansk, PL, ¹³Ospedale P. Pederzoli, Peschiera del Garda, IT, ¹⁴Bristol Myers Squibb, Princeton, US, ¹⁵Bristol Myers Squibb, Princeton, NJ, US, ¹⁶Greenslopes Private Hospital, Brisbane, AU

14:45 - 14:55

Invited Discussant LBA81 and 1786MO

S. Liu, Lombardi Cancer Center Georgetown University, Washington, US

14:55 - 15:05

Q&A



15:05 - 15:15

LBA83 - PECATI: A phase II trial to evaluate the efficacy and safety of lenvatinib in combination with pembrolizumab in pretreated advanced B3-thymoma and thymic carcinoma

J. Remon Masip¹, P. Bironzo², N. Girard³, L. Bigay-Game⁴, O.J. Juan Vidal⁵, J. De Castro Carpeño⁶, N. Reguart Aransay⁷, L. Greillier⁸, S. Cousin⁹, E. Dansin¹⁰, M. Majem¹¹, R. Bernabe Caro¹², J. Mosquera Martinez¹³, M. Diaz¹⁴, A. Meza¹⁴, D. Alcalá-López¹⁴, A. Sanz¹⁵, L. Righi¹⁶, S. Novello¹⁷, B. Besse¹, ¹Institut Gustave Roussy, Villejuif, Cedex, FR, ²Azienda Ospedaliera Universitaria San Luigi Gonzaga, Orbassano, IT, ³Institut Curie, Paris, FR, ⁴Centre Hospitalier Universitaire de Toulouse - Hopital Larrey, Toulouse, FR, ⁵Hospital Universitari i Politècnic La Fe, Valencia, ES, ⁶Hospital Universitario La Paz, Madrid, ES, ⁷Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ⁸Assistance Publique Hopitaux de Marseille, Marseille, FR, ⁹Institut Bergonie, Bordeaux, FR, ¹⁰Centre Oscar Lambret, Lille, FR, ¹¹Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ¹²Hospital Universitario Virgen del Rocio, Seville, ES, ¹³CHUAC - Complejo Hospitalario Universitario A Coruña, A Coruña, ES, ¹⁴Medica Scientia Innovation Research (MEDSIR) - Oncoclínicas&Co, Jersey City (New Jersey, USA), Sao Paulo (Brazil), Barcelona, ES, ¹⁵Medica Scientia Innovation Research (MEDSIR) - Oncoclínicas&Co, Jersey City (New Jersey, USA), Sao Paulo (Brazil), Barcelona, ES, ¹⁶University of Turin, Torino, IT, ¹⁷Università Degli Studi Di Torino - Orbassano, Orbassano, IT

15:15 - 15:25

Invited Discussant LBA83

E. Blackhall, The Christie NHS Foundation Trust, Manchester, GB

15:25 - 15:30

Q&A

14:00 - 15:30

Type: Educational session

Granada Auditorium - Hall 6

Title: New treatment algorithm in the treatment of metastatic breast cancer in 2024

Chair(s): Barbara Pistilli, FR; Cristina Saura Manich, ES

14:00 - 14:25

Hormone-receptor positive breast cancer

L. Del Mastro, IRCCS Ospedale Policlinico San Martino, Genova, IT

14:25 - 14:50

HER2 positive breast cancer

B. Pistilli, Institut Gustave Roussy, Villejuif, Cedex, FR

14:50 - 15:15

Triple negative breast cancer

G. Curigliano, IEO - Istituto Europeo di Oncologia, Milan, IT

15:15 - 15:30

Q&A and discussion



14:00 - 15:30 **Type: Educational session** **Burgos Auditorium - Hall 5**
Title: Therapeutic options beyond AR pathway inhibitors: What do we choose next?
 Chair(s): Dana Rathkopf, US; Gerhardt Attard, GB

14:00 - 14:25 **Are cytotoxics still the next option?**
E. Castro, Hospital Universitario 12 de Octubre, Madrid, ES

14:25 - 14:50 **Will theranostics become standard of care?**
S. Gillessen, EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, CH

14:50 - 15:15 **Novel therapeutic approaches for ARPI-resistant disease**
G. Attard, University College London, London, GB

15:15 - 15:30 **Q&A and discussion**

14:00 - 15:30 **Type: Educational session** **Salamanca Auditorium - Hall 5**
Title: Antibody drug conjugates (ADCs): Are there new therapeutic approaches in gynaecological cancers?
 Chair(s): Susana Banerjee, GB; Frederik Marmé, DE

14:00 - 14:20 **Visiting the basics: Rationale and MoA**
S. Banerjee, The Royal Marsden Hospital - Chelsea, London, GB

14:20 - 14:40 **ADCs in ovarian cancer**
D. Lorusso, Humanitas San Pio X, Milan, IT

14:40 - 15:00 **ADCs in endometrial and cervical cancer**
T. Van Gorp, University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE

15:00 - 15:20 **How to manage safety**
I. Colombo, EOC - Ospedale Regionale di Bellinzona e Valli, San Giovanni, Bellinzona, CH

15:20 - 15:30 **Q&A and discussion**



14:00 - 15:30	Type: Proffered Paper session Title: Proffered paper session 1: GU tumours, non-prostate Chair(s): Petros Grivas, US; Manuela Schmidinger, AT	Santander Auditorium - Hall 5
---------------	---	-------------------------------

14:00 - 14:10 **LBA73 - Tivozanib–nivolumab vs tivozanib monotherapy in patients with renal cell carcinoma (RCC) following 1 or 2 prior therapies including an immune checkpoint inhibitor (ICI): Results of the phase III TiNivo-2 study**

T. Choueiri¹, R. Motzer², K. Beckermann³, P. Barthelemy⁴, R. Iacovelli⁵, S. Emambux⁶, J. Molina Cerrillo⁷, B. Garmez⁸, P.M. Coelho Barata⁹, R. McKay¹⁰, A. Chehrizi-Raffle¹¹, H. Hammers¹², D. Heng¹³, E. Braendle¹⁴, B. McGregor¹, L. Albiges¹⁵, ¹Dana Farber Cancer Institute, Boston, US, ²MSKCC - Memorial Sloan Kettering Cancer Center, New York, US, ³Vanderbilt University Medical Center, Nashville, US, ⁴ICANS - Institut de Cancérologie Strasbourg Europe, Strasbourg, FR, ⁵Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Catholic University of Rome, Rome, IT, ⁶CHU Poitiers - Jean Bernard Hôpital, Poitiers, FR, ⁷Ramón y Cajal University Hospital, Madrid, ES, ⁸Sarah Cannon Research Institute, Nashville, US, ⁹University Hospitals Seidman Cancer Center, Cleveland, US, ¹⁰University of California San Diego, San Diego, US, ¹¹City of Hope Comprehensive Cancer Center, Duarte, US, ¹²UTSW - University of Texas Southwestern Medical Center, Dallas, US, ¹³Tom Baker Cancer Centre, Calgary, CA, ¹⁴AVEO Pharmaceuticals, Inc., Boston, US, ¹⁵Institut Gustave Roussy, Villejuif, Cedex, FR

14:10 - 14:20 **LBA74 - Final analysis of the phase III LITESPARK-005 study of belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC)**

B. Rini¹, C. Suarez Rodriguez², L. Albiges³, K. Jalkanen⁴, G.A. De Velasco Oria⁵, M. Burotto⁶, P. Ghatalia⁷, R. Iacovelli⁸, E. Lam⁹, E. Verzoni¹⁰, M. Gumus¹¹, W. Stadler¹², C. Kollmannsberger¹³, B. Melichar¹⁴, B. Venugopal¹⁵, J. Lin¹⁶, R. Perini¹⁷, D. Vickery¹⁶, T. Choueiri¹⁸, T. Powles¹⁹, ¹Vanderbilt Ingram Cancer Center, Nashville, US, ²Vall d'Hebron University Hospital, Barcelona, ES, ³Institut Gustave Roussy, Villejuif, Cedex, FR, ⁴Helsinki University Hospital, Comprehensive Cancer Center, Helsinki, FI, ⁵Hospital Universitario 12 de Octubre, Madrid, ES, ⁶Bradford Hill-Clinical Center, Recoleta, CL, ⁷Fox Chase Cancer Center - Main Campus, Philadelphia, US, ⁸Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT, ⁹UCHealth Cancer Care - Anschutz Medical Campus - University of Colorado Cancer Center, Aurora, US, ¹⁰Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ¹¹Istanbul Medeniyet University, Prof.Dr. Suleyman Yalcin City Hospital, Istanbul, TR, ¹²The University of Chicago, Chicago, US, ¹³BC Cancer Agency - Vancouver, Vancouver, CA, ¹⁴Palacký University and University Hospital, Olomouc, CZ, ¹⁵BWSSC - Beatson West of Scotland Cancer Centre - NHS Greater Glasgow and Clyde, Glasgow, GB, ¹⁶Merck & Co., Inc. - Rahway, Rahway, US, ¹⁷Merck & Co., Inc., Rahway, US, ¹⁸Dana Farber Cancer Institute, Boston, US, ¹⁹St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB



14:20 - 14:30

LBA75 - Prospective randomised phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer: Results of the SUNNIFORECAST trial

L. Bergmann¹, M. Ahrens², L. Albiges³, M. Gross Goupil⁴, E. Boleti⁵, G. Gravis⁶, A. Flechon⁷, M.-O. Grimm⁸, S. Rausch⁹, P. Barthelemy¹⁰, D. Castellano Gauna¹¹, B. Mellado Gonzalez¹², P. Ivanyi¹³, A. Floercken¹⁴, C. Suarez Rodriguez¹⁵, J.P. Maroto Rey¹⁶, V. Gruenwald¹⁷, I. Burkholder¹⁸, A. Hartmann¹⁹, J. Haanen²⁰, ¹Universitätsklinikum Frankfurt (Johannes-Wolfgang Goethe Institute), Frankfurt am Main, DE, ²University Hospital Frankfurt, Frankfurt, DE, ³Institut Gustave Roussy, Villejuif, Cedex, FR, ⁴CHU Bordeaux - Hopital St. André, Bordeaux, FR, ⁵Royal Free Hospital School of Medicine, London, GB, ⁶IPC - Institut Paoli-Calmettes, Marseille, Cedex, FR, ⁷Centre Léon Bérard, Lyon, FR, ⁸Universitätsklinikum Jena, Jena, DE, ⁹Eberhard Karls University, Tuebingen, DE, ¹⁰Institut de Cancérologie Strasbourg Europe, Strasbourg, FR, ¹¹Hospital Universitario 12 de Octubre, Madrid, ES, ¹²Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ¹³MHH - Medizinische Hochschule Hannover, Hannover, DE, ¹⁴Universitätsklinik Charité - Campus Virchow Klinikum, Berlin, DE, ¹⁵Vall d'Hebron University Hospital, Barcelona, ES, ¹⁶Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ¹⁷University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE, ¹⁸University of Applied Sciences of the Saarland, Saarbrücken, DE, ¹⁹Universitätsklinikum Erlangen, Erlangen, DE, ²⁰NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL

14:30 - 14:40

Invited Discussant LBA73, LBA74 and LBA75

M. Schmidinger, Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT

14:40 - 14:50

Q&A

14:50 - 15:00

1959O - BL-B01D1, an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic urothelial carcinoma (UC)

D. Ye¹, X. Bian², T. Yang³, S. Jiang⁴, M. Cao⁵, X. Hua⁶, S. Xiao⁶, H. Wang⁷, H. Zhu⁷, Y. Zhu⁸, ¹Fudan University Cancer, Shanghai, CN, ²Fudan University Shanghai Cancer Center, Shanghai, CN, ³Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, CN, ⁴Hunan Cancer Hospital, Changsha, CN, ⁵Zhujiang Hospital of Southern Medical University, Guangzhou, CN, ⁶Baili-Bio (Chengdu) Pharmaceutical Co., Ltd., Chengdu, CN, ⁷SystImmune Inc., Redmond, US, ⁸Sichuan Biokin Pharmaceutical Co., Ltd, Chengdu, CN



- 15:00 - 15:10 **16900 - NKT2152, a novel oral HIF-2α inhibitor, in participants (pts) with previously treated advanced clear cell renal carcinoma (ccRCC): Preliminary results of a phase I/II study**
E. Jonasch¹, B. McGregor², P. Msaouel¹, T. Logan³, E. Hall⁴, M. Bilen⁵, G. Falchook⁶, B. Shuch⁷, Y. Zakharia⁸, R. Hauke⁹, M. Gordon¹⁰, A.-R. Naqash¹¹, C. Ryan¹², R. Srinivasan¹³, J. Xiao¹⁴, W. Sun¹⁴, M. Esguerra¹⁴, G. Lu¹⁴, J. Lager¹⁴, T. Choueiri², ¹The University of Texas M. D. Anderson Cancer Center, Houston, US, ²Dana Farber Cancer Institute, Boston, US, ³Indiana University Simon Cancer Center, Indianapolis, US, ⁴University of Washington, Seattle, US, ⁵Winship Cancer Institute of Emory University, Atlanta, US, ⁶Sarah Cannon Research Institute (SCRI) at HealthONE, Denver, US, ⁷UCLA - David Geffen School of Medicine, Los Angeles, US, ⁸University of Iowa Hospitals and Clinics, Iowa City, US, ⁹Nebraska Cancer Specialists - Methodist Estabrook Cancer Center, Omaha, US, ¹⁰HonorHealth Research Institute, Scottsdale, US, ¹¹Stephenson Cancer Center, Oklahoma University Health Science Center, Oklahoma City, US, ¹²Oregon Health Science University, Portland, US, ¹³National Cancer Institute, Bethesda, US, ¹⁴NiKang Therapeutics, Inc., Wilmington, US
- 15:10 - 15:20 **Invited Discussant 19590 and 16900**
J. Rosenberg, MSKCC - Memorial Sloan Kettering Cancer Center, New York, US
- 15:20 - 15:30 **Q&A**

14:00 - 15:30 **Type: Special symposium** **Valencia Auditorium - Hall 5**
Title: Beyond coding neoantigens: What else is there for T cells to see?
 Chair(s): Yardena Samuels, IL; Sebastian Amigorena, FR

- 14:00 - 14:05 **Introduction and scientific background**
S. Amigorena, Institut Curie, Paris, FR
- 14:05 - 14:20 **Endogenous retroelements in cancer immunity**
G. Kassiotis, The Francis Crick Institute, London, GB
- 14:20 - 14:35 **Bacterial derived antigens**
Y. Samuels, Weizmann Institute of Science, Rehovot, IL
- 14:35 - 14:50 **Noncoding regions as a source of targetable tumour-specific antigens**
S. Amigorena, Institut Curie, Paris, FR
- 14:50 - 15:05 **Neoantigens derived from tryptophan depletion**
R. Agami, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL

15:05 - 15:25	Discussion	
15:25 - 15:30	Conclusions and perspectives <u>Y. Samuels</u> , Weizmann Institute of Science, Rehovot, IL	
14:00 - 15:30	Type: Special symposium Title: New endpoints in early clinical trials Chair(s): Neeltje Steeghs, NL; Anastasios Stathis, CH	Alicante Auditorium - Hall 3
14:00 - 14:05	Introduction and scientific background <u>A. Stathis</u> , EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, CH	
14:05 - 14:20	Innovative imaging techniques to evaluate response <u>E.G.E. De Vries</u> , UMCG - University Medical Center Groningen, Groningen, NL	
14:20 - 14:35	PK of complex drugs: Strategies to find recommended dosages <u>N. Steeghs</u> , NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL	
14:35 - 14:50	Incorporating ctDNA into RECIST v1.1: Steps ahead <u>E. Garralda</u> , Vall d'Hebron University Hospital, Barcelona, ES	
14:50 - 15:05	PRO's as endpoint in early phase clinical trials <u>M. Di Maio</u> , Azienda Ospedaliera Ordine Mauriziano - Presidio Umberto I, Torino, IT	
15:05 - 15:25	Q&A and discussion	
15:25 - 15:30	Conclusions and perspectives <u>N. Steeghs</u> , NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL	



14:00 - 15:30	Type: Proffered Paper session Title: Proffered paper session: CNS tumours Chair(s): Monika Hegi, CH; Evangelia Razis, GR	Pamplona Auditorium - Hall 3
14:00 - 14:10	4400 - First in human study of the mRNA-based cancer vaccine CVGBM in patients (pts) with newly diagnosed and surgically resected MGMT-unmethylated glioblastoma (GBM): First results from the dose escalation phase <u>G. Tabatabai</u>¹, P. Freres², M. Glas³, P. Hau⁴, L. Von Baumgarten⁵, M. Van Den Bent⁶, M. Burger⁷, C. Seidel⁸, U. Herrlinger⁹, I. Mildenberger¹⁰, B. Neyns¹¹, H. Schafer¹², A. Wick¹³, M. Falk¹⁴, L. De Freitas Chama¹⁵, P. Kelemen¹⁴, F. Schwenke¹⁴, S. Koch¹⁵, P. Romer Roche¹⁴, U. Gnad-Vogt¹⁴, ¹University Hospital Tübingen, Tübingen, DE, ²Liège University Hospital, Liège, BE, ³University Medicine Essen, University Duisburg-Essen, Essen, DE, ⁴University Hospital Regensburg, Regensburg, DE, ⁵LMU, Munich, DE, ⁶Erasmus MC Cancer Institute, Rotterdam, NL, ⁷Goethe University Frankfurt, University Hospital, Frankfurt, DE, ⁸University Leipzig Medical Center, Leipzig, DE, ⁹University Hospital Bonn, Bonn, DE, ¹⁰Heidelberg University, Mannheim, DE, ¹¹Universitair Ziekenhuis Brussel, Brussels, BE, ¹²University of Freiburg, Freiburg, DE, ¹³Heidelberg University Hospital, Heidelberg, DE, ¹⁴CureVac SE, Wiesbaden, DE, ¹⁵CureVac SE, Tübingen, DE	
14:10 - 14:20	4410 - A phase I clinical trial on the intracranial administration of autologous CD1c(BDCA-1)&#x2b; /CD141(BDCA-3)&#x2b; myeloid dendritic cells (myDC) in combination with ipilimumab (IPI) and nivolumab (NIVO) in patients with recurrent high-grade glioma (rHGG) <u>B. Neyns</u>¹, I. Dirven¹, L. Lescrauwaet², M. Cammaert¹, W. Geens², X. Geeraerts¹, L. Stevens¹, S. Brock², M. Kockx³, H. Everaert¹, A.-M. Van Binst¹, S. Tuyaerts¹, J. Duerinck¹, ¹Vrije Universiteit Brussel - Faculty of Medicine & Pharmacy, Brussels, BE, ²UZ Brussel - Universitair Ziekenhuis Brussel, Jette, BE, ³CellCarta, Antwerpen, BE	
14:20 - 14:30	4420 - A phase I clinical trial of intrathecal injection of allogeneic CAR-&#x3b3;&#x3b4;T cells targeting B7H3 for the treatment of patients with recurrent glioblastoma X. Li¹, W. Ma², Y. Gu³, Y. Sui², X. Zhang¹, C. Wang¹, W. Gan⁴, J. Chen⁴, L. Wang⁴, Y. Zhang⁴, Y. Zhang⁵, <u>Y. Huang</u>¹, ¹the fourth Hospital affiliated to Soochow University, Suzhou, CN, ²Unicet Biotech, Beijing, CN, ³Soochow University, Suzhou, CN, ⁴Dushu Lake Hospital affiliated to Soochow University, Suzhou, CN, ⁵Tsinghua University, Beijing, CN	
14:30 - 14:40	Invited Discussant 4400, 4410 and 4420 <u>E. Tabouret</u>, CHU La Timone Adultes, Marseille, FR	
14:40 - 14:50	Q&A	



14:50 - 15:00	4430 - A perioperative study of safusidenib in patients with IDH1 mutated glioma <u>J. Whittle</u>¹, M. Rosenthal¹, M. Spiteri², S. Cain³, M. Topp¹, S. Shaya¹, J. Jones³, A. Valkovic², O. Fatunla², J. Dimou³, R. Tobler², S. Roberts-Thomson³, D. Mcardle³, E. Lui³, B. Nijagal⁴, S. Grimmond⁵, S. Best², S. Freytag², K. Drummond³, ¹Peter MacCallum Cancer Centre, Melbourne, AU, ²WEHI - Walter and Eliza Hall Institute of Medical Research, Parkville, AU, ³Royal Melbourne Hospital, Melbourne, AU, ⁴Bio21, Melbourne, AU, ⁵University of Melbourne Centre for Cancer Research (UMCCR) - Victorian Comprehensive Cancer Centre, Parkville, AU
15:00 - 15:10	4440 - The prognostic impact of CDKN2A/B heterozygous deletions in IDH-mutant glioma <u>E. Ippen</u>¹, T. Hielscher², K. Göbel³, D. Friedel³, D. Reuss³, A. Von Deimling³, W. Wick¹, F. Sahm⁴, A. Suwala³, ¹Heidelberg University Hospital, Heidelberg, DE, ²Department of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, DE, ³University Hospital Heidelberg, Dept. of Neuropathology, Heidelberg, DE, ⁴University Hospital of Heidelberg, Heidelberg, DE
15:10 - 15:20	Invited Discussant 4430 and 4440 <u>M. Hegi</u>, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH
15:20 - 15:30	Q&A
14:00 - 15:30	Type: Special symposium Oviedo Auditorium - Hall 3 Title: Why neoadjuvant immunotherapy is the future for melanoma Chair(s): Christian Blank, NL; Helen Gogas, GR
14:00 - 14:05	Introduction and scientific background <u>H. Gogas</u>, National and Kapodistrian University of Athens - School of Medicine, Athens, GR
14:05 - 14:20	Basic science rationale <u>S. Patel</u>, University of Colorado Anschutz Medical Campus, Aurora, US
14:20 - 14:35	Summary of clinical trials so far <u>P. Ascierto</u>, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Napoli, IT
14:35 - 14:50	Personalised immunotherapy approach and future <u>C. Blank</u>, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL
14:50 - 15:05	Which patients need surgery? <u>A. Van Akkooi</u>, Melanoma Institute Australia, Wollstonecraft, AU
15:05 - 15:25	Q&A and discussion
15:25 - 15:30	Conclusions and perspectives <u>C. Blank</u>, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL



14:00 - 15:30

Type: Mini Oral session

Toledo Auditorium - Hall 3

Title: Mini oral session 1: Haematological malignancies

Chair(s): Sara Garrido Paniagua, ES; Ya Hwee Tan, SG; Marco Ladetto, IT

14:00 - 14:05

799MO - The primary results from a randomized double-blind phase II study of rovadictinib versus hydroxyurea in patients with myelofibrosis

L. Pan¹, Z. Xu², W. Yu³, X. Shen⁴, Z. Zhang⁵, Z. Jiao⁶, X. Zhao⁷, M. Hou⁸, X. Du⁹, H. Ma¹⁰, M. Duan¹¹, H. Peng¹², M. Yang¹³, W. Wang¹⁴, T. Gong¹⁵, D. Ding¹⁶, D. Wang¹⁶, Z. Xiao¹⁷, ¹West China Hospital of Sichuan University, chengdu, CN, ²Chinese Academy of Medical Sciences & Peking Union Medical College, tianjin, CN, ³Binzhou Medical College Affiliated Hospital, binzhou, CN, ⁴Heping Hospital of Changzhi Medical College, Changzhi, CN, ⁵Affiliated Hospital of ChengDe Medical University, chengde, CN, ⁶Xingtai People's Hospital, Xingtai, CN, ⁷Tianjin People's Hospital, Tianjin, CN, ⁸Qilu Hospital of Shandong University, jinan, CN, ⁹Guangdong provincial people's hospital, Guangzhou, CN, ¹⁰Cangzhou People's Hospital, Cangzhou, CN, ¹¹Peking Union Medical College Hospital, beijing, CN, ¹²The Second Xiangya Hospital, Central South University, changsha, CN, ¹³The First Affiliated Hospital Of Anhui Medical University, Hefei, CN, ¹⁴The Affiliated Hospital of Qingdao University, Qingdao, CN, ¹⁵Hematology Research Center of Harbin First Hospital, Harbin, CN, ¹⁶Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Nanjing, CN, ¹⁷Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, CN

14:05 - 14:10

800MO - First report of BCL-2 inhibitor TQB3909 in pts with relapsed or refractory non-Hodgkin lymphoma (NHL) and acute myeloid leukemia (AML): Data from a phase I study

J. Qi¹, J. Li², W. Xu², X. Zhao³, Q. Yin⁴, Y. Li⁵, F. Xu⁶, H. Huang⁷, J. Li⁸, W. Qian⁹, Q. Zhao¹⁰, J. Wang¹¹, ¹Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences, Tianjin, CN, ²Jiangsu Province Hospital/The First Affiliated Hospital of Nanjing Medical University, Nanjing, CN, ³Tianjin People's Hospital, Tianjin, CN, ⁴Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, CN, ⁵Hunan Cancer Hospital & The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, CN, ⁶Mianyang Central Hospital, Mianyang, CN, ⁷Sun Yat-sen University Cancer Center, Guangzhou, CN, ⁸Qilu Hospital of Shandong University, jinan, CN, ⁹The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, CN, ¹⁰CTTQ - Chia Tai Tianqing Pharmaceutical Group Co., Ltd. - Nanjing Site, Nanjing, CN, ¹¹Institute of Hematology&Blood Diseases Hospital, Chinese Academy of Medical Sciences& Peking Union Medical College, Tianjin, CN



14:10 - 14:15

801MO - Efficacy and safety of a phase II study: Timdarpaccept (IMM01) combined with azacitidine (AZA) as the first-line treatment in adults with chronic myelomonocytic leukemia (CMML)

H. Tong¹, S. Gao², W. Yang³, J. Li⁴, Q. Yin⁵, X. Zhao⁶, X. Yan⁷, S. Tu⁸, F. Li⁹, H. Yang¹⁰, R. Hu¹¹, S. Wang¹², L. Ma¹³, Z. Wang¹⁴, Z. Dong¹⁵, Q. Lu¹⁴, W. Tian¹⁴, Z. Xiao¹⁶, J. Wang¹⁷, ¹The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, CN, ²The First Hospital of Jilin University, Changchun, CN, ³Shengjing Hospital affiliated to China Medical University, Shenyang, CN, ⁴Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, CN, ⁵Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, CN, ⁶Tianjin People's Hospital, Tianjin, CN, ⁷The First Hospital of China Medical University, Shenyang, Liaoning Province, CN, ⁸Zhujiang Hospital of Southern Medical University, Guangzhou, CN, ⁹The First Affiliated Hospital of Nanchang University, Nanchang, CN, ¹⁰The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, CN, ¹¹Xuanwu Hospital of Capital Medical University, Beijing, CN, ¹²Fujian Medical University Union Hospital, Fuzhou, CN, ¹³The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, CN, ¹⁴ImmuneOnco Biopharmaceuticals (Shanghai) Inc., Shanghai, CN, ¹⁵ImmuneOnco Biopharmaceuticals (Shanghai) Inc, Shanghai, CN, ¹⁶Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences, Tianjin, CN, ¹⁷Institute of Hematology&Blood Diseases Hospital, Chinese Academy of Medical Sciences& Peking Union Medical College, Tianjin, CN

14:15 - 14:30

Invited Discussant 799MO, 800MO and 801MO

S. Garrido Paniagua, VHIO - Vall d'Hebron Institute of Oncology, Barcelona, ES

14:30 - 14:35

802MO - Real-world comparison of overall survival between BCMA - bispecific and CAR-T therapies in multiple myeloma

J. Song¹, G. Kim², R. Memon¹, K.-Y. Chi¹, Y. Chang³, A. Mehta¹, ¹Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, US, ²Pusan National University Hospital, Busan, KR, ³National Cheng Kung University Hospital, Tainan City, TW

14:35 - 14:40

803MO - CAR T cells reside in the bone marrow and inhibits healthy hematopoiesis

M. Ben Khelil¹, J. Srikanthan¹, R. Jelin¹, A. Arbab², L. Marcos-Kovandzic¹, R. Amine-Hneineh³, A. Pages², V. Verge², M. Aglave¹, J. Baptiste Micol³, M. Sabourin-Cousin², C. Quivoron², C. Marzac², L. Zitvogel¹, C. Castilla-Llorente³, C. Bigenwald¹, ¹Gustave Roussy, Villejuif, FR, ²Institut Gustave Roussy, Villejuif, Cedex, FR, ³Gustave Rousy, Villejuif, FR

14:40 - 14:45

804MO - Gut microbiota composition is predictive of CAR-T cells response and its modulation enhances CAR-T cells activity

L. Marcos-Kovandzic¹, J. Rengassamy², G. Ferrere³, J. Srikanthan¹, S. Durand⁴, L. Derosa⁵, C. Bigenwald⁵, L. Zitvogel², ¹Gustave Rousy, Villejuif, FR, ²Institut Gustave Roussy, Villejuif, Cedex, FR, ³Gustave Roussy - Cancer Campus, Villejuif, FR, ⁴Gustave Roussy - INSERM U1030, Villejuif, Cedex, FR, ⁵Institut Gustave Roussy, Villejuif, FR

14:45 - 15:00

Invited Discussant 802MO, 803MO and 804MO

Y.H. Tan, NCCS - National Cancer Centre Singapore, Singapore, SG



- 15:00 - 15:05 **805MO - Real-world efficacy and safety of tisagenlecleucel (CTL019) for relapse or refractory follicular lymphoma patients included in the early access program through the French DESCAR-T registry**
E. Bachy¹, C. Thieblemont², R. Houot³, S. Choquet⁴, G. Cartron⁵, G. Brisou⁶, O. Casasnovas⁷, F.-X. Gros⁸, F. Morschhauser⁹, F. Jardin¹⁰, L. Ysebaert¹¹, D. Beziz¹², C. Droumaguet-Gregoire¹², A. Filipovics¹², P. Miquel¹², C. Oprea¹², ¹Hôpital Lyon Sud – HCL, Pierre-Bénite, FR, ²Hôpital Saint Louis AP-HP, Paris, FR, ³CHU de Rennes – Hôpital Pontchaillou, Rennes, FR, ⁴Hôpital de la Pitié Salpêtrière – AP-HP, Paris, FR, ⁵CHU de Montpellier, Montpellier, FR, ⁶Institut Paoli-Calmettes, Marseille, FR, ⁷Hôpital François Mitterrand, Dijon, FR, ⁸CHU de Bordeaux – Hôpital Haut-Lévêque, Pessac, FR, ⁹Hopital Claude Huriez, Lille, FR, ¹⁰Centre Henri Becquerel, Rouen, FR, ¹¹Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, FR, ¹²Novartis Pharma S.A.S., Rueil-Malmaison, FR
- 15:05 - 15:10 **806MO - Phase Ib study of NT-17 (efineptakin alfa), a long-acting IL-7, post-CD19-directed CAR T cell therapy in diffuse large B-cell lymphoma (DLBCL)**
A. Ghobadi¹, L. Budde², K. Stermer³, S. Ferrando-Martinez³, B.H. Lee³, J. Dipersio¹, ¹Washington University School of Medicine in St. Louis, St. Louis, US, ²City of Hope National Medical Center, Duarte, US, ³NeolImmuneTech, Inc., Rockville, US
- 15:10 - 15:15 **807MO - High efficacy and safety of interleukin-6-knockdown CD19-targeted CAR-T cells in relapsed/refractory B-ALL patients**
L. Yu¹, L. Kang¹, S. Xue², X. Tang², X. Lou¹, C. Qian², W. Gong², M. Xu², H. Zhou², Z. Yao², W. Wang¹, M. Li¹, N. Xu¹, Z. Yu¹, S. Chen², H. Qiu², H. Dai², Y. Xu², D. Wu², ¹Shanghai Unicar-Therapy Bio-Medicine Technology Co.,Ltd, Shanghai, CN, ²The First Affiliated Hospital of Soochow University, Suzhou, CN
- 15:15 - 15:20 **808MO - Value of early post-treatment FDG PET/CT in diffuse large B-cell lymphoma patients receiving chimeric antigen receptor T cell therapy**
S.A. Mirshahvalad, A. Kohan, R. Kulanthaivelu, Y. Chin, C. Chen, D. Hodgson, R. Kridel, S. Bhella, U. Metser, P. Veit-Haibach, UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA
- 15:20 - 15:35 **Invited Discussant 805MO, 806MO, 807MO and 808MO**
M. Ladetto, Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, IT

14:00 - 15:30	Type: Educational session Title: Improving the assessment of citizens perception of risk Chair(s): Christine Chomienne, FR; Amil Druzic, BA	Zaragoza Auditorium - CC5
----------------------	---	----------------------------------

14:00 - 14:25 **Lessons from France's Cancer Barometers**
J. Foucaud, INCa - Institut National du Cancer, Boulogne-Billancourt, FR

14:25 - 14:50 **Social media intervention**
A. Druzic, Clinical Centre University of Sarajevo, Sarajevo, BA

14:50 - 15:15 **Socio psychological impact and implementation issues**

G. Evans, The University of Manchester, Manchester, GB

15:15 - 15:30 **Q&A and discussion**

14:00 - 15:30

Type: Special session

Cartagena Auditorium - Hall 7

Title: ESMO-MCBS: A practical tool with public health implications

Chair(s): Sjoukje Oosting, NL; Nathan Cherny, IL

14:00 - 14:05

Introduction

S. Oosting, UMCG - University Medical Center Groningen, Groningen, NL

14:05 - 14:20

How to handle bias in study design and reporting for ESMO-MCBS grading

N. Cherny, Shaare Zedek Medical Center, Jerusalem, IL

14:20 - 14:35

Progression-free survival: Should it be used as a primary end point for registration of anticancer treatments and what is the role of the ESMO-MCBS?

B. Gyawali, KAHS - Karnali Academy of Health Sciences, Chandannath, NP

14:35 - 14:50

ESMO-MCBS coming of age: can we extend beyond registration studies?

S. Oosting, UMCG - University Medical Center Groningen, Groningen, NL

14:50 - 15:05

EU HTA Regulation: State of play for cancer medicines

M. Matthews, European Commission, Brussels, BE

15:05 - 15:30

Conclusions and perspectives

N. Cherny, Shaare Zedek Medical Center, Jerusalem, IL

14:00 - 15:00

Type: Young Oncologists session

Tarragona Auditorium - Hall 7

Title: YO Vesalius talk - Becoming an independent investigator: The journey from a young oncologist to leading your own team

Chair(s): Pablo Mando, AR; Rille Pihlak, GB

14:00 - 15:00

Becoming an independent investigator: The journey from a young oncologist to leading your own team

R. Dent¹, F. André², E. Smyth³, ¹NCCS - National Cancer Centre Singapore, Singapore, SG,

²Gustave Roussy - Cancer Campus, Villejuif, FR, ³Cambridge University Hospitals NHS Foundation Trust, Cambridge, GB



16:00 - 17:30	Type: Mini Oral session Title: Mini oral session: Sarcoma Chair(s): Joanna Szkandera, AT; Aisha Miah, GB; Cesar Serrano, ES	Alicante Auditorium - Hall 3
16:00 - 16:05	LBA80 - Siremadlin (S) and ribociclib (R) in patients (pt) with advanced well-differentiated/dedifferentiated liposarcomas (WD/DD LPS) and other molecularly selected cancers: Final analysis of the MEGAMOST &#x201c;Ribociclib/HDM201&#x201d; basket study <u>M. Brahmi</u>¹, O. Tredan¹, C. Gomez-Roca², A. Italiano³, E. Saada⁴, F. Bertucci⁵, A. Le Cesne⁶, P. Cassier¹, I. Treilleux¹, S. Chabaud⁷, G. Fournier Garin¹, D. Perol¹, J.-Y. Blay¹, A. Dufresne¹, ¹Centre Léon Bérard, Lyon, FR, ²IUCT - Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, Cedex, FR, ³Institute Bergonié - Centre Régional de Lutte Contre le Cancer (CLCC), Bordeaux, FR, ⁴Centre Anticancer Antoine Lacassagne, Nice, FR, ⁵IPC - Institut Paoli-Calmettes, Marseille, FR, ⁶Gustave Roussy - Cancer Campus, Villejuif, FR, ⁷Centre de recherche en cancerologie de Lyon (CRCL), Lyon, FR	
16:05 - 16:10	1720MO - A phase II study of palbociclib combined with the PD-1 inhibitor retifanlimab in patients with advanced dedifferentiated liposarcoma <u>E. Rosenbaum</u>¹, L.-X. Qin², M. Dickson³, S. Movva², C. Kelly¹, J. Chan¹, P. Chi², L. Banks², M.L. Keohan², M. Gounder³, R. Maki², J. Cho¹, M. Biniakewitz¹, R. Desir-Camille¹, J. Erinjeri², R. Lefkowitz², C. Antonescu¹, S. Singer², W.D. Tap², S. D'Angelo², ¹Memorial Sloan Kettering Cancer Center, New York, US, ²MSKCC - Memorial Sloan Kettering Cancer Center, New York, US, ³Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US	
16:10 - 16:15	1721MO - Safety and efficacy of olutasidenib, an IDH1 mutant inhibitor, for the treatment of recurrent/relapsed or locally advanced or metastatic IDH1 mutated chondrosarcoma R. Jones¹, R. Groisberg², J.-Y. Blay³, H. Colman⁴, M. De La Fuente⁵, M. Milhem⁶, P. Roxburgh⁷, M.M. Chao⁸, H. Tian⁸, <u>F. Duffaud</u>⁹, C. Massard¹⁰, B. Van Tine¹¹, ¹The Royal Marsden Hospital - Chelsea, London, GB, ²Rutgers Cancer Institute of New Jersey, New Brunswick, US, ³Centre Léon Bérard, Lyon, FR, ⁴University of Utah Health - Cancer Hospital, Salt Lake City, US, ⁵Sylvester Comprehensive Cancer Center - University of Miami, Miami, US, ⁶University of Iowa Hospitals and Clinics, Iowa City, US, ⁷University of Glasgow, School of Cancer Sciences, Bearsden, GB, ⁸Rigel Pharmaceuticals, Inc, S. San Francisco, US, ⁹CHU La Timone Adultes, Marseille, FR, ¹⁰Gustave Roussy - Cancer Campus, Villejuif, FR, ¹¹Washington University School of Medicine, St. Louis, US	
16:15 - 16:30	Invited Discussant LBA80, 1720MO and 1721MO <u>J. Szkandera</u>, Medical University Graz-Center for Medical Research, Graz, AT	



- 16:30 - 16:35 **1722MO - Updated efficacy results of olverembatinib (HQP1351) in patients with succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST) and potential mechanisms of action (MOA)**
H. Qiu¹, C. Yang², Z. Zhou¹, Y. Zhou³, X. Wan⁴, N. Li⁴, K. Tao⁵, Y. Li⁶, X. Wu⁷, Z. Chen², L. Men², Y. Xiong², E. Liang⁸, C. Wang⁸, D. Yang², Y. Zhai², R.-H. Xu⁹, ¹Sun Yat-sen University Cancer Center, Guangzhou, CN, ²Guangzhou Healthquest Pharma Co., Ltd., Guangzhou, CN, ³Fudan University Shanghai Cancer Center, Shanghai, CN, ⁴Henan Cancer Hospital, Zhengzhou, CN, ⁵Union Hospital Medical College Huazhong University of Science and Technology, Wuhan, CN, ⁶Guangdong Provincial People's Hospital, Guangzhou, CN, ⁷Chinese People's Liberation Army General Hospital, Beijing, CN, ⁸Ascentage Pharma Group Inc., Rockville, US, ⁹Sun Yat-sen University Cancer Center, Guangzhou, CN
- 16:35 - 16:40 **1723MO - Axitinib plus avelumab in patients with unresectable/metastatic gastrointestinal stromal tumor (GIST) after failure of standard therapy: Single-arm phase II study (AXAGIST)**
P. Rutkowski¹, A. Klimczak¹, P. Teterycz¹, T. Switaj¹, P. Rogala¹, M. Pantaleo², K. Kozak¹, ¹Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, PL, ²Policlinico Sant'Orsola-Malpighi, Bologna, IT
- 16:40 - 16:45 **1724MO - The final results of pulmonary resectable metastases of osteosarcoma with antiangiogenic and chemotherapy (PROACH): An open-label, single-arm phase II clinical trial**
Q. Bao¹, J. Wen², Z. Zhang², X. Yang², Y. Shen², W. Zhang³, ¹Ruijin Hospital - Shanghai Jiao Tong University School of Medicine, Shanghai, CN, ²Ruijin Hospital - Shanghai Jiao Tong University School of Medicine, Shanghai, China, CN, ³Shanghai Ruijin Hospital, Shanghai Jiao Tong University, College of Medicine, Shanghai, CN
- 16:45 - 17:00 **Invited Discussant 1722MO, 1723MO and 1724MO**
A. Miah, The Royal Marsden Hospital - Chelsea, London, GB
- 17:00 - 17:05 **1725MO - IMMUNOSARC II master trial (phase II of sunitinib and nivolumab): Results from the clear cell sarcoma (CCS) cohort: A GEIS, ISG, and UCL study**
J. Martin-Broto¹, E. Palmerini², C.M. Valverde Morales³, A. Sebio Garcia⁴, A. Redondo⁵, S. Stacchiotti⁶, S. Strauss⁷, G. Grignani⁸, S. Aliberti⁹, R. Diaz Beveridge¹⁰, E. Gonzalez Billalabeitia¹¹, J. Cruz Jurado¹², A. Gutierrez Garcia¹³, P. Ledesma¹⁴, D. Da Silva Moura¹, N. Hindi Muñiz¹, ¹Hospital Universitario Fundacion Jimenez Diaz, Madrid, ES, ²Istituto Ortopedico Rizzoli, Bologna, IT, ³Vall d'Hebron University Hospital, Barcelona, ES, ⁴Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ⁵Hospital Universitario La Paz, Madrid, ES, ⁶Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ⁷University College London Hospitals NHS Foundation Trust, London, GB, ⁸AOU Città della Salute e della Scienza Torino, Torino, IT, ⁹IRCCS - Istituto di Candiolo - FPO, Candiolo, IT, ¹⁰Hospital Universitario la Fe, Valencia, ES, ¹¹Hospital Universitario 12 de Octubre, Madrid, ES, ¹²Hospital Universitario de Canarias, San Cristobal de la Laguna, ES, ¹³Hospital Universitario Son Espases, Palma de Mallorca, ES, ¹⁴Sofpromed, Palma de Mallorca, ES



17:05 - 17:10

1726MO - Updated efficacy and safety of botensilimab plus balstilimab in patients with refractory metastatic sarcoma from an expanded phase I study

B. Wilky¹, J. Trent², A.M. Tsimberidou³, M. Gordon⁴, A. El-Khoueiry⁵, A. Bullock⁶, B. Henick⁷, M. Agulnik⁸, D. Mahadevan⁹, A. Singh¹⁰, W. Wu¹¹, M. Avagyan¹¹, J. Patel¹¹, J. Grossman¹¹, S. O'Day¹², G. Schwartz¹³, R. Jones¹⁴, ¹UCHealth Cancer Care - Anschutz Medical Campus - University of Colorado Cancer Center, Aurora, US, ²Sylvester Comprehensive Cancer Center, Miami, US, ³The University of Texas MD Anderson Cancer Center, Houston, US, ⁴HonorHealth Research Institute, Scottsdale, US, ⁵USC - University of Southern California - Keck School of Medicine, Los Angeles, US, ⁶Beth Israel Deaconess Medical Center, Boston, US, ⁷Columbia University Medical Center College of Physicians & Surgeons - New York Presbyterian Hospital, New York, US, ⁸City of Hope Comprehensive Cancer Center, Duarte, US, ⁹UT Health San Antonio MD Anderson Cancer Center, San Antonio, US, ¹⁰Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, US, ¹¹Agenus Inc - Corporate HQ, R&D and Vaccine Manufacturing, Lexington, US, ¹²Agenus Inc, Lexington, US, ¹³Case Comprehensive Cancer Center, Cleveland, US, ¹⁴The Royal Marsden Hospital and Institute of Cancer Research, London, GB

17:10 - 17:15

1727MO - Can proteomics predict metastatic relapse in leiomyosarcoma (LMS)? Development of an 8 protein signature in a 350 sample study including a validation cohort

E. Connolly¹, D. Bucio-Noble¹, S. Cai¹, A. Singh¹, J. Koh¹, R. Karim², A. Lazar³, R. Lim⁴, R. Morey³, G. Ratnayake⁵, P. Hains¹, L. Ye⁶, D. Ingram³, C. Scott⁴, P. Robinson¹, H. Barker⁴, E. Nassif Haddad⁷, L. Horvath⁶, P. Grimison⁶, R. Reddel¹, ¹Children's Medical Research Institute, Sydney, AU, ²Royal Prince Alfred Hospital-Labs-Anatomical Pathology, Camperdown, AU, ³The University of Texas M. D. Anderson Cancer Center, Houston, US, ⁴WEHI - Walter and Eliza Hall Institute of Medical Research, Parkville, AU, ⁵The Royal Children's Hospital Melbourne, Parkville, AU, ⁶Chris O'Brien Lifehouse, Camperdown, AU, ⁷The University of Texas MD Anderson Cancer Center - Main Building, Houston, US

17:15 - 17:30

Invited Discussant 1725MO, 1726MO and 1727MO

C. Serrano, Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES



16:00 - 17:30	Type: Proffered Paper session Title: Proffered paper session: Breast cancer, metastatic Chair(s): Christos Sotiriou, BE; Karen Gelmon, CA	Barcelona Auditorium - Hall 2
16:00 - 16:10	LBA18 - Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-advanced/metastatic breast cancer (mBC) with or without brain metastases (BM): DESTINYBreast-12 primary results N. Lin¹, E. Ciruelos², G. Jerusalem³, V. Mueller⁴, N. Niihara⁵, G. Viale⁶, R. Bartsch⁷, C. Kurzedder⁸, R. Connolly⁹, S. Baron-Hay¹⁰, M. Gion Cortes¹¹, V. Guarneri¹², G. Bianchini¹³, H. Wildiers¹⁴, S. Escrivá-De-Romaní¹⁵, M. Prahlanad¹⁶, H. Bridge¹⁷, S. Verma¹⁸, N. Harbeck¹⁹, ¹Dana-Farber Cancer Institute, Boston, US, ²Hospital Universitario 12 de Octubre, Madrid, ES, ³CHU Liège and Liège University, Liège, BE, ⁴University Medical Center Hamburg-Eppendorf, Hamburg, DE, ⁵Tokai University School of Medicine, Kanagawa, JP, ⁶European Institute of Oncology IRCCS, Milan, IT, ⁷Medical University of Vienna, Vienna, AT, ⁸University Hospital Basel, Basel, CH, ⁹Cork University Hospital, Cork, IE, ¹⁰Royal North Shore Hospital, St Leonards, AU, ¹¹Beata María Ana Hospital, Madrid, ES, ¹²University of Padova, Padova, IT, ¹³IRCCS Ospedale San Raffaele, Milan, IT, ¹⁴University Hospitals Leuven, KU Leuven, Leuven, BE, ¹⁵Vall d'Hebron Institute of Oncology, Barcelona, ES, ¹⁶AstraZeneca, Cambridge, GB, ¹⁷AstraZeneca, Macclesfield, GB, ¹⁸AstraZeneca, Gaithersburg, US, ¹⁹LMU University Hospital, Munich, DE	
16:10 - 16:20	3400 - Efficacy, safety and biomarker analysis of ICARUS-BREAST01: A phase II study of patritumab deruxtecan (HER3-DXd) in patients (pts) with HR-/HER2- advanced breast cancer (ABC) B. Pistilli¹, L. Pierotti¹, M. Lacroix-Triki¹, C. Viciér², J.-S. Frenel³, V. D'Hondt⁴, F. Dalenc⁵, T. Bachelot⁶, A. Ducoulombier⁷, M.-A. Benderra⁸, D. Loirat⁹, D. Mayeur¹⁰, G. Nachabeh¹¹, A. Sporchia¹², F. Suto¹³, S. Michiels¹⁴, N. Corcos¹¹, M.F. Mosele¹, F. André¹, G. Montagnac¹, ¹Gustave Roussy Cancer Campus, Villejuif, FR, ²IPC - Institut Paoli-Calmettes, Marseille, Cedex, FR, ³ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, ⁴ICM - Institut du Cancer de Montpellier, Montpellier, Cedex, FR, ⁵Oncopole Claudius Regaud- IUCT, Toulouse, FR, ⁶Centre Léon Bérard, Lyon, FR, ⁷Centre Anticancer Antoine Lacassagne, Nice, FR, ⁸Hopital Tenon AP-HP, Paris, Cedex, FR, ⁹Institut Curie, Paris, FR, ¹⁰Centre Georges-François Leclerc (Dijon), Dijon, FR, ¹¹Gustave Roussy - Cancer Campus, Villejuif, FR, ¹²Daiichi Sankyo Italia S.p.A., Rome, IT, ¹³Daiichi Sankyo Co., Ltd. - Shinagawa R&D Center, Shinagawa-ku, JP, ¹⁴Institut Gustave Roussy, Villejuif, Cedex, FR	
16:20 - 16:30	Invited Discussant LBA18 and 3400 C. Saura Manich, Vall d'Hebron University Hospital, Barcelona, ES	
16:30 - 16:45	Q&A	



16:45 - 16:55

LBA19 - Capivasertib (C) & paclitaxel (P) as first-line treatment of metastatic triple-negative breast cancer (mTNBC): The CAPItello-290 phase III trial

P. Schmid¹, H. McArthur², J. Cortés³, B. Xu⁴, F. Cardoso⁵, M.L. Casalnuovo⁶, U. Demirci⁷, R. Freitas Jr⁸, J. Ghosh⁹, R. Hegg¹⁰, H. Iwata¹¹, Y.A. Lopez Chuken¹², M. Nechaeva¹³, M. Robson¹⁴, R. Villalobos Valencia¹⁵, A. Lloyd¹⁶, C. D'Cruz¹⁷, A. Foxley¹⁶, Y.H. Park¹⁸, ¹Barts Cancer Institute, Queen Mary University, London, GB, ²UT Southwestern Medical Center, Dallas, US, ³IBCC, Pangaea Group & IOB Madrid, Institute of Oncology, Barcelona, ES, ⁴Cancer Hospital of Chinese Academy of Medical Sciences, Beijing, CN, ⁵Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, PT, ⁶CENIT Centro Medico de Neurociencias, Buenos Aires, AR, ⁷Memorial Ankara Hospital, Ankara, TR, ⁸Hospital Araújo Jorge, Goiania, BR, ⁹TATA Medical Center, Kolkata, IN, ¹⁰São Paulo State Government Women's Health Reference Center, São Paulo, BR, ¹¹Aichi Cancer Center Hospital, Aichi, JP, ¹²iCAN Oncology Center, Monterrey, MX, ¹³Arkhangelsk Regional Clinical Oncology Dispensary, Arkhangelsk, RU, ¹⁴Memorial Sloan-Kettering Cancer Center, New York, US, ¹⁵Consultorio Centro de la Torre Médica Dalinde (Oncología Médica), Mexico City, MX, ¹⁶AstraZeneca, Cambridge, GB, ¹⁷AstraZeneca, Waltham, US, ¹⁸Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR

16:55 - 17:05

LBA20 - First-line carboplatin-cyclophosphamide (CC) versus paclitaxel (P) with or without atezolizumab (atezo) for metastatic triple negative breast cancer (mTNBC): Results from a multicenter, randomized phase IIb trial: The Triple-B study (BOOG 2013-01)

M. Kok¹, R. Voorthuis², L. De Boo², A. Van Rossum², I. Mandjes¹, S. Balduzzi³, M. Chelushkin², E. Rosenberg², H. Horlings², C. Loo², J. Heijns⁴, M. Agterhof⁵, B. De Valk⁶, A.-M. Riel⁷, A. Van Der Velden⁸, M. Dercksen⁹, A. Imholz¹⁰, A.E. Van Leeuwen-Stok¹¹, H. Oosterkamp¹², S. Linn², ¹Netherlands Cancer Institute, Amsterdam, NL, ²NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ³NKI - Netherlands Cancer Institute, Amsterdam, NL, ⁴Amphia Ziekenhuis-location Molengracht, Breda, NL, ⁵St. Antonius Hospital, Nieuwegein, NL, ⁶Spaarne Hospital Hoofddorp, Hoofddorp, NL, ⁷ETZ Elisabeth Hospital, Tilburg, NL, ⁸Martini Hospital, Groningen, NL, ⁹Maxima Medisch Centrum -Veldhoven, Veldhoven, NL, ¹⁰Deventer Ziekenhuis, Deventer, NL, ¹¹BOOG Study Center, Utrecht, NL, ¹²HMC - Haaglanden Medisch Centrum - Westeinde, Den Haag, NL

17:05 - 17:15

Invited Discussant LBA19 and LBA20

K. Gelmon, BC Cancer Agency - Vancouver, Vancouver, CA

17:15 - 17:30

Q&A

16:00 - 17:30

Type: Educational session

Madrid Auditorium - Hall 2

Title: The rapidly changing treatment landscape of early triple negative breast cancer

Chair(s): Joana Ribeiro, FR; Popi Siziopikou, US

16:00 - 16:25

Novel data in the field of immune checkpoint blockade for eTNBC

S. Tolaney, Dana Farber Cancer Institute, Boston, US



16:25 - 16:50 **Treatments for eTNBC patients with non-pCR after chemo-immunotherapy**
J. Ribeiro, Gustave Roussy - Cancer Campus, Villejuif, FR

16:50 - 17:15 **How to treat stage I TNBC?**
D. Cescon, Princess Margaret Cancer Centre, Toronto, CA

17:15 - 17:30 **Q&A and discussion**

16:00 - 17:30 **Type: Proffered Paper session** **Sevilla Auditorium - Hall 2**
Title: Proffered paper session 1: GI tumours, upper digestive
 Chair(s): Sarah Derks, NL; Angela Lamarca, ES

16:00 - 16:10 **LBA38 - Iparomlimab and tuvonralimab (QL1706) with bevacizumab and/or chemotherapy in first-line (1L) treatment of advanced hepatocellular carcinoma (aHCC): A randomized, open-label, phase II/III study (DUBHE-H-308)**

S. Qin¹, J. Fan², F. Yang³, J. Zhou², Y. Zhang⁴, D. Cai⁵, Z. Yu⁶, Y. Chen⁷, X. Shi⁸, D. Li⁹, Y. Li⁹, J. Yao¹⁰, Y. Tan¹¹, D. Wu¹², X. Yang¹³, M. Da¹³, L. Li¹⁴, P. Shao¹⁵, X. Kang¹⁴, ¹Tianyinshan Hospital, Nanjing, CN, ²Zhongshan Hospital Affiliated to Fudan University, Shanghai, CN, ³Nanjing Medical University, Nanjing, CN, ⁴Cancer Hospital Affiliated to Harbin Medical University, Harbin, CN, ⁵The Second Affiliated Hospital of Chongqing Medical University, Chongqing, CN, ⁶The First Affiliated Hospital of Zhengzhou University, Zhengzhou, CN, ⁷The First Affiliated Hospital of Chongqing Medical University, Chongqing, CN, ⁸Shandong Cancer Hospital Affiliated to Shandong University, Jinan, CN, ⁹Chongqing University Cancer Hospital, Chongqing, CN, ¹⁰The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, CN, ¹¹The First Affiliated Hospital of Bengbu Medical University, Bengbu, CN, ¹²Hubei Cancer Hospital, Wuhan, CN, ¹³Gansu Provincial Hospital, Lanzhou, CN, ¹⁴Qilu Pharmaceutical Co., Ltd., Jinan, CN, ¹⁵Qilu Pharmaceutical Co. Ltd, Jinan, CN

16:10 - 16:20 **LBA39 - Updated efficacy and safety data from IMbrave050: Phase III study of adjuvant atezolizumab (atezo) & bevacizumab (bev) vs active surveillance in patients (pts) with resected or ablated high-risk hepatocellular carcinoma (HCC)**

A. Yopp¹, M. Kudo², M. Chen³, A.-L. Cheng⁴, A. Kaseb⁵, H.C. Lee⁶, S. Qin⁷, E. Cha⁸, S. Hack⁸, Q. Lian⁹, J. Spahn¹⁰, C. Wu¹¹, P. Chow¹², ¹UT Southwestern Medical Center, Dallas, US, ²Kindai University Hospital, Osaka, JP, ³Sun Yat-Sen University Cancer Center, Guangzhou, CN, ⁴NTUH - National Taiwan University Hospital, Taipei, TW, ⁵The University of Texas M. D. Anderson Cancer Center, Houston, US, ⁶Asan Medical Center - University of Ulsan, Seoul, KR, ⁷Jinling Hospital of Nanjing University of Chinese Medicine, Nanjing, CN, ⁸Genentech, Inc. - Member of the Roche Group, South San Francisco, US, ⁹Genentech, Inc., South San Francisco, US, ¹⁰Genentech Inc. - Roche - USA, South San Francisco, US, ¹¹Roche (China) Holding Ltd, Shanghai, CN, ¹²NCCS - National Cancer Centre Singapore, Singapore, SG

16:20 - 16:30 **Invited Discussant LBA38 and LBA39**
M. Lowery, Trinity College Dublin, Dublin, IE

16:30 - 16:45 **Q&A**



16:45 - 16:55 **LBA62 - Preoperative modified FOLFIRINOX (mFOLFIRINOX) with or without chemoradiation (CRT) in borderline resectable pancreatic cancer (BRPC): Results from the randomized phase II trial PANDAS/PRODIGE 44**

A. Lambert¹, O. Bouche², A. Ayav³, J.-B. Bachet⁴, L. Schwarz⁵, G. Piessen⁶, V. Vendrely⁷, V. Laurent³, E. Thibaudeau⁸, L. Miglianico⁹, Y. Rinaldi¹⁰, P. Hammel¹¹, T. Conroy¹, ¹Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre-lès-Nancy, FR, ²Hopital Robert Debré - CHU de Reims, Reims, FR, ³CHRU de Nancy - Hôpitaux de Brabois, Vandœuvre-lès-Nancy, FR, ⁴Groupe Hospitalier Pitié Salpêtrière, Paris, FR, ⁵CHU de Rouen Normandie, Rouen, FR, ⁶C.H.U. Claude Huriez, Lille, FR, ⁷CHU de Bordeaux-Hôpital Haut-Lévêque, Pessac, FR, ⁸ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, ⁹Centre Hospitalier Privé Saint-Grégoire, Saint-Grégoire, FR, ¹⁰Hopital Européen Marseille, Marseille, FR, ¹¹APHP, hopital Paul Brousse, VILLEJUIF, FR

16:55 - 17:05 **LBA40 - Primary results from the phase III ALTN-AK105-III-02 study: Anlotinib plus penpulimab versus sorafenib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)**

J. Zhou¹, J. Fan¹, S.C. Jiao², L. Bai², J. Luo³, Y. Bai⁴, Y. Pan⁵, Y. Gao⁶, R. Shi⁷, W. Zhang⁸, J. Zheng⁹, X. Hua¹⁰, X. Aibing¹¹, S. Hu¹², M. Da¹³, R. Wang¹⁴, J. Ma¹⁵, W. Jia¹⁶, W. Wu¹⁷, C. Peng¹⁸, ¹Zhongshan Hospital Affiliated to Fudan University, Shanghai, CN, ²Chinese PLA General Hospital (301 Military Hospital), Beijing, CN, ³Hunan Cancer Hospital and The Afliated Cancer Hospital of Xiangya School of Medicine, Changsha, CN, ⁴Harbin Medical University Affiliated Cancer Hospital, Harbin, CN, ⁵The Affiliated Cancer Hospital of Guizhou Medical University, Guiyang, CN, ⁶The First Affiliated Hospital of Anhui Medical University, Hefei, CN, ⁷The Affiliated Hospital of Zunyi Medical University, Zunyi, CN, ⁸Gansu Wuwei Tumor Hospital, Wuwei, CN, ⁹Hainan General Hospital, Haikou, CN, ¹⁰Liaoning Cancer Hospital & Institute, Shenyang, CN, ¹¹Nantong Fifth People's Hospital/Nantong Tumor Hospital, Nantong, CN, ¹²Hubei Cancer Hospital, Wuhan, CN, ¹³Gansu Provincial Hospital, Lanzhou, CN, ¹⁴The First Affiliated Hospital of Bengbu Medical College, Bengbu, CN, ¹⁵The First Affiliated Hospital of Guangxi Medical University, Nanning, CN, ¹⁶Anhui Provincial Hospital, Hefei, CN, ¹⁷The sixth people's hospital of shenyang, Shenyang, CN, ¹⁸Hunan Provincial People's Hospital, Changsha, CN

17:05 - 17:15 **Invited Discussant LBA62 and LBA40**

R. Shroff, University of Arizona Cancer Center, Tucson, US

17:15 - 17:30 **Q&A**

16:00 - 17:30 **Type: Special symposium** **Bilbao Auditorium - Hall 2**
Title: Lung cancer interception: New approaches to lung cancer screening and prevention
 Chair(s): Torsten Blum, DE; Pan-Chyr Yang, TW

16:00 - 16:05 **Introduction and scientific background**
P.-C. Yang, NTUH - National Taiwan University Hospital, Taipei City, TW

16:05 - 16:20 **The current state-of-the-art in lung cancer screening**
T. Blum, HELIOS Klinikum Emil von Behring Berlin-Zehlendor, Berlin, DE

16:20 - 16:35 **Should we be screening in never smokers for NSCLC?**
P.-C. Yang, NTUH - National Taiwan University Hospital, Taipei City, TW

16:35 - 16:50 **Immunotherapy and beyond for lung cancer prevention**
J. Zhang, MD Anderson Cancer Center, Houston, US

16:50 - 17:05 **Biomarker discovery for lung cancer early detection**
R. Dziadziuszko, Medical University of Gdansk, Gdansk, PL

17:05 - 17:25 **Q&A and discussion**

17:25 - 17:30 **Conclusions and perspectives**
T. Blum, HELIOS Klinikum Emil von Behring Berlin-Zehlendorf, Berlin, DE

16:00 - 17:30 **Type: Special symposium** **Granada Auditorium - Hall 6**
Title: Can we expand bladder preservation by optimal use of systemic therapy and biomarkers?
 Chair(s): Srikala Sridhar, CA; Leslie Ballas, US

16:00 - 16:05 **Introduction and scientific background**
L. Ballas, Keck School of Medicine - University of Southern California USC, Los Angeles, US

16:05 - 16:20 **Could optimal systemic therapy be adequate without locoregional therapy?**
S. Sridhar, UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA

16:20 - 16:35 **Biomarkers and prediction of clinical complete response**
E. Schaake, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL

16:35 - 16:50 **Clinical responders: Option of chemoradiation?**
L. Ballas, Keck School of Medicine - University of Southern California USC, Los Angeles, US

16:50 - 17:05 **The role of urologist in bladder preservation strategies**
J. Catto, University of Sheffield Medical School, Sheffield, GB

17:05 - 17:25 **Q&A and discussion**

17:25 - 17:30 **Conclusions and perspectives**
S. Sridhar, UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA



16:00 - 17:30	Type: Proffered Paper session Title: Proffered paper session: Investigational immunotherapy Chair(s): Fiona Thistlethwaite, GB; Ana Martins Ferreira Varges Gomes, PT	Burgos Auditorium - Hall 5
16:00 - 16:10	9880 - A phase I/II trial (LOKON003) evaluating tumor microenvironment (TME) gene engineering using a viral vector combined with atezolizumab in advanced malignant melanoma O. Hamid¹, V. Rydén², I. Mehmi¹, D. Wang³, M. Patel³, J. Krause⁴, L. Sandin⁵, H. Grauers Wiktorin⁶, T. Lövgren⁶, E. Eriksson⁵, J. Leja Jarblad⁵, A. Loskog⁵, <u>G. Ullenhag</u>², ¹A Cedars Sinai Affiliate, Los Angeles, US, ²Uppsala University Hospital and Uppsala University, Uppsala, SE, ³Baylor College of Medicine, Houston, US, ⁴Uppsala University and Uppsala University Hospital, Uppsala, SE, ⁵Lokon Pharma AB, Uppsala, SE, ⁶Uppsala University, Uppsala, SE	
16:10 - 16:20	9890 - Novel gene therapy in advanced solid malignancies: A phase I/II clinical trial A. Hahn¹, S. Irenaeus¹, J. Wenthe², E. Eriksson², A. Schiza¹, H. Dahlstrand³, U. Olsson-Strömberg⁴, J. Krause⁴, A. Sundin⁴, L. Sandin², J. Leja Jarblad², M. Liljefors³, <u>A. Loskog</u>¹, G. Ullenhag¹, ¹Uppsala University - Rudbeck Laboratory, Uppsala, SE, ²Lokon Pharma AB, Uppsala, SE, ³Karolinska University Hospital, Stockholm, SE, ⁴Uppsala University Hospital, Uppsala, SE	
16:20 - 16:30	Invited Discussant 9880 and 9890 <u>K. Harrington</u>, ICR - Institute of Cancer Research - Chester Beatty Laboratories, London, GB	
16:30 - 16:40	Q&A	
16:40 - 16:50	9900 - Final results from phase I, first-in-human, dose escalation study of a first-in-class anti-ILT2 antibody, SAR444881, alone and with pembrolizumab or cetuximab, in patients with advanced solid tumors <u>R. Perets</u>¹, S.M. Stemmer², R. Geva³, T. Golan⁴, M. Fakhri⁵, J. Cohen⁶, C. Lieu⁷, Z. Jin⁸, P. Lorusso⁹, I. Friedman¹⁰, M. Hakim¹¹, D. Haves Ziv¹¹, S. Hashmueli¹¹, I. Mandel¹¹, T. Ben Moshe¹¹, N. Crawford¹², G. Abbadessa¹³, R. Perez¹², M. Wu¹³, M. Borad¹⁴, ¹Rambam Medical Center, Haifa, IL, ²Rabin Medical Centre-Beilinson Hospital, Petah Tikva, IL, ³Tel Aviv Sourasky Medical Center, Tel Aviv, IL, ⁴Sheba Medical Center, Ramat Gan, Tel Aviv University, Tel Aviv, IL, ⁵City of Hope Comprehensive Cancer Center, Duarte, US, ⁶Sharett Institute of Oncology, Hadassah Cancer Research Institute and Wohl Institute for Translational Medicine, Hadassah-Hebrew University Medical Center, Jerusalem, IL, ⁷University of Colorado Cancer Center, Aurora, US, ⁸Mayo Clinic, Rochester, US, ⁹Yale Comprehensive Cancer Center, Yale University School of Medicine, New Haven, US, ¹⁰Previously employed at Biond Biologics Ltd, Misgav Industrial Park, Misgav, IL, ¹¹Biond Biologics Ltd, Misgav Industrial Park, Misgav, IL, ¹²Sanofi, Bridgewater, US, ¹³Sanofi, Cambridge, US, ¹⁴Mayo Clinic Cancer Center, Scottsdale, US	



16:50 - 17:00	9910 - First-in-human (FIH) phase I data of HST-1011, an oral CBL-B inhibitor, in patients with advanced solid tumors <u>R. Sanborn</u> ¹ , M. Patel ² , J. Rodon ³ , K. Thein ⁴ , C. Friedman ⁵ , D. Levitz ⁶ , I. Ngirailemesang ⁷ , A. Goodman ⁸ , P. Agarwal ⁹ , E. Friedman ¹⁰ , H. Danaee ¹⁰ , K. Robell ¹⁰ , S. Jaeger ¹⁰ , H. Sun ¹⁰ , E. Debanne ¹⁰ , J. Dunn ¹⁰ , E. Wright ¹⁰ , T. Reilly ¹⁰ , J. Luke ¹¹ , A. Redig ¹⁰ , ¹ Earle A. Chiles Research Institute at the Robert W. Franz Cancer Center, Portland, US, ² Florida Cancer Specialists, Fort Myers, US, ³ The University of Texas MD Anderson Cancer Center - Main Building, Houston, US, ⁴ Comprehensive Cancer Centers of Nevada, Las Vegas, US, ⁵ Memorial Sloan Kettering Cancer Center, New York, US, ⁶ Montefiore Medical Center - Moses Campus, Bronx, US, ⁷ Providence Cancer Institute Franz Clinic, Portland, US, ⁸ University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, US, ⁹ Abramson Cancer Center - University of Pennsylvania, Philadelphia, US, ¹⁰ HotSpot Therapeutics, Boston, US, ¹¹ University of Pittsburgh Cancer Institute, Pittsburgh, US	
17:00 - 17:10	9920 - Pembrolizumab for HPV-associated recurrent respiratory papillomatosis <u>S. Pai</u> ¹ , A. Muniappan ² , J.C. Park ³ , A. Friedman ⁴ , N. Campbell ⁵ , S. Krantz ⁵ , K.-Y. Shin ⁶ , P. Song ⁷ , T. Carroll ⁸ , W. Faquin ³ , A. Oneill ⁶ , R. Franco ⁷ , ¹ Yale University School of Medicine, New Haven, US, ² Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, US, ³ MGH - Massachusetts General Hospital, Boston, US, ⁴ University of Cincinnati Cancer Center, Cincinnati, US, ⁵ NorthShore University HealthSystem-Evanston Hospital, Evanston, US, ⁶ Dana Farber Cancer Institute, Boston, US, ⁷ Massachusetts Eye and Ear Infirmary, Boston, US, ⁸ Brigham and Women's Hospital, Boston, US	
17:10 - 17:20	Invited Discussant 9900, 9910 and 9920 <u>A. Martins Ferreira Varges Gomes</u> , Centro Hospitalar Universitário do Algarve - Hospital de Faro EPE-SNS, Faro, PT	
17:20 - 17:30	Q&A	
16:00 - 17:30	Type: Educational session Title: Oncofertility: What every HCP involved in cancer care should know Chair(s): Matteo Lambertini, IT; Christine Wyns, BE	Salamanca Auditorium - Hall 5
16:00 - 16:20	Risk of gonadal toxicities with anticancer therapies with a focus on newer treatments <u>I. Demeestere</u> , ULB - Université Libre de Bruxelles, Brussels, BE	
16:20 - 16:40	Fertility preservation and beyond in female patients with cancer <u>M. Lambertini</u> , IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT	
16:40 - 17:00	Fertility preservation and beyond in male patients with cancer <u>C. Wyns</u> , Cliniques Universitaires Saint-Luc (UCLouvain Saint-Luc), Woluwe-Saint-Lambert, BE	



17:00 - 17:20 **Addressing sexual health in female and male patients with cancer**
C. Bergerot, Oncoclinicas&Co - Medica Scientia Innovation Research (MEDSIR), Sao Paulo, BR

17:20 - 17:30 **Q&A and discussion**

16:00 - 17:30 **Type: Proffered Paper session** **Santander Auditorium - Hall 5**
Title: Proffered paper session 1: Developmental therapeutics
 Chair(s): Elena Garralda, ES; Lillian Siu, CA

16:00 - 16:10 **6030 - First clinical results from a phase I trial of PRT3789: A first-in-class intravenous SMARCA2 degrader, in patients with advanced solid tumors with a SMARCA4 mutation**
R. Guo¹, A. Dowlati², I. Dagogo-Jack³, J. Vibert⁴, A. Spira⁵, V. Moreno Garcia⁶, S. Puneekar⁷, E. Calvo⁸, G. Sonpavde⁹, M. Awad¹⁰, J. Riess¹¹, T. Hernandez Guerrero¹², B. Herzberg¹³, A. Italiano¹⁴, A. Swalduz¹⁵, P. Lorusso¹⁶, E. Smit¹⁷, E. Garon¹⁸, W. Novotny¹⁹, T.A. Yap²⁰, ¹Memorial Sloan Kettering Cancer Center, Commack, US, ²University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, US, ³Massachusetts General Hospital, Boston, US, ⁴Gustave Roussy, Villejuif, Cedex, FR, ⁵Virginia Cancer Research (VCS) Research Institute, NEXT Oncology-Virginia, Fairfax, US, ⁶START Madrid-FJD, Hospital Universitario Fundación Jiménez Díaz, Madrid, ES, ⁷NYU Langone Health, New York, US, ⁸START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Madrid, ES, ⁹AdventHealth Cancer Institute, Orlando, US, ¹⁰Dana Farber Cancer Institute, Boston, US, ¹¹UC Davis Comprehensive Cancer Center, Sacramento, US, ¹²START Barcelona - HM Nou Delfos, Barcelona, ES, ¹³Columbia University Herbert Irving Comprehensive Cancer Center, New York, US, ¹⁴Institute Bergonié, Bordeaux, FR, ¹⁵Léon Bérard Centre, Lyon, FR, ¹⁶Yale Cancer Center, New Haven, US, ¹⁷Universiteit Leiden, Leiden, NL, ¹⁸David Geffen School of Medicine at UCLA, Santa Monica, US, ¹⁹Prelude Therapeutics Incorporated, Wilmington, US, ²⁰The University of Texas, MD Anderson Cancer Center, Houston, US

16:10 - 16:20 **6120 - Preliminary results from a phase I study of CFT1946, a novel BIDAC degrader in mutant BRAF V600 solid tumors**
M. Vieito¹, M. Mckean², A. Spira³, E. Rosen⁴, J. Rodon⁵, V. Moreno Garcia⁶, V. Gambardella⁷, O. Saavedra⁸, S. Cousin⁹, P. Cassier¹⁰, I. Korakis¹¹, B. Van Tine¹², V. Ma¹³, A. Ali¹⁴, E. Hinojosa¹⁴, R. Lobbardi¹⁴, H. Liu¹⁴, E. Hurh¹⁴, L. Reyno¹⁴, E. Buchbinder¹⁵, ¹Vall d'Hebron University Hospital, Barcelona, ES, ²Sarah Cannon Research Institute, Nashville, US, ³Virginia Cancer Specialist, Fairfax, US, ⁴Memorial Sloan Kettering Cancer Center, New York, US, ⁵University of Texas MD Anderson Cancer Center, Houston, US, ⁶Hospital Fundación Jiménez Díaz, Madrid, ES, ⁷INCLIVA Biomedical Research Institute, Valencia, ES, ⁸NEXT Oncology, Barcelona, Spain, Barcelona, ES, ⁹Institut Bergonie, Bordeaux, FR, ¹⁰Centre Léon Bérard, Lyon, FR, ¹¹IUCT - Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, FR, ¹²Washington University School of Medicine, St. Louis, US, ¹³University of Wisconsin Carbone Cancer Center, Madison, US, ¹⁴C4 Therapeutics, Inc, Watertown, US, ¹⁵Dana Farber Cancer Institute, Boston, US

16:20 - 16:30 **Invited Discussant 6030 and 6120**
C. Le Tourneau, Institut Curie, Paris, FR



16:30 - 16:40

Q&A

16:40 - 16:50

6050 - YL201, a novel B7H3-targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors: Results from a first-in-human phase I study

H. Zhao¹, Y. Ma¹, X. Meng², L. Wu³, Y. Fan⁴, Y. Zheng⁵, Z. Liu⁶, Y. Ji⁷, D. Lv⁸, S. Luo⁹, D. Sommerhalder¹⁰, S. Fu¹¹, Y. Huang¹², Y. Yang¹², W. Fang¹², Y. Zhao¹², Y. Wang⁵, S. Chin¹³, T. Xue¹³, L. Zhang¹², ¹Sun Yat-sen University Cancer Center, Guangzhou, CN, ²Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, CN, ³Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, CN, ⁴Zhejiang Cancer Hospital - Cancer Research Institute, Hangzhou, CN, ⁵The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, CN, ⁶Jiangxi Cancer Hospital, Nanchang, CN, ⁷The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, CN, ⁸Taizhou Hospital of Zhejiang Province, Taizhou, CN, ⁹Henan Cancer Hospital, Zhengzhou, CN, ¹⁰NEXT OncologyTM, San Antonio, US, ¹¹The University of Texas M. D. Anderson Cancer Center, Houston, US, ¹²Sun Yat-Sen University Cancer Center, Guangzhou, CN, ¹³MediLink Therapeutics (Suzhou) Co., Ltd, Suzhou, CN

16:50 - 17:00

6060 - Initial results from a first-in-human study of the B7-H4-directed antibody-drug conjugate (ADC) AZD8205 (puxitatug samrotecan) in patients with advanced/metastatic solid tumors

E. Meric-Bernstam¹, Y. Naito², S. Gaillard³, T. Shimo⁴, V. Chung⁵, A. Davis⁶, T. Proia⁷, A. Ayyoub⁸, M. Kulkarni⁸, S. Upadhyay⁹, N. Miller⁹, N. Luheshi⁹, A. Varga⁹, D.-Y. Oh¹⁰, L. Miles¹¹, ¹University of Texas MD Anderson Cancer Center, Houston, US, ²National Cancer Center Hospital East, Kashiwa, JP, ³Johns Hopkins University, Baltimore, US, ⁴National Cancer Center Hospital, Chuo-ku, JP, ⁵City of Hope Comprehensive Cancer Center, Duarte, US, ⁶Washington University School of Medicine in St. Louis, St. Louis, US, ⁷AstraZeneca, Waltham, US, ⁸AstraZeneca, Gaithersburg, US, ⁹AstraZeneca, Cambridge, GB, ¹⁰Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, KR, ¹¹Peter MacCallum Cancer Centre, Parkville, AU



17:00 - 17:10

6070 - Interim results of a phase I study of SGN-PDL1V (PF-08046054) in patients with PDL1-expressing solid tumors

M. Oliva Bernal¹, S. Ochsenreither², C. Le Tourneau³, S. Champiat⁴, R. Saleh⁵, K. Burkitt⁶, L. Nabell⁷, N. Steeghs⁸, A. Spreafico⁹, A. Minchom¹⁰, A. Patnaik¹¹, J. Call¹², E. Fontana¹³, N. Kotecki¹⁴, E. Garraida¹⁵, A. Zivi¹⁶, J. Riess¹⁷, S. Gupta¹⁸, R. Zhang¹⁸, M. Gillison¹⁹, ¹Institut Catala d'Oncologia - Hospital Duran i Reynals (ICO L'Hospitalet), Hospitalet de Llobregat, ES, ²Charité - Universitätsmedizin Berlin, Berlin, DE, ³Institut Curie, Paris, FR, ⁴Gustave Roussy, Villejuif, Cedex, FR, ⁵McGill University Health Centre - Royal Victoria Hospital, Montreal, CA, ⁶University Hospitals Cleveland Medical Center, Cleveland, US, ⁷University of Alabama at Birmingham, Birmingham, US, ⁸Netherlands Cancer Institute, Amsterdam, Amsterdam, NL, ⁹UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA, ¹⁰The Royal Marsden Hospital, London, London, GB, ¹¹The START Center for Cancer Research, San Antonio, US, ¹²The START Center for Cancer Research, West Valley City, US, ¹³Sarah Cannon Research Institute SCRI UK, London, GB, ¹⁴Institute Jules Bordet, Anderlecht, BE, ¹⁵Hospital Universitari Vall d'Hebron, Barcelona, ES, ¹⁶Azienda Ospedaliera Universitaria Integrata Verona/Centro Ricerche Cliniche di Verona, Verona, IT, ¹⁷UC Davis Comprehensive Cancer Center, Sacramento, US, ¹⁸Pfizer Inc, Bothell, US, ¹⁹University of Texas MD Anderson Cancer Center, Houston, US

17:10 - 17:20

Invited Discussant 6050, 6060 and 6070

L. Siu, Princess Margaret Cancer Centre, Toronto, CA

17:20 - 17:30

Q&A

16:00 - 17:30

Type: Special symposium

Valencia Auditorium - Hall 5

Title: Personalised immunotherapy strategies for head and neck cancers

Chair(s): Amanda Psyrri, GR; Ingeborg Tinhofer-Keilholz, DE

16:00 - 16:05

Introduction and scientific background

A. Psyrri, Attikon University Hospital, Haidari, GR

16:05 - 16:20

Harnessing the immune system as a therapeutic tool in the treatment of head and neck cancers

K. Lauber, LMU - Ludwig Maximilians University of Munich, Munich, DE

16:20 - 16:35

Cell-based immunotherapeutic approaches head and neck cancers

C. Hinrichs, Rutgers Cancer Institute of New Jersey, New Brunswick, US

16:35 - 16:50

Latest developments in virus targeting approaches for the management of head and neck cancers

A. Psyrri, Attikon University Hospital, Haidari, GR

16:50 - 17:05

Personalised anti-tumour vaccines

J.-P. Machiels, Cliniques Universitaires Saint-Luc (UCLouvain Saint-Luc), Woluwe-Saint-Lambert, BE

17:05 - 17:25 **Q&A and discussion**

17:25 - 17:30 **Conclusions and perspectives**

I. Tinhofer-Keilholz, Charité - Universitätsmedizin Berlin, Berlin, DE

16:00 - 17:30 **Type: Mini Oral session** **Pamplona Auditorium - Hall 3**
Title: Mini oral session: NETs and endocrine tumours
 Chair(s): Sophie Leboulleux, CH; Rocio Garcia-Carbonero, ES; Staffan Welin, SE

16:00 - 16:05 **1925MO - Regomune study: A phase II study of regorafenib + avelumab in solid tumors. Results of the radioiodine-refractory differentiated thyroid cancer (RR-DTC)**
Y. Godbert¹, S. Cousin², C. Bellera³, J.-P. Guégan⁴, J. Hadoux⁵, C. Gomez-Roca⁶, P. Cassier⁷, S. Hescot⁸, M. Vinches⁹, C. Cantarel¹⁰, J. Palussière¹¹, M. Kind¹¹, I. Soubeyran¹², A. Bessede⁴, A. Italiano¹, ¹Institute Bergonié - Centre Régional de Lutte Contre le Cancer (CLCC), Bordeaux, FR, ²Institut Bergonie, Bordeaux, FR, ³Univ. Bordeaux, Inserm, Bordeaux, FR, ⁴Explicyte, Bordeaux, FR, ⁵Institut Gustave Roussy, Villejuif, Cedex, FR, ⁶IUCT - Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, Cedex, FR, ⁷Centre Léon Bérard, Lyon, FR, ⁸Institut Curie, Paris, FR, ⁹ICM - Institut du Cancer de Montpellier, Montpellier, Cedex, FR, ¹⁰Inserm CIC1401, Bordeaux, FR, ¹¹Institut Bergonié, Bordeaux, FR, ¹²Institute Bergonié, Bordeaux, FR

16:05 - 16:10 **1926MO - Radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) patients treated with lenvatinib monotherapy: Real-world treatment patterns and clinical outcomes in Europe and Canada**
L. Locati¹, T. Alonso Gordo², L. Lamartina³, M. Luster⁴, O. Rajkovic-Hooley⁵, N. Reynolds⁵, G. Milligan⁵, C. Cooper⁵, I. Brown⁶, H. Saal⁷, J. Borbolla Escoboza⁷, K. Newbold⁸, ¹University of Pavia, Pavia, IT, ²Ramón y Cajal University Hospital, Madrid, ES, ³Gustave Roussy - Cancer Campus, Villejuif, FR, ⁴University Hospital Marburg, Marburg, DE, ⁵Adelphi Real World, Bollington, GB, ⁶Eisai Europe Ltd. (UK), Hatfield, GB, ⁷Eisai Inc., Nutley, US, ⁸The Royal Marsden Hospital - Chelsea, London, GB

16:10 - 16:25 **Invited Discussant 1925MO and 1926MO**
S. Leboulleux, HUG - Hopitaux Universitaires de Geneve, Geneva, CH

16:25 - 16:30 **1145MO - CVM-005: Phase IIa study of CVM-1118, a novel oral anti-vasculogenic mimicry (VM) agent, in advanced neuroendocrine tumors (NET) after progression on prior therapy**
C.J. Yen¹, M.-H. Chen², Y.Y. Chen³, L.-Y. Bai⁴, J.-S. Chen⁵, J.C.-H. Hsieh⁶, Y.-H. Shih⁷, I.-C. Wu⁸, Y.-L. Chen⁹, C.-M. Chen⁹, T.-Y. Chao⁹, Y.-W. Chu⁹, D.-S. Chien⁹, ¹National Cheng Kung University Hospital, Tainan City, TW, ²Taipei Veterans General Hospital, Taipei City, TW, ³Chang Gung Medical Foundation - Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City, TW, ⁴China Medical University Hospital, Taichung City, TW, ⁵Chang Gung Medical Foundation - Linkou Chang Gung Memorial Hospital, Taoyuan City, TW, ⁶New Taipei Municipal Tucheng Hospital, New Taipei City, TW, ⁷Taichung Veterans General Hospital, Taichung City, TW, ⁸Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City, TW, ⁹TaiRx, Inc., Taipei City, TW



16:30 - 16:35

1146MO - Interim analysis of CABONEN: A multicenter phase II trial investigating cabozantinib in patients with advanced, low proliferative NEN G3

A.O. Koenig¹, J. Reinecke¹, J. Halfen², K. Lang², U. König¹, R. Tostmann², N. Kirchhof², T. Asendorf², D. Hörsch³, A. Kröcher⁴, M. Quante⁵, V. Ellenrieder¹, N. Schulte⁶, T. Wirth⁷, A. Weich⁸, L. Apostolidis⁹, S. Krug¹⁰, A. Rinke¹¹, M. Pavel¹², ¹Universitätsmedizin Göttingen, Goettingen, DE, ²UMG - Universitätsmedizin Göttingen, Göttingen, DE, ³Zentralklinik Bad Berka GmbH, Bad Berka, DE, ⁴Dresden University, Dresden, DE, ⁵Universitätsklinikum Freiburg - Klinik für Innere Medizin II, Freiburg im Breisgau, DE, ⁶Zentrum für Geriatrische Onkologie und Biologie in der Metropolregion Rhein Neckar (ZOBEL), Mannheim, DE, ⁷MHH - Medizinische Hochschule Hannover, Hannover, DE, ⁸UKW - University Hospital Würzburg, Würzburg, DE, ⁹National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg, DE, ¹⁰University Hospital Heidelberg, Heidelberg, DE, ¹¹UKGM - Uniklinikum Giessen und Marburg - Standort Marburg, Marburg, DE, ¹²Universitätsklinikum Erlangen - Medizinische Klinik 1, Erlangen, DE

16:35 - 16:40

1147MO - Ramucirumab in combination with dacarbazine in patients with progressive well-differentiated metastatic pancreatic neuroendocrine tumors (RamuNET): An AIO phase II multicenter single-arm study

S. Krug¹, L. Apostolidis², A.O. Koenig³, A. Rinke⁴, J. Schrader⁵, T. Ettrich⁶, H. Jann⁷, M. Oberbeck⁸, D. Hörsch⁹, T. Gress⁴, T. Kegel¹⁰, M. Richter¹¹, S. Behl⁸, J. Steighardt¹¹, P. Michl¹², ¹University Hospital Heidelberg, Heidelberg, DE, ²National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg, DE, ³Universitätsmedizin Göttingen, Goettingen, DE, ⁴UKGM - Uniklinikum Giessen und Marburg - Standort Marburg, Marburg, DE, ⁵University Hospital Hamburg, Hamburg, DE, ⁶University Hospital Of Ulm - Oberer Eselsberg, Ulm, DE, ⁷Universitätsklinik Charité, Campus Virchow Klinikum, Berlin, DE, ⁸University Hospital Halle/Saale, Halle/Saale, DE, ⁹Zentralklinik Bad Berka GmbH, Bad Berka, DE, ¹⁰UKH - Universitätsklinikum Halle (Saale), Halle (Saale), DE, ¹¹University of Halle/Saale, Halle, DE, ¹²UKHD - Universitätsklinikum Heidelberg, Heidelberg, DE

16:40 - 16:55

Invited Discussant 1145MO, 1146MO and 1147MO

R. Garcia-Carbonero, University Hospital 12 De Octubre, Madrid, ES

16:55 - 17:00

1148MO - A multivariate efficacy analysis of [177Lu]Lu-DOTA-TATE in the NETTER 2 study

M. Pavel¹, D. Ferone², D. Halperin³, S. Myrehaug⁴, K. Herrmann⁵, P. Kunz⁶, B. Chasen³, J. Capdevila Castillon⁷, S. Tafuto⁸, D.-Y. Oh⁹, C. Yoo¹⁰, S. Falk¹¹, T. Halfdanarson¹², I. Folitar¹³, Y. Zhang¹⁴, W. De Herder¹⁵, S. Singh⁴, ¹Uniklinikum Erlangen, Friedrich Alexander University Erlangen-Nuernberg, Erlangen, DE, ²IRCCS Policlinico San Martino and DiMI, University of Genova, Genova, IT, ³MD Anderson Cancer Center, Houston, US, ⁴Sunnybrook Odette Cancer Center, Toronto, CA, ⁵University of Duisburg-Essen, and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, DE, ⁶Yale University, New Haven, US, ⁷Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, ⁸Istituto Nazionale Tumori IRCCS, Fondazione G. Pascale, Naples, IT, ⁹Cancer Research Institute, Seoul National University College of Medicine, Seoul, KR, ¹⁰University of Ulsan College of Medicine, Seoul, KR, ¹¹University Hospitals Bristol NHS Foundation Trust, Bristol, GB, ¹²Mayo Clinic, Rochester, US, ¹³Novartis Pharma AG, Basel, CH, ¹⁴Novartis Pharmaceuticals Corp, East Hanover, US, ¹⁵Erasmus MC, Rotterdam, NL

17:00 - 17:05 **1149MO - Carcinoid heart disease in patients with advanced small-intestinal neuroendocrine tumours and carcinoid syndrome: A retrospective experience of two centers of excellence**

L. Algeri¹, L. Falkman², F. Spada¹, V. Bagnardi³, S. Frassoni³, S. Boselli¹, D. Cardinale⁴, M. Zanobini⁵, J. Crona², L. Benini¹, D. Tamayo¹, A. Russo⁶, G. Badalamenti⁶, S. Welin², N. Fazio¹,
¹European Institute of Oncology (IEO), IRCCS, Milan, IT, ²Uppsala University Hospital, Uppsala, SE,
³University of Milano-Bicocca, Milan, IT, ⁴IEO - Istituto Europeo di Oncologia IRCCS, Milan, IT,
⁵Centro Cardiologico Monzino, Milan, IT, ⁶University of Palermo, Palermo, IT

17:05 - 17:20 **Invited Discussant 1148MO and 1149MO**

S. De Dosso, EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, CH

16:00 - 17:00 **Type: Special session** **Oviedo Auditorium - Hall 3**
Title: ESMO Virtual Plenary revisited
 Chair(s): Michail Ignatiadis, BE; David Planchard, FR; Ilaria Colombo, CH

16:00 - 16:05 **Introduction**

16:05 - 16:17 **VP5-2023: Primary results from BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030), a randomised phase III trial of first-line atezolizumab (atezo) combined with a platinum doublet and bevacizumab (bev) for metastatic (stage IVB), persistent or recurrent cervical cancer (R/M CC)**

L. Randall, Virginia Commonwealth University Medical College of Virginia Campus, Richmond, US

16:17 - 16:29 **VP1-2024: RATIONALE-315: Event-free survival (EFS) and overall survival (OS) of neoadjuvant tislelizumab (TIS) plus chemotherapy (CT) with adjuvant TIS in resectable non-small cell lung cancer (NSCLC)**

D. Yue, TMUCIH - Tianjin Medical University Cancer Institute and Hospital, Tianjin, CN

16:29 - 16:41 **VP2-2024: Fuzuloparib with or without apatinib in HER2- metastatic breast cancer (mBC) patients (pts) with germline BRCA1/2 mutations (gBRCA1/2m): A randomized phase III trial**

H. Li, Peking University Cancer Hospital and Institute, Beijing, CN

16:41 - 17:00 **Q&A and discussion with the investigators**

16:00 - 17:30 **Type: Educational session** **Zaragoza Auditorium - CC5**
Title: The dark age of single cancer screening is over
 Chair(s): Dario Trapani, IT; Nadir Arber, IL

16:00 - 16:25 **Prevention**

R. Benamouzig, Hopital Avicenne AP-HP, Bobigny, FR

16:25 - 16:50 **Multi-cancer early detection tests: Caveats and future potential**

C. Swanton, Francis Crick Institute, London, GB

16:50 - 17:15 **Integrated Cancer Prevention Center: One Stop Shop**
N. Arber, Tel Aviv Sourasky Medical Center-(Ichilov), Tel Aviv, IL

17:15 - 17:30 **Q&A and discussion**

16:00 - 18:00 **Type: Special session** **Cartagena Auditorium - Hall 7**
Title: 9th ESMO Designated Centres of Integrated Oncology and Palliative Care session and awards: Specific considerations for integration of oncology and palliative care
 Chair(s): Jayne Wood, GB; Anna Reyners, NL

16:00 - 16:05 **Introduction**
J. Wood, The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, GB

16:05 - 16:15 **DC stratification survey**
J. Wood, The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, GB

16:15 - 16:30 **Time toxicity of cancer treatment**
R. Giusti, AOU Sant'Andrea, Rome, IT

16:30 - 16:35 **Q&A**

16:35 - 16:50 **Early, integrated palliative care in older adults with cancer**
G. Liposits, Regional Hospital West Jutland, Herning, DK

16:50 - 16:55 **Q&A**

16:55 - 17:10 **Socioeconomic disparities in delivery of specialized palliative care at the end of life**
C. Zimmermann, UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA

17:10 - 17:15 **Q&A**

17:15 - 17:35 **Session conclusion and outline of next steps: DC community panel discussion**
A. Reyners, UMCG - University Medical Center Groningen, Groningen, NL

17:35 - 18:00 **Designated Centres Awards**
A. Reyners¹, J. Wood², ¹UMCG - University Medical Center Groningen, Groningen, NL, ²The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, GB



16:00 - 17:30	Type: Young Oncologists session Title: YO Mentorship session Chair(s): Deniz Can Guven, TR; Angelika Starzer, AT	Tarragona Auditorium - Hall 7
16:00 - 16:00	Career path: Tertiary or district hospital <u>L. Popovic</u> , Oncology Institute of Vojvodina, Sremska Kamenica, RS	
16:00 - 16:00	Career path: Academia <u>A.H. Partridge</u> , Dana Farber Cancer Institute, Boston, US	
16:00 - 16:00	Career path: Academia <u>M. Di Maio</u> , Azienda Ospedaliera Ordine Mauriziano - Presidio Umberto I, Torino, IT	
16:00 - 16:00	Career path: Clinician scientist <u>S. Turajlic</u> , The Royal Marsden Hospital - Chelsea, London, GB	
16:00 - 16:00	Career path: Clinician scientist <u>J. Mateo</u> , Vall d'Hebron University Hospital, Barcelona, ES	
16:00 - 16:00	Career path: Clinical trialist – Early and late phase clinical trials <u>G. Curigliano</u> , IEO - Istituto Europeo di Oncologia, Milan, IT	
16:00 - 16:00	Career path: Policy making and public health <u>J. Tabernero</u> , Vall d'Hebron University Hospital, Barcelona, ES	
16:00 - 16:00	Career path: Industry <u>N. Denduluri</u> , AstraZeneca, Gaithersburg, US	
16:00 - 16:00	Clinics and research in LMIC <u>B. Gyawali</u> , KAHS - Karnali Academy of Health Sciences, Chandannath, NP	
16:00 - 16:20	EONS: Cancer nurses <u>J. De Munter</u> , UZ Gent - Universitair Ziekenhuis Gent, Gent, BE	
16:20 - 16:40	W4O <u>H. Linardou</u> , Metropolitan Hospital, Athens, GR	
18:00 - 19:30	Type: Industry Satellite Symposium Title: Johnson & Johnson - Optimising the personalisation of GU cancer care Chair(s): Patrizia Giannatempo, IT; Alison Birtle, GB	Santander Auditorium - Hall 5
18:00 - 18:10	Welcome and Introduction <u>P. Giannatempo</u> ¹ , <u>A. Birtle</u> ² , ¹ Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ² Royal Preston Hospital, Preston, GB	



- 18:10 - 18:18 **Unveiling real-world evidence: Exploring the PSA Response in mHSPC**
A. Birtle, Royal Preston Hospital, Preston, GB
- 18:18 - 18:26 **Efficacy and QoL in mHSPC – finding the right balance**
A. Rodriguez-Vida, Hospital del Mar - Parc de Salut Mar, Barcelona, ES
- 18:26 - 18:34 **The significance of BRCA1/2 mutations in mCRPC outcomes**
E. Verzoni, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT
- 18:34 - 18:47 **Panel discussion**
P. Giannatempo¹, A. Birtle², A. Rodriguez-Vida³, E. Verzoni¹, ¹Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ²Royal Preston Hospital, Preston, GB, ³Hospital del Mar - Parc de Salut Mar, Barcelona, ES
- 18:47 - 18:59 **The evolving patient pathway in mUC: What do the changing guidelines mean for treatment sequencing?**
S. Crabb, Southampton General Hospital, Southampton, GB
- 18:59 - 19:12 **FGFR testing: Why, how, when?**
V. Gruenwald, University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE
- 19:12 - 19:24 **Optimising patient care: Managing adverse events**
S. Crabb¹, V. Gruenwald², ¹Southampton General Hospital, Southampton, GB, ²University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE
- 19:24 - 19:30 **Summary and Close**
P. Giannatempo¹, A. Birtle², ¹Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ²Royal Preston Hospital, Preston, GB

18:00 - 19:30 Type: Industry Satellite Symposium Valencia Auditorium - Hall 5
Title: Pfizer Oncology - Breaking new ground: PARPi + ARPi combination therapy in mCRPC
Chair(s): Neal Shore, US

- 18:00 - 18:10 **Welcome and Introductions**
N. Shore, Atlantic Urology Clinics, LLC, Myrtle Beach, US
- 18:10 - 18:30 **Beyond BRCA: examining the evidence for novel PARPi combinations in mCRPC**
A. Merseburger, UKSH - Universitätsklinikum Schleswig-Holstein - Campus Lübeck, Lübeck, DE
- 18:30 - 18:50 **Harnessing the potential of HRR gene profiling to inform treatment decisions**
E. Efsthathiou, Houston Methodist, houston, US



18:50 - 19:15 **Patient-centered approaches - who should we treat with PARPi and how?**
N. Shore¹, A. Merseburger², E. Efstathiou³, ¹Atlantic Urology Clinics, LLC, Myrtle Beach, US,
²UKSH - Universitätsklinikum Schleswig-Holstein - Campus Lübeck, Lübeck, DE, ³Houston
 Methodist, houston, US

19:15 - 19:25 **Q&A**
N. Shore¹, A. Merseburger², E. Efstathiou³, ¹Atlantic Urology Clinics, LLC, Myrtle Beach, US,
²UKSH - Universitätsklinikum Schleswig-Holstein - Campus Lübeck, Lübeck, DE, ³Houston
 Methodist, houston, US

19:25 - 19:30 **Conclusion**
N. Shore, Atlantic Urology Clinics, LLC, Myrtle Beach, US

18:00 - 19:30 **Type: Industry Satellite Symposium** **Alicante Auditorium - Hall 3**
Title: Gilead Oncology - The Journey of ADCs in Metastatic NSCLC: Past, Present and Future
 Chair(s): Sanjay Popat, GB

18:00 - 18:05 **Welcome and Introduction - The Journey of ADCs in Metastatic NSCLC: Past, Present and Future**
S. Popat, The Royal Marsden Hospital - NHS Foundation Trust, London, GB

18:05 - 18:20 **The Unmet Needs and Limitations of Current Treatment Options in Metastatic NSCLC**
D. Planchard, Institut Gustave Roussy, Villejuif, Cedex, FR

18:20 - 18:50 **ADCs in Metastatic NSCLC**
M. Garassino, University of Chicago Department of Medicine - Section of Hematology/Oncology, Chicago, US

18:50 - 19:15 **The future of ADCs in Lung Cancer**
M. Johnson, Sarah Cannon Research Institute-Cancer Centre, Nashville, US

19:15 - 19:30 **Panel discussion and Q&A**
S. Popat¹, D. Planchard², M. Johnson³, M. Garassino⁴, ¹The Royal Marsden Hospital - NHS Foundation Trust, London, GB, ²Institut Gustave Roussy, Villejuif, Cedex, FR, ³Sarah Cannon Research Institute-Cancer Centre, Nashville, US, ⁴University of Chicago Department of Medicine - Section of Hematology/Oncology, Chicago, US

18:00 - 19:30 **Type: Industry Satellite Symposium** **Pamplona Auditorium - Hall 3**
Title: Servier - Advancements in Metastatic Pancreatic Cancer: Which perspectives for patients?
 Chair(s): Eric Van Cutsem, BE; Teresa Macarulla Mercade, ES

18:00 - 18:05 **Introduction**
E. Van Cutsem, UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE



- 18:05 - 18:20 **Navigating the latest news and guidelines in Metastatic Pancreatic Cancer**
G. Prager, Universitätskliniken der MedUni Wien - AKH Wien, Vienna, AT
- 18:20 - 18:40 **Integrating new data into current clinical practice: Key learnings from Napoli 3 study**
T. Macarulla Mercade, Vall d'Hebron Institute of Oncology - Cellex Center, Barcelona, ES
- 18:40 - 18:55 **Focusing on long term benefits: insights from NALLONG study**
J.-L. Van Laethem, Erasme University Hospital-(Universite Libre de Bruxelles), Brussels, BE
- 18:55 - 19:05 **Exploring Recent Clinical Data: Perspectives from the Japanese Experience**
M. Ikeda, National Cancer Center Hospital East, Kashiwa, JP
- 19:05 - 19:25 **Panel discussion**
E. Van Cutsem¹, T. Macarulla Mercade², G. Prager³, J.-L. Van Laethem⁴, M. Ikeda⁵, ¹UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ²Vall d'Hebron Institute of Oncology - Cellex Center, Barcelona, ES, ³Universitätskliniken der MedUni Wien - AKH Wien, Vienna, AT, ⁴Erasme University Hospital-(Universite Libre de Bruxelles), Brussels, BE, ⁵National Cancer Center Hospital East, Kashiwa, JP
- 19:25 - 19:30 **Conclusion**
T. Macarulla Mercade, Vall d'Hebron Institute of Oncology - Cellex Center, Barcelona, ES

18:00 - 19:30 **Type: Industry Satellite Symposium** **Oviedo Auditorium - Hall 3**
Title: AstraZeneca - Strategies in motion: improving NSCLC patient care across all stages
Chair(s): Martin Reck, DE; Lizza Hendriks, NL

- 18:00 - 18:10 **Welcome address: charting a path forward in NSCLC care**
M. Reck¹, L. Hendriks², ¹LungenClinic Grosshansdorf, Grosshansdorf, DE, ²Maastricht University Medical Center (MUMC), Maastricht, NL
- 18:10 - 18:23 **Resectable NSCLC: navigating an expanding treatment landscape**
M. Reck, LungenClinic Grosshansdorf, Grosshansdorf, DE
- 18:23 - 18:36 **Unresectable NSCLC: guiding treatment decisions to optimise outcomes**
A.R. Filippi, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT
- 18:36 - 18:48 **Expert perspectives on early-stage NSCLC: Panel discussion and live Q&A**
M. Reck¹, L. Hendriks², ¹LungenClinic Grosshansdorf, Grosshansdorf, DE, ²Maastricht University Medical Center (MUMC), Maastricht, NL
- 18:48 - 19:01 **Metastatic EGFRm NSCLC: re-defining possibilities through emerging therapies**
L. Hendriks, Maastricht University Medical Center (MUMC), Maastricht, NL

19:01 - 19:14 **Metastatic NSCLC without actionable genomic alterations: addressing unmet needs in care**

N. Reinmuth, Asklepios-Fachklinikum, Gauting, DE

19:14 - 19:26 **Expert perspectives on metastatic NSCLC: Panel discussion and live Q&A**

M. Reck, LungenClinic Grosshansdorf, Grosshansdorf, DE

19:26 - 19:30 **Closing Remarks**

L. Hendriks¹, M. Reck², ¹Maastricht University Medical Center (MUMC), Maastricht, NL,
²LungenClinic Grosshansdorf, Grosshansdorf, DE

18:00 - 19:30 **Type: Industry Satellite Symposium** **Toledo Auditorium - Hall 3**
Title: Stemline. A Menarini Group - Treatment Strategies and Sequencing After ET + CDK4/6i for Patients with ER+/HER2- Advanced Breast Cancer
Chair(s): Peter Schmid, GB

18:00 - 18:10 **Introduction**

P. Schmid, Cancer Research UK Barts Centre - Barts and The London School of Medicine and Dentistry, London, GB

18:10 - 18:30 **Treatment Landscape for ER+/HER2- Advanced Breast Cancer**

V. Kaklamani, Mays Cancer Center - UT Health San Antonio MD Anderson Cancer Center, San Antonio, US

18:30 - 18:50 **Emerging Biomarkers in Breast Cancer**

F. Marmé, UMM - Universitaetsklinikum Mannheim - Medizinische Fakultät, Mannheim, DE

18:50 - 19:00 **Key Takeaways**

P. Schmid, Cancer Research UK Barts Centre - Barts and The London School of Medicine and Dentistry, London, GB

19:00 - 19:30 **Discussion and Q&A**

P. Schmid¹, V. Kaklamani², F. Marmé³, ¹Cancer Research UK Barts Centre - Barts and The London School of Medicine and Dentistry, London, GB, ²Mays Cancer Center - UT Health San Antonio MD Anderson Cancer Center, San Antonio, US, ³UMM - Universitaetsklinikum Mannheim - Medizinische Fakultät, Mannheim, DE



14.09.2024

08:30 - 10:00

Type: Proffered Paper session

Barcelona Auditorium - Hall 2

Title: Proffered paper session: NSCLC metastatic

Chair(s): Benjamin Besse, FR; Marina Garassino, US

08:30 - 08:40

LBA52 - Interim analysis of GALAXIES Lung-201: Phase II, randomized, open-label platform study of belrestotug plus dostarlimab in patients (pts) with previously untreated locally advanced/metastatic (LA/M) PD-L1 high (TPS ≥50%) non-small cell lung cancer (NSCLC)

D.R. Spigel¹, E. Korbenfeld², H. Hayashi³, R. Corre⁴, B.C. Cho⁵, A. Psyrri⁶, M. Cobo Dols⁷, E. Parkhomenko⁸, D. Baxter⁹, N. Patel⁸, F. Trinchese¹⁰, I. Diaz-Padilla¹⁰, M. Reck¹¹, ¹Sarah Cannon Research Institute, Nashville, US, ²Hospital Britanico de Buenos Aires, Buenos Aires, AR, ³Kindai University Faculty of Medicine, Osaka, JP, ⁴CH Quimper, Quimper, Cedex, FR, ⁵Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, KR, ⁶National and Kapodistrian University of Athens, Attikon University Hospital, Athens, GR, ⁷Regional and Virgen de la Victoria University Hospitals, IBIMA, Malaga, ES, ⁸GSK, Stevenage, GB, ⁹GSK, Collegeville, US, ¹⁰GSK, Baar, CH, ¹¹LungenClinic, Grosshansdorf, DE

08:40 - 08:50

LBA53 - Nivolumab (NIVO) plus relatlimab with platinum-doublet chemotherapy (PDCT) vs NIVO ± PDCT as first-line (1L) treatment (tx) for stage IV or recurrent NSCLC: Results from the randomized phase II RELATIVITY-104 study

N. Girard¹, M. Burotto², L. Paz-Ares³, M. Reck⁴, M. Schenker⁵, A. Lingua⁶, F.J. Orlandi⁷, J. Naidoo⁸, E. Beardley⁹, V. Velcheti¹⁰, G. Martinengo¹¹, E. Felip¹², Y. Zhang¹³, P. Kasbekar¹³, M. Chowdhury¹³, T. Spires¹³, A. Tendolkar¹³, M. Cobo Dols¹⁴, ¹Institut Curie, Paris, FR, ²Bradford Hill Centro de Investigación Clínica, Santiago, CL, ³Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid, Madrid, ES, ⁴Airway Research Center North, German Center for Lung Research LungClinic, Grosshansdorf, DE, ⁵SF Nectarie Oncology Center, Craiova, RO, ⁶Instituto Médico Río Cuarto, Río Cuarto, AR, ⁷Orlandi Oncología, Providencia, CL, ⁸Beaumont Hospital, RCSI University of Health Sciences, Dublin, IE, ⁹Frankston Hospital -- Peninsula Health, Frankston, AU, ¹⁰NYU Perlmutter Cancer Center (Long Island), New York, US, ¹¹Sanatorio Parque SA, Rosario, AR, ¹²Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, ES, ¹³Bristol-Myers Squibb, Princeton, US, ¹⁴Hospital Regional Universitario (Carlos Haya), Málaga, ES

08:50 - 09:00

Invited Discussant LBA52 and LBA53

M. Garassino, University of Chicago Department of Medicine - Section of Hematology/Oncology, Chicago, US

09:00 - 09:10

Q&A



09:10 - 09:20

LBA54 - Amivantamab plus chemotherapy vs chemotherapy in EGFR-mutated, advanced non-small cell lung cancer after disease progression on osimertinib: Second interim overall survival from MARIPOSA-2

S. Popat¹, K. Reckamp², R. Califano³, S.-H. Lee⁴, B. Melosky⁵, J. Wang⁶, Y. Wang⁷, M.R. García Campelo⁸, E. Felip⁹, N. Girard¹⁰, R. Gentzler¹¹, W. Nassib William Junior¹², T. Takahashi¹³, M. Nagasaka¹⁴, J. Bauml¹⁵, S. Shah¹⁵, B. Diorio¹⁶, P.-L. Chu¹⁷, B.C. Cho¹⁸, A. Passaro¹⁹, ¹Royal Marsden Hospital NHS Foundation Trust and The Institute of Cancer Research, London, GB, ²Cedars-Sinai Medical Center, Los Angeles, US, ³The Christie NHS Foundation Trust and Division of Cancer Sciences, The University of Manchester, Manchester, GB, ⁴Sungkyunkwan University School of Medicine, Seoul, KR, ⁵British Columbia Cancer Agency, Vancouver, CA, ⁶Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN, ⁷West China Hospital of Sichuan University, Chengdu, Sichuan, CN, ⁸Hospital Universitario A Coruña, A Coruña, ES, ⁹Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona, Barcelona, ES, ¹⁰Institut du Thorax Curie-Montsouris, Paris, France; Paris Saclay University, Université de Versailles Saint-Quentin-en-Yvelines, Île-de-France, Paris, FR, ¹¹University of Virginia Cancer Center, Charlottesville, US, ¹²Beneficência Portuguesa de São Paulo, and Grupo Oncoclínicas, São Paulo, BR, ¹³Shizuoka Cancer Center, Nagaizumi, JP, ¹⁴University of California Irvine School of Medicine, Orange, US, ¹⁵Janssen Research & Development, Spring House, US, ¹⁶Janssen Research & Development, Raritan, US, ¹⁷Janssen Research & Development, Titusville, US, ¹⁸Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, KR, ¹⁹European Institute of Oncology IRCCS, Milan, IT

09:20 - 09:30

LBA55 - Mechanisms of acquired resistance to first-line amivantamab plus lazertinib versus osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer: An early analysis from the phase III MARIPOSA study

B. Besse¹, S.-H. Lee², S. Lu³, D. Stroyakovskiy⁴, O. Yazici⁵, J. Rodriguez Cid⁶, H. Hayashi⁷, D. Nguyen⁸, J.C.-H. Yang⁹, M. Gottfried¹⁰, A.C. Gelatti¹¹, S. Owen¹², S.-H. Ou¹³, M. Ennis¹⁴, S. Sethi¹⁴, J. Bauml¹⁴, J. Zhang¹⁴, J. Curtin¹⁴, B.C. Cho¹⁵, ¹Paris-Saclay University, Gustave Roussy, Villejuif, FR, ²Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, ³Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, CN, ⁴Moscow City Oncology Hospital No. 62, Moscow, RU, ⁵Gazi University Faculty of Medicine, Ankara, TR, ⁶Médica Sur Ciudad de México, Ciudad de México, MX, ⁷Kindai University Faculty of Medicine, Osaka, JP, ⁸City of Hope National Medical Center, Duarte, US, ⁹National Taiwan University Cancer Center, Taipei, TW, ¹⁰Meir Medical Center, Kfar-Saba, IL, ¹¹Hospital Sao Lucas da PUCRS, Porto Alegre-RS, BR, ¹²McGill University Health Centre, Cedars Cancer Centre, Montreal, CA, ¹³Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, US, ¹⁴Janssen Research & Development, Spring House, US, ¹⁵Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, KR



09:30 - 09:40

12530 - Phase I/II ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumours

A. Drilon¹, J. Lin², M. Johnson³, C. Baik⁴, L. Paz-Ares⁵, B. Besse⁶, J. Mazieres⁷, A. Swalduz⁸, A. Minchom⁹, J. Reuss¹⁰, S. Gadgeel¹¹, J. Riess¹², G. Liu¹³, B. Solomon¹⁴, D.R. Camidge¹⁵, W. Swe¹⁶, Y. Sun¹⁶, J. Shen¹⁶, V. Zhu¹⁶, E. Felip¹⁷, ¹Memorial Sloan Kettering Cancer Center & Weill Cornell Medical College, New York, US, ²Massachusetts General Hospital, Boston, US, ³Sarah Cannon Research Institute-Cancer Centre, Nashville, US, ⁴Fred Hutchinson Cancer Center, Seattle, US, ⁵Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid, Madrid, ES, ⁶Institut Gustave Roussy, Villejuif, Cedex, FR, ⁷Institut Claudius Rigaud, Toulouse, FR, ⁸Centre Léon Bérard, Lyon, FR, ⁹The Royal Marsden Hospital, London, GB, ¹⁰Lombardi Cancer Center Georgetown University, Washington, US, ¹¹Henry Ford Cancer Center/Henry Ford Health, Detroit, US, ¹²UC Davis Comprehensive Cancer Center, Sacramento, US, ¹³Princess Margaret Cancer Center, Toronto, CA, ¹⁴Peter MacCallum Cancer Center, Melbourne, AU, ¹⁵University of Colorado Cancer Center, Aurora, US, ¹⁶Nuvalent, Inc., Cambridge, US, ¹⁷Vall d'Hebron Institute of Oncology, Universitat Autònoma, Barcelona, ES

09:40 - 09:50

Invited Discussant LBA54, LBA55 and 12530

J. Wolf, Universitätsklinikum Köln (AöR), Cologne, DE

09:50 - 10:00

Q&A

08:30 - 10:00

Type: Proffered Paper session

Madrid Auditorium - Hall 2

Title: Proffered paper session 2: GI tumours, upper digestive

Chair(s): Tania Fleitas, ES; Filippo Pietrantonio, IT

08:30 - 08:40

LBA58 - A randomized phase III trial of perioperative chemotherapy (periop CT) with or without preoperative chemoradiotherapy (preop CRT) for resectable gastric cancer (AGITG TOPGEAR): Final results from an intergroup trial of AGITG, TROG, EORTC and CCTG

T. Leong¹, B. Smithers², M. Michael¹, K. Haustermans³, R. Wong⁴, V. GebSKI⁵, R. Oconnell⁶, J. Zalcbberg⁷, A. Boussioutas⁸, M. Findlay⁹, D. Willis¹⁰, A. Moore¹¹, F. Lordick¹², C. O'Callaghan¹³, C. Swallow¹⁴, G. Darling¹⁵, A. Strickland¹⁶, M. Liberman¹⁷, L. Mineur¹⁸, J. Simes⁵, ¹Peter MacCallum Cancer Centre, Melbourne, AU, ²University of Queensland - School of Medical Sciences, St Lucia, AU, ³UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ⁴Princess Margaret Hospital, Toronto, CA, ⁵University of Sydney, Sydney, AU, ⁶NHMRC Clinical Trials Centre, Camperdown, AU, ⁷Alfred Hospital, Melbourne, AU, ⁸Monash University, Clayton, AU, ⁹University of Auckland Faculty of Medical & Health Sciences, Auckland, NZ, ¹⁰Sunshine Coast University Hospital, Birtinya, AU, ¹¹Trans Tasman Radiation Oncology Group, Waratah, AU, ¹²Universitätsklinikum Leipzig - Universitäres Krebszentrum Leipzig, Leipzig, DE, ¹³Canadian Cancer Trials Group, Kingston, CA, ¹⁴Mount Sinai Hospital, Toronto, CA, ¹⁵Department of Surgery Dalhousie University Halifax Canada, Halifax, CA, ¹⁶Monash Health - Monash Medical Centre, Clayton, AU, ¹⁷Centre Hospitalier de Université to Montréal (CHUM), Montreal, CA, ¹⁸Institut du Cancer Avignon-Provence - Sainte-Catherine, Avignon, FR



08:40 - 08:50

LBA59 - Modified FOLFOX plus/minus nivolumab and ipilimumab vs FLOT plus nivolumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Final results of the IKF-AIO-Moonlight trial

S. Lorenzen¹, T. Goetze², P. Thuss-Patience³, J. Riera Knorrenschild⁴, E. Goekkurt⁵, T. Dechow⁶, T. Ettrich⁷, R.D. Hofheinz⁸, K. Luley⁹, D. Pink¹⁰, U. Lindig¹¹, G. Folprecht¹², G. Schuch¹³, M. Bitzer¹⁴, V. Heinemann¹⁵, S. Angermeier¹⁶, C. Bolling¹⁷, S. Junge², C. Paulig², S.-E. Al-Batran², ¹Klinikum Rechts der Isar - Technische Universität München, Munich, DE, ²Frankfurter Institut für Klinische Krebsforschung IKF GmbH, Frankfurt am Main, DE, ³Charité - Universitätsmedizin Berlin, Berlin, DE, ⁴Universitätsklinikum Marburg, Marburg, DE, ⁵Hämatologisch-Onkologische Praxis Eppendorf HOPE, Hamburg, DE, ⁶Onkologie Ravensburg, Ravensburg, DE, ⁷Ulm University Hospital, Ulm, DE, ⁸Universitätsmedizin Mannheim, Mannheim, DE, ⁹University Hospital Schleswig-Holstein, Lübeck, DE, ¹⁰Universität Greifswald Klinik und Poliklinik für Innere Medizin C, Hämatologie und Onkologie, Transplantationszentrum, Palliativmedizin, Bad Saarow, DE, ¹¹Universitätsklinikum Jena, Jena, DE, ¹²Universitätsklinikum Carl Gustav Carus Dresden, Dresden, DE, ¹³Hämatologisch-Onkologische Praxis Altona, Hamburg, DE, ¹⁴University Hospital Tübingen, Tübingen, DE, ¹⁵LMU Klinikum, Munich, DE, ¹⁶Klinikum Ludwigsburg, Ludwigsburg, DE, ¹⁷Agaplesion Markus Krankenhaus, Frankfurt am Main, DE

08:50 - 09:00

Invited Discussant LBA58 and LBA59

T. Fleitas, Hospital Clinico Universitario de Valencia, Valencia, ES

09:00 - 09:15

Q&A

09:15 - 09:25

14000 - Final overall survival for the phase III, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2⁺ advanced, unresectable or metastatic G/GEJ adenocarcinoma

Y. Janjigian¹, A. Kawazoe², Y. Bai³, J. Xu⁴, S. Lonardi⁵, J.-P. Metges⁶, P. Yanez Weber⁷, L. Wyrwicz⁸, L. Shen⁹, Y. Ostapenko¹⁰, M. Bilici¹¹, H.C. Chung¹², K. Shitara², M. Mahave¹³, E. Van Cutsem¹⁴, J. Tabernero¹⁵, L. Xu¹⁶, K. Sharan¹⁶, P. Bhagia¹⁶, S.Y. Rha¹², ¹MSKCC - Memorial Sloan Kettering Cancer Center, New York, US, ²National Cancer Center Hospital East, Kashiwa, JP, ³Harbin Medical University, Harbin, CN, ⁴The Fifth Medical Center of Chinese PLA General Hospital/Beijing 302 Hospital, Beijing, CN, ⁵IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, ⁶University Hospital of Brest, Brest, FR, ⁷Clinica Alemana de Temuco S.A., Temuco, CL, ⁸Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, PL, ⁹Peking University Cancer Hospital and Institute, Beijing, CN, ¹⁰National Cancer Institute of the Ministry of Health of Ukraine, Kiev, UA, ¹¹Ataturk University Medical Faculty, Erzurum, TR, ¹²Yonsei University College of Medicine, Seoul, KR, ¹³FALP - Fundacion Arturo Lopez Perez - Instituto Oncologico, Providencia, CL, ¹⁴UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ¹⁵Vall d'Hebron University Hospital, Barcelona, ES, ¹⁶Merck & Co., Inc., Rahway, US



09:25 - 09:35 **14010 - Trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2-positive (HER2+) esophageal, gastric or gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03 (DG-03)**

Y. Janjigian¹, H. Van Laarhoven², S.Y. Rha³, V. Kozlov⁴, D.-Y. Oh⁵, A. Gravina⁶, L. Rapatoni⁷, H. Shoji⁸, R.D. Hofheinz⁹, L.-T. Chen¹⁰, H. Ford¹¹, M. Chenard-Poirier¹², S. Raoufmoghaddam¹³, C. Lloyd¹⁴, C. Zhang¹⁵, C. Mateo¹⁶, J. Lee¹⁷, ¹Memorial Sloan Kettering Cancer Center, New York, US, ²Amsterdam UMC, Amsterdam, NL, ³Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, KR, ⁴Novosibirsk State Medical University, Novosibirsk, RU, ⁵Seoul National University College of Medicine, Seoul, KR, ⁶Istituto Nazionale Tumori, Napoli, IT, ⁷University of São Paulo, Ribeirão Preto, BR, ⁸National Cancer Center Hospital, Tokyo, JP, ⁹University of Heidelberg, Mannheim, DE, ¹⁰National Health Research Institutes, Taiwan, TW, ¹¹Cambridge University Hospitals NHS Foundation Trust, Cambridge, GB, ¹²CHU de Québec, Québec, CA, ¹³AstraZeneca, Cambridge, GB, ¹⁴AstraZeneca, New York, US, ¹⁵AstraZeneca, Gaithersburg, US, ¹⁶AstraZeneca, Barcelona, ES, ¹⁷Samsung Medical Center, Sungkyunkwan University, Seoul, KR

09:35 - 09:45 **Invited Discussant 14000 and 14010**

E. Pietrantonio, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT

09:45 - 10:00 **Q&A**

08:30 - 10:00 **Type: Educational session** **Sevilla Auditorium - Hall 2**
Title: Addressing uncertainties in the management of urothelial and renal cell carcinomas
 Chair(s): Petros Grivas, US; Bernadett Szabados, GB

08:30 - 08:50 **Circulating vs tissue-based biomarkers**

B. Szabados, Cancer Research UK Barts Centre - Barts and The London School of Medicine and Dentistry, London, GB

08:50 - 09:10 **What is the role of rechallenge with the same class of agents in advanced disease?**

Y. Loriot, Institut Gustave Roussy, Villejuif, Cedex, FR

09:10 - 09:30 **How to manage patients with durable response on systemic therapy? Optimal therapy duration and role de-escalation?**

D. Robbrecht, Erasmus MC Cancer Institute, Rotterdam, NL

09:30 - 09:50 **Building on standard therapies: Novel agents and promising combinations**

B. Perez Valderrama, Hospital Universitario Virgen del Rocio, Seville, ES

09:50 - 10:00 **Q&A and discussion**



08:30 - 10:00	Type: Mini Oral session Title: Mini oral session: Head and neck cancer Chair(s): Paolo Bossi, IT; Ester Orlandi, IT; Makoto Tahara, JP	Bilbao Auditorium - Hall 2
08:30 - 08:35	848MO - Phase II open-label randomized study of pembrolizumab with or without bevacizumab in platinum-resistant recurrent/metastatic nasopharyngeal carcinoma (R/M NPC) <u>W.Q. Chong</u>¹, J.L. Low¹, K. Sooi¹, R. Soo¹, C. Le¹, H.L. Teo², J. Samol², G. Goh³, L.R. Kong³, R. Dasgupta⁴, S.-M. Chia⁴, R. Wong³, A. Gopinathan⁵, J.K. Tay⁶, D. Eu⁶, R. Tsang⁶, K.-S. Loh⁶, B.C. Tai⁷, Y.C. Lim³, B.-C. Goh¹, ¹National University Cancer Institute Singapore, Singapore, SG, ²National Healthcare Group - Tan Tock Seng Hospital, Singapore, SG, ³Cancer Science Institute (CSI) - National University of Singapore (NUS), Singapore, SG, ⁴A*STAR - Agency for Science, Technology and Research, Singapore, SG, ⁵NUH - National University Hospital (S) Pte. Ltd., Singapore, SG, ⁶NUS - National University of Singapore, Singapore, SG, ⁷National University of Singapore (NUS) - Faculty of Science, Singapore, SG	
08:35 - 08:40	850MO - Phase II randomized trial of chemotherapy followed by surgery and PORT versus surgery and PORT for organ preservation of T3 and T4a (selected T4b) sinonasal squamous cell carcinoma (SNC): A trial of the ECOG-ACRIN cancer research group (EA3163) <u>N. Saba</u>¹, Y. Flamand², D.T. Lin³, C. Chung⁴, M.W. McDonald⁵, S. Flampouri⁵, S.A. Khan⁶, C.H. Snyderman⁷, E. Hanna⁸, Y.H. El-Sayed⁹, C.A. Solares¹, F. Duan¹⁰, A. Ho¹¹, M.A. Samuels¹², P.L. Swiecicki¹³, R.M. Subramaniam¹⁴, A. Chakravarthy¹⁵, B. Burtneess¹⁶, ¹Winship Cancer Institute of Emory University, Atlanta, US, ²Harvard Medical School, Boston, US, ³Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, US, ⁴H. Lee Moffitt Cancer Center & Research Institute - Magnolia Campus, Tampa, US, ⁵Winship Cancer Institute/Emory University, Atlanta, US, ⁶Stanford University Medical Center, Stanford, US, ⁷UPMC Hillman Cancer Center, Pittsburgh, US, ⁸MD Anderson Cancer Center, Houston, US, ⁹UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, ¹⁰Brown University, Providence, US, ¹¹Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US, ¹²Banner MD Anderson Cancer Center, Gilbert, US, ¹³Rogel Cancer Center, Ann Arbor, US, ¹⁴University of Notre Dame Australia, Fremantle, AU, ¹⁵Vanderbilt University Medical Center, Nashville, US, ¹⁶Yale University School of Medicine - Yale Cancer Center, New Haven, US	
08:40 - 08:45	867MO - Epigenetic therapy modulates the tumor microenvironment to sensitize anti-PD-1 refractory head and neck cancers to immunotherapy S. Pai¹, T. Qin², <u>A. Mattox</u>¹, J. Campbell³, J.C. Park⁴, K.-Y. Shin⁵, P. Sadow⁴, W. Faquin⁴, R. Haddad⁵, M. Pittet⁶, C. Garri⁴, T. Mempel⁷, A. Oneill⁵, M. Sartor⁸, ¹Yale University School of Medicine, New Heaven, US, ²University of Michigan, Ann Arbor, US, ³University of Washington, Seattle, US, ⁴MGH - Massachusetts General Hospital, Boston, US, ⁵Dana Farber Cancer Institute, Boston, US, ⁶University of Geneva - Faculty of Medicine, Geneva, CH, ⁷Harvard Medical School, Boston, US, ⁸University of Michigan Hospital, Ann Arbor, US	
08:45 - 09:00	Invited Discussant 848MO, 850MO and 867MO <u>P. Bossi</u>, IRCCS Humanitas Research Hospital, Rozzano, IT	



09:00 - 09:05

851MO - Final analysis of a phase II/III trial of post-operative chemoradiotherapy comparing 3-weekly cisplatin with weekly cisplatin in high-risk patients with squamous cell carcinoma of the head and neck (JCOG1008)

M. Tahara¹, N. Kiyota², H. Fujii³, Y. Asada⁴, H. Mitani⁵, Y. Hirayama⁶, N. Nishio⁷, Y. Onozawa⁸, N. Hanai⁹, A. Ohkoshi¹⁰, N. Monden¹¹, M. Nagaoka¹², S. Minami¹³, T. Fujii¹⁴, K. Tanaka¹⁵, S. Yoshimoto¹⁶, T. Kodaira⁹, J. Mizusawa¹⁷, K. Nakamura¹⁸, R. Hayashi¹, ¹National Cancer Center Hospital East, Kashiwa, JP, ²Kobe University Hospital, Kobe, JP, ³Jichi Medical University Hospital, Shimotsuke, JP, ⁴Miyagi Cancer Center, Natori, JP, ⁵The Cancer Institute Hospital of JFCR, Koto-ku, JP, ⁶Hyogo Cancer Center, Akashi, JP, ⁷Nagoya University Hospital, Nagoya, JP, ⁸Shizuoka Cancer Center, Shizuoka, JP, ⁹Aichi Cancer Center Hospital, Nagoya, JP, ¹⁰Tohoku University Hospital, Sendai, JP, ¹¹NHO Shikoku Cancer Center, Matsuyama, JP, ¹²Jikei University School of Medicine, Tokyo, JP, ¹³NHO Tokyo Medical Center, Tokyo, JP, ¹⁴OICI - Osaka International Cancer Institute, Osaka, JP, ¹⁵Kindai University School of Medicine - Main Campus, Osaka, JP, ¹⁶NCCH - National Cancer Center Hospital-Tsukiji Campus, Chuo-ku, JP, ¹⁷National Cancer Center - Tsukiji Campus, Chuo-ku, JP, ¹⁸National Cancer Center, Tokyo, JP

09:05 - 09:10

LBA37 - Final results: Randomized assessment of cisplatin dosing interval for ototoxicity (RADIO) trial comparing chemoradiation (CRT) with cisplatin q3weekly to weekly for locally advanced squamous cell carcinoma of the head and neck (LASCCHN)

M. Kuruvilla¹, B. Meyers², M. Smoragiewicz³, P. Stewart¹, S. Ghedira³, L. Bordeleau², K. Chan³, S. Hotte², C. Parker⁴, D. Palma¹, D.-H. Kim², I. Karam³, P. Lang¹, N. Read¹, V. Venkatesan¹, A. Nichols¹, A. Louie³, R. Kim¹, G. Pond⁵, E. Winquist¹, ¹Western University, London, CA, ²Escarpment Cancer Research Institute, Hamilton, CA, ³University of Toronto, North York, CA, ⁴London Health Sciences Centre, London, CA, ⁵McMaster University, Hamilton, CA

09:10 - 09:15

852MO - REWRITE–GORTEC 2018-02: Radiotherapy-durvalumab without prophylactic neck irradiation in squamous cell carcinoma of the head and neck

J. Castelli¹, X. Sun², E. Neveu³, T.V. Nguyen⁴, Y. Tao⁵, L. Martin⁶, U. Schick⁷, C. Sire⁸, T. Leroy⁹, N. Vulquin¹⁰, B. Calderon¹¹, J. Thariat¹², S. Guihard¹³, X. Liem¹⁴, O. Arsene¹⁵, L. Sinigaglia¹⁶, B. Campillo-Gimenez¹, J. Bourhis¹⁷, ¹Univ Rennes, CLCC Eugène Marquis, Inserm, LTSI – UMR 1099, Rennes, FR, ²CHRU Besançon and HNFC, Besançon, FR, ³Centre Eugene - Marquis, Rennes, FR, ⁴Gustave Roussy - Cancer Campus, Villejuif, FR, ⁵Institut Gustave Roussy, Villejuif, Cedex, FR, ⁶Clinique des Ormeaux, Le Havre, FR, ⁷CHRU Brest - Hopital Augustin Morvan, Brest, FR, ⁸Groupe Hospitalier de Bretagne Sud - Site du Scorff, Lorient, FR, ⁹Centre de Cancérologie Les Dentellières, Valenciennes, FR, ¹⁰Centre Georges-François Leclerc (Dijon), Dijon, FR, ¹¹Institut Sainte-Catherine, Avignon, FR, ¹²Centre Francois Baclesse, Caen, Cedex, FR, ¹³Centre Paul Strauss Centre de Lutte contre le Cancer, Strasbourg, FR, ¹⁴Centre Oscar Lambret, Lille, FR, ¹⁵Centre Hospitalier Simone Veil de Blois, Blois, Cedex, FR, ¹⁶GORTEC, Tours, FR, ¹⁷CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH

09:15 - 09:30

Invited Discussant 851MO, LBA37 and 852MO

E. Orlandi, Centro Nazionale di Adroterapia Oncologica - CNAO, Pavia, IT



09:30 - 09:35 **853MO - Setanaxib plus pembrolizumab for the treatment of recurrent or metastatic squamous cell carcinoma of the head & neck: Results of a randomized, double-blind phase II trial**

J. Fayette¹, G. Thomas², A. Daste³, M. Rotarski⁴, B. Castelo⁵, A. Rullan⁶, A. Levine⁷, R. Philipson⁷, K. Harrington⁸, ¹Centre Léon Bérard, Lyon, FR, ²University of Southampton, Southampton, GB, ³CHU Bordeaux - Hopital St. André, Bordeaux, FR, ⁴Centre Oncologie du Pays Basque, Bayonne, FR, ⁵Hospital Universitario La Paz, Madrid, ES, ⁶The Royal Marsden Hospital - Chelsea, London, GB, ⁷Calliditas Therapeutics AB, Stockholm, SE, ⁸Institute of Cancer Research/Royal Marsden, London, GB

09:35 - 09:40 **854MO - Avelumab-cetuximab-radiotherapy (RT) versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Final analysis of randomized phase III GORTEC 2017-01 REACH trial**

Y. Tao¹, A. Auperin², X. Sun³, X. Liem⁴, C. Sire⁵, L. Martin⁶, Y. Pointreau⁷, C. Borel⁸, M.-C. Kaminsky-Forrett⁹, J. Miroir¹⁰, F. Rolland¹¹, A. Coutte¹², F. Clatot¹³, L. Sinigaglia¹⁴, J. Thariat¹⁵, C. Even¹⁶, E. Saada¹⁷, J. Guigay¹⁴, J. Bourhis¹⁸, ¹Institut Gustave Roussy, Villejuif, FR, ²Gustave Roussy - Cancer Campus, Villejuif, FR, ³CHRU Besançon and HNFC, Besançon, FR, ⁴Centre Oscar Lambret, Lille, FR, ⁵South Brittany Hospital, Lorient, FR, ⁶Clinique des Ormeaux, Le Havre, FR, ⁷ILC-Centre Jean Bernard, Le Mans, FR, ⁸ICANS - Institut de Cancérologie Strasbourg Europe, Strasbourg, FR, ⁹Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre-lès-Nancy, FR, ¹⁰Centre Jean PERRIN, Clermont-Ferrand, Cedex, FR, ¹¹ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, ¹²CHU Amiens-Picardie - Site Sud, Amiens, FR, ¹³Centre Henri Becquerel, Rouen, FR, ¹⁴GORTEC, Tours, FR, ¹⁵Centre Francois Baclesse, Caen, Cedex, FR, ¹⁶Institut Gustave Roussy, Villejuif, Cedex, FR, ¹⁷Centre Anticancer Antoine Lacassagne, Nice, FR, ¹⁸CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH

09:40 - 09:55 **Invited Discussant 853MO and 854MO**

M. Tahara, National Cancer Center Hospital East, Kashiwa, JP

08:30 - 10:00

Type: Special symposium

Granada Auditorium - Hall 6

Title: Gynaecological cancer: How can technology help the fight?

Chair(s): Florence Joly Lobbedez, FR; Linda Mileschkin, AU

08:30 - 08:35

Introduction and scientific background

L. Mileschkin, Peter MacCallum Cancer Center, Melbourne, AU

08:35 - 08:50

Digitalising the patient journey

F. Joly Lobbedez, Centre Francois Baclesse, Caen, Cedex 5, FR

08:50 - 09:05

Whole genome sequencing: What are the benefits?

C. Gourley, Cancer Research UK Edinburgh Centre, Edinburgh, GB

09:05 - 09:20

Latest liquid biopsy techniques

N. Normanno, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Napoli, IT



09:20 - 09:35 **Artificial intelligence applications**
T. Bosse, Leiden University Medical Center, Leiden, NL

09:35 - 09:55 **Q&A and discussion**

09:55 - 10:00 **Conclusions and perspectives**
E. Joly Lobbedez, Centre Francois Baclesse, Caen, Cedex 5, FR

08:30 - 10:00 **Type: Special symposium** **Burgos Auditorium - Hall 5**
Title: Precision medicine in NEN: Where we are
 Chair(s): Annemiek Walenkamp, NL; Marco Volante, IT

08:30 - 08:35 **Introduction and scientific background**
A. Walenkamp, UMCG - University Medical Center Groningen, Groningen, NL

08:35 - 08:50 **The molecular landscape of neuroendocrine neoplasms**
C. Thirlwell, University of Bristol - Bristol Medical School, Bristol, GB

08:50 - 09:05 **The value of circulating tumour DNA in neuroendocrine neoplasms**
A. Walenkamp, UMCG - University Medical Center Groningen, Groningen, NL

09:05 - 09:20 **Precision systemic therapy in NEN**
J. Capdevila Castillon, Vall d'Hebron University Hospital, Barcelona, ES

09:20 - 09:35 **Precision radionuclide therapy**
A. Kjaer, Rigshospitalet, Copenhagen, DK

09:35 - 09:55 **Q&A and discussion**

09:55 - 10:00 **Conclusions and perspectives**
M. Volante, University of Turin, Torino, IT

08:30 - 10:00 **Type: Special symposium** **Santander Auditorium - Hall 5**
Title: Hot topics in sarcoma
 Chair(s): Breelyn Wilky, US; Tom Wei-Wu Chen, TW

08:30 - 08:35 **Introduction and scientific background**
B. Wilky, UCHHealth Cancer Care - Anschutz Medical Campus - University of Colorado Cancer Center, Aurora, US

08:35 - 08:50 **Landmark trials in soft tissue sarcomas (incl. LPS/LMS)**
E. Hatipoglu, The Royal Marsden Hospital - NHS Foundation Trust, London, GB

- 08:50 - 09:05 **Landmark trials in bone and joint sarcomas**
S. Stacchiotti, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT
- 09:05 - 09:20 **Landmark trials in immunotherapy**
B. Wilky, UCHHealth Cancer Care - Anschutz Medical Campus - University of Colorado Cancer Center, Aurora, US
- 09:20 - 09:35 **Landmark trials in GIST**
S. Bauer, W TZ - Westdeutsches Tumorzentrum Essen, Essen, DE
- 09:35 - 09:55 **Q&A and discussion**
- 09:55 - 10:00 **Conclusions and perspectives**
T.W.-W. Chen, NTU - National Taiwan University - College of Medicine, Taipei City, TW

08:30 - 10:00 **Type: Educational session** **Valencia Auditorium - Hall 5**
Title: Exploiting the microbiome to improve treatment outcomes
Chair(s): Bertrand Routy, CA; Göran Jönsson, SE

- 08:30 - 08:55 **How the microbiome affects immunotherapy**
B. Routy, CRCHUM - Centre de recherche du CHUM, Montreal, CA
- 08:55 - 09:20 **Tumour antigens derived from bacteria**
M. Rescigno, Humanitas University, Milan, IT
- 09:20 - 09:45 **Improving anti-tumour immunity with engineered bacteria**
J. Theys, Maastricht University, Maastricht, NL
- 09:45 - 10:00 **Q&A and discussion**

08:30 - 10:00 **Type: Educational session** **Pamplona Auditorium - Hall 3**
Title: Common clinical problems in neuro-oncology
Chair(s): Martin McCabe, GB; Dieta Brandsma, NL

- 08:30 - 08:50 **Rational molecular testing for treatment of gliomas**
L. Schweizer, Institute of Neurology (Edinger Institute), Frankfurt am Main, DE
- 08:50 - 09:10 **Comprehensive molecular profiling of AYA patients: An EORTC-SPECTA proof of concept study**
M. McCabe, The University of Manchester, Manchester, GB
- 09:10 - 09:30 **Assessing patient fitness for treatment of gliomas**
J. Furtner, MedUni Wien - Medical University of Vienna, Vienna, AT



09:30 - 09:50 **Radionecrosis and pseudoprogression**
N. Galldiks, Universitätsklinikum Köln (AöR), Köln, DE

09:50 - 10:00 **Q&A and discussion**

08:30 - 10:00 **Type: Educational session** **Oviedo Auditorium - Hall 3**
Title: Treatment of elderly patients with haematological malignancies
 Chair(s): Stefano Luminari, IT; Eva Kimby, SE

08:30 - 08:50 **AML/MDS**
M. Heuser, MHH - Medizinische Hochschule Hannover, Hannover, DE

08:50 - 09:10 **Multiple myeloma**
N. Van De Donk, Amsterdam UMC - Vrije University Medical Centre (VUmc), Amsterdam, NL

09:10 - 09:30 **Diffuse large B cell lymphoma**
B. Chapuy, Charite, Campus Benjamin Franklin Medizinische Klinik III, Berlin, DE

09:30 - 09:50 **Follicular lymphoma**
S. Luminari, Policlinico di Modena, Modena, IT

09:50 - 10:00 **Q&A and discussion**

08:30 - 10:00 **Type: Special session** **Zaragoza Auditorium - CC5**
Title: POWG 1: Biomarkers in everyday clinical practice
 Chair(s): Mila Petrova, BG; Gabor Liposits, DK

08:30 - 08:50 **Biomarkers in the treatment of breast cancer: Importance and pitfalls**
F. André, Gustave Roussy - Cancer Campus, Villejuif, FR

08:50 - 09:10 **How to read commercial NGS test: Tips and tricks for practicing oncologists**
C.B. Westphalen, LMU Klinikum der Universität München, Munich, DE

09:10 - 09:30 **Biomarkers for mCRPC: To test or not to test**
E. Castro, Hospital Universitario 12 de Octubre, Madrid, ES

09:30 - 09:50 **Biomarkers in daily practice**
R. Vidra, The Regional Institute of Gastroenterology and Hepatology, Cluj-Napoca, RO

09:50 - 10:00 **Q&A and discussion**

08:30 - 10:00	Type: EONS session Title: EONS17 Opening session and Keynote lecture Chair(s): Virpi Sulosaari, FI	Ronda Auditorium - Hall 7
08:30 - 08:40	Welcome address <u>V. Sulosaari</u> , TUAS - Turku University of Applied Sciences, Turku, FI	
08:40 - 08:50	Welcome from Spanish Oncology Nursing Society (Sociedad Española de Enfermería Oncológica, SEEO) <u>J. Serra López</u> , Hospital de la Santa Creu i Sant Pau, Barcelona, ES	
08:50 - 08:55	Welcome from ESMO <u>A. Cervantes</u> , Hospital Clinico Universitario de Valencia, Valencia, ES	
08:55 - 09:15	Keynote lecture: Shaping the future of cancer nursing: The case for disruption in the pursuit of meaningful and equitable innovation <u>A. Drury</u> , DCU - Dublin City University, Dublin, IE	
09:15 - 09:45	Panel discussion on past, present and future: Where are we going? <u>J. Serra López</u> ¹ , <u>V. Sulosaari</u> ² , <u>H. Ullgren</u> ³ , <u>J. De Munter</u> ⁴ , ¹ Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ² TUAS - Turku University of Applied Sciences, Turku, FI, ³ Karolinska University Hospital-Solna, Solna, SE, ⁴ UZ Gent - Universitair Ziekenhuis Gent, Gent, BE	
09:45 - 10:00	Lifetime Achievement Award, RECaN Award, NRDA Award	
09:00 - 09:45	Type: Challenge your Expert Title: How to optimally counsel my melanoma patients for adjuvant therapy Chair(s): Helen Gogas, GR	Salamanca Auditorium - Hall 5
09:00 - 09:20	Presentation by Expert <u>J. Larkin</u> , The Royal Marsden Hospital - Chelsea, London, GB	
09:20 - 09:45	Discussion led by Chair <u>H. Gogas</u> , National and Kapodistrian University of Athens - School of Medicine, Athens, GR	
09:00 - 09:45	Type: Challenge your Expert Title: Pharmacologically manipulating evolution Chair(s): Manuel Irimia, ES	Alicante Auditorium - Hall 3
09:00 - 09:20	Presentation by Expert <u>T. Graham</u> , ICR - Institute of Cancer Research, London, GB	
09:20 - 09:45	Discussion led by Chair <u>M. Irimia</u> , Universitat Pompeu Fabra - Centre for Genomic Regulation, Barcelona, ES	



09:00 - 10:00	Type: Young Oncologists session Title: YO Boxing session Chair(s): Elizabeth Connolly, AU; Emre Kocakavuk, DE	Cartagena Auditorium - Hall 7
09:00 - 09:10	Should we try immunotherapy for all patients with advanced cancer? - Yes <u>M. Chalabi</u> , Netherlands Cancer Institute, Amsterdam, NL	
09:10 - 09:20	Should we try immunotherapy for all patients with advanced cancer? - No <u>K.H.J. Lim</u> , The Francis Crick Institute, London, GB	
09:20 - 09:30	Discussion	
09:30 - 09:40	Who should be responsible for cancer survivorship - Oncologists <u>M. Lustberg</u> , Yale University School of Medicine, New Haven, US	
09:40 - 09:50	Who should be responsible for cancer survivorship - General practitioners <u>A. Indini</u> , Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT	
09:50 - 10:00	Discussion	
10:00 - 11:00	Type: Special session Title: Climate Change Task Force: How to build more sustainable and environment-friendly oncology care Chair(s): Mathilde Jalving, NL; Seamus O'Reilly, IE	Tarragona Auditorium - Hall 7
10:00 - 10:10	Moving towards a sustainable academic society: Update from the ESMO Climate Change Task Force <u>M. Jalving</u> , UMCG - University Medical Center Groningen, Groningen, NL	
10:10 - 10:20	Waste reduction through redispensing unused oral anticancer drugs <u>C. Bekker</u> , Radboud University Medical Center, Nijmegen, NL	
10:20 - 10:30	Planetary health and pharma: Challenges and opportunities <u>A. Booth</u> , University of Oxford, Oxford, GB	
10:30 - 10:40	Reducing climate impact of care pathways <u>M. Piffoux</u> , Centre Léon Bérard, Lyon, FR	
10:40 - 11:00	Discussion: How can ESMO support you in making your practice more sustainable? <u>M. Jalving</u> ¹ , <u>S. O'Reilly</u> ² , ¹ UMCG - University Medical Center Groningen, Groningen, NL, ² CUH - Cork University Hospital, Cork, IE	



10:15 - 11:30 **Type: Multidisciplinary session** **Alicante Auditorium - Hall 3**
Title: Cancer-associated thrombosis: Management of pulmonary embolism
 Chair(s): Karin Jordan, DE; Elene Mariamidze, GE

10:15 - 10:20 **Presentation of case/condition**
E. Mariamidze, Todua Clinic, Tbilisi, GE

10:20 - 10:40 **Prevention strategies of venous thromboembolism**
G. Gerotziafas, Institut Universitaire de Cancérologie AP-HP. Sorbonne Université, Hôpital Tenon, Paris, FR

10:40 - 11:00 **Treatment strategies and duration of anticoagulation in cancer-associated pulmonary embolism**
L. Jara-Palomares, Hospital Universitario Virgen del Rocío, Seville, ES

11:00 - 11:20 **Prevention and management of catheter-associated venous thrombosis in adults with cancer**
C. Ay, MedUni Wien - Medical University of Vienna, Vienna, AT

11:20 - 11:30 **Discussion**

10:15 - 11:55 **Type: Mini Oral session** **Barcelona Auditorium - Hall 2**
Title: Mini oral session: Breast cancer, early stage
 Chair(s): Kevin Kalinsky, US; Lisa Carey, US; Fatima Cardoso, PT

10:15 - 10:20 **233MO - Ovarian function suppression in HR-positive, HER2-positive breast cancer: An exploratory analysis from the HERA trial**
 S. Moon, S.J. Bae, Y. Kook, B. Seung Ho, L. Minji, S.G. Ahn, J. Jeong, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, KR

10:20 - 10:25 **234MO - Explaining the relationships between age, endocrine therapy persistence and risk of recurrence in hormone-positive early breast cancer: A nationwide cohort study**
E. Dumas¹, F. Jochum², F. Coussy², A.-S. Hamy-Petit³, A. Majdlin², S. Houzard⁴, C. Le Bihan-Benjamin⁴, F. Reyat², P. Gougis², M.J. Stensrud¹, ¹Ecole polytechnique Fédérale de Lausanne, Lausanne, CH, ²Institut Curie, Paris, FR, ³Hopital René Huguenin - Institut Curie, Saint-Cloud, FR, ⁴INCa - Institut National du Cancer, Boulogne-Billancourt, FR



10:25 - 10:30

235MO - Efficacy and safety of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in younger patients (pts) with HR+/HER2− early breast cancer (EBC) in NATALEE

S. Loi¹, E. Stringer-Reasor², J.-S. Frenel³, M. Reinisch⁴, R. Oregan⁵, M. De Laurentiis⁶, Y.H. Park⁷, A. O'Dea⁸, Y.-S. Lu⁹, V. Gonzalez¹⁰, M. Gao¹¹, S. Waters¹², H. Hu¹³, B. Xu¹⁴, ¹Peter MacCallum Cancer Centre, Melbourne, AU, ²O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, US, ³ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, ⁴Kliniken Essen Mitte, Essen, DE, ⁵University of Rochester Cancer Center – Wilmot Cancer Institute, Rochester, US, ⁶Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Napoli, IT, ⁷Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR, ⁸University of Kansas Medical Center, Westwood, US, ⁹NTUH - National Taiwan University Hospital, Taipei City, TW, ¹⁰TRIO - Translational Research in Oncology, Montevideo, UY, ¹¹Novartis Pharma AG, Basel, CH, ¹²Novartis Ireland Limited, Dublin, IE, ¹³Novartis Pharmaceuticals Corporation, East Hanover, US, ¹⁴Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, Beijing, CN

10:30 - 10:45

Invited Discussant 233MO, 234MO and 235MO

K. Kalinsky, Winship Cancer Institute of Emory University, Atlanta, US

10:45 - 10:50

236MO - Pathologic complete response and survival after neoadjuvant chemotherapy in stage I TNBC: A registry-based study

M. De Graaf¹, R. Gielen¹, S. Balduzzi¹, S. Siesling², S. Linn¹, M. Kok¹, ¹Netherlands Cancer Institute, Amsterdam, NL, ²IKNL - Netherlands Comprehensive Cancer Organisation, Utrecht, NL

10:50 - 10:55

237MO - TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy without immunotherapy

M. Martin Jimenez¹, O. Gluz², G. Villacampa³, S. Lopez-Tarruella Cobo⁴, U. Nitz⁵, S. Cobo⁶, F. Brasó-Maristany⁷, M. Christgen⁸, Y. Jerez Gilarranz⁴, S. Kummel⁹, B. Conte¹⁰, I. Echavarria Diaz-Guardamino⁴, M.K. Graeser-Mayer¹¹, H. Kreipe¹², M. Del Monte-Millan¹³, B. Herrero Lopez⁴, C. Perou¹⁴, L. Pare Brunet¹⁵, A. Prat¹⁰, N. Harbeck¹⁶, ¹Hospital General Universitario Gregorio Marañón, Madrid, ES, ²West German Study Group, Monchengladbach Bethesda Klinik, Monchengladbach, DE, ³Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, ⁴Hospital General Universitario Gregorio Marañón, Madrid, ES, ⁵West German Study Group, Monchengladbach, Germany, Monchengladbach, DE, ⁶Hospital Clinic de Barcelona, Barcelona, ES, ⁷IDIBAPS - Fundació de Recerca Clinic Barcelona - Institut d'Investigacions Biomediques August Pi i Sunyer, Barcelona, ES, ⁸MHH - Medizinische Hochschule Hannover, Hannover, DE, ⁹Hannover, Essen, DE, ¹⁰Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ¹¹West German Study Group, Monchengladbach, Monchengladbach, DE, ¹²Hannover Medical School, Hannover, DE, ¹³Hospital General Universitario Gregorio Marañón - Fundación Investigación Biomedica, Madrid, ES, ¹⁴UNC - Lineberger Comprehensive Cancer Center, Chapel Hill, US, ¹⁵Reveal Genomics, S.L., Barcelona, ES, ¹⁶West German Study Group, Monchengladbach, Munich, DE



10:55 - 11:00

238MO - PROMENADE: PembROLizuMab for early triple negative ER-low breast caNcer, reAl world frEnch cohort

F. Cherifi¹, L. Cabel², C. Bousrih³, E. Volant⁴, F. Dalenc⁵, B. Mery⁶, M. Auvray Kuentz⁷, M. Alexandre⁸, L. Benistant⁹, M. Leheurteur¹⁰, C. Bailleux¹¹, M. Debled¹², J.-S. Frenel¹³, D. Loirat², F.C. Bidard², S. Aho¹⁴, A. Glenet¹⁵, J. Ribeiro¹⁶, F. Christy¹, G. Emile¹⁷, ¹Centre Francois Baclesse, Caen, Cedex, FR, ²Institut Curie, Paris, FR, ³Institut Gustave Roussy, Villejuif, Cedex, FR, ⁴Cancéropôle Grand Ouest - CHU Nantes Immeuble Deurbroucq, Nantes, FR, ⁵Oncopole Claudius Regaud- IUCT, Toulouse, FR, ⁶Center Leon Berard, Lyon, FR, ⁷Centre Eugène Marquis, Rennes, FR, ⁸ICM - Institut du Cancer de Montpellier, Montpellier, Cedex, FR, ⁹ICANS - Institut de Cancérologie Strasbourg Europe, Strasbourg, FR, ¹⁰Centre Henri Becquerel, Rouen, FR, ¹¹Centre Anticancer Antoine Lacassagne, Nice, FR, ¹²Institute Bergonié - Centre Régional de Lutte Contre le Cancer (CLCC), Bordeaux, FR, ¹³ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, ¹⁴Institut de Cancérologie de Lorraine, Nancy, FR, ¹⁵IUCT Oncopole, Toulouse, FR, ¹⁶Gustave Roussy - Cancer Campus, Villejuif, FR, ¹⁷Centre Francois Baclesse, Caen, FR

11:00 - 11:05

LBA14 - Intensified alkylating chemotherapy with autologous stem cell rescue (IACT) or conventional chemotherapy followed by olaparib (CCT-O) in stage III, HER2-negative, homologous recombination deficient (HRD) breast cancer (BC): Survival results of the randomized-controlled SUBITO trial

S. Linn¹, R. Seefat¹, V. De Jong¹, S. Vliek², S. Balduzzi¹, R. Bijlsma³, M. Jongen-Lavrencic⁴, I. Mandjes¹, M. Delfos¹, M. Schot¹, M. Van Rosmalen⁵, V. Retel⁶, I. Eekhout¹, E. Kuip⁷, A. Gonçalves⁸, J. Nuver⁹, M. Wymenga¹⁰, I. Konings¹¹, V. Tjan-Heijnen¹², A. Jager¹³, ¹NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ²UMC - University Medical Center Utrecht, Utrecht, NL, ³UMC-University Medical Center Utrecht, Utrecht, NL, ⁴Erasmus University Medical Center, Rotterdam, NL, ⁵Erasmus MC, Rotterdam, NL, ⁶The Netherlands Cancer Institute, Amsterdam, NL, ⁷Radboud University Medical Center, Nijmegen, NL, ⁸IPC - Institut Paoli-Calmettes, Marseille, Cedex, FR, ⁹UMCG - University Medical Center Groningen, Groningen, NL, ¹⁰MST - Medisch Spectrum Twente, Enschede, NL, ¹¹Amsterdam UMC - Vrije University Medical Centre (VUmc), Amsterdam, NL, ¹²Maastricht University Medical Center (MUMC), Maastricht, NL, ¹³Erasmus Medical Center Cancer Institute, Rotterdam, NL

11:05 - 11:20

Invited Discussant 236MO, 237MO, 238MO and LBA14

L. Carey, UNC - The University of North Carolina at Chapel Hill - School of Medicine, Chapel Hill, US



11:20 - 11:25

LBA15 - Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) plus durvalumab (Durva) treatment strategy in the neoadjuvant setting: Results from the I-SPY 2.2 trial

M. Trivedi¹, R. Shatsky², R. Nanda³, H. Rugo⁴, C. Omene⁵, K. Kalinsky⁶, E. Roussos Torres⁷, B. Thomas⁸, A. Sanford⁹, K. Albain¹⁰, A. Clark¹¹, C. Falkson¹², C. Isaacs¹³, A. Thomas¹⁴, J. Tseng¹⁵, L. Van'T Veer¹⁶, N. Hylton¹⁶, D. Yee¹⁷, C. Yau¹⁶, L. Esserman¹⁶, ¹Columbia University Vagelos College of Physicians and Surgeons, New York, US, ²University of California San Diego - UCSD, La Jolla, US, ³The University of Chicago, Chicago, US, ⁴UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, ⁵Rutgers Cancer Institute of New Jersey, New Brunswick, US, ⁶Winship Cancer Institute of Emory University, Atlanta, US, ⁷USC - University of Southern California - Norris Comprehensive Cancer Center, Los Angeles, US, ⁸Sparrow Regional Cancer Center, Lansing, US, ⁹Sanford Cancer Center, Sioux Falls, US, ¹⁰Loyola University Medical Center LUMC, Maywood, US, ¹¹Abramson Cancer Center - University of Pennsylvania, Philadelphia, US, ¹²University of Rochester Medical Center, Rochester, US, ¹³Lombardi Cancer Center Georgetown University, Washington, US, ¹⁴Duke Cancer Institute, Durham, US, ¹⁵City of Hope, Corona, US, ¹⁶UCSF - University of California San Francisco, San Francisco, US, ¹⁷Masonic Cancer Center - University of Minnesota, Minneapolis, US

11:25 - 11:30

LBA16 - Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) in the neoadjuvant setting: Results from the I-SPY 2.2 trial

K. Khoury¹, J. Meisel², J. Chien³, A. Wallace⁴, M. Arora⁵, M. Rozenblit⁶, N. Williams⁷, R. Nanda⁸, V. Borges⁹, E. Stringer-Reasor¹, J. Boughey¹⁰, C. Nangia¹¹, C. Vaklavas¹², H. Rugo¹³, L. Van'T Veer³, A. Demichele¹⁴, N. Hylton³, D. Yee¹⁵, C. Yau³, L. Esserman³, ¹University of Alabama at Birmingham, Birmingham, US, ²Emory University, Atlanta, US, ³UCSF - University of California San Francisco, San Francisco, US, ⁴University of California San Diego - UCSD, La Jolla, US, ⁵UC Davis Comprehensive Cancer Center, Sacramento, US, ⁶Yale University, New Haven, US, ⁷OSUCCC - The Ohio State University Comprehensive Cancer Center - James, Columbus, US, ⁸The University of Chicago, Chicago, US, ⁹UCHealth Cancer Care - Anschutz Medical Campus - University of Colorado Cancer Center, Aurora, US, ¹⁰Mayo Clinic Cancer Center, Phoenix, US, ¹¹Hoag Cancer Center, Newport Beach, US, ¹²University of Utah Health - Huntsman Cancer Institute, Salt Lake City, US, ¹³UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, ¹⁴University of Pennsylvania-Perelman Center for Advanced Medicine, Philadelphia, US, ¹⁵Masonic Cancer Center - University of Minnesota, Minneapolis, US



11:30 - 11:35

LBA17 - Survival outcome of neoadjuvant endocrine therapy + trastuzumab and pertuzumab (ET+T+P) vs. de-escalated chemotherapy (CT)+T+P in hormone receptor positive (HR+)/HER2+ early breast cancer (EBC): WSG-TP-II trial

O. Gluz¹, U. Nitz², M. Christgen³, S. Kummel⁴, J. Holtschmidt⁵, J. Schumacher⁶, A. Hartkopf⁷, K. Luedtke-Heckenkamp⁸, M. Just⁹, R. Von Schumann¹⁰, S. Polata¹¹, T. Schinköthe¹², M.K. Graeser-Mayer¹³, R. Kates¹³, R. Würstlein¹², H. Kreipe³, N. Harbeck¹⁴, ¹Evangelisches Krankenhaus Bethesda Klinik, Mönchengladbach, DE, ²West German Study Group, Mönchengladbach, DE, ³MHH - Medizinische Hochschule Hannover, Hannover, DE, ⁴Kliniken Essen Mitte Evang. Huysens-Stiftung, Essen, DE, ⁵St. Elisabeth Clinics Hohenlind, Cologne, DE, ⁶Palleos GmbH, Wiesbaden, DE, ⁷University Hospital of Tübingen, Tuebingen, DE, ⁸Franziskus-Hospital Harderberg - Niels-Stensen-KlinikenGmbH, Georgsmarienhütte, DE, ⁹Onkologische Schwerpunktpraxis, Greifswald, DE, ¹⁰Johanniter Bethesda Moenchengladbach, Moenchengladbach, DE, ¹¹Oncological Center Spandau, Berlin, DE, ¹²LMU Klinikum der Universität München, Munich, DE, ¹³Westdeutsche Studiengruppe GmbH, Mönchengladbach, DE, ¹⁴LMU University Hospital, Munich, DE

11:35 - 11:40

239MO - TILs and overall survival (OS) in HER2+ early breast cancer (eBC): 10-year (yr) updated analysis of the ShorthER trial

M.V. Dieci¹, G. Bisagni², S. Bartolini³, A. Schirone⁴, L. Cavanna⁵, A. Musolino⁶, F. Giotta⁷, A. Rimanti⁸, O. Garrone⁹, E. Bertone¹⁰, K. Cagossi¹¹, S. Sarti¹², A. Ferro¹³, F. Piacentini¹⁴, E. Orvieto¹⁵, M. Sanders¹⁶, F. Miglietta¹, S. Balduzzi¹⁷, R. D'Amico¹⁸, V. Guarneri¹, ¹Università degli Studi di Padova - DiSCOG, Padova, IT, ²Department of Oncology and Advanced Technologies, Azienda USL-IRCCS, Reggio Emilia, IT, ³AUSL Bologna - Sede Legale, Bologna, IT, ⁴Arcispedale Sant'Anna - AOU di Ferrara, Ferrara, IT, ⁵AUSL di Piacenza - Ospedale Guglielmo da Saliceto, Piacenza, IT, ⁶Università Degli Studi Di Parma - Facoltà di Medicina e Chirurgia, Parma, IT, ⁷Istituto Oncologico Bari, Bari, IT, ⁸Carlo Poma Hospital, ASST Mantova, Mantova, Italy, Mantova, IT, ⁹Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, IT, ¹⁰S. Anna Hospital, Torino, Italy, torino, IT, ¹¹Ospedale Ramazzini - AUSL Modena, Carpi, IT, ¹²IRST - Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRCCS S.r.l., Meldola, IT, ¹³Ospedale Santa Chiara - APSS, Trento, IT, ¹⁴Azienda Ospedaliero - Universitaria Policlinico di Modena, Modena, IT, ¹⁵Ulss 5 Polesana, Rovigo, Italy, Rovigo, IT, ¹⁶Vanderbilt University Pathology, Microbiology and Immunology, Nashville, US, ¹⁷University of Modena and Reggio Emilia, Modena, Italy, Modena MO, IT, ¹⁸University of Modena and Reggio Emilia, Modena, IT

11:40 - 11:55

Invited Discussant LBA15, LBA16, LBA17 and 239MO

F. Cardoso, Champalimaud Foundation - Champalimaud Clinical Center, Lisbon, PT

10:15 - 11:45

Type: Educational session

Madrid Auditorium - Hall 2

Title: Molecular characterisation and novel targeted therapies in gastroesophageal and pancreatic cancer

Chair(s): Sarah Derks, NL; Rupert Langer, AT

10:15 - 10:40

New developments in molecular characterisation

R. Langer, Kepler Universitaetsklinikum - Med Campus III, Linz, AT

10:40 - 11:05 **Molecular testing in gastric and oesophageal cancer**
M. Kwon, Ajou University School of Medicine, Suwon, KR

11:05 - 11:30 **Novel targeted therapies for pancreatic cancer**
D. Melisi, AOU Integrata di Verona - Ospedale Borgo Roma, Verona, IT

11:30 - 11:45 **Q&A and discussion**

10:15 - 11:45 **Type: Educational session** **Sevilla Auditorium - Hall 2**
Title: Updates on the treatment of thymic epithelial tumours
 Chair(s): Jordi Remon Masip, FR; Heather Wakelee, US

10:15 - 10:35 **Emerging molecular targets**
A. Roden, Mayo Clinic - Rochester, Rochester, US

10:35 - 10:55 **The role of surgery in the treatment of thymic tumours**
E. Ruffini, University of Turin, Torino, IT

10:55 - 11:15 **Current standards and advances in radiation for thymic tumours**
R. Dziadziuszko, Medical University of Gdansk, Gdansk, PL

11:15 - 11:35 **Systemic treatment for thymic tumours**
J. Remon Masip, Institut Gustave Roussy, Villejuif, Cedex, FR

11:35 - 11:45 **Q&A and discussion**

10:15 - 11:45 **Type: Special symposium** **Bilbao Auditorium - Hall 2**
Title: What's on the horizon for metastatic prostate cancer patients?
 Chair(s): Karim Fizazi, FR; Niven Mehra, NL

10:15 - 10:20 **Introduction and scientific background**
N. Mehra, Radboud University Medical Center, Nijmegen, Nijmegen, NL

10:20 - 10:35 **B7-H3 as therapeutic target for PC**
J. Carmichael, The Royal Marsden Hospital - NHS Foundation Trust, London, GB

10:35 - 10:50 **DLL-3 targeted therapy for neuroendocrine PC**
H. Beltran, Dana Farber Cancer Institute, Boston, US

10:50 - 11:05 **T cell engagers in prostate cancer**
N. Agarwal, University of Utah Health - Huntsman Cancer Institute, Salt Lake City, US



11:05 - 11:20	Targeting epigenetic pathways <u>W. Zwart</u> , Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (NKI-AVL), Amsterdam, NL	
11:20 - 11:40	Q&A and discussion	
11:40 - 11:45	Conclusions and perspectives <u>K. Fizazi</u> , Institut Gustave Roussy, Villejuif, Cedex, FR	
10:15 - 11:45	Type: Special symposium Title: Are we targeting the right antigens? Chair(s): Alena Gros, ES; Samra Turajlic, GB	Granada Auditorium - Hall 6
10:15 - 10:20	Introduction and scientific background <u>A. Gros</u> , Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES	
10:20 - 10:35	Should we target surface vs intracellular antigens? <u>M. Butler</u> , UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA	
10:35 - 10:50	Should we target single or multiple antigens? <u>C. Puig-Saus</u> , UCLA, Los Angeles, US	
10:50 - 11:05	Should we target shared or unique antigens? <u>S. Turajlic</u> , The Royal Marsden Hospital - Chelsea, London, GB	
11:05 - 11:20	Tumour or microenvironment target? <u>E. Sahai</u> , The Francis Crick Institute, London, GB	
11:20 - 11:40	Q&A and discussion	
11:40 - 11:45	Conclusions and perspectives <u>S. Turajlic</u> , The Royal Marsden Hospital - Chelsea, London, GB	
10:15 - 11:45	Type: Educational session Title: Recent breakthroughs in the treatment of endemic NPC Chair(s): Brigette Ma, HK; Pierre Blanchard, FR	Burgos Auditorium - Hall 5
10:15 - 10:40	Changing the treatment paradigm in the treatment of recurrent/metastatic NPC <u>B. Ma</u> , The Chinese University of Hong Kong, Sha Tin, HK	
10:40 - 11:05	Individualising induction and concurrent systemic therapy in locally advanced NPC <u>M.L.K. Chua</u> , NCCS - National Cancer Centre Singapore, Singapore, SG	



11:05 - 11:30 **Biomarker driven adjuvant therapy in locally advanced NPC**

P. Blanchard, Institut Gustave Roussy, Villejuif, FR

11:30 - 11:45 **Q&A and discussion**

10:15 - 11:45	Type: Proffered Paper session Title: Proffered paper session: Melanoma and other skin tumours Chair(s): Karijn Suijkerbuijk, NL; Ivan Marquez-Rodas, ES	Salamanca Auditorium - Hall 5
---------------	---	--------------------------------------

10:15 - 10:25 **10760 - Primary analysis of the EORTC 1208 Minitub trial: Prospective registry of sentinel node (SN) positive melanoma patients with minimal SN tumor burden**

A. Van Akkooi¹, D. Massi², M. Kicinski³, P. Brackley⁴, D. Gruenhagen⁵, M. Rastrelli⁶, M. Signh⁷, H. Peach⁸, B. Peric⁹, C. Caracò¹⁰, V. Boecxstaens¹¹, M. Moncrieff¹², S. Marreaud³, R. Louis³, G. De Schaetzen³, S. Koljenovic¹³, B. Van De Wiel¹⁴, M. Mandalà¹⁵, M. Cook¹⁶, A. Eggermont¹⁷,
¹Melanoma Institute Australia, Wollstonecraft, AU, ²UniFI - Università degli Studi di Firenze, Firenze, IT, ³EORTC AISBL/IVZW - European Organisation for Research and Treatment of Cancer, Brussels, BE, ⁴Whiston Hospital, Prescot, GB, ⁵Erasmus MC - Daniel den Hoed Cancer Center, Rotterdam, NL, ⁶IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, ⁷St George's Hospital, London, GB, ⁸Leeds Teaching Hospitals NHS Trust, Leeds, GB, ⁹Institute of Oncology Ljubljana, Ljubljana, SI, ¹⁰Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Napoli, IT, ¹¹University Hospital Leuven, Leuven, BE, ¹²Norfolk and Norwich University Hospital, Norwich, GB, ¹³UZA - University Hospital Antwerp, Edegem, BE, ¹⁴NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ¹⁵Università degli Studi di Perugia, Perugia, IT, ¹⁶University of Manchester, Manchester, GB, ¹⁷UMC - University Medical Center Utrecht, Utrecht, NL

10:25 - 10:35 **10820 - KEYMAKER-U02 substudy 02C: Neoadjuvant pembrolizumab (pembro) and investigational agents followed by adjuvant pembro for stage IIIB-D melanoma**

G. Long¹, C. Robert², A. Hill³, C. Gaudy Marqueste⁴, D. Portnoy⁵, R. Shapira-Frommer⁶, J. Cohen⁷, M. Khattak⁸, C. Lebbe⁹, A. Menzies¹, G. Markel¹⁰, G. Bar-Sela¹¹, W. Sharfman¹², C. Pages¹³, O. Hamid¹⁴, J. Mehnert¹⁵, N. Jing¹⁶, M. Kalabis¹⁷, C. Krepler¹⁸, R. Dummer¹⁹, ¹Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, AU, ²Institut de Cancérologie Gustave Roussy, Université Paris-Sud, and Paris- Saclay University, Villejuif-Grand Paris, FR, ³Tasman Oncology Research, Southport, AU, ⁴CEPCM, APHM, Aix- Marseille Université, Marseille, FR, ⁵West Cancer Center & Research Institute, Germantown, US, ⁶Sheba Medical Center, Tel Aviv, IL, ⁷Hadassah Medical Centre, Jerusalem, PS, ⁸Fiona Stanley Hospital/Edith Cowan University, Perth, AU, ⁹Université Paris Cité, Dermatolo-Oncology AP-HP, Hôpital Saint-Louis, Paris, FR, ¹⁰Rabin Medical Center, Petah Tikva, IL, ¹¹Emek Medical Center, Afula, IL, ¹²Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, US, ¹³Institut Claudius Regaud - IUCT Oncopole, Toulouse, Cedex, FR, ¹⁴The Angeles Clinic and Research Institute, Los Angeles, US, ¹⁵New York University Grossman School of Medicine, Laura and Isaac Perlmutter Cancer Center at NYU, New York, US, ¹⁶Merck & Co., Inc. - Rahway, Rahway, US, ¹⁷Merck & Co., Inc., North Wales, US, ¹⁸Merck & Co. Inc., Rahway, US, ¹⁹University hospital Zurich, Zurich, CH



10:35 - 10:45

Invited Discussant 10760 and 10820

M. Donia, Herlev Hospital - National Center for Cancer Immune Therapy (CCIT-DK), Herlev, DK

10:45 - 10:55

Q&A

10:55 - 11:05

LBA41 - Long-term survival with neoadjuvant therapy in melanoma: Updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

G. Long¹, C. Blank², R. Amaria³, T. Hieken⁴, S. Sandhu⁵, M. Barros⁶, T.C. Mitchell⁷, Z. Eroglu⁸, I. Samoylenko⁹, P. Rutkowski¹⁰, D. Johnson¹¹, I. Pires Da Silva¹², K. Perry¹³, H. Tawbi¹⁴, M. Block¹⁵, P. Ascierto¹⁶, E. Burton¹⁷, A. Van Akkooi¹³, R. Scolyer¹⁸, A. Menzies¹⁹, ¹Melanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, AU, ²NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ³The M.D. Anderson Cancer Center, Houston, US, ⁴Mayo Clinic, Rochester, US, ⁵Peter MacCallum Cancer Centre, Melbourne, AU, ⁶A. C. Camargo Cancer Center - Fundacao Antonio Prudente, Sao Paulo, BR, ⁷Abramson Cancer Center of the University of Pennsylvania, Philadelphia, US, ⁸H. Lee Moffitt Cancer Center & Research Institute - Magnolia Campus, Tampa, US, ⁹N.N. Blokhin National Medical Research Center of Oncology, Moscow, RU, ¹⁰Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, PL, ¹¹Vanderbilt University Medical Center, Nashville, US, ¹²Melanoma Institute Australia, The University of Sydney, Sydney, AU, ¹³Melanoma Institute Australia, Wollstonecraft, AU, ¹⁴The University of Texas MD Anderson Cancer Center, Houston, US, ¹⁵Mayo Clinic - Rochester, Rochester, US, ¹⁶Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT, ¹⁷The MD Anderson Cancer Center, Houston, US, ¹⁸Melanoma Institute Australia and Charles Perkins Centre at The University of Sydney, Tissue Pathology and Diagnostic Oncology - Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, AU, ¹⁹Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Wollstonecraft, AU

11:05 - 11:15

LBA42 - Distant metastasis-free survival of neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in resectable, macroscopic stage III melanoma: The NADINA trial

M. Lucas¹, A. Menzies², M. Lopez-Yurda³, R. Scolyer⁴, B. Van De Wiel¹, R. Saw⁵, W. Van Houdt¹, N. Maher⁶, A. Torres Acosta¹, M. Boers-Sonderen⁷, G. Hospers⁸, M. Carlino⁹, J.W. De Groot¹⁰, E. Kapiteijn¹¹, K. Suijkerbuijk¹², P. Rutkowski¹³, S. Sandhu¹⁴, A. Van Der Veldt¹⁵, G. Long¹⁶, C. Blank¹, ¹NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ²Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, AU, ³Netherlands Cancer Institute, Amsterdam, NL, ⁴Melanoma Institute Australia and Charles Perkins Centre at The University of Sydney, Tissue Pathology and Diagnostic Oncology - Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, AU, ⁵Royal Prince Alfred Hospital, Camperdown, AU, ⁶Melanoma Institute Australia, Wollstonecraft, AU, ⁷Radboud University Medical Center, Nijmegen, Nijmegen, NL, ⁸UMCG - University Medical Center Groningen, Groningen, NL, ⁹Crown Princess Mary Cancer Centre Westmead, Westmead, AU, ¹⁰Isala Hospital, Zwolle, NL, ¹¹Leiden University Medical Center (LUMC), Leiden, NL, ¹²UMC - University Medical Center Utrecht, Utrecht, NL, ¹³Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, PL, ¹⁴Peter MacCallum Cancer Centre, Melbourne, AU, ¹⁵Erasmus MC - University Medical Center, Rotterdam, NL, ¹⁶Melanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, AU



11:15 - 11:25 **Invited Discussant LBA41 and LBA42**
I. Marquez-Rodas, Hospital General Universitario Gregorio Marañón - Fundación Investigación Biomedica, Madrid, ES

11:25 - 11:35 **Q&A**

10:15 - 11:45 **Type: Mini Oral session** **Santander Auditorium - Hall 5**
Title: Mini oral session: NSCLC metastatic
 Chair(s): Adrianus Johannes De Langen, NL; Mariana Brandão, BE; Sai-Hong Ou, US

10:15 - 10:20 **1254MO - Safety and anti-tumour activity of zipalertinib in NSCLC patients (pts) with EGFR exon 20 insertion (ex20ins) mutations who received prior amivantamab**
A. Passaro¹, H.A. Yu², D. Nguyen³, V. Lee⁴, R. Soo⁵, S.H. Kim⁶, H. Daga⁷, D.S.W. Tan⁸, S.-W. Kim⁹, O.J. Juan Vidal¹⁰, Z. Piotrowska¹¹, E. Keeton¹², T. Liu¹², S. Li¹², J. Jones¹², G. Ruiter¹³, ¹European Institute of Oncology IRCCS, Milan, IT, ²Memorial Sloan Kettering Cancer Center, New York, US, ³City of Hope Comprehensive Cancer Center, Duarte, US, ⁴The University of Hong Kong, Hong Kong, HK, ⁵National University Cancer Institute Singapore, Singapore, SG, ⁶Seoul National University Bundang Hospital, Seongnam, KR, ⁷Osaka City General Hospital, Osaka, JP, ⁸NCCS - National Cancer Centre Singapore, Singapore, SG, ⁹Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, ¹⁰Hospital Universitari i Politècnic La Fe, Valencia, ES, ¹¹MGH - Massachusetts General Hospital, Boston, US, ¹²Cullinan Therapeutics, Inc., Cambridge, US, ¹³Netherlands Cancer Institute, Amsterdam, NL

10:20 - 10:25 **1255MO - A phase II safety and efficacy study of PM8002/BNT327 in combination with chemotherapy in patients with EGFR-mutated non-small cell lung cancer (NSCLC)**
Y.-L. Wu¹, Z. Wang¹, Y. Cheng², J. Fang³, X. Meng⁴, Y. Pan⁵, H. Zhao⁶, Y. Zhao⁷, H. Su⁸, M. Sun⁹, T. Zhou¹⁰, P. Duan¹¹, D. Lv¹², Y. Wang¹³, Y. Du¹⁴, W. Zuo¹⁵, P. Zhang¹⁶, T. Zhang¹⁷, ¹Guangdong Province People's Hospital, Guangzhou, CN, ²Jilin Cancer Hospital, Changchun, CN, ³Peking University Cancer Hospital, Beijing, CN, ⁴Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, CN, ⁵The First Affiliated Hospital of USTC Anhui Provincial Hospital, Hefei, CN, ⁶Shanghai Sixth People's Hospital, Shanghai, CN, ⁷Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, CN, ⁸The Fourth Military Medical University, Xi'an, CN, ⁹Cental Hospital Affiliated to Shandong First Medical University, Jinan, CN, ¹⁰Changzhou Cancer Hospital, Changzhou, CN, ¹¹Chengdu Hospital of Integrated Traditional Chinese and Western Medicine, Chengdu, CN, ¹²Taizhou Hospital of Zhejiang Province, Linhai, CN, ¹³Affiliated Cancer Hospital of Harbin Medical University, Harbin, CN, ¹⁴The First Affiliated Hospital of Anhui Medical University, Hefei, CN, ¹⁵The First Affiliated Hospital of Nanchang University, Nanchang, CN, ¹⁶Shanghai Pulmonary Hospital, Shanghai, CN, ¹⁷The First Affiliated Hospital of Chongqing Medical University, Chongqing, CN



- 10:25 - 10:30 **1256MO - Phase I/II ARROS-1 study of zidesamtinib (NVL-520) in ROS1 fusion-positive solid tumours**
B. Besse¹, A. Drilon², B.C. Cho³, D.R. Camidge⁴, J. Neal⁵, C.-C. Lin⁶, S. Liu⁷, M. Nagasaka⁸, S. Kao⁹, E. Felip¹⁰, A.J. Van Der Wekken¹¹, C.C. Lin¹², J. Bauman¹³, S. Gadgeel¹⁴, M. Samant¹⁵, J. Shen¹⁵, Y. Sun¹⁵, V. Zhu¹⁵, V. Upadhyay¹⁵, J. Lin¹⁶, ¹Institut Gustave Roussy, Villejuif, Cedex, FR, ²Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, New York, US, ³Yonsei Cancer Center, Seoul, KR, ⁴University of Colorado Cancer Center, Aurora, US, ⁵Stanford Cancer Institute, Palo Alto, US, ⁶National Taiwan University Hospital, Taipei, TW, ⁷Georgetown Lombardi Comprehensive Cancer Center, Washington, US, ⁸University of California Irvine, Orange, US, ⁹Chris O'Brien Lifecare, Camperdown, AU, ¹⁰Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, ES, ¹¹University of Groningen, University Medical Center Groningen, Groningen, NL, ¹²National Cheng Kung University Hospital, Tainan, TW, ¹³Fox Chase Cancer Center, Philadelphia, US, ¹⁴Henry Ford Cancer Center, Detroit, US, ¹⁵Nuvalent, Inc., Cambridge, US, ¹⁶Massachusetts General Hospital, Boston, US
- 10:30 - 10:45 **Invited Discussant 1254MO, 1255MO and 1256MO**
A.J. De Langen, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL
- 10:45 - 10:50 **1257MO - ABBV-400, a c-Met protein-targeting antibody-drug conjugate (ADC), in patients (Pts) with advanced EGFR wildtype (WT) non-squamous (NSQ) non-small cell lung cancer (NSCLC): Results from a phase I study**
M. De Miguel¹, N. Yamamoto², J. Raimbourg³, B.C. Cho⁴, M. Gottfried⁵, S. Stemmer⁶, J. Goldman⁷, M. Blaney⁸, T. Jennaro⁸, A. Vasilopoulos⁸, R.R. Li⁸, K. Freise⁸, M. Neagu Aristide⁸, G. Morrison-Thiele⁸, Z. Hunter⁸, M. Burns⁸, D.R. Camidge⁹, ¹CIOCC HM Sanchinarro, Madrid, ES, ²National Cancer Center Hospital, Tokyo, JP, ³Institut de Cancérologie de l'Ouest, Saint-Herblain, FR, ⁴Yonsei University College of Medicine, Seoul, KR, ⁵Tel Aviv University, Tel Aviv, IL, ⁶Institute of Oncology, Davidoff Center, Rabin Medical Center, Petah Tikva, IL, ⁷David Geffen School of Medicine at UCLA, Los Angeles, US, ⁸AbbVie Inc., North Chicago, US, ⁹University of Colorado Cancer Center, Aurora, US
- 10:50 - 11:00 **1258MO - Low dose versus standard dose pembrolizumab for treatment of stage IV stage non-small cell lung carcinoma: Results of the pre-planned interim analysis of the NVALT-30 clinical trial**
M. Van Den Heuvel¹, V. Van Der Noort², R. Ter Heine¹, ¹Radboud University Medical Center, Nijmegen, NL, ²NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL
- 11:00 - 11:15 **Invited Discussant 1257MO and 1258MO**
M. Brandão, Institute Jules Bordet, Anderlecht, BE



11:15 - 11:20

LBA56 - Updated efficacy and safety from the phase II PHAROS study of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC)

G. Riely¹, M.-J. Ahn², J. Clarke³, I. Dagogo-Jack⁴, E. Felip⁵, F. Gelsomino⁶, J. Goldman⁷, M. Hussein⁸, M. Johnson⁹, D. Morgensztern¹⁰, E. Nadal¹¹, M. Offin¹, M. Provencio Pulla¹², S. Ramalingam¹³, E. Smit¹⁴, A. Tsao¹⁵, A. Alcasid¹⁶, T. Usari¹⁷, K. Wilner¹⁸, B. Johnson¹⁹, ¹Memorial Sloan Kettering Cancer Center, New York, US, ²Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, ³Duke Cancer Institute, Durham, US, ⁴Massachusetts General Hospital, Boston, US, ⁵Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, ES, ⁶IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, IT, ⁷David Geffen School of Medicine, University of California Los Angeles, Los Angeles, US, ⁸Sarah Cannon Research Institute, Leesburg, US, ⁹Sarah Cannon Research Institute, Nashville, US, ¹⁰Washington University School of Medicine, St. Louis, US, ¹¹Catalan Institute of Oncology, Barcelona, ES, ¹²Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, ES, ¹³Winship Cancer Institute of Emory University, Atlanta, US, ¹⁴Leiden University Medical Center, Leiden, NL, ¹⁵The University of Texas MD Anderson Cancer Center, Houston, US, ¹⁶Pfizer, Collegeville, US, ¹⁷Pfizer, Milan, IT, ¹⁸Pfizer, La Jolla, US, ¹⁹Dana-Farber Cancer Institute, Boston, US

11:20 - 11:25

LBA57 - Adagrasib (ADA) vs docetaxel (DOCE) in patients (pts) with KRASG12C-mutated advanced NSCLC and baseline brain metastases (BM): Results from KRYSTAL-12

F. Barlesi¹, W. Yao², M. Duruisseaux³, L. Doucet⁴, J. Shi⁵, O.J. Juan Vidal⁶, Y.-C. Kim⁷, M.R. García Campelo⁸, A. Azkárte Martínez⁹, S. Lu¹⁰, R. Jotte¹¹, E. Felip¹², G. Lo Russo¹³, M. Reck¹⁴, Y. Zhang¹⁵, N. Hu¹⁵, M. Michenzie¹⁶, T.S.K. Mok¹⁷, ¹Gustave Roussy, Villejuif, France, Paris Saclay University, Le Kremlin-Bicêtre, FR, ²Sichuan Cancer Hospital & Institute, Chengdu, CN, ³Hospices Civils de Lyon Cancer Institute, Lyon, France, Cancer Research Center of Lyon, UMR INSERM 1052, CNRS 5286, Lyon, France, Université Claude Bernard Lyon 1, Université de Lyon, Lyon, FR, ⁴Institut de Cancérologie de l'Ouest, Saint-Herblain, FR, ⁵Linyi Cancer Hospital, Linyi, CN, ⁶Hospital Universitari i Politècnic La Fe, Valencia, ES, ⁷Chonnam National University Medical School and CNU Hwasun Hospital, Hwasun, KR, ⁸Complejo Hospitalario Universitario A Coruña, A Coruña, ES, ⁹Hospital Universitario Son Espases, Palma, ES, ¹⁰Shanghai Jiao Tong University, Shanghai, CN, ¹¹US Oncology Research, Denver, US, ¹²Universitat Autònoma de Barcelona, Barcelona, ES, ¹³Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT, ¹⁴LungenClinic, Grosshansdorf, DE, ¹⁵Bristol Myers Squibb, Princeton, US, ¹⁶Mirati Therapeutics, a Bristol Myers Squibb company, San Diego, US, ¹⁷Chinese University of Hong Kong, Hong Kong, HK



11:25 - 11:30

1259MO - Encorafenib plus binimetinib in patients (pts) with previously untreated BRAF V600E-mutant advanced non-small cell lung cancer (NSCLC): An open-label, multicenter phase II trial (IFCT-1904 ENCO-BRAF)

D. Planchard¹, J. Mazieres², C. Mascaux³, F. Guisier⁴, P. Tomasini⁵, M. Wislez⁶, D. Moro-Sibilot⁷, S. Cousin⁸, A. Cortot⁹, S. Couraud¹⁰, V. Fallet¹¹, C. Guguen¹², A. Lagrange¹³, A.-C. Madroszyk Flandin¹⁴, J. Otto¹⁵, M. Pérol¹⁶, B. Roch¹⁷, E. Amour¹⁸, F. Morin¹⁸, C. Ricordel¹⁹, ¹Gustave Roussy, Villejuif, Cedex, FR, ²Centre Hospitalier Universitaire de Toulouse, Toulouse, FR, ³Hopitaux Universitaires de Strasbourg - Nouvel Hopital Civil, Strasbourg, FR, ⁴CHU de Rouen Normandie, Rouen, FR, ⁵Assistance Publique Hôpitaux de Marseille, Marseille, FR, ⁶Hôpital Cochin (Hôpitaux Universitaires Paris Centre), Paris, FR, ⁷CHU Grenoble Alpes, Grenoble, FR, ⁸Institut Bergonie, Bordeaux, FR, ⁹Institut Cœur Poumon, Lille, FR, ¹⁰Hôpital Lyon Sud, Hospices Civils de Lyon, Pierre-Bénite, FR, ¹¹Tenon Hospital, Assistance Publique Hôpitaux de Paris and GRC 4, Therascan, Sorbonne Université, Paris, FR, ¹²Centre Hospitalier Général du Mans, Le Mans, FR, ¹³Centre Georges-François Leclerc, Dijon, FR, ¹⁴IPC - Institut Paoli-Calmettes, Marseille, Cedex, FR, ¹⁵Centre Antoine Lacassagne, Nice, FR, ¹⁶Centre Léon Bérard, Lyon, FR, ¹⁷Arnaud de Villeneuve University Hospital, Montpellier, FR, ¹⁸French Cooperative Thoracic Intergroup (IFCT), Paris, FR, ¹⁹Hopital Pontchaillou, CHU Rennes, INSERM, OSS, UMR_S 1242, Univ Rennes 1, Rennes, FR

11:30 - 11:45

Invited Discussant LBA56, LBA57 and 1259MO

S.-H. Ou, UCI Health Chao Family Comprehensive Cancer Center, Orange, US

10:15 - 11:45

Type: Special session

Toledo Auditorium - Hall 3

Title: Dissecting Cancer of Unknown Primary: Case presentation and expert insights

Chair(s): Linda Mileshtkin, AU; Alwin Krämer, DE

10:15 - 10:20

Case Presentation: Patient with unfavourable visceral CUP- Part 1

N. Cook, The Christie NHS Foundation Trust, Manchester, GB

10:20 - 10:35

Current and novel omics technologies for identifying the primary

H. Wasan, Hammersmith Hospital - Imperial College Healthcare NHS Trust, London, GB

10:35 - 10:50

Optimal workflows for diagnosis and management of CUP patients

L. Mileshtkin, Peter MacCallum Cancer Center, Melbourne, AU

10:50 - 11:00

Q&A

11:00 - 11:05

Case Presentation: Patient with unfavourable visceral CUP- Part 2

N. Cook, The Christie NHS Foundation Trust, Manchester, GB

11:05 - 11:20

Optimising trial design and therapeutic strategies targeting driver molecular aberrations in CUP

A. Krämer, DKFZ - German Cancer Research Center, Heidelberg, DE

11:20 - 11:35 **The elusive CUP biologic signature: are we missing a primary or a biology?**
M. Esteller, Josep Carreras Leukaemia Research Institute (IJC), Badalona, ES

11:35 - 11:45 **Q&A**

10:15 - 11:45 **Type: Educational session** **Zaragoza Auditorium - CC5**
Title: ESMO and WHO: Tackling cancer worldwide
 Chair(s): Jean-Yves Blay, FR; Bente Mikkelsen, CH

10:15 - 10:40 **Partnering with ESMO on game-changing tools to improve cancer prevention and control worldwide**
A. Ilbawi, WHO - World Health Organization, Geneva, CH

10:40 - 11:05 **Where does the world stand on achieving Universal Health Coverage by 2030?**
R. Casolino, WHO - World Health Organization, Geneva, CH

11:05 - 11:30 **The WHO Pandemic Accord and the review of the International Health Regulations (IHR): The need to include cancer prevention and control**
J. Martin-Moreno, Hospital Clinico Universitario de Valencia, Valencia, ES

11:30 - 11:45 **Q&A and discussion**

10:15 - 11:45 **Type: EONS session** **Ronda Auditorium - Hall 7**
Title: Health promotion, prevention and screening
 Chair(s): Eugenia Trigos Arjona, ES; Remziye Semerci, TR

10:15 - 10:30 **Innovations in cancer screening: Emerging technologies and their clinical impact**
R. Albu, Association of European Cancer Leagues, Brussels, BE

10:30 - 10:45 **The role of schools in cancer prevention: Strategies for involving school nurses and teachers in promoting healthy habits**
J. Jackson, RCC - Regionalt cancercentrum Stockholm - Gotland, Stockholm, SE

10:45 - 11:00 **PrEvCan (Cancer Prevention across Europe): Key learning experiences and impact**
L. Sharp, RCC - Regionalt cancercentrum Stockholm - Gotland, Stockholm, SE

11:00 - 11:10 **CN82 - Nurses management of malnutrition risk in cancer patients: The importance of screening tools**
E. Favot¹, S. Libriani², C. Mazzega Fabbro¹, ¹CRO Aviano - Centro di Riferimento Oncologico - IRCCS, Aviano, IT, ²Università degli Studi di Udine, Udine, IT

11:10 - 11:20 **CN26 - Association of life satisfaction, emotional support, social isolation with lung cancer screening adherence among US Adults**
H. Poghosyan, S. Sarkar, Yale University, Orange, US

11:20 - 11:45 **Q&A and discussion**

10:15 - 11:45 **Type: EONS session** **Segovia Auditorium - Hall 7**
Title: Quality improvement in cancer care
 Chair(s): Virpi Sulosaari, FI; Nikolina Dodlek, CY

10:15 - 10:35 **Assessing oncology nurse practitioner students' clinical competency and capability**
E. Furlong, National University of Ireland - University College Dublin, Dublin, IE

10:35 - 10:55 **How to plan and implement quality improvement projects**
V. Sulosaari, TUAS - Turku University of Applied Sciences, Turku, FI

10:55 - 11:15 **Interact interprofessional training**
N. Dodlek, Cyprus University of Technology - Nursing Science, Limassol, CY

11:15 - 11:25 **CN59 - Activity and outcomes of a Translational Research Unit coordinated by nursing**
M.P. Andueza¹, E. Navarcorena Zabalza¹, Y. Iragorri Barberena¹, M. Ayensa Burgui¹, I. Gracia Ilundain², I. Navamuel Andueza¹, A. Ojer Perea¹, M. Navamuel Andueza¹, M.F. Sanmamed¹, M. Rodríguez-Ruiz¹, R. Pio¹, A. Gonzalez Hernandez¹, M.A. Fortuño¹, J.P. De Torres¹, L.M. Seijo Maceiras¹, M.D. Lozano¹, I. Melero², L. Montuenga¹, J.L. Perez Gracia¹, M. Ocon¹, ¹CCUN - Cancer Center Clinica Universidad de Navarra, Pamplona, ES, ²Clinica Universidad de Navarra, Pamplona, ES

11:25 - 11:35 **CN83 - Transforming cancer care - The impact of Cancer@Home initiatives: Phase I**
D. Chiappetta, Alfred Health, Melbourne, AU

11:35 - 11:45 **Q&A and discussion**

10:45 - 11:30 **Type: Challenge your Expert** **Pamplona Auditorium - Hall 3**
Title: Young onset of colorectal cancer: What do we need to know
 Chair(s): Irit Ben-Aharon, IL

10:45 - 11:05 **Presentation by Expert**
K. Ng, Dana Farber Cancer Institute, Boston, US

11:05 - 11:30 **Discussion led by Chair**
I. Ben-Aharon, Rambam Health Care Campus, Haifa, IL



10:45 - 11:30 **Type: Challenge your Expert** **Oviedo Auditorium - Hall 3**
Title: Moving forwards with ADCs in advanced disease
Chair(s): Seock-Ah Im, KR

10:45 - 11:05 **Presentation by Expert**
A. Bardia, UCLA - David Geffen School of Medicine, Los Angeles, US

11:05 - 11:30 **Discussion led by Chair**
S.-A. Im, SNUH - Seoul National University Hospital, Seoul, KR

10:45 - 11:30 **Type: Young Oncologists session** **Cartagena Auditorium - Hall 7**
Title: YO Brunch 1
Chair(s): Maria Kfoury, FR; Pablo Mando, AR

10:45 - 10:45 **How to utilise open data sources to start research projects?**
R. Dienstmann, Grupo Oncoclinicas, Sao Paulo, BR

11:45 - 12:45 **Type: Special session** **Tarragona Auditorium - Hall 7**
Title: Mentor the mentor
Chair(s): Teresa Amaral, DE

11:45 - 11:45 **Table 1**
R. Riechelmann¹, M. Van Der Heijden², ¹A.C. Camargo Cancer Center - Unidade Antonio Prudente, Sao Paulo, BR, ²Netherlands Cancer Institute, Amsterdam, NL

11:45 - 11:45 **Table 2**
S. Loi¹, T. Powles², ¹Peter MacCallum Cancer Centre, Melbourne, AU, ²St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB

11:45 - 11:45 **Table 3**
A. Psyrri¹, Z. Saridaki-Zoras², ¹Attikon University Hospital, Haidari, GR, ²Metropolitan Hospital, Athens, GR

11:45 - 11:45 **Table 4**
E. Smyth¹, G. De Castro Jr.², ¹Cambridge University Hospitals NHS Foundation Trust, Cambridge, GB, ²ICESP - Instituto do Cancer do Estado de Sao Paulo, Sao Paulo, BR

11:45 - 11:45 **Table 5**
A. Letsch¹, M. Garassino², ¹Universitätsklinikum Schleswig Holstein Campus Kiel II, Kiel, DE, ²University of Chicago Department of Medicine - Section of Hematology/Oncology, Chicago, US



12:00 - 12:35	Type: Keynote lecture Title: DNA repair pathways: Leveraging science in order to exploit the tumour Achilles Heel – A journey of discovery and perseverance Chair(s): Charlie Gourley, GB	Madrid Auditorium - Hall 2
12:00 - 12:05	Introduction <u>C. Gourley</u>, Cancer Research UK Edinburgh Centre, Edinburgh, GB	
12:05 - 12:20	Team science to find and target an “Achilles Heel” through PARP inhibition <u>A. Tutt</u>, ICR - Institute of Cancer Research, London, GB	
12:20 - 12:35	Beyond PARP inhibition: New preclinical science entering the clinic <u>A. D'Andrea</u>, Dana Farber Cancer Institute, Boston, US	
12:00 - 13:30	Type: EONS Industry Satellite Symposium Title: MSD - Improving the experience of care for women with gynaecological cancers: Lessons from cervical and endometrial cancer policy Chair(s): Silvija Piskorjanac, HR; Carlos Fernandes Cargaleiro, GB	Ronda Auditorium - Hall 7
12:00 - 12:05	Welcome and introduction <u>S. Piskorjanac</u>, KBC Osijek - Clinical Medical Center Osijek, Osijek, HR	
12:05 - 12:15	Patient perspective – a personal experience of living with cervical cancer <u>A. Gardiner</u>, Mantis Entertainment Limited, Godalming, GB	
12:15 - 12:35	What have we learned from 10 years’ progress in the prevention, diagnosis and treatment of cervical cancers and where do policy makers and health systems go next? <u>D. Kelly</u>, Cardiff University - School of Healthcare Sciences, Cardiff, GB	
12:35 - 13:05	Improving the future of care for women with endometrial cancer – IHE report <u>T. Hofmarcher</u>, IHE-The Swedish Institute for Health Economics, Lund, SE	
13:05 - 13:25	Panel discussion and Q&A <u>S. Piskorjanac</u>¹, <u>C. Fernandes Cargaleiro</u>², <u>A. Gardiner</u>³, <u>D. Kelly</u>⁴, <u>T. Hofmarcher</u>⁵, ¹KBC Osijek - Clinical Medical Center Osijek, Osijek, HR, ²Guy's Hospital, London, GB, ³Mantis Entertainment Limited, Godalming, GB, ⁴Cardiff University - School of Healthcare Sciences, Cardiff, GB, ⁵IHE-The Swedish Institute for Health Economics, Lund, SE	
13:25 - 13:30	Conclusion remarks <u>S. Piskorjanac</u>¹, <u>C. Fernandes Cargaleiro</u>², ¹KBC Osijek - Clinical Medical Center Osijek, Osijek, HR, ²Guy's Hospital, London, GB	



12:00 - 13:00	Type: EONS session Title: EONS Rapid-fire session 1 Chair(s): Amanda Drury, IE	Segovia Auditorium - Hall 7
12:00 - 12:10	Opening remarks and instructions <u>A. Drury</u> , DCU - Dublin City University, Dublin, IE	
12:10 - 12:15	CN31 - Social disparities in the survival of women with breast cancer in Brazil R.M. Pessanha ¹ , L.S. Dell'antonio ¹ , C.S. Dellantônio ² , W.R. Grippa ¹ , <u>L.C. Lopes-Júnior</u> ¹ , ¹ Universidade Federal do Espírito Santo, Campus de Maruípe, Vitoria, BR, ² Hospital Sirio Libanes, Sao Paulo, BR	
12:15 - 12:20	CN32 - Socioeconomic status and cancer: An umbrella review and burden estimation study <u>Y. He</u> ¹ , S. Li ¹ , K. Chen ² , K. Tao ² , X. Ma ¹ , ¹ West China Hospital and State Key Laboratory Of Biotherapy of Sichuan University, Chengdu, CN, ² Sichuan University, Chengdu, CN	
12:20 - 12:25	CN71 - A nurse-led clinic stepped-care intervention for rectal cancer survivors with bowel problems <u>E. Pape</u> ¹ , Y. Van Nieuwenhove ¹ , D. Van De Putte ² , K. Geboes ³ , G. Van Ramshorst ¹ , ¹ UZ Gent - Universitair Ziekenhuis Gent, Gent, BE, ² Ghent University Hospital, Ghent, BE, ³ UZ Gent - University Hospital Ghent, Gent, BE	
12:25 - 12:30	CN72 - "I thought I was probably going to die due to people's looking at me with pity": A phenomenological qualitative study on the lived cancer stigma experiences of breast cancer patients <u>T. Pehlivan Saribudak</u> ¹ , E. Mertek ² , D.K. Korkmaz ² , G.D. Acar ² , i. Dogan ² , ¹ Istanbul Arel University, Istanbul, TR, ² Istanbul Arel University, Istanbul, TR	
12:30 - 12:35	CN78 - The effects of lumbar sympathetic ganglion block therapy on secondary lower limb lymphedema <u>H.-Q. Huang</u> ¹ , Y. Sun ² , J. Lin ² , H. Zheng ¹ , ¹ Fujian Cancer Hospital, Fuzhou, CN, ² Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, CN	
12:35 - 12:40	CN87 - Risk stratification for cardiotoxicity and follow-up in breast cancer patients treated with anthracycline and/or trastuzumab: An exploratory analysis of patient records <u>L.-M. Kinnaer</u> ¹ , J. Van Hulle ¹ , E. Naert ² , F. Tromp ³ , A. De Pauw ² , H. Denys ² , N. Van Titelboom ⁴ , D. Serruys ⁴ , ¹ Ghent University, Gent, BE, ² UZ Gent - University Hospital Ghent, Gent, BE, ³ Ghent University Hospital, Gent, BE, ⁴ AZ Sint-Lucas Gent - Campus Sint-Lucas, Gent, BE	
12:40 - 12:45	CN6 - Integration of specialized mobile palliative unit care into management of patients with thoracic malignancies: A single center experience <u>A. Muratovic</u> ¹ , M. Lopuh ² , K. Mohorcic ¹ , E. Markocic Rojc ³ , U. Jancic ¹ , ¹ University Clinic of Respiratory and Allergic Diseases Golnik, Golnik, SI, ² General Hospital Jesenice, Jesenice, SI, ³ General Hospital Isola, Izola, SI	



12:45 - 12:50 **CN88 - The effectiveness of virtual reality use in cancer patients: A systematic review**
T. Ucgun, E. Akgün Çitak, Baskent University, Ankara, TR

12:50 - 12:55 **CN49 - Staying or leaving the pediatric oncology clinic: Nurses' challenges in care and voices of struggle: A qualitative study**
R. Semerci¹, A. Akça Sümengen², I. Ercan Koyuncu³, E.H. Savaş⁴, A. Ay³, M. Erkul⁵, ¹Koc University Hospital, FATİH, TR, ²The University of Alabama at Birmingham, Birmingham, US, ³Baskent University, Ankara, TR, ⁴Koc University - School of Nursing, Istanbul, TR, ⁵Antalya Bilim University, Antalya, TR

12:30 - 14:00 **Type: Patient Advocacy session** **Zaragoza Auditorium - CC5**
Title: Understanding the cancer journey
 Chair(s): Ines Vaz Luis, FR; Natacha Bolanos Fernandez, ES

12:30 - 12:45 **The impact of a cancer diagnosis, advocacy and empowerment through the cancer journey**
N. Bolanos Fernandez, Lymphoma Coalition, Madrid, ES

12:45 - 13:00 **Doctor / patient relationships (acted out): The right and wrong way of communicating**
I. Vaz Luis, Institut Gustave Roussy, Villejuif, Cedex, FR

13:00 - 13:15 **The difficulties of moving from second to third line treatment**
J. Pelouchova, Diagnoza leukemie, z.s, Prague, CZ

13:15 - 13:30 **The fear of recurrence: Best practice in coping with the psychological burden**
L. Travado, Champalimaud Foundation - Champalimaud Clinical Center, Lisbon, PT

13:30 - 13:45 **It's not that easy to survive!**
S. Lavallé, Luxembourg Institute of Health, Luxembourg, LU

13:45 - 14:00 **Discussion**

13:00 - 14:30 **Type: Industry Satellite Symposium** **Burgos Auditorium - Hall 5**
Title: Bristol Myers Squibb - Evolving Patient-Centered Therapies for Metastatic NSCLC
 Chair(s): Jarushka Naidoo, IE

13:00 - 13:05 **Welcome and Introduction**
J. Naidoo, Beaumont Hospital, Dublin, IE

13:05 - 13:13 **The Importance of Patient Empowerment During Their Journey**
T. Conneran, KRAS Kickers, Charlotte, US

13:13 - 13:28 **PD-L1 <1% in Metastatic NSCLC: Guiding Treatment Decisions for Potential Durable Outcomes in a Patient Population With Unmet Needs**
L. Paz-Ares, Hospital Universitario 12 de Octubre, Madrid, ES



- 13:28 - 13:43 **Kicking Off Targeted Medicine for Patients With KRAS G12C-Mutated Metastatic NSCLC**
J. Naidoo, Beaumont Hospital, Dublin, IE
- 13:43 - 13:58 **Next-Generation Tyrosine Kinase Inhibitors: The Evolving Treatment Landscape of Cancers With ROS1 or NTRK Fusions**
A. Drilon, Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US
- 13:58 - 14:28 **Panel Discussion: What Would Be Your Treatment Decision?**
J. Naidoo¹, L. Paz-Ares², T. Conneran³, A. Drilon⁴, ¹Beaumont Hospital, Dublin, IE, ²Hospital Universitario 12 de Octubre, Madrid, ES, ³KRAS Kickers, Charlotte, US, ⁴Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US
- 14:28 - 14:30 **Closing Remarks**
J. Naidoo, Beaumont Hospital, Dublin, IE

13:00 - 14:30	Type: Industry Satellite Symposium Title: Pfizer - Maximising the Metastatic Breast Cancer Treatment Paradigm and Looking Ahead Chair(s): Javier Cortés, ES	Salamanca Auditorium - Hall 5
----------------------	---	--------------------------------------

- 13:00 - 13:03 **Welcome and Introduction**
J. Cortés, INTERNATIONAL BREAST CANCER CENTER, IBCC, Barcelona, ES
- 13:03 - 14:03 **Interactive Grand Rounds: Clinical Decision-Making in 1L HR+/HER2- MBC**
J. Cortés¹, H. Rugo², C. Criscitiello³, ¹INTERNATIONAL BREAST CANCER CENTER, IBCC, Barcelona, ES, ²UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, ³IEO - Istituto Europeo di Oncologia IRCCS, Milan, IT
- 14:03 - 14:18 **What's on the Horizon for Patients With MBC?**
S. Tolaney¹, C. Criscitiello², ¹Dana Farber Cancer Institute, Boston, US, ²IEO - Istituto Europeo di Oncologia IRCCS, Milan, IT
- 14:18 - 14:28 **Panel Discussion and Audience Q&A**
J. Cortés¹, H. Rugo², C. Criscitiello³, ¹INTERNATIONAL BREAST CANCER CENTER, IBCC, Barcelona, ES, ²UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, ³IEO - Istituto Europeo di Oncologia IRCCS, Milan, IT
- 14:28 - 14:30 **Closing Remarks**
J. Cortés, INTERNATIONAL BREAST CANCER CENTER, IBCC, Barcelona, ES



13:00 - 14:30	Type: Industry Satellite Symposium Title: AstraZeneca - Unfolding the future: The evolution of HR+ mBC with ET and ADCs Chair(s): Komal Jhaveri, US	Santander Auditorium - Hall 5
13:00 - 13:10	The changing treatment landscape: Considering the options <u>K. Jhaveri</u> , Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US	
13:10 - 13:25	A new ET era: Maximising benefits <u>F.C. Bidard</u> , Institut Curie, Paris, FR	
13:25 - 13:35	Case-based discussion: Role of biomarkers <u>K. Jhaveri</u> ¹ , <u>F.C. Bidard</u> ² , <u>P. Tarantino</u> ³ , <u>E. Ciruelos</u> ⁴ , ¹ Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US, ² Institut Curie, Paris, FR, ³ Dana Farber Cancer Institute, Boston, US, ⁴ Hospital Universitario 12 de Octubre, Madrid, ES	
13:35 - 13:50	Age of ADCs: What next after ET <u>P. Tarantino</u> , Dana Farber Cancer Institute, Boston, US	
13:50 - 14:00	Case-based discussion: Role of ADCs <u>K. Jhaveri</u> ¹ , <u>F.C. Bidard</u> ² , <u>P. Tarantino</u> ³ , <u>E. Ciruelos</u> ⁴ , ¹ Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US, ² Institut Curie, Paris, FR, ³ Dana Farber Cancer Institute, Boston, US, ⁴ Hospital Universitario 12 de Octubre, Madrid, ES	
14:00 - 14:10	The new paradigm: Considerations when tailoring treatment for HR+ mBC <u>E. Ciruelos</u> , Hospital Universitario 12 de Octubre, Madrid, ES	
14:10 - 14:25	Optimizing care discussion and Q&A <u>K. Jhaveri</u> ¹ , <u>F.C. Bidard</u> ² , <u>P. Tarantino</u> ³ , <u>E. Ciruelos</u> ⁴ , ¹ Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US, ² Institut Curie, Paris, FR, ³ Dana Farber Cancer Institute, Boston, US, ⁴ Hospital Universitario 12 de Octubre, Madrid, ES	
14:25 - 14:30	close <u>K. Jhaveri</u> , Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US	

13:00 - 14:30	Type: Industry Satellite Symposium Title: Merck Healthcare KGaA - Sequencing is Key: Unlocking Individualized Treatment in Bladder Cancer Chair(s): Enrique Grande, ES	Valencia Auditorium - Hall 5
13:00 - 13:05	Welcome and introduction <u>E. Grande</u> , MD Anderson Cancer Center Madrid, Madrid, ES	
13:05 - 13:25	Navigating first-line treatment approaches in Ia/mUC <u>A. Birtle</u> , Royal Preston Hospital, Preston, GB	

13:25 - 13:45 **Improving outcomes with first-line maintenance therapy and exploring patient selection**
S. Hussain, University of Sheffield Medical School, Sheffield, GB

13:45 - 14:05 **Optimizing treatment sequencing: Learnings from Real-World Evidence and Clinical Experience**
P. Barthelemy, ICANS - Institut de Cancérologie Strasbourg Europe, Strasbourg, FR

14:05 - 14:20 **Audience Q&A**
E. Grande¹, S. Hussain², P. Barthelemy³, A. Birtle⁴, ¹MD Anderson Cancer Center Madrid, Madrid, ES, ²University of Sheffield Medical School, Sheffield, GB, ³ICANS - Institut de Cancérologie Strasbourg Europe, Strasbourg, FR, ⁴Royal Preston Hospital, Preston, GB

14:20 - 14:30 **Closing Remarks**
E. Grande, MD Anderson Cancer Center Madrid, Madrid, ES

13:00 - 14:30 **Type: Industry Satellite Symposium** **Alicante Auditorium - Hall 3**
Title: Servier - Optimizing the continuum of care for Metastatic Colorectal Cancer patients in 3L setting and beyond
 Chair(s): Michel Ducreux, FR; Lukas Weiss, AT

13:00 - 13:10 **Introduction**
M. Ducreux, Gustave Roussy - Cancer Campus, Villejuif, FR

13:10 - 13:30 **Navigating the current treatment landscape in 3L mCRC and beyond**
C. Cremolini, AOU Pisana - Stabilimento di Santa Chiara, Pisa, IT

13:30 - 13:45 **Evolving strategies in 3L mCRC treatment**
L. Weiss, Uniklinikum Salzburg - Landeskrankenhaus, Salzburg, AT

13:45 - 14:05 **Patient cases: clinical insights and treatment options in 3rd and beyond**
K. Heinrich, Hospital Munich Grosshadern - Ludwig-Maximilians-University (LMU), Munich, DE

14:05 - 14:25 **Panel discussion: Insights from experts' perspectives on future therapies in colorectal cancer management**
M. Ducreux¹, L. Weiss², C. Cremolini³, K. Heinrich⁴, ¹Gustave Roussy - Cancer Campus, Villejuif, FR, ²Uniklinikum Salzburg - Landeskrankenhaus, Salzburg, AT, ³AOU Pisana - Stabilimento di Santa Chiara, Pisa, IT, ⁴Hospital Munich Grosshadern - Ludwig-Maximilians-University (LMU), Munich, DE

14:25 - 14:30 **Conclusion**
L. Weiss, Uniklinikum Salzburg - Landeskrankenhaus, Salzburg, AT



13:00 - 14:30	Type: Industry Satellite Symposium Title: PeerView Oncology - How to Make Multifactorial Clinical Decisions in HR+, HER2- EBC and MBC: Guiding Precision Amid Growing Complexity Chair(s): Stephen Johnston, GB	Pamplona Auditorium - Hall 3
13:00 - 13:05	Welcome, Introduction, and Goal Setting <u>S. Johnston</u>, The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, GB	
13:05 - 13:20	Conducting Risk Assessment to Identify Patients With High-Risk HR+, HER2- EBC: Evolving Standards and Current Guidance <u>M. Goetz</u>, Mayo Clinic, Rochester, US	
13:20 - 13:35	Maximizing the Potential of Adjuvant CDK4/6 Inhibition to Reduce the Risk of Recurrence in High-Risk HR+, HER2- EBC: Evidence and Practicalities <u>S. Johnston</u>, The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, GB	
13:35 - 13:50	Managing Adverse Events and Improving Adherence/Persistence in High-Risk HR+, HER2- EBC: Impactful Strategies to Help Patients Stay on Therapy <u>V. Guarneri</u>, University of Padua, Padova, IT	
13:50 - 13:55	Q&A With Focus on HR+, HER2- EBC <u>S. Johnston</u>¹, <u>M. Goetz</u>², <u>V. Guarneri</u>³, ¹The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, GB, ²Mayo Clinic, Rochester, US, ³University of Padua, Padova, IT	
13:55 - 14:10	Analyzing the Latest Evidence on CDK4/6 Inhibitors in HR+, HER2- MBC: Essential Updates and Implications for Practice <u>M. Goetz</u>, Mayo Clinic, Rochester, US	
14:10 - 14:25	Individualizing the Selection and Use of CDK4/6 Inhibitors in HR+, HER2- MBC: Key Factors and Modern Practice Principles <u>V. Guarneri</u>, University of Padua, Padova, IT	
14:25 - 14:30	Q&A With Focus on HR+, HER2- MBC, Synthesis, and Conclusions <u>S. Johnston</u>¹, <u>M. Goetz</u>², <u>V. Guarneri</u>³, ¹The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, GB, ²Mayo Clinic, Rochester, US, ³University of Padua, Padova, IT	
13:00 - 14:30	Type: Industry Satellite Symposium Title: Novartis - Preparing for the future: Radioligand therapy as an essential pillar in oncology Chair(s): Leonhard Schätz, CH	Oviedo Auditorium - Hall 3
13:00 - 13:10	Opening Remarks: Introduction to Healthcare System Readiness (HCS) Readiness for Radioligand Therapies (RLT) in Oncology <u>L. Schätz</u>, Novartis Campus Basel, Basel, CH	



- 13:10 - 13:40 **Panelists' insights - Multi-stakeholder Perspectives on Overcoming Barriers to Establishing RLT in Oncology**
L. Schätz¹, K. Herrmann², E. Briers³, E. Castro⁴, D. Deandreis⁵, ¹Novartis Campus Basel, Basel, CH, ²WTZ - Westdeutsches Tumorzentrum Essen, Essen, DE, ³Europa Uomo - The European Prostate Cancer Coalition, Antwerpen, BE, ⁴Hospital Universitario 12 de Octubre, Madrid, ES, ⁵Institut Gustave Roussy, Villejuif, Cedex, FR
- 13:40 - 14:10 **Multi-Stakeholder Panel Discussion: A Multidisciplinary Approach to Navigating Challenges and Embracing Opportunities to Unlock HCS Readiness for RLT**
L. Schätz¹, K. Herrmann², E. Briers³, E. Castro⁴, D. Deandreis⁵, ¹Novartis Campus Basel, Basel, CH, ²WTZ - Westdeutsches Tumorzentrum Essen, Essen, DE, ³Europa Uomo - The European Prostate Cancer Coalition, Antwerpen, BE, ⁴Hospital Universitario 12 de Octubre, Madrid, ES, ⁵Institut Gustave Roussy, Villejuif, Cedex, FR
- 14:10 - 14:20 **Open Forum: Q&A Session**
L. Schätz¹, K. Herrmann², E. Briers³, E. Castro⁴, D. Deandreis⁵, ¹Novartis Campus Basel, Basel, CH, ²WTZ - Westdeutsches Tumorzentrum Essen, Essen, DE, ³Europa Uomo - The European Prostate Cancer Coalition, Antwerpen, BE, ⁴Hospital Universitario 12 de Octubre, Madrid, ES, ⁵Institut Gustave Roussy, Villejuif, Cedex, FR
- 14:20 - 14:30 **Closing Session: Final Thoughts**
L. Schätz¹, K. Herrmann², E. Briers³, E. Castro⁴, D. Deandreis⁵, ¹Novartis Campus Basel, Basel, CH, ²WTZ - Westdeutsches Tumorzentrum Essen, Essen, DE, ³Europa Uomo - The European Prostate Cancer Coalition, Antwerpen, BE, ⁴Hospital Universitario 12 de Octubre, Madrid, ES, ⁵Institut Gustave Roussy, Villejuif, Cedex, FR

13:00 - 14:30	Type: Industry Satellite Symposium Title: Gilead Oncology - There is another way: Utilising ADCs to improve outcomes in patients with triple-negative and HR+/HER2-negative mBC Chair(s): Lisa Carey, US	Toledo Auditorium - Hall 3
----------------------	--	-----------------------------------

- 13:00 - 13:05 **Welcome and introduction**
L. Carey, UNC - The University of North Carolina at Chapel Hill - School of Medicine, Chapel Hill, US
- 13:05 - 13:20 **ADCs as a treatment option in previously treated triple-negative and HR+/HER2-negative mBC**
L. Carey, UNC - The University of North Carolina at Chapel Hill - School of Medicine, Chapel Hill, US
- 13:20 - 14:00 **Optimising treatment outcomes with ADCs in previously treated mTNBC and HR+/HER2-negative mBC**
A. Llombart Cussac, Hospital Arnau de Vilanova, Valencia, ES



14:00 - 14:20 **Exploring ADCs as treatment options in earlier lines of mBC**

S. Loi, Peter MacCallum Cancer Centre, Melbourne, AU

14:20 - 14:30 **Q&A and closing remarks**

L. Carey¹, A. Llombart Cussac², S. Loi³, ¹UNC - The University of North Carolina at Chapel Hill - School of Medicine, Chapel Hill, US, ²Hospital Arnau de Vilanova, Valencia, ES, ³Peter MacCallum Cancer Centre, Melbourne, AU

13:00 - 14:00	Type: Special session Title: ESMO General Assembly	Cartagena Auditorium - Hall 7
14:00 - 15:30	Type: EONS session Title: ESMO-EONS collaborative session: Cancer and sexuality Chair(s): Karin Jordan, DE; Eugenia Trigos Arjona, ES	Ronda Auditorium - Hall 7

14:00 - 14:05 **Welcome and opening remarks**

J. De Munter¹, E. Trigos Arjona², ¹UZ Gent - Universitair Ziekenhuis Gent, Gent, BE, ²Hospital Universitari i Politècnic La Fe, Valencia, ES

14:05 - 14:25 **Talking about sex after cancer: Adapting, testing and evaluating an eLearning resource to enhance healthcare professional provision of sexual support for patients with cancer and their partners**

S. Bingham, Ulster University, Jordanstown, GB

14:25 - 14:45 **Sexuality in cancer survivors**

I. Tsatsou, 251 Hellenic Airforce General Hospital, Athens, GR

14:45 - 15:25 **Discussion on cancer and sexuality**

15:25 - 15:30 **Q&A and discussion**

14:00 - 16:00	Type: EONS session Title: N.U.R.T.U.R.E. - Time to invest in cancer nurses Chair(s): Nikolina Dodlek, CY; Grigorios Kotronoulas, GB	Segovia Auditorium - Hall 7
---------------	---	------------------------------------

14:00 - 14:10 **Welcome and opening remarks**

N. Dodlek¹, G. Kotronoulas², ¹Cyprus University of Technology - Nursing Science, Limassol, CY, ²University of Glasgow, Glasgow, GB

14:10 - 14:30 **Early signs and symptoms? Who is the silent one?**

G. Kotronoulas, University of Glasgow, Glasgow, GB

14:30 - 14:50 **Building up resilience in cancer nursing: Strategies and skills**

D. Protopiros¹, S. Islamcevic², ¹Ministry of Health, Athens, GR, ²University Clinical Center Zagreb - Gynecological Cancer Center, Zagreb, HR

14:50 - 15:10	Coping strategies burnout and stress <u>A. Charalambous</u> , Cyprus University of Technology - Nursing Science, Limassol, CY
15:10 - 15:30	Work-life balance workshop <u>C. Díez De Los Ríos De La Serna</u> ¹ , <u>R. Semerci</u> ² , ¹ University of Glasgow, Glasgow, GB, ² Koc University Hospital, Istanbul, TR
15:30 - 15:50	NURTURE and prevention in cancer nursing <u>A. Kassianos</u> , Cyprus University of Technology, Cyprus, GR
15:50 - 16:00	Q&A and closing remarks
14:45 - 16:15	Type: Special symposium Title: Next generation immunotherapies in thoracic malignancies Chair(s): <u>Nathalie Chaput-Gras</u> , FR; <u>Lizza Hendriks</u> , NL Madrid Auditorium - Hall 2
14:45 - 14:50	Introduction and scientific background <u>L. Hendriks</u> , Maastricht University Medical Center (MUMC), Maastricht, NL
14:50 - 15:05	Targeting T cells beyond PD-1/PD-L1 axis: Other checkpoints inhibitors and costimulatory receptors agonists <u>N. Chaput-Gras</u> , Institut Gustave Roussy, Villejuif, Cedex, FR
15:05 - 15:20	Immune-cell engagers <u>A. Sacher</u> , UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA
15:20 - 15:35	Vaccines <u>J. Aerts</u> , Erasmus MC - University Medical Center, Rotterdam, NL
15:35 - 15:50	Cellular therapies <u>M. Lotem</u> , Hadassah Ein Kerem, Jerusalem, IL
15:50 - 16:10	Q&A and discussion
16:10 - 16:15	Conclusions and perspectives <u>N. Chaput-Gras</u> , Institut Gustave Roussy, Villejuif, Cedex, FR



14:45 - 16:15

Type: Proffered Paper session

Sevilla Auditorium - Hall 2

Title: Proffered paper session: Gynaecological cancers

Chair(s): Charlie Gourley, GB; Ana Oaknin, ES

14:45 - 14:55

7110 - Avelumab & methotrexate to eradicate low-risk gestational trophoblastic tumors in first-line setting: TROPHAMET phase I/II trial

B. You¹, J.-P. Lotz², P. Descargues³, F. Joly Lobbedez⁴, T. De La Motte Rouge⁵, C. Lebreton⁶, L. Gladieff⁷, P. Follana⁸, M. Jamelot⁹, J. Massardier³, T. Hajri¹⁰, M. Alves-Ferreira³, S. Bin³, C. Langlois-Jacques¹⁰, M. Bonjour³, A. Roux¹⁰, C. Desauw¹¹, M. Provansal Gross¹², F. Golfier¹⁰, P.-A. Bolze¹⁰, ¹Lyon Sud Hospital Center - HCL, Pierre-Bénite, FR, ²Hopital Tenon AP-HP, Paris, Cedex, FR, ³Hospices Civiles de Lyon - HCL - Lyon University Hospital Center, Lyon, FR, ⁴Centre Francois Baclesse, Caen, Cedex, FR, ⁵Centre Eugene - Marquis, Rennes, FR, ⁶Institute Bergonié - Centre Régional de Lutte Contre le Cancer (CLCC), Bordeaux, FR, ⁷Institut Universitaire du Cancer - Toulouse- Oncopole, Toulouse, FR, ⁸Centre Anticancer Antoine Lacassagne, Nice, FR, ⁹Institut Universitaire de Cancérologie AP-HP. Sorbonne Université, Hôpital Tenon, Paris, FR, ¹⁰Hospices Civiles de Lyon - HCL - Lyon University Hospital Center, Pierre Benite (Lyon), FR, ¹¹C.H.U. Claude Huriez, Lille, FR, ¹²Institute Paoli Calmettes, Marseille, FR

14:55 - 15:05

LBA28 - ENGOT-en11/GOG-3053/KEYNOTE-B21: A phase III study of pembrolizumab or placebo in combination with adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer

T. Van Gorp¹, L. Rob², W. Lu³, F. Backes⁴, F. Ortaç⁵, K. Hasegawa⁶, S. Hietanen⁷, A. Savarese⁸, A. Laenen⁹, Y.M. Kim¹⁰, L. Bodnar¹¹, M.P. Barretina Ginesta¹², L. Gilbert¹³, B. Pothuri¹⁴, X. Chen¹⁵, J. Lichfield¹⁶, W. Wang¹⁷, R. Orlowski¹⁸, A. Lortholary¹⁹, B. Slomovitz²⁰, ¹UZ Leuven, Leuven, BE, ²Department of Obstetrics & Gynaecology; and Central and Eastern European Gynecologic Oncology Group (CEEGOG), Prague, CZ, ³Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, CN, ⁴Ohio State University and James Cancer Hospital; and Gynecologic Oncology Group (GOG), Columbus, US, ⁵and Turkish Society of Gynecologic Oncology (TRSGO), Ankara, TR, ⁶Saitama Medical University International Medical Center, Saitama, JP, ⁷Turku University Hospital and University of Turku; TYKS Cancer Centre, FICAN West, Organization of EU Cancer Institutes, Finland; and Nordic Society of Gynaecological Oncology - Clinical Trial Unit (NSGO-CTU), Turku, FI, ⁸and Multicenter Italian Trials in Ovarian Cancer and Gynecologic Malignancies (MITO), Rome, IT, ⁹KU Leuven; and Belgian and Luxembourg Gynaecological Oncology Group (BGOG), Leuven, BE, ¹⁰Asan Medical Center, University of Ulsan, Seoul, KR, ¹¹Mazovia Regional Hospital, Siedlce Oncology Center; and European Network of Gynaecological Oncological Trial (ENGOT) groups - Polish Group of Gynaecological Oncology (PGOG), Siedlce, PL, ¹²Medical School University of Girona; and Spanish Ovarian Cancer Research Group (GEICO), Girona, ES, ¹³McGill University Health Centre; Research-Institute, McGill University Health Centre; and Gerald Bronfman Department of Oncology, McGill University, Montreal, CA, ¹⁴Perlmutter Cancer Center, NYU Langone Health; and Gynecologic Oncology Group (GOG), New York, US, ¹⁵Obstetrics and Gynecology Hospital of Fudan University; and Shanghai Gynecologic Oncology Group (SGOG), Shanghai, CN, ¹⁶MSD, London, GB, ¹⁷MSD, Shanghai, CN, ¹⁸Merck & Co., Inc., Rahway, US, ¹⁹Hôpital Privé du Confluent; and National Investigators Group for the Study of Ovarian and Breast Cancers (GINECO), Nantes, FR, ²⁰and Gynecologic Oncology Group (GOG) Foundation, Miami Beach, US



15:05 - 15:15

Invited Discussant 7110 and LBA28

C. Marth, Innsbruck Medical University, Innsbruck, AT

15:15 - 15:30

Q&A

15:30 - 15:40

LBA29 - Final overall survival (OS) in patients (pts) with newly diagnosed advanced ovarian cancer (aOC) treated with niraparib (nir) first-line (1L) maintenance: Results from PRIMA/ENGOT-OV26/GOG-3012

A. González-Martín¹, B. Pothuri², M.P. Barretina Ginesta³, W.S. Graybill⁴, I. Vergote⁵, C. McCormick⁶, M.R. Mirza⁷, R. Moore⁸, D. Lorusso⁹, R. O'Cearbhaill¹⁰, G. Freyer¹¹, D. O'Malley¹², F. Heitz¹³, M. Shahin¹⁴, I. Bruchim¹⁵, W. Bradley¹⁶, N. Compton¹⁷, I. Malinowska¹⁸, A. Redondo¹⁹, B. Monk²⁰, ¹Translational Oncology Group, CIMA, Universidad de Navarra, Cancer Center Clínica Universidad de Navarra, Madrid, and Grupo Español de Investigación en Cáncer ginecológico (GEICO), Madrid, ES, ²Laura & Isaac Perlmutter Cancer Center, NYU Langone Health, New York, US, ³Institut Català d'Oncologia, Girona Biomedical Research Institute (IDIBGI-CERCA), Girona University, and GEICO, Girona, ES, ⁴Medical University of South Carolina, Charleston, US, ⁵Leuven Cancer Institute, and Belgium and Luxembourg Gynaecological Oncology Group (BGOG), Leuven, BE, ⁶present affiliation, Johns Hopkins Hospital, Baltimore, US, ⁷Rigshospitalet, Copenhagen University Hospital, Copenhagen, and Nordic Society of Gynaecologic Oncology-Clinical Trial Unit, Copenhagen, DK, ⁸Wilmot Cancer Institute, Department of Obstetrics and Gynecology, University of Rochester, Rochester, US, ⁹present affiliation Humanitas San Pio X, Milan, Humanitas University, Pieve Emanuele, Milan, IT, ¹⁰Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College and GOG Foundation, New York, US, ¹¹Centre Hospitalier Lyon-Sud Hospices Civils de Lyon, Oullins-Pierre-Bénite, FR, ¹²The Ohio State University and the James Comprehensive Cancer Center, Columbus, US, ¹³Kliniken Essen-Mitte, Essen, Germany and Dept for Gynecology with the Center for the Oncologic Surgery Charité Campus Virchow-Klinikum, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität zu Berlin, Berlin Institute of Health, Berlin, DE, ¹⁴Hanjani Institute for Gynecologic Oncology, Abington Hospital-Jefferson Health, Asplundh Cancer Pavilion, Sidney Kimmel Medical College of Thomas Jefferson University, Willow Grove, US, ¹⁵Hillel Yaffe Medical Center, Hadera, Israel, Technion Institute of Technology, and Israeli Society of Gynecologic Oncology (ISGO), Haifa, IL, ¹⁶Medical College of Wisconsin, Milwaukee, US, ¹⁷Compton Statistical Consulting Limited, Westerham, GB, ¹⁸GSK, Waltham, US, ¹⁹Hospital Universitario La Paz – IdiPAZ, Madrid, ES, ²⁰present affiliation GOG Foundation; Florida Cancer Specialists and Research Institute, West Palm Beach, US



15:40 - 15:50

LBA30 - ATHENA-COMBO, a phase III, randomized trial comparing rucaparib (RUCA) + nivolumab (NIVO) combination therapy vs RUCA monotherapy as maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC)

B. Monk¹, A. Oaknin², D. O'Malley³, M. Wilson⁴, D. Lorusso⁵, S. Westin⁶, A. Oza⁷, F. Zagouri⁸, T. Herzog⁹, O. Mikheeva¹⁰, C. Parkinson¹¹, R. Coleman¹², M.C. Lim¹³, A. Chudecka-Glaz¹⁴, R. Eskander¹⁵, I. Bruchim¹⁶, S. Ghamande¹⁷, D. Despain¹⁸, K. Fujiwara¹⁹, R. Kristeleit²⁰, ¹Florida Cancer Specialists and Research Institute, West Palm Beach, US, ²Medical Oncology Service, Vall d'Hebron Institute of Oncology, Vall d'Hebron Barcelona Hospital Campus, Barcelona, ES, ³The Ohio State University, James Cancer Center, Columbus, US, ⁴Auckland City Hospital, Auckland, NZ, ⁵Fondazione Policlinico Universitario Gemelli IRCCS, and Humanitas San Pio X, Milan, IT, ⁶The University of Texas MD Anderson Cancer Center, Houston, US, ⁷Princess Margaret Hospital Cancer Centre, Toronto, CA, ⁸Alexandra Hospital, National and Kapodistrian University of Athens, Athens, GR, ⁹University of Cincinnati, Cincinnati, US, ¹⁰Limited Liability Company MedPomosch, Saint-Petersburg, RU, ¹¹Cambridge University Hospitals NHS Foundation Trust, Cambridge, GB, ¹²US Oncology Research, The Woodlands, US, ¹³National Cancer Center Korea, Goyang, KR, ¹⁴Pomeranian Medical University, Szczecin, PL, ¹⁵Gynecology and Reproductive Sciences, University of California, La Jolla, US, ¹⁶Hillel Yaffe Medical Center affiliated with the Technion, Institute of Technology, Hadera, IL, ¹⁷Georgia Cancer Center at Augusta University, Augusta, US, ¹⁸pharma&, New York, US, ¹⁹Saitama Medical University International Medical Center, Saitama, JP, ²⁰Guy's and St Thomas' NHS Foundation Trust, London, GB

15:50 - 16:00

Invited Discussant LBA29 and LBA30

P. Harter, KEM | Evang. Kliniken Essen-Mitte gGmbH, Essen, DE

16:00 - 16:15

Q&A

14:45 - 16:00

Type: Multidisciplinary session

Bilbao Auditorium - Hall 2

Title: Mesothelioma and the role of multidisciplinary team

Chair(s): Alessandra Curioni-Fontecedro, CH; Eric Lim, GB

14:45 - 14:50

Presentation of case/condition

D. O'Reilly, St James's Hospital, Dublin, IE

14:50 - 15:10

Advances in pathology and biomarker discovery in mesothelioma

F. Galateau-Sallé, Centre Léon Bérard, Lyon, FR

15:10 - 15:30

Thoracic surgery for mesothelioma: The old and the new

E. Lim, Royal Brompton Hospital, London, GB

15:30 - 15:50

Systemic therapy for mesothelioma: A growing landscape

A. Curioni-Fontecedro, Cantonal Hospital Fribourg, Villar sur Glane, CH

15:50 - 16:00

Discussion



14:45 - 16:15

Type: Mini Oral session

Granada Auditorium - Hall 6

Title: Mini oral session: GI tumours, lower

Chair(s): Claire Gallois, FR; Dirk Arnold, DE; Sara Lonardi, IT

14:45 - 14:50

515MO - Encorafenib & cetuximab (EC) & FOLFIRI for BRAF V600E-mutant metastatic colorectal cancer (mCRC): Updated results from the BREAKWATER safety lead-in (SLI)

J. Tabernero¹, T. Yoshino², T.W. Kim³, R. Yaeger⁴, J. Desai⁵, H. Wasan⁶, E. Van Cutsem⁷, F. Ciardiello⁸, T. Maughan⁹, C. Eng¹⁰, J. Tie⁵, M.E. Elez Fernandez¹, S. Lonardi¹¹, T. Usari¹², E. Hahn¹³, S. Dychter¹⁴, G. Ferrier¹⁵, X. Zhang¹⁶, S. Kopetz¹⁷, ¹Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, UVic-UCC, Barcelona, ES, ²National Cancer Center Hospital East, Kashiwa, JP, ³Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, ⁴Memorial Sloan Kettering Cancer Center, New York, US, ⁵Peter MacCallum Cancer Centre, Melbourne, AU, ⁶Hammersmith Hospital, Division of Cancer, Imperial College, London, GB, ⁷University Hospital Gasthuisberg and University of Leuven, Leuven, BE, ⁸University of Campania Luigi Vanvitelli, Napoli, IT, ⁹MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford, GB, ¹⁰Vanderbilt-Ingram Cancer Center, Nashville, US, ¹¹Veneto Institute of Oncology-IRCCS, Padova, IT, ¹²Pfizer, Inc., Milan, IT, ¹³Pfizer, Inc, Boulder, US, ¹⁴Pfizer, Inc., La Jolla, US, ¹⁵Pfizer Inc, New York, US, ¹⁶Pfizer, Inc., South San Francisco, US, ¹⁷MD Anderson Cancer Center, Houston, US

14:50 - 14:55

516MO - Zanidatamab (Zani) & chemotherapy (CT) in first-line (1L) human epidermal growth factor receptor 2-positive (HER2&) advanced/metastatic colorectal cancer (mCRC)

S.Y. Rha¹, K.-W. Lee², S. Lee³, Y.-K. Kang⁴, S. Chandana⁵, A. Escalante⁶, C. Xie⁷, P. Garfin⁷, S. Iqbal⁸, ¹Yonsei Cancer Center, Yonsei University College of Medicine, Yonsei University Health System, Seoul, KR, ²Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, KR, ³Korea University Anam Hospital, Korea University College of Medicine, Seoul, KR, ⁴Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, ⁵The Cancer & Hematology Centers, Grand Rapids, US, ⁶ICEGCLINIC, Santiago, CL, ⁷Jazz Pharmaceuticals, Philadelphia, US, ⁸University of Southern California Norris Comprehensive Cancer Center, Los Angeles, US



14:55 - 15:00

518MO - Update analysis of the randomized phase II study comparing FOLFIRI plus ramucirumab (RAM) versus FOLFOXIRI plus RAM as first-line treatment for patients with metastatic colorectal cancer: WJOG9216G (RECAST)

K. Yamazaki¹, Y. Kito², H. Shoji³, T. Yamada⁴, T. Tsushima¹, S. Mitani⁵, K. Shiraishi⁶, H. Yasui⁷, H. Hara⁸, K. Shimozaaki⁹, T. Esaki¹⁰, Y. Shinohara¹¹, T. Tsuzuki¹², S. Kajiura¹³, K. Yoshimura¹⁴, K. Sakai⁵, K. Nishio¹⁵, H. Kawakami⁵, S. Hironaka¹⁶, K. Muro¹⁷, ¹Shizuoka Cancer Center, Shizuoka, JP, ²Ishikawa Prefectural Central Hospital, Kanazawa, JP, ³National Cancer Center Hospital, Tokyo, JP, ⁴University of Tsukuba, Tsukuba, JP, ⁵Kindai University - Faculty of Medicine, Osaka, JP, ⁶National Hospital Organization, Nagoya Medical Center, Nagoya, JP, ⁷Kobe City Medical Center General Hospital, Kobe, JP, ⁸Saitama Cancer Center, Ina, JP, ⁹Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, JP, ¹⁰National Hospital Organization Kyushu Cancer Center, Fukuoka, JP, ¹¹JCHO - Japan Community Healthcare Organization Kyushu Hospital, Kitakyushu, JP, ¹²Himeji Red Cross Hospital, Himeji, JP, ¹³Toyama University Hospital, Toyama, JP, ¹⁴Hiroshima University Hospital, Hiroshima, JP, ¹⁵Kindai University School of Medicine - Main Campus, Osaka, JP, ¹⁶Kyorin University Faculty of Medicine, Mitaka, JP, ¹⁷Aichi Cancer Center Hospital, Nagoya, JP

15:00 - 15:15

Invited Discussant 515MO, 516MO and 518MO

C. Gallois, HEGP - Hopital Europeen Georges-Pompidou - AP-HP, Paris, FR

15:15 - 15:20

508MO - Organ preservation in early rectal adenocarcinoma: 5-year results of the randomized opera trial

S. Ben Dhia¹, N. Barbet², T. Pace-Loscos³, R. Schiappa⁴, J.P. Gerard³, L. Mineur⁵, A. Dhadda⁶, A. Sun Myint⁷, J. Doyen⁴, ¹Antoine Lacassagne Center, Nice, FR, ²ORLAM - Centre de Radiothérapie Bayard à Lyon Villeurbanne, Villeurbanne, FR, ³CLCC - Centre Antoine Lacassagne, Nice, FR, ⁴Centre Anticancer Antoine Lacassagne, Nice, FR, ⁵institut du cancer Avignon, Avignon, FR, ⁶Castle Hill Hospital - Hull University Teaching Hospitals NHS Trust, Cottingham, GB, ⁷University of Liverpool - School of Medicine, Liverpool, GB

15:20 - 15:25

510MO - Long-term survival and organ preservation with pembrolizumab in localized MSI-H/dMMR solid tumors

K. Ludford¹, M. Lapelusa², W. Qiao¹, J. Thomas¹, N. You², S. Thirumurthi², D. Maru¹, B. Iorgulescu¹, S. Kopetz³, M. Overman³, ¹MD Anderson Cancer Center, Houston, US, ²University of Texas MD Anderson Cancer Center, Houston, US, ³The University of Texas MD Anderson Cancer Center - Main Building, Houston, US

15:25 - 15:40

Invited Discussant 508MO and 510MO

D. Arnold, Asklepios Klinik Altona - Hämatologie, internistische Onkologie, Palliativmedizin und Rheumatologie, Hamburg, DE



15:40 - 15:45

511MO - Third line rechallenge with cetuximab (Cet) and irinotecan in circulating tumor DNA (ctDNA) selected metastatic colorectal cancer (mCRC) patients: The randomized phase II CITRIC trial

C. Santos Vivas¹, J. Vidal Barrull², C. Fernandez Rodriguez², F. Salvà Ballabrera³, V. Alonso-Orduna⁴, R. Garcia-Carbonero⁵, F. Losa⁶, N. Tarazona Llaveró⁷, M.J. Safont Aguilera⁸, F. Rivera Herrero⁹, L. Layos Romero¹⁰, M.J. Ortiz Morales¹¹, A. Salud¹², J. Alcaide-Garcia¹³, D. Paez¹⁴, X. Hernandez-Yagüe¹⁵, R. Alvarez Gallego¹⁶, R. Vera¹⁷, B. Bellosillo Paricio², C. Montagut Viladot²,
¹ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), L'Hospitalet de Llobregat, ES, ²Hospital del Mar - Parc de Salut Mar, Barcelona, ES, ³Vall d'Hebron University Hospital, Barcelona, ES, ⁴Hospital Miguel Servet, Zaragoza, ES, ⁵University Hospital 12 De Octubre, Madrid, ES, ⁶Hospital de Sant Joan Despi Moisès Broggi, Sant Joan Despi, ES, ⁷Hospital Clínico Universitario de Valencia, Valencia, ES, ⁸CHGUV - Consorcio Hospital General Universitario de Valencia, Valencia, ES, ⁹HUMV - Hospital Universitario Marques de Valdecilla, Santander, ES, ¹⁰ICO - Institut Català d'Oncologia Badalona (Hospital Universitario Germans Trias i Pujol), Badalona, ES, ¹¹Hospital Universitario Reina Sofía, Córdoba, ES, ¹²Hospital Arnau de Vilanova - Lleida, Alpicat, ES, ¹³Hospital Regional Universitario Málaga Carlos Haya, Málaga, ES, ¹⁴Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ¹⁵ICO Girona - Institut Català d'Oncologia Girona, Girona, ES, ¹⁶CIOCC - Centro Integral Oncológico Clara Campal, Hospital Universitario HM Sanchinarro, Madrid, ES, ¹⁷HUN - Hospital Universitario de Navarra - Navarrabiomed-IdiSNA, Pamplona, ES

15:45 - 15:50

513MO - Amivantamab plus FOLFOX or FOLFIRI in metastatic colorectal cancer: Results from OrigAMI-1, an open-label, phase Ib/II study

F. Pietrantonio¹, G.F. Ho², Y.-L. Su³, E. Chen⁴, Y. Yuan⁵, P.-J. Voon⁶, X. Liang⁷, D. Jonker⁸, F. Longo Muñoz⁹, J. Hecht¹⁰, S. Chandana¹¹, D. Arnold¹², R. Bhattacharya¹³, J. Curtin¹⁴, S. Maul¹⁵, R. Iwasawa¹⁴, S. Chowdhury¹⁶, R. Schnepf¹⁴, M. Baig¹⁴, Y.S. Hong¹⁷, ¹Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT, ²Clinical Oncology Unit, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, MY, ³Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City, TW, ⁴Princess Margaret Cancer Centre University Health Network, Toronto, CA, ⁵The Second Affiliated Hospital of Zhejiang University College of Medicine, Hangzhou, CN, ⁶Department of Radiotherapy and Oncology, Sarawak General Hospital, Sarawak, MY, ⁷Hubei Cancer Hospital, Wuhan, CN, ⁸The Ottawa Hospital Research Institute, University of Ottawa, Ottawa, CA, ⁹Hospital Universitario Ramón y Cajal, Madrid, ES, ¹⁰UCLA Jonsson Comprehensive Cancer Center, Santa Monica, US, ¹¹START Midwest, Grand Rapids, US, ¹²Asklepios Klinik Altona, Hamburg, DE, ¹³Janssen Research & Development, Raritan, US, ¹⁴Janssen Research & Development, Spring House, US, ¹⁵Janssen Research & Development, Los Angeles, US, ¹⁶Janssen Research & Development, Cambridge, US, ¹⁷Asan Medical Center, Seoul, KR

15:50 - 15:55 **514MO - The efficacy and safety of ivonescimab with or without ligufalimab in combination with FOLFOXIRI as first-line (1L) treatment for metastatic colorectal cancer (mCRC)**

Y. Deng¹, H. Liu², L. Xie³, J. Zhang¹, H. Hu¹, Z. Liu⁴, W. Wang⁵, X. Yu⁶, Z.M. Wang⁶, B. Li⁶, Y. Xia⁶,
¹The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, CN, ²Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CN, ³Yunnan Cancer Hospital, Kunming, CN, ⁴Hunan Cancer Hospital, Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, CN, ⁵The First People's Hospital of Foshan, Foshan, CN, ⁶Akeso Biopharma Inc., Zhongshan, CN

15:55 - 16:10 **Invited Discussant 511MO, 513MO and 514MO**

S. Lonardi, IOV - Istituto Oncologico Veneto IRCCS, Padova, IT

14:45 - 16:00 **Type: Multidisciplinary session** **Burgos Auditorium - Hall 5**
Title: Treatment of lobular breast cancer (ILC): From pitfalls to opportunities
Chair(s): Jens Huober, CH; Ava Kwong, HK

14:45 - 14:50 **Presentation of case/condition**

J. Huober, Kantonsspital St. Gallen, St. Gallen, CH

14:50 - 15:05 **Challenges and novel avenues of imaging ILC**

T. Van Nijnatten, Maastricht University Medical Center (MUMC), Maastricht, NL

15:05 - 15:20 **Pitfalls in diagnosis of ILC**

G. Floris, UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE

15:20 - 15:35 **Local treatment for ILC: Do's and don'ts**

A. Kwong, The University of Hong Kong - Li Ka Shing Faculty of Medicine, Hong Kong, HK

15:35 - 15:50 **Systemic treatment for ILCs**

J. Huober, Kantonsspital St. Gallen, St. Gallen, CH

15:50 - 16:00 **Discussion**



14:45 - 16:15	Type: Proffered Paper session Title: Proffered paper session 1: Basic science & Translational research Chair(s): Philippe Bedard, CA; Ana Vivancos, ES	Salamanca Auditorium - Hall 5
14:45 - 14:55	10 - The somatic mutation landscape of the normal and malignant pancreas <u>P. Nicola</u>¹, A.R.J. Lawson¹, P. Scott¹, F. Abascal¹, A. Cagan¹, L. Harvey¹, Y. Hooks¹, H. Savin¹, K.T.A. Mahbubani², B. Basu³, M. Stratton¹, A. Paterson⁴, K. Saeb-Parsy⁴, I. Martincorena¹, ¹Wellcome Trust Sanger Institute, Hinxton, GB, ²University of Cambridge, Cambridge, GB, ³Addenbrooke's Hospital and University of Cambridge, Cambridge, GB, ⁴Addenbrooke's Hospital, Cambridge, Cambridge, GB	
14:55 - 15:05	LBA9 - Clinical insights from ultra-sensitive tumour-informed ctDNA tracking across the TRACERx cohort J. Black¹, T. Karasaki², C. Abbott³, S. Boyle³, B. Li³, M. Al Bakir⁴, W.K. Liu⁵, S. Veeriah², M. Jamal-Hanjani⁶, N. Mcgranahan⁶, A. Frankell⁷, R. Chen³, <u>C. Swanton</u>⁴, ¹UCL Cancer Institute - UCL - London's Global University, London, GB, ²The Francis Crick Institute, London, GB, ³Personalis, Inc. - Headquarters (Office and Laboratory), Menlo Park, US, ⁴Francis Crick Institute, London, GB, ⁵UCL - University College London, London, GB, ⁶UCL Cancer Institute - Paul O'Gorman Building, London, GB, ⁷Early Cancer Institute, Cambridge, GB	
15:05 - 15:15	Invited Discussant 10 and LBA9 <u>A. Vivancos</u>, Vall d'Hebron University Hospital, Barcelona, ES	
15:15 - 15:25	Q&A	
15:25 - 15:35	630 - Transcriptional features of stage IIT4N0/III colon cancer associated with residual disease and ctDNA status after surgery in the PEGASUS trial <u>E. Medico</u>¹, F. Buffa², C. Isella¹, G. Skenderi², L. Lazzari³, M. Prisciandaro⁴, S. Lonardi⁵, N. Tarazona Llaveró⁶, C. Montagut Viladot⁷, A. Sartore Bianchi⁸, M.G. Zampino⁹, M.E. Elez Fernandez¹⁰, C. Santos Vivas¹¹, M. Mandalà¹², S. Tamberi¹³, A. Calon¹⁴, A. Cervantes⁶, S. Siena⁸, A. Bardelli¹⁵, S. Marsoni³, ¹Candiolo Cancer Institute, FPO-IRCCS and University of Torino, Candiolo, IT, ²Università Bocconi; IFOM ETS - The AIRC Institute of Molecular Oncology, Milan, IT, ³IFOM ETS - The AIRC Institute of Molecular Oncology, Milan, IT, ⁴Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ⁵IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, ⁶INCLIVA Biomedical Research Institute, Valencia; CIBERONC, Instituto de Salud Carlos III, Madrid, ES, ⁷Hospital del Mar, Barcelona, ES, ⁸Università degli Studi di Milano; ASST Grande Ospedale Metropolitano Niguarda, Milan, IT, ⁹IEO - Istituto Europeo di Oncologia IRCCS, Milan, IT, ¹⁰Vall d'Hebron University Hospital, Barcelona, ES, ¹¹ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), L'Hospitalet de Llobregat, ES, ¹²University of Perugia, Santa Maria della Misericordia University Hospital of Perugia, Perugia, IT, ¹³Ospedale degli Infermi - AUSL Romagna, Faenza, Ravenna, IT, ¹⁴Hospital del Mar Research Institute, Barcelona, ES, ¹⁵Molecular Biotechnology Center, University of Torino, Torino, IT	

15:35 - 15:45	640 - Clinical validation of a tissue-agnostic genome-wide methylome enrichment assay for MRD in head and neck cancers G. Liu¹, L. Ailles¹, <u>S.H. Huang</u>¹, K. Rey-Mcintyre¹, B. Brown², J.T. Jones², Y. Wang², C. Melton², J. Bergener³, J. Zhang², O. Hall², J. Min², S.Y. Shen³, J. Provance², E. Sosa², B. Allen², A. Licon², J. Zhang², A.-R. Hartman², D. De Carvalho³, ¹UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA, ²Adela, Inc., Foster City, US, ³Adela, Inc., Toronto, CA
15:45 - 15:55	650 - Cancer treatment monitoring using cell-free DNA fragmentomes <u>R. Fijneman</u>¹, L. Rinaldi², Z. Skidmore³, B. Alipanahi², L. Keefer³, I. Van 't Erve⁴, K. Lumbard³, J. Carey³, B. Chesnick³, S. Cristiano², N. Dracopoli³, R. Scharpf⁵, G. Meijer¹, A. Leal², V. Velculescu⁶, ¹NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ²Delfi Diagnostics, Inc., Baltimore, US, ³Delfi Diagnostics, Baltimore, US, ⁴Netherlands Cancer Institute, Amsterdam, NL, ⁵Johns Hopkins University School of Medicine, Baltimore, US, ⁶Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center, Baltimore, US
15:55 - 16:05	Invited Discussant 630, 640 and 650 <u>H. Zhao</u>, CRUK - Cancer Research UK Cambridge Institute - University of Cambridge, Cambridge, GB
16:05 - 16:15	Q&A
14:45 - 16:00	Type: Multidisciplinary session Valencia Auditorium - Hall 5 Title: Biochemical failure post-local therapy: An opportunity for tailored treatment? Chair(s): Pierre Blanchard, FR; Derya Tilki, DE
14:45 - 14:50	Presentation of case/condition <u>P. Blanchard</u>, Institut Gustave Roussy, Villejuif, FR
14:50 - 15:10	Surveillance/minimal intervention for good risk disease <u>D. Tilki</u>, UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE
15:10 - 15:30	Intensification of systemic treatment for poor risk disease <u>D. Rathkopf</u>, MSKCC - Memorial Sloan Kettering Cancer Center, New York, US
15:30 - 15:50	PSMA PET as a game changer for decision making? <u>D. Oprea-Lager</u>, Amsterdam UMC - Vrije University Medical Centre (VUmc), Amsterdam, NL
15:50 - 16:00	Discussion



14:45 - 16:15 **Type: Educational session** **Alicante Auditorium - Hall 3**
Title: New developments in the treatment of sarcomas in 2024
 Chair(s): Joanna Szkandera, AT; Sandra Strauss, GB

- 14:45 - 15:05 **New developments in pathology and molecular biology**
E. Wardelmann, University Hospital Muenster-Gerhard Domagk Institute of Pathology, Muenster, DE
- 15:05 - 15:25 **New developments in the treatment of soft tissue sarcomas**
K. Boye, Oslo University Hospital - The Norwegian Radium Hospital, Oslo, NO
- 15:25 - 15:45 **New developments in the treatment of GIST**
C. Serrano, Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES
- 15:45 - 16:05 **New developments in the treatment of bone sarcomas**
S. Strauss, University College London Hospitals NHS Foundation Trust, London, GB
- 16:05 - 16:15 **Q&A and discussion**

14:45 - 16:25 **Type: Proffered Paper session** **Pamplona Auditorium - Hall 3**
Title: Proffered paper session: Supportive and palliative care
 Chair(s): Matteo Lambertini, IT; Jayne Wood, GB

- 14:45 - 14:55 **18140 - Breastfeeding in women with hormone receptor-positive breast cancer who conceived after temporary interruption of endocrine therapy: Results from the POSITIVE trial**
 H. Azim Jr¹, S. Niman², A.H. Partridge², M. Ruggeri³, M. Colleoni⁴, C. Saura Manich⁵, C. Shimizu⁶, A. Satersdal⁷, J. Kroep⁸, K. Gelmon⁹, F. Amant¹⁰, A. Mailliez¹¹, H. Moore¹², T. Ferreiro¹³, S. El-Abed¹⁴, R. Gelber², O. Pagani¹⁵, F. Peccatori¹⁶, ¹Cairo Cure Oncology Center, Cairo, EG, ²Dana Farber Cancer Institute, Boston, US, ³International Breast Cancer Study Group, Bern, CH, ⁴IEO - Istituto Europeo di Oncologia, Milan, IT, ⁵Vall d'Hebron University Hospital, Barcelona, ES, ⁶NCGM - National Center for Global Health and Medicine, Shinjuku-ku, JP, ⁷Oslo University Hospital, Oslo, NO, ⁸LUMC-Leiden University Medical Center, Leiden, NL, ⁹BC Cancer Agency - Vancouver, Vancouver, CA, ¹⁰UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ¹¹Centre Oscar Lambret, Lille, FR, ¹²Taussig Cancer Center-Cleveland Clinic, Cleveland, US, ¹³Soul Reconnect, Barcelona, ES, ¹⁴Breast International Group (BIG) - AISBL, Brussels, BE, ¹⁵Interdisciplinary Cancer Service Hospital Riviera, Geneva, CH, ¹⁶IEO - Istituto Europeo di Oncologia IRCCS, Milan, IT



14:55 - 15:05

18150 - Breastfeeding after breast cancer in young BRCA carriers: Results from an international cohort study

E. Blondeaux¹, V. Delucchi¹, E. Mariamidze², R. Bernstein Molho³, A.-S. Hamy-Petit⁴, A. Ferrari⁵, S. Linn⁶, H.J. Kim⁷, E. Agostinetto⁸, S. Paluch-Shimon⁹, A. Toss¹⁰, A. Di Meglio¹¹, J. Balmaña¹², R. Yerushalmi¹³, K. Rodriguez-Wallberg¹⁴, I. Demeestere¹⁵, H. Azim Jr¹⁶, F. Peccatori¹⁷, A.H. Partridge¹⁸, M. Lambertini¹, ¹IRCCS Ospedale Policlinico San Martino, Genova, IT, ²Todua Clinic, Tbilisi, GE, ³Chaim Sheba Medical Center, Ramat Gan, IL, ⁴Université Paris Cité, Institut Curie, Paris, FR, ⁵Fondazione IRCCS Policlinico San Matteo, Pavia, IT, ⁶Netherlands Cancer Institute (NKI), Amsterdam, NL, ⁷Asan Medical Center - University of Ulsan, Seoul, KR, ⁸Institute Jules Bordet, Brussels, BE, ⁹Hadassah University Hospital - Ein Kerem, Jerusalem, IL, ¹⁰Azienda Ospedaliero - Universitaria Policlinico di Modena, Modena, IT, ¹¹Institut Gustave Roussy, Villejuif, Cedex, FR, ¹²Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, ¹³Rabin Medical Center Davidoff Cancer Centre, Beilinson Campus, Petah Tikva, IL, ¹⁴Karolinska Institute and Reproductive Medicine, Karolinska University Hospital, Huddinge, SE, ¹⁵ULB - Université Libre de Bruxelles, Brussels, BE, ¹⁶Cairo Cure Oncology Center, Cairo, EG, ¹⁷IEO - Istituto Europeo di Oncologia IRCCS, Milan, IT, ¹⁸Dana Farber Cancer Institute, Boston, US

15:05 - 15:15

Invited Discussant 18140 and 18150

M.A. Franzoi, Institut Gustave Roussy, Villejuif, Cedex, FR

15:15 - 15:22

Q&A

15:22 - 15:32

LBA82 - Efficacy and safety of ponesegromab, a first-in-class, monoclonal antibody inhibitor of growth differentiation factor 15, in patients with cancer cachexia: A randomized, placebo-controlled, phase II study

J. Crawford¹, J. Groarke², S. Collins³, S. Lubaczewski⁴, E. Roeland⁵, T. Naito⁶, A. Hendifar⁷, M. Fallon⁸, K. Takayama⁹, T. Asmis¹⁰, R. Dunne¹¹, M. Rossulek¹², R. Qiu², A. Saxena², ¹Duke University Medical Center, Durham, US, ²Pfizer Inc, Cambridge, US, ³Pfizer R&D UK Ltd, Kent, GB, ⁴Pfizer Inc, Collegeville, US, ⁵Oregon Health and Science University, Portland, US, ⁶Shizuoka Cancer Center, Shizuoka, JP, ⁷Cedars-Sinai Medical Center, Los Angeles, US, ⁸Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, GB, ⁹Kyoto Prefectural University of Medicine, Kyoto, JP, ¹⁰The Ottawa Hospital Cancer Centre, Ottawa, CA, ¹¹University of Rochester Medical Center, Rochester, US, ¹²Pfizer Inc, Tampa, US



15:32 - 15:42

18160 - A multicentre, randomized, double-blind, placebo-controlled study of olanzapine-based triplet antiemetic therapy for prevention of delayed and persistent nausea and vomiting induced by trastuzumab deruxtecan in patients with metastatic breast cancer: ERICA study (WJOG14320B)

H. Sakai¹, J. Tsurutani¹, Y. Ozaki², H. Ishiguro³, K. Nozawa⁴, T. Yamanaka⁵, H. Kameoka⁶, K. Matsumoto⁷, T. Iwasa⁸, M. Tokiwa⁹, M. Tsuneizumi¹⁰, Y. Miyoshi¹¹, C. Kitagawa¹², M. Yamamoto¹³, Y. Takano¹⁴, C. Imamura¹, Y. Chiba¹⁵, D. Takiguchi¹⁶, T. Ezumi¹⁶, T. Takano²,
¹Showa University, Tokyo, JP, ²Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, JP, ³Saitama Medical University International Medical Center, Hidaka, JP, ⁴Aichi Cancer Center Hospital, Nagoya, JP, ⁵Kanagawa Cancer Center, Yokohama, JP, ⁶National Hospital Organization Shikoku Cancer Center, Matsuyama, JP, ⁷Hyogo Cancer Center, Akashi, JP, ⁸Kindai University Faculty of Medicine, Osaka, JP, ⁹Kobe City Medical Center General Hospital, Kobe, JP, ¹⁰Shizuoka General Hospital, Shizuoka, JP, ¹¹Hyogo College of Medicine, Nishinomiya, JP, ¹²NHO Nagoya Medical Center, Nagoya, JP, ¹³Hokkaido Cancer Center, Sapporo, JP, ¹⁴Nagoya University Hospital, Nagoya, JP, ¹⁵Kindai University Hospital, Osakasayama, JP, ¹⁶Daiichi Sankyo Co., Ltd., Tokyo, JP

15:42 - 15:52

14760 - Haloperidol and lorazepam for agitated delirium in patients with advanced cancer: A multicenter, double-blind, randomized clinical trial (RCT)

D. Hui¹, A. Delarosa¹, J.-S. Tsai², S.-Y. Cheng², D. Urbauer³, E. Delfabbro⁴, A. Kuzhiyil⁵, A. Azhar¹, M. Tang¹, K. Rowe⁵, T. Nguyen¹, C.-A. Yao², H.-L. Huang², J.-K. Peng², W.-Y. Hu², S. Admane¹, R. Dev¹, P. Bramati¹, S. Shete³, E. Bruera¹,
¹The University of Texas MD Anderson Cancer Center, Houston, US, ²National Taiwan University, Taipei City, TW, ³University of Texas MD Anderson Cancer Center, Houston, US, ⁴Augusta University Medical Center, Augusta, US, ⁵Virginia Commonwealth University Massey Comprehensive Cancer Center, Richmond, US

15:52 - 16:02

LBA61 - Conventional oral morphine vs. IV patient-controlled analgesia (IPCA) with either hydromorphone (HM) continuous infusion plus rescue dose (CIRD) or HM bolus-only (BO) for severe cancer pain: A randomized phase III study

R. Lin¹, L. He², M. Lu³, Q. Wan⁴, Y. Chen⁵, J. Liu⁶, X. Lu⁷, L. Zhuang⁸, Z. Zhang⁹, L. Gong¹⁰, Y. Luo¹¹, T. Ren¹², L. Cao¹³, J. Liu¹⁴, H. Zou¹⁵, L. Cui¹⁶, C. Shang¹⁷, S. Chen¹⁸, S. Lin¹⁹, C. Huang²⁰,
¹Fujian Cancer Hospital, Fuzhou, CN, ²Chengdu Fifth People's Hospital, Chengdu, CN, ³Yichang Central People's Hospital, Yichang, CN, ⁴Cancer Hospital Affiliated to Guizhou Medical University, Guiyang, CN, ⁵Zhumadian Central Hospital, Zhumadian, CN, ⁶Xingtai People's Hospital, Xingtai, CN, ⁷Zhongshan Hospital Xiamen University, Xiamen, CN, ⁸Yunnan Cancer Hospital, Kunming, CN, ⁹Hainan Cancer Hospital, Haikou, CN, ¹⁰Cancer Hospital of the University of Chinese Academy of Sciences/ Zhejiang Cancer Hospital, Hangzhou, CN, ¹¹Qinghai University Hospital, Xining, CN, ¹²The First Affiliated Hospital of Chengdu Medical College, Chengdu, CN, ¹³Chengdu Qingbaijiang District People's Hospital, Chengdu, CN, ¹⁴People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, CN, ¹⁵Cancer Hospital Affiliated to Harbin Medical University, Harbin, CN, ¹⁶Changan Hospital, XiAn, CN, ¹⁷The Fifth People's Hospital of Qinghai Province/ Qinghai Province Cancer Hospital, Xining, CN, ¹⁸Liuzhou workers' Hospital, Liuzhou, CN, ¹⁹Fujian Medical University - Qishan Campus, Fuzhou, CN, ²⁰Fujian Medical University Xiamen Humanity Hospital, Xiamen, CN

16:02 - 16:17 **Invited Discussant LBA82, 1816O, 1476O and LBA61**
J. Wood, The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, GB

16:17 - 16:25 **Q&A**

14:45 - 16:15 **Type: Mini Oral session** **Oviedo Auditorium - Hall 3**
Title: Mini oral session: Developmental therapeutics
 Chair(s): Teresa Amaral, DE; Christophe Massard, FR; Alex A. Adjei, US

14:45 - 14:50 **613MO - A phase I clinical trial evaluating exarafenib, a selective pan-RAF inhibitor in combination with binimetinib in NRAS-mutant (NRASMut) melanoma (Mel) & BRAF-altered solid tumors**
P. Cassier¹, J. Mehnert², R. Kim³, B. Chmielowski⁴, M. Millward⁵, C. Perez⁶, M. Gonzalez Cao⁷, V. Gambardella⁸, M. Mckean⁹, M. Brose¹⁰, Y. Xing¹¹, G. Long¹², A. Kelly¹³, G. Lee¹⁴, P. Severson¹⁴, R. Williams¹⁴, C. Gaudy Marqueste¹⁵, ¹Centre Léon Bérard, Lyon, FR, ²Laura and Isaac Perlmutter Cancer Center, New York, US, ³H. Lee Moffitt Cancer Center University of South Florida, Tampa, US, ⁴UCLA - David Geffen School of Medicine, Los Angeles, US, ⁵University of Western Australia, Perth, AU, ⁶Florida Cancer Specialists, Fort Myers, US, ⁷Instituto Oncologico Dr Rosell, Dexeus University Hospital, Barcelona, ES, ⁸Hospital Clinico Universitario de Valencia, Valencia, ES, ⁹Sarah Cannon Research Institute, Nashville, US, ¹⁰Sidney Kimmel Cancer Center Jefferson Northeast, Philadelphia, US, ¹¹COH - City of Hope Comprehensive Center, Duarte, US, ¹²Melanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, AU, ¹³Kinnate Biopharma, San Diego, US, ¹⁴Kinnate Biopharma Inc., San Diego, US, ¹⁵AP-HM - CHU La Timone Enfants, Marseille, FR

14:50 - 14:55 **614MO - Type II RAF inhibitor tovorafenib in recurrent/refractory (R/R) melanoma or other solid tumors with RAF fusions and/or RAF1 amplification**
M. Vieito¹, E. Garraalda¹, I. Mehmi², C. Gaudy Marqueste³, B. O'neil⁴, T. Medina⁵, A. Body⁶, A.M. Arance⁷, S. Kummar⁸, Y. Najjar⁹, P. Bedard¹⁰, C. Chu¹¹, C. Mckenna¹¹, S. Hume¹¹, L. Kopp¹¹, J. Lee¹², ¹Vall d'Hebron University Hospital, Barcelona, ES, ²The Angeles Clinic & Research Institute, Inc., Los Angeles, US, ³CEPCM, Hopital de La Timone - APMH, Aix-Marseille University, Marseille, FR, ⁴Community Hospital Oncology Physicians, Indianapolis, US, ⁵University of Colorado Cancer Center Anschutz Cancer Pavilion, Aurora, US, ⁶Monash Medical Center and Monash University, Clayton, AU, ⁷Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ⁸OHSU Knight Cancer Institute - Center for Health and Healing Building 1 - South Waterfront, Portland, US, ⁹University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, US, ¹⁰Princess Margaret Cancer Centre, University Health Network, Toronto, CA, ¹¹Day One Biopharmaceuticals, Brisbane, US, ¹²Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR

14:55 - 15:10 **Invited Discussant 613MO and 614MO**
T. Amaral, Skin Cancer Clinical Trials Center, University of Tuebingen, Tübingen, DE



15:10 - 15:15

615MO - Phase I/II study of D3S-001, a second generation KRAS G12C inhibitor in advanced/metastatic solid tumors with KRAS G12C mutations

B.C. Cho¹, S. Lu², M.A. Lee³, Z. Song⁴, J. Park⁵, S.M. Lim⁶, Z. Li², J. Zhao⁷, G. Richardson⁸, Y. Zhang⁹, J. Zhang¹⁰, A. Liu¹¹, C. Chen¹², J. Wang¹², J. Chen¹², A. Wang¹², J. Zhang¹², Z. Chen¹², T.S.K. Mok¹³, M. Johnson¹⁴, ¹Yonsei Cancer Center, Seoul, KR, ²Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, CN, ³The Catholic University of Korea - Seoul St. Mary's Hospital - Catholic Medical Center, Seoul, KR, ⁴Zhejiang Cancer Hospital, Hangzhou, CN, ⁵Macquarie University - Faculty of Medicine, Health and Human Sciences, Sydney, AU, ⁶Yonsei University College of Medicine, Seoul, KR, ⁷Beijing Cancer Hospital, Beijing, CN, ⁸Oncology Clinics Victoria - Cabrini Malvern Hospital, Malvern, AU, ⁹Cancer Hospital Affiliated to Harbin Medical University, Harbin, CN, ¹⁰Ruijin Hospital - Shanghai Jiao Tong University School of Medicine, Shanghai, CN, ¹¹2nd Affiliated Hospital of Nanchang University, Nanchang, CN, ¹²D3 Bio, Shanghai, CN, ¹³Prince of Wales Hospital - Li Ka Shing Specialist Clinics, Sha Tin, HK, ¹⁴Sarah Cannon Research Institute, Nashville, US

15:15 - 15:20

616MO - Long-term follow-up of single-agent divarasib in patients with KRAS G12C-positive solid tumors

E. Garrauda¹, M. Patel², T.W. Kim³, A. Sacher⁴, M. Forster⁵, A. Santoro⁶, J. Desai⁷, L. Paz-Ares⁸, A. Falcon Gonzalez⁹, M. De Miguel¹⁰, S. Bowyer¹¹, R. Dziadziuszko¹², S.H. Kim¹³, S.-W. Han¹⁴, M. Krebs¹⁵, P. Lorusso¹⁶, R. Cosman¹⁷, J. Chang¹⁸, T. Jun¹⁸, W. Miller¹⁹, ¹Vall d'Hebron University Hospital, Barcelona, ES, ²Florida Cancer Specialists/Sarah Cannon Research Institute, Fort Myers, US, ³Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR, ⁴UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA, ⁵University College London/University College London Hospitals NHS Trust, London, GB, ⁶IRCCS Humanitas Research Hospital- Humanitas Cancer Center, Milan, IT, ⁷Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, Melbourne, AU, ⁸Hospital Universitario 12 de Octubre, Madrid, ES, ⁹Hospital Universitario Virgen del Rocio, Seville, ES, ¹⁰CIOCC - Centro Integral Oncológico Clara Campal, Hospital Universitario HM Sanchinarro, Madrid, ES, ¹¹Linear Clinical Research Ltd., Perth, AU, ¹²Medical University of Gdansk, Gdansk, PL, ¹³Seoul National University Bundang Hospital, Seongnam, KR, ¹⁴Seoul National University Hospital, Seoul, KR, ¹⁵The Christie NHS Foundation Trust, Manchester, GB, ¹⁶Yale School of Medicine - Radiology and Biomedical Imaging, New Haven, US, ¹⁷St Vincent's Hospital Sydney, Garvan Institute of Medical Research, Faculty of Medicine, University of New South Wales, Darlinghurst, AU, ¹⁸Genentech, Inc., South San Francisco, US, ¹⁹Jewish General Hospital McGill University, Montreal, CA

15:20 - 15:35

Invited Discussant 615MO and 616MO

C. Massard, Gustave Roussy - Cancer Campus, Villejuif, FR

15:35 - 15:40

617MO - Safety and tolerability of INCB123667, a selective CDK2 inhibitor, in patients (pts) with advanced solid tumors: A phase I study

M. Simonelli¹, D. Lorusso², K. Homicsko³, F. Seguy⁴, M. Kinder⁵, Q. Liu⁵, E. Croft⁵, S. Kitano⁶, ¹IRCCS Humanitas Research Hospital, Rozzano, IT, ²Fondazione Policlinico Universitario Agostino Gemelli IRCCS Rome and Humanitas San Pio X, Milan, IT, ³Ludwig Institute for Cancer Research, UNIL and Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, CH, ⁴Incyte Biosciences International Sàrl, Morges, CH, ⁵Incyte Corporation, Wilmington, US, ⁶The Cancer Institute Hospital of JFCR, Tokyo, JP



- 15:40 - 15:45 **618MO - Phase Ib/II first-in-class novel combination trial of next generation CDK4-selective inhibitor PF-07220060 and next generation CDK2-selective inhibitor PF-07104091 in HR+ HER2- metastatic breast cancer and advanced solid tumors**
T.A. Yap¹, F. Yan², S. Sadeghi³, T.T. Lin⁴, F. Liu⁵, L. Malky⁶, M. Golmakani⁷, A. Moreau⁸, H. Neumann⁹, L. Zhou⁷, D. Juric¹⁰, M. Sharma¹¹, ¹The University of Texas MD Anderson Cancer Center - Main Building, Houston, US, ²Swedish Cancer Institute - Medical Oncology - First Hill, Seattle, US, ³David Geffen School of Medicine at UCLA - Translational Oncology Research Laboratory (TORL), Santa Monica, US, ⁴Pfizer Inc., New York, US, ⁵Pfizer Inc., San Diego, US, ⁶Pfizer, Kirkland, CA, ⁷Pfizer, San Diego, US, ⁸Pfizer, Bridgewater, US, ⁹Pfizer Inc - USA, New London, US, ¹⁰MGH - Massachusetts General Hospital, Boston, US, ¹¹START Midwest, Grand Rapids, US
- 15:45 - 15:50 **619MO - Camonsertib (cam) monotherapy in patients (pts) with advanced cancers harboring ATM loss-of-function (LoF)**
B. Carneiro¹, E. Rosen², E. Fontana³, E. Lee⁴, N. Mettu⁵, S. Lheureux⁶, R. Plummer⁷, I. Silverman⁸, J. Schonhoft⁸, J. Yang⁸, G. Gomez⁸, K. Fei⁸, D. Ulanet⁸, P. Basciano⁸, T.A. Yap⁹, M. Hoejgaard¹⁰, ¹Warren Alpert Medical School of Brown University, Providence, US, ²Memorial Sloan Kettering Cancer Center, New York, US, ³Sarah Cannon Research Institute SCRI UK, London, GB, ⁴Dana Farber Cancer Institute, Boston, US, ⁵Duke University Medical Center, Durham, US, ⁶Princess Margaret Hospital, and PMHC, Toronto, CA, ⁷Newcastle University, Newcastle upon Tyne, GB, ⁸Repare Therapeutics Inc., Cambridge, US, ⁹The University of Texas MD Anderson Cancer Center, Houston, US, ¹⁰Rigshospitalet, Copenhagen, DK
- 15:50 - 16:05 **Invited Discussant 617MO, 618MO and 619MO**
A.A. Adjei, Cleveland Clinic Main Campus, Cleveland, US

14:45 - 16:15	Type: Special symposium Title: CAR T cells and bispecifics Chair(s): Martin Hutchings, DK; Eva Kimby, SE	Toledo Auditorium - Hall 3
----------------------	--	-----------------------------------

- 14:45 - 14:50 **Introduction and scientific background**
M. Hutchings, Rigshospitalet, Copenhagen, DK
- 14:50 - 15:10 **Myeloma**
P. Rodriguez-Otero, Clinica Universidad de Navarra, Madrid, ES
- 15:10 - 15:30 **Follicular lymphoma**
E. Kimby, Karolinska University Hospital and Karolinska Institute - Huddinge, Stockholm, SE
- 15:30 - 15:50 **Diffuse large B cell lymphoma**
M. Hutchings, Rigshospitalet, Copenhagen, DK

15:50 - 16:10 **Q&A and discussion**

16:10 - 16:15 **Conclusions and perspectives**

E. Kimby, Karolinska University Hospital and Karolinska Institute - Huddinge, Stockholm, SE

14:45 - 16:15 **Type: Patient Advocacy session** **Zaragoza Auditorium - CC5**
Title: Challenges in access to new oncology medicines
 Chair(s): Natacha Bolanos Fernandez, ES; Eva-Maria Strömsholm, FI

14:45 - 15:00 **Challenges for EU regulators**

J. Garcia Burgos, EMA - European Medicines Agency, Amsterdam, NL

15:00 - 15:15 **Challenges for national HTA bodies**

A. Schiel, Norwegian Medical Products Agency, Oslo, NO

15:15 - 15:30 **Challenges for national policy makers**

V. Voiculescu, MagiCAMP, Bucharest, RO

15:30 - 15:45 **Inequalities across countries**

L. Bowers, OECD, Paris, FR

15:45 - 16:00 **A global perspective on access to oncology medicine: Where we do stand?**

A. Ilbawi, WHO - World Health Organization, Geneva, CH

16:00 - 16:15 **Discussion**

14:45 - 16:15 **Type: Special session** **Cartagena Auditorium - Hall 7**
Title: ESMO Women for Oncology Forum -Empowering women in oncology:
Exploring solutions to today's challenges across oncology fields
 Chair(s): Helena Linardou, GR

14:45 - 14:50 **Welcome**

H. Linardou, Metropolitan Hospital, Athens, GR

14:50 - 15:10 **Working in gender equality: Progress and challenges in research and innovation**

Z. Altamirano, Ministerio de Igualdad, Madrid, ES

15:10 - 15:15 **Introduction**

H. Linardou, Metropolitan Hospital, Athens, GR



15:15 - 15:55

Panel discussion

Y. Freund¹, J. Gralow², M. Guckenberger³, C. Pompili⁴, ¹Hôpitaux Universitaires Pitié Salpêtrière - Charles Foix, Paris, FR, ²American Society of Clinical Oncology (ASCO), Alexandria, US, ³USZ - University Hospital Zürich, Zurich, CH, ⁴University of Leeds - Institute of Cancer and Pathology (LICAP), Leeds, GB

15:55 - 16:15

Q&A

15:00 - 15:45

Type: Challenge your Expert

Santander Auditorium - Hall 5

Title: Targeted therapies in biliary tract cancer: Emerging targets and strategies

Chair(s): Maeve Lowery, IE

15:00 - 15:20

Presentation by Expert

S. Chan, The Chinese University of Hong Kong - Sino Building, Sha Tin, HK

15:20 - 15:45

Discussion led by Chair

M. Lowery, Trinity College Dublin, Dublin, IE

15:00 - 16:00

Type: Young Oncologists session

Tarragona Auditorium - Hall 7

Title: YO Medical students session: ESMO for medical students and young physicians

Chair(s): Andres Cervantes, ES; Matteo Lambertini, IT

15:00 - 15:15

ESMO Medical Students Course

A. Cervantes, Hospital Clinico Universitario de Valencia, Valencia, ES

15:15 - 15:30

Developing a career in medical oncology: From the ESMO Medical Student Course to a successful career

A. Starzer, Medizinische Universitaet Wien, Vienna, AT

15:30 - 16:00

Guided poster walk

M. Moutafi¹, A. Starzer², R. Pihlak³, M. Kfoury⁴, ¹Attikon University Hospital, Haidari, GR, ²Medizinische Universitaet Wien, Vienna, AT, ³St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB, ⁴IPC - Institut Paoli-Calmettes, Marseille, Cedex 09, FR

16:15 - 17:45

Type: EONS session

Ronda Auditorium - Hall 7

Title: Cancer nursing and precision health

Chair(s): Hazal Özdemir Koyu, TR; Lena Sharp, SE

16:15 - 16:30

Where is cancer nursing in precision health?

H. Ullgren, Karolinska University Hospital-Solna, Solna, SE

16:30 - 16:45

Genomic data management in precision oncology nursing

C. Díez De Los Ríos De La Serna, University of Glasgow, Glasgow, GB

16:45 - 17:00	Optimizing the role of advanced practice nurses at the core of precision health: Achieving comprehensive, patient-centred cancer services <u>S. Colomer-Lahiguera</u>, Institute of Higher Education and Research in Healthcare - IUFRS, CHUV, Lausanne, CH
17:00 - 17:10	CN28 - Racial disparities in immune-related adverse events in patients with lung cancer treated with immune checkpoint inhibitors K. Uttam Chandani¹, S. Agrawal², M. Raval¹, H. Khan³, ¹New York Medical College/Landmark Medical Center, Woonsocket, US, ²Smt. N.H.L Municipal Medical College, Ahmedabad, IN, ³Lifespan Cancer Institute - Rhode Island Hospital, Providence, US
17:10 - 17:20	CN64 - Three-year evaluation of an immunotherapy late effects screening clinic J. Bird¹, S. Danson², D. Greenfield¹, J. Brown³, ¹Weston Park Hospital - Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, GB, ²University of Sheffield, Weston Park Hospital, Sheffield, GB, ³University of Sheffield Medical School, Sheffield, GB
17:20 - 17:30	CN90 - To get through to survive: Exploring the symptom cluster management process during oncological treatment from the perspective of patients with lung cancer <u>K. Karlsson</u>¹, M. Larsson¹, K. Ahlberg², C. Olsson¹, A. Erlandsson¹, ¹Karlstad University, Karlstad, SE, ²Sahlgrenska Academy Institute of Health and Care Sciences at the University of Gothenburg, Gothenburg, SE
17:30 - 17:45	Q&A and discussion
16:15 - 17:45	Type: EONS Industry Satellite Symposium Segovia Auditorium - Hall 7 Title: AstraZeneca - Management of adverse events in lung cancer antibody-drug conjugate (ADC) treatment Chair(s): Fernanda Conceição, PT
16:15 - 16:20	Welcome and introduction <u>F. Conceição</u>, Champalimaud Foundation - Champalimaud Clinical Center, Lisbon, PT
16:20 - 16:40	What are the ADCs and main AEs? <u>N. Girard</u>, Institut Curie, Paris, FR
16:40 - 17:00	Pharmacovigilance in management of ADC related AEs <u>D. Van Balen</u>, Netherlands Cancer Institute, Amsterdam, NL
17:00 - 17:20	Role of cancer nurse in prophylaxis, early detection, and management of ADC related adverse events <u>A. Rodriguez-Ortega</u>, ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), Hospitalet de Llobregat, ES



17:20 - 17:40

Discussion and Q&A

F. Conceição¹, N. Girard², D. Van Balen³, A. Rodriguez-Ortega⁴, ¹Champalimaud Foundation - Champalimaud Clinical Center, Lisbon, PT, ²Institut Curie, Paris, FR, ³Netherlands Cancer Institute, Amsterdam, NL, ⁴ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), Hospitalet de Llobregat, ES

17:40 - 17:45

Conclusion remarks

F. Conceição, Champalimaud Foundation - Champalimaud Clinical Center, Lisbon, PT

16:30 - 18:15

Type: Proffered Paper session

Barcelona Auditorium - Hall 2

Title: Presidential Symposium I: Practice-changing trials

Chair(s): Andres Cervantes, ES; Karin Jordan, DE

16:30 - 16:42

LBA1 - A randomized multicenter open label phase III trial comparing enzalutamide vs a combination of Radium-223 (Ra223) and enzalutamide in asymptomatic or mildly symptomatic patients with bone metastatic castration-resistant prostate cancer (mCRPC): First results of EORTC-GUCC 1333/PEACE-3

S. Gillessen¹, A. Choudhury², F. Saad³, E. Gallardo⁴, A. Soares⁵, Y. Loriot⁶, R.S. McDermott⁷, A. Rodriguez-Vida⁸, P. Isaacson⁹, F. Nolè¹⁰, F. Melo Cruz¹¹, T. Roumeguere¹², K.G. Daugaard¹³, R. Yamamura¹⁴, F. Lecouvet¹⁵, C. Coens¹⁶, B. Fournier¹⁶, B. Tombal¹⁵, ¹EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, CH, ²The Christie NHS Foundation Trust, Manchester, GB, ³Centre Hospitalier de Université to Montréal (CHUM), Montreal, CA, ⁴Hospital Universitario Parc Taulí, Sabadell, ES, ⁵Hospital Israelita Albert Einstein (Morumbi) - Pavilhao Vicky e Joseph Safra, Sao Paulo, BR, ⁶Institut Gustave Roussy, Villejuif, Cedex, FR, ⁷Tallaght University Hospital, Dublin, Ireland, Dublin, IE, ⁸Hospital del Mar - Parc de Salut Mar, Barcelona, ES, ⁹Hospital Moinhos de Vento, Porto Alegre, Brazil, Porto Alegre, BR, ¹⁰IEO - Istituto Europeo di Oncologia IRCCS, Milan, IT, ¹¹Rede D'Or Sao Luiz, Brasilia, BR, ¹²Erasmus Hospital - Université Libre de Bruxelles (ULB), Brussels, BE, ¹³Rigshospitalet, Copenhagen, DK, ¹⁴Hospital Beneficencia Portuguesa de Sao Paulo - Mirante, Sao Paulo, BR, ¹⁵Cliniques Universitaires Saint-Luc (UCLouvain Saint-Luc), Woluwe-Saint-Lambert, BE, ¹⁶EORTC AISBL/IVZW - European Organisation for Research and Treatment of Cancer, Brussels, BE

16:42 - 16:52

Invited Discussant LBA1

K. Fizazi, Institut Gustave Roussy, Villejuif, Cedex, FR



16:52 - 17:04

LBA2 - POD1UM-303/InterAACT 2: Phase III study of retifanlimab with carboplatin-paclitaxel (c-p) in patients (Pts) with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC) not previously treated with systemic chemotherapy (Chemo)

S. Rao¹, E. Samalin-Scalzi², L. Evesque³, M. Ben Abdelghani⁴, F. Morano⁵, A. Roy⁶, L. Dahan⁷, S. Tamberi⁸, A. Dhadda⁹, M. Saunders¹⁰, N. Casanova¹¹, R. Guimbaud¹², A. Lievre¹³, J. Maurel¹⁴, M. Fakhri¹⁵, P. Zhang¹⁶, J. Harrison¹⁶, M. Jones¹⁶, J.-P. Spano¹⁷, P. Rochefort¹⁸, ¹Royal Marsden Hospital NHS Foundation Trust, Surrey, GB, ²Institut Régional du Cancer de Montpellier, Montpellier, FR, ³Centre Antoine Lacassagne, Nice, FR, ⁴Centre Paul Strauss, Strasbourg, FR, ⁵Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT, ⁶Flinders University, Bedford Park, AU, ⁷Hôpital de la Timone, Marseille, FR, ⁸Presidio Ospedaliero Ravenna, Ravenna, IT, ⁹Castle Hill Hospital, Cottingham, GB, ¹⁰The Christie Hospital, Manchester, GB, ¹¹Leeds Cancer Centre, Leeds, GB, ¹²CHU de Toulouse, Toulouse, FR, ¹³CHU Rennes - Hopital Pontchaillou, Rennes, FR, ¹⁴Hospital Clinic de Barcelona, CIBEREHD, Barcelona, ES, ¹⁵City of Hope National Medical Center, Duarte, US, ¹⁶Incyte Corporation, Wilmington, US, ¹⁷Groupe Hospitalier Pitie-Salpetriere, Paris, FR, ¹⁸Centre Léon Bérard, Lyon, FR

17:04 - 17:14

Invited Discussant LBA2

D. Modest, Charité - Universitätsmedizin Berlin, Berlin, DE

17:14 - 17:26

7090 - Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: Overall survival results from the randomized, double-blind, phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study

D. Lorusso¹, Y. Xiang², K. Hasegawa³, G. Scambia¹, M. Leiva Gálvez⁴, P. Ramos Elias⁵, A. Acevedo⁶, M. Bednarikova⁷, A.J. Gomes⁸, F. Contreras Mejia⁹, A. Reiss¹⁰, F. Zagouri¹¹, J.-Y. Lee¹², V. Saevets¹³, A. Ayhan¹⁴, P. Liu¹⁵, K. Yamada¹⁵, M. Puglisi¹⁵, S. Pignata¹⁶, L. Duska¹⁷, ¹Fondazione Policlinico Universitario A. Gemelli IRCCS and Catholic University of the Sacred Heart, Rome, IT, ²National Clinical Research Center for Obstetric & Gynecologic Diseases, Peking Union Medical College Hospital, Beijing, CN, ³Saitama Medical University International Medical Center, Saitama, JP, ⁴Instituto de Oncologia y Radioterapia Clínica Ricardo Palma, Lima, PE, ⁵Edificio Integra Medical Center, Guatemala City, GT, ⁶Oncocentro, Viña del Mar, CL, ⁷Masaryk University, Brno, CZ, ⁸Liga Norte Riograndense Contra o Câncer, Natal, BR, ⁹Instituto Nacional de Cancerología, Bogotá, CO, ¹⁰Rambam Medical Center, Haifa, IL, ¹¹Alexandra General Hospital, Athens, GR, ¹²Yonsei University College of Medicine, Seoul, KR, ¹³Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine, Chelyabinsk, RU, ¹⁴Baskent University, Ankara, TR, ¹⁵Merck & Co., Inc., Rahway, US, ¹⁶Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, IT, ¹⁷University of Virginia School of Medicine, Charlottesville, US

17:26 - 17:36

Invited Discussant 7090

R. Nout, Erasmus MC - University Medical Center, Rotterdam, NL



17:36 - 17:48 **LBA3 - Transarterial chemoembolization (TACE) with or without lenvatinib (len) & pembrolizumab (pembro) for intermediate-stage hepatocellular carcinoma (HCC): Phase III LEAP-012 study**

J. Llovet¹, R. Finn², Z. Ren³, Y. Guo⁴, G. Han⁵, H. Lin⁶, J. Zheng⁷, S. Ogasawara⁸, H. Li⁹, J.H. Kim¹⁰, H. Zhao¹¹, C. Li¹², D.C. Madoff¹³, R.M. Ghobrial¹⁴, A. El-Khoueiry¹⁵, A. Vogel¹⁶, X. Peng¹⁷, K. Mody¹⁸, L. Dubrovsky¹⁷, M. Kudo¹⁹, ¹Icahn School of Medicine at Mount Sinai, New York, US, ²Geffen School of Medicine at UCLA, Los Angeles, US, ³Zhongshan Hospital, Fudan University, Shanghai, CN, ⁴Nanfang Hospital, Southern Medical University, Guangzhou, CN, ⁵Digestive Diseases Hospital, Xi'an International Medical Center Hospital, Northwest University, Xi'an, CN, ⁶Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Fuzhou, CN, ⁷Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Haikou, CN, ⁸Graduate School of Medicine, Chiba University, Chiba, JP, ⁹Henan Cancer Hospital, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, CN, ¹⁰Korea University Guro Hospital, Seoul, KR, ¹¹Peking Union Medical College Hospital, Beijing, CN, ¹²West China Hospital of Sichuan University, Chengdu, CN, ¹³Yale School of Medicine, New Haven, US, ¹⁴Sherrie and Alan Conover Center for Liver Disease and Transplantation, JC Walter Jr. Center for Transplantation, Houston Methodist Hospital, Houston, US, ¹⁵USC Norris Comprehensive Cancer Center, Los Angeles, US, ¹⁶Hannover Medical School, Hannover, DE, ¹⁷Merck & Co., Inc., Rahway, US, ¹⁸Eisai Inc., Nutley, US, ¹⁹Kindai University Faculty of Medicine, Osaka, JP

17:48 - 17:58 **Invited Discussant LBA3**
A. Lamarca, Hospital Universitario Fundacion Jimenez Diaz, Madrid, ES

17:58 - 18:15 **Q&A and discussion**

16:30 - 18:00 **Type: Special symposium** **Sevilla Auditorium - Hall 2**
Title: Evolving biomarkers in metastatic disease: Liquid, solid or both?
Chair(s): Sandra Ximena Franco Millan, CO; Christos Sotiriou, BE

16:30 - 16:35 **Introduction and scientific background**
C. Sotiriou, Institute Jules Bordet, Brussels, BE

16:35 - 16:50 **Liquid biopsy: Promises and challenges**
M. Ignatiadis, Institute Jules Bordet, Brussels, BE

16:50 - 17:05 **Tissue biopsy: Capturing tumour microenvironment and beyond**
F. Penault-Llorca, Jean Perrin Center, Clermont-Ferrand, FR

17:05 - 17:20 **Novel imaging approaches: Towards a better estimation of response**
G. Cook, King's College Hospital, London, GB

17:20 - 17:35 **AI in oncology: Understanding the limits and challenges of data and model deployment**
A. Grigoriadis, King's College London Guy's Hospital - NHS Foundation Trust, London, GB

17:35 - 17:55 **Q&A and discussion**

17:55 - 18:00 **Conclusions and perspectives**

S.X. Franco Millan, CTIC Centro de Tratamiento e Investigacion Sobre Cancer, Bogota, CO

16:30 - 17:45

Type: Multidisciplinary session

Granada Auditorium - Hall 6

Title: MRD or molecular tumour board case report

Chair(s): Sherene Loi, AU; Federica Di Nicolantonio, IT

16:30 - 16:35

Presentation of case/condition

P. Bironzo, Azienda Ospedaliera Universitaria San Luigi Gonzaga, Orbassano, IT

16:35 - 16:55

Navigating the molecular tumour board and genomic reports

J. Mateo, Vall d'Hebron University Hospital, Barcelona, ES

16:55 - 17:15

MRD learning from breast cancer

S. Loi, Peter MacCallum Cancer Centre, Melbourne, AU

17:15 - 17:35

Liquid biopsies across the disease spectrum; learning from colorectal cancer

N. Starling, The Royal Marsden Hospital - Chelsea, London, GB

17:35 - 17:45

Q&A and discussion

16:30 - 18:00

Type: Educational session

Zaragoza Auditorium - CC5

Title: Can pragmatic clinical trials and optimisation of treatments support development, access and value?

Chair(s): Denis Lacombe, BE; Beate Wieseler, DE

16:30 - 16:40

Pragmatic trials: General introduction

D. Lacombe, EORTC AISBL/IVZW - European Organisation for Research and Treatment of Cancer, Brussels, BE

16:40 - 17:00

The Cancer Medicine Forum of the EMA

F. Pignatti, European Medicines Agency - Amsterdam, Amsterdam, NL

17:00 - 17:20

Designing, running and funding deescalation clinical trials

D. Goldstein, Rabin Medical Center, Petah Tikva, IL

17:20 - 17:40

RCT and RWD for HTA decision making

B. Wieseler, IQWiG, Köln, DE

17:40 - 18:00

Q&A and discussion



17:00 - 17:45	Type: Challenge your Expert Title: Is it possible to treat brain metastases without RT in 2024? Chair(s): Evangelia Razis, GR	Alicante Auditorium - Hall 3
17:00 - 17:20	Presentation by Expert <u>A.S. Berghoff</u> , Universitätskliniken der MedUni Wien - AKH Wien, Vienna, AT	
17:20 - 17:45	Discussion led by Chair <u>E. Razis</u> , Hygeia Hospital, Marousi, GR	
18:30 - 20:00	Type: Industry Satellite Symposium Title: AbbVie Inc. - Targeting un-MET Needs in Cancer: The Emerging Role of Antibody-Drug Conjugates (ADCs) Chair(s): Benjamin Besse, FR	Burgos Auditorium - Hall 5
18:30 - 18:33	Welcome and Introduction <u>B. Besse</u> , Institut Gustave Roussy, Villejuif, Cedex, FR	
18:33 - 18:40	History of c-Met: Lessons Learned <u>B. Besse</u> , Institut Gustave Roussy, Villejuif, Cedex, FR	
18:40 - 18:55	Rethinking c-Met as a Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC) <u>A. Passaro</u> , IEO - Istituto Europeo di Oncologia IRCCS, Milan, IT	
18:55 - 19:15	Targeting c-Met in Advanced NSCLC with ADCs <u>N. Girard</u> , Institut Curie, Paris, FR	
19:15 - 19:30	Rethinking c-Met as a Therapeutic Target in Gastrointestinal Cancers (GI) <u>J. Strickler</u> , Duke Cancer Center, Durham, US	
19:30 - 19:45	Emerging Evidence on c-Met Targeting in GI <u>E. Van Cutsem</u> , UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE	
19:45 - 19:55	Panel Discussion, Q&A, and Closing <u>B. Besse</u> ¹ , <u>A. Passaro</u> ² , <u>N. Girard</u> ³ , <u>J. Strickler</u> ⁴ , <u>E. Van Cutsem</u> ⁵ , ¹ Institut Gustave Roussy, Villejuif, Cedex, FR, ² IEO - Istituto Europeo di Oncologia IRCCS, Milan, IT, ³ Institut Curie, Paris, FR, ⁴ Duke Cancer Center, Durham, US, ⁵ UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE	
19:55 - 20:00	Closing <u>B. Besse</u> , Institut Gustave Roussy, Villejuif, Cedex, FR	



18:30 - 20:00	Type: Industry Satellite Symposium Title: AstraZeneca - The emerging treatment landscape in advanced and recurrent endometrial cancer Chair(s): Nicole Concin, AT	Salamanca Auditorium - Hall 5
18:30 - 18:45	Molecular heterogeneity in endometrial cancer – addressing the unmet medical needs <u>N. Concin</u> , Landeskrankenhaus - Universitaetskliniken Innsbruck, Innsbruck, AT	
18:45 - 19:15	dMMR advanced/recurrent endometrial cancer – advances, wins and challenges <u>M.R. Mirza</u> , Rigshospitalet, Copenhagen, DK	
19:15 - 19:45	pMMR advanced/recurrent endometrial cancer – advances, wins and challenges <u>E. Van Nieuwenhuysen</u> , UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE	
19:45 - 20:00	Q&A Discussion <u>N. Concin</u> ¹ , <u>M.R. Mirza</u> ² , <u>E. Van Nieuwenhuysen</u> ³ , ¹ Landeskrankenhaus - Universitaetskliniken Innsbruck, Innsbruck, AT, ² Rigshospitalet, Copenhagen, DK, ³ UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE	
18:30 - 20:00	Type: ESMO Colloquium Title: ESMO Colloquium supported by Eli Lilly and Company - Hormone-receptor (+), HER2 (-) advanced breast cancer: The biology and treatment landscape post-progression after CDK4/6 inhibition Chair(s): Joyce O'Shaughnessy, US; Cristina Saura Manich, ES	Santander Auditorium - Hall 5
18:30 - 18:40	Welcome and introduction <u>J. O'Shaughnessy</u> , Texas Oncology - Baylor Sammons Cancer Center, Dallas, US	
18:40 - 18:55	Biological insights in the endocrine and CDK4/6 pathways of cellular signal transduction and mechanisms of primary/acquired resistance in HR(+)/HER2(-) breast cancer <u>E. Lim</u> , Garvan Institute of Medical Research, Darlinghurst, AU	
18:55 - 19:10	Presentation of a clinical case: State of the art management of patients with HR(+)/HER2(-) advanced breast cancer progressing after aromatase inhibitor+CDK4/6-inhibitor therapy <u>C. Saura Manich</u> , Vall d'Hebron University Hospital, Barcelona, ES	
19:10 - 19:25	HR(+)/HER2(-) advanced breast cancer: How can biology inform us on optimising the precision therapeutic strategies in 1L and 2L post progression after endocrine+CDK4/6i? <u>P. Aftimos</u> , Institute Jules Bordet, Anderlecht, BE	
19:25 - 19:40	A glimpse of the future: Ongoing research on novel therapeutics for advanced breast cancer patients post-progression on endocrine+CDK4/6-inhibition <u>J. O'Shaughnessy</u> , Texas Oncology - Baylor Sammons Cancer Center, Dallas, US	



19:40 - 19:55 **Q&A and discussion**

19:55 - 20:00 **Concluding remarks**

C. Saura Manich, Vall d'Hebron University Hospital, Barcelona, ES

18:30 - 20:00

Type: Industry Satellite Symposium

Valencia Auditorium - Hall 5

Title: GSK - Optimizing long term patient outcomes with PARPi treatment for advanced ovarian cancer

Chair(s): Antonio González-Martín, ES

18:30 - 18:32

Introduction

A. González-Martín, Clinica Universidad de Navarra, Madrid, ES

18:32 - 18:47

Appraising the progress in the management of advanced ovarian cancer

D. Lorusso, Humanitas San Pio X, Milan, IT

18:47 - 19:07

Contextualizing clinical trials when evaluating the right treatment for patients

R. Coleman, The US Oncology Network, The Woodlands, US

19:07 - 19:27

Long term efficacy with PARPi monotherapy in maintenance treatment of advanced ovarian cancer

A. González-Martín, Clinica Universidad de Navarra, Madrid, ES

19:27 - 19:47

From data to clinical practice; understanding opportunities and challenges

T. Herzog, UCCI - University of Cincinnati Cancer Institute, Cincinnati, US

19:47 - 19:57

Panel discussion

A. González-Martín¹, D. Lorusso², R. Coleman³, T. Herzog⁴, ¹Clinica Universidad de Navarra, Madrid, ES, ²Humanitas San Pio X, Milan, IT, ³The US Oncology Network, The Woodlands, US, ⁴UCCI - University of Cincinnati Cancer Institute, Cincinnati, US

19:57 - 20:00

Closing remarks

A. González-Martín, Clinica Universidad de Navarra, Madrid, ES

18:30 - 20:00

Type: Industry Satellite Symposium

Alicante Auditorium - Hall 3

Title: Ipsen - Kidney cancer puzzles – from insights to progress

Chair(s): Laurence Albiges, FR

18:30 - 18:35

Welcome and Introduction

L. Albiges, Institut Gustave Roussy, Villejuif, Cedex, FR

18:35 - 18:45

The adjuvant puzzle: how do we pick the right patient?

J. Bedke, Klinikum Stuttgart - Katharinenhospital (KH), Stuttgart, DE



18:45 - 19:15 **How can you select the best 1L option for your patient?**
S. Pal¹, L. Albiges², ¹City of Hope Comprehensive Cancer Center, Duarte, US, ²Institut Gustave Roussy, Villejuif, Cedex, FR

19:15 - 19:30 **How can we simplify sequencing?**
G.A. De Velasco Oria, Hospital Universitario 12 de Octubre, Madrid, ES

19:30 - 19:55 **Burning questions: what riddles remain?**
L. Albiges¹, J. Bedke², G.A. De Velasco Oria³, S. Pal⁴, ¹Institut Gustave Roussy, Villejuif, Cedex, FR, ²Klinikum Stuttgart - Katharinenhospital (KH), Stuttgart, DE, ³Hospital Universitario 12 de Octubre, Madrid, ES, ⁴City of Hope Comprehensive Cancer Center, Duarte, US

19:55 - 20:00 **Closing Remarks**
L. Albiges, Institut Gustave Roussy, Villejuif, Cedex, FR

18:30 - 20:00 **Type: Industry Satellite Symposium** **Pamplona Auditorium - Hall 3**
Title: Eisai Inc. - Evolving Treatment Sequence for Renal Cell Carcinoma
 Chair(s): Toni Choueiri, US; Manuela Schmidinger, AT

18:30 - 18:35 **Welcome and Introduction**
T. Choueiri, Dana Farber Cancer Institute, Boston, US

18:35 - 18:55 **aRCC 1L treatment selection**
B. Rini, Vanderbilt Ingram Cancer Center, Nashville, US

18:55 - 19:15 **Managing response to IO-TKI combinations in 1L RCC**
V. Gruenwald, University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE

19:15 - 19:35 **New perspectives in the post IO setting**
M. Schmidinger, Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT

19:35 - 19:55 **Round table case discussions, Q&A**
T. Choueiri, Dana Farber Cancer Institute, Boston, US

19:55 - 20:00 **Summary and key takeaways**
M. Schmidinger, Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT

18:30 - 20:00 **Type: Industry Satellite Symposium** **Oviedo Auditorium - Hall 3**
Title: Bristol Myers Squibb - A decade of anti—PD-1—based therapies for melanoma: looking beyond the curves
 Chair(s): Eva Muñoz-Couselo, ES

18:30 - 18:35 **Welcome and introduction**
E. Muñoz-Couselo, Vall d'Hebron University Hospital, Barcelona, ES

18:35 - 19:15	The past, present, and future for melanoma therapy <u>M. Postow</u> , Memorial Sloan Kettering 60th Street Outpatient Center, New York, US
19:15 - 19:30	2024 treatment in focus: immuno-oncology for the neoadjuvant/perioperative setting <u>C. Hoeller</u> , MedUni Wien - Medical University of Vienna, Vienna, AT
19:30 - 19:55	Navigating treatment in the neoadjuvant/perioperative setting: an interactive conversation <u>E. Muñoz-Couselo</u> ¹ , <u>M. Postow</u> ² , <u>C. Hoeller</u> ³ , ¹ Vall d'Hebron University Hospital, Barcelona, ES, ² Memorial Sloan Kettering 60th Street Outpatient Center, New York, US, ³ MedUni Wien - Medical University of Vienna, Vienna, AT
19:55 - 20:00	Summary and close <u>E. Muñoz-Couselo</u> , Vall d'Hebron University Hospital, Barcelona, ES
18:30 - 20:00	Type: Industry Satellite Symposium Title: Takeda - Navigating Later-Line Metastatic Colorectal Cancer: The Latest Data Guiding Treatment Selection and Sequencing Chair(s): Howard Hochster, US Toledo Auditorium - Hall 3
18:30 - 18:35	Chair Welcome and Introductions <u>H. Hochster</u> , Rutgers Cancer Institute of New Jersey, New Brunswick, US
18:35 - 18:45	Navigating Complexities in Patient Cases: What's Your Next Treatment for Refractory Disease? <u>S. Stintzing</u> , Charité - Universitätsmedizin Berlin, Berlin, DE
18:45 - 19:10	Treatment Options in Refractory mCRC <u>R. Garcia-Carbonero</u> , University Hospital 12 De Octubre, Madrid, ES
19:10 - 19:25	Factors Impacting Treatment Choice in Refractory Setting <u>H. Hochster</u> , Rutgers Cancer Institute of New Jersey, New Brunswick, US
19:25 - 19:50	Live Panel Q&A Session <u>H. Hochster</u> , Rutgers Cancer Institute of New Jersey, New Brunswick, US
19:50 - 20:00	Panel Discussion: Patient Case Study Review <u>H. Hochster</u> , Rutgers Cancer Institute of New Jersey, New Brunswick, US



15.09.2024

08:30 - 10:00

Type: Mini Oral session

Barcelona Auditorium - Hall 2

Title: Mini oral session 1: Breast cancer, metastatic

Chair(s): Christos Sotiriou, BE; Patricia Lorusso, US

08:30 - 08:35

341MO - Impact of aging on the genetic and transcriptional landscape of advanced breast cancer: an AURORA program (BIG 14-01) subanalysis

G. Zoppoli¹, F. Ravera², F. Santaniello³, L. Ferrando⁴, D. Venet⁵, J.A. Seoane⁶, F. Richard⁷, E. Munzone⁸, S. Hatse⁷, A. Ballestrero¹, T. Antonioli Crestani⁹, V. Adam⁹, A. Irrthum⁹, P. Aftimos¹⁰, A.L. Guerrero Zotano¹¹, D. Cameron¹², M. Piccart¹⁰, C. Desmedt⁷, M. Benelli¹³, H. Wildiers⁷,
¹Università degli Studi di Genova, Ospedale Policlinico San Martino IRCCS, Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC), Genova, IT, ²Università degli Studi di Genova, Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC), Genova, IT, ³Università degli Studi di Firenze, Fondazione Sandro Pitigliani per la lotta contro i tumori ONLUS, Prato, IT, ⁴Ospedale Policlinico San Martino IRCCS, Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC), Genova, IT, ⁵Institute Jules Bordet University Hospital, Brussels, BE, ⁶Vall d'Hebron Institute of Oncology, Barcelona, ES, ⁷KU Leuven, Leuven, BE, ⁸IEO - Istituto Europeo di Oncologia, Milan, IT, ⁹Breast International Group (BIG) - AISBL, Brussels, BE, ¹⁰Institute Jules Bordet, Anderlecht, BE, ¹¹IVO - Fundación Instituto Valenciano de Oncología, Valencia, ES, ¹²Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, GB, ¹³Università degli Studi di Firenze,, Prato, IT

08:35 - 08:40

342MO - Metastatic hormone receptor-positive breast cancer outcomes in 628 patients with BRCA1, BRCA2, or PALB2 pathogenic variants: Real-world data analysis of genomics and targeted therapy sequencing

G. Parkinson¹, M. Lustberg², S. Nazari³, A. Elliott³, G. Sledge⁴, R. Jeselsohn⁵, E. Hsu⁶, R. Sobol⁷, A. Sandoval-Leon⁸, R. Gopalakrishnan⁹, I.(. Makhoul¹⁰, L. Nye¹¹, A. Kurian¹², F. Lynce⁵, S. Graff¹³,
¹Lifespan Cancer Institute - Rhode Island Hospital, Providence, US, ²Yale University School of Medicine, New Haven, US, ³Caris Life Sciences - Headquarters, Irving, US, ⁴Caris Life Sciences, Phoenix, US, ⁵Dana Farber Cancer Institute, Boston, US, ⁶Warren Alpert Medical School of Brown University, Providence, US, ⁷Brown University, Providence, US, ⁸Miami Cancer Institute, Baptist Health South Florida, Miami, US, ⁹Mount Sinai Comprehensive Cancer Center, Miami Beach, US, ¹⁰CARTI Cancer Center, Little Rock, US, ¹¹University of Kansas Medical Center, Westwood, US, ¹²Stanford University School of Medicine, Stanford, US, ¹³Lifespan Cancer Institute, Warren Albert Medical School of Brown University, Providence, US



08:40 - 08:45

LBA21 - Human epidermal growth factor receptor 2 (HER2)-low and HER2-ultralow status determination in tumors of patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (mBC) in DESTINY-Breast06 (DB-06)

R. Salgado¹, A. Bardia², G. Curigliano³, X. Hu⁴, R. Dent⁵, J.-Y. Pierga⁶, J. Tsurutani⁷, H. Wildiers⁸, G.R.R. Ricciardi⁹, C. Marchiò¹⁰, F. Penault-Llorca¹¹, C. Bor-Angelier¹², A. Andrzejuk-Cwik¹³, A. Darilay¹⁴, T. Matsuo¹⁵, R. Shami¹⁵, F. Jones¹⁵, G. Viale¹⁶, ¹ZAS Hospitals, Antwerp, BE, ²Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, US, ³IEO, IRCCS, Milan, IT, ⁴Fudan University Shanghai Cancer Center, Shanghai, CN, ⁵National Cancer Centre Singapore, Singapore, SG, ⁶Institut Curie and Université Paris Cité, Paris, FR, ⁷Showa University Hospital, Tokyo, JP, ⁸University Hospitals Leuven, Leuven, BE, ⁹Papardo Hospital, Messina, IT, ¹⁰FPO-IRCCS Candiolo Cancer Institute, Candiolo, IT, ¹¹University Clermont Auvergne, INSERM U1240 (Molecular Imaging & Theragnostic Strategies [IMOST]), Clermont-Ferrand, FR, ¹²Central Laboratory, Labcorp Drug Development, MEYRIN, CH, ¹³AstraZeneca, Warsaw, PL, ¹⁴AstraZeneca, Gaithersburg, US, ¹⁵AstraZeneca, Cambridge, GB, ¹⁶IEO European Institute of Oncology, IRCCS, Milan, IT

08:45 - 08:50

343MO - Unraveling the mechanisms of action and resistance to trastuzumab deruxtecan (T-DXd): Supplementary biomarker analyses from DAISY trial

M.F. Mosele¹, A. Lusque², V. Dieras³, E. Deluche⁴, A. Ducoulombier⁵, B. Pistilli⁶, T. Bachelot⁷, F. Viret⁸, C. Levy⁹, Y. Pradat¹⁰, N. Signolle¹⁰, L. Le Bescond¹¹, D. Tran¹, N. Droin⁶, M. Kobayashi¹², T. Kakewaga¹², M. Deloger¹⁰, M. Jimenez¹³, M. Lacroix-Triki¹⁴, F. André¹⁰, ¹Gustave Roussy - Cancer Campus, VILLEJUIF, FR, ²Institut Claudius Regaud, Toulouse, FR, ³Centre Eugene - Marquis, Rennes, FR, ⁴CHU Limoges - Hopital Dupuytren, Limoges, FR, ⁵Centre Anticancer Antoine Lacassagne, Nice, FR, ⁶Institut Gustave Roussy, Villejuif, Cedex, FR, ⁷Centre Léon Bérard, Lyon, FR, ⁸IPC - Institut Paoli-Calmettes, Marseille, FR, ⁹Centre Francois Baclesse, Caen, FR, ¹⁰Gustave Roussy - Cancer Campus, Villejuif, FR, ¹¹Institut Gustave Roussy - INSERM UMR 981, Villejuif, FR, ¹²Daiichi Sankyo Co., Ltd., Tokyo, JP, ¹³Unicancer, Paris, Cedex, FR, ¹⁴Institut Gustave Roussy, Villejuif, FR

08:50 - 09:05

Invited Discussant 341MO, 342MO, LBA21 and 343MO

C. Sotiriou, Institute Jules Bordet, Brussels, BE



09:05 - 09:10

344MO - ESG401, a novel Trop2 antibody-drug conjugate (ADC), and its efficacy evidence in HER2-negative metastatic breast cancer with brain metastases

E. Ma¹, F. Qiu², Z. Tong³, J. Wang⁴, Y. Shi³, L. Li⁵, G. Yu⁶, H. Shi⁷, X. Wu⁸, A. Liu⁹, Y. Zhang¹⁰, H. Wang¹¹, Y. Cheng¹², H. Yang¹³, H. Li¹⁴, J. Chang¹⁵, Q. Zhou¹⁶, ¹Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, Beijing, CN, ²The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang, CN, ³TMUCIH - Tianjin Medical University Cancer Institute and Hospital, Tianjin, CN, ⁴Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN, ⁵The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, CN, ⁶Weifang People's Hospital, Weifang, CN, ⁷First Affiliated Hospital of Gannan Medical university, Ganzhou, CN, ⁸Hubei Cancer Hospital, wuhan, CN, ⁹The Second Affiliated Hospital of Nanchang University, Nanchang, CN, ¹⁰Beijing Hospital, Beijing, CN, ¹¹Nanchang People's Hospital Affiliated of Nanchang Medical College, Nanchang, CN, ¹²Jilin Cancer Hospital, Changchun, CN, ¹³Affiliated Hospital of Hebei University, Baoding, CN, ¹⁴Peking University Cancer Hospital and Institute, Beijing, CN, ¹⁵The Affiliated Hospital of Guizhou Medical University, guizhou, CN, ¹⁶Shanghai Escugen Biotechnology Co., Ltd, Shanghai, CN

09:10 - 09:15

LBA22 - Effects of trastuzumab deruxtecan (T-DXd) vs choice of chemotherapy (TPC) on patient-reported outcomes (PROs) in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer (mBC): Results from DESTINY-Breast06

X. Hu¹, G. Curigliano², K. Yonemori³, A. Bardia⁴, C. Barrios⁵, J. Sohn⁶, C. Levy⁷, W. Jacot⁸, J. Tsurutani⁹, K. Mezei¹⁰, A. Roborel De Climens¹¹, X. Wu¹², N. Begbie¹³, Z. Mbanya¹³, R. Dent¹⁴, ¹Fudan University Shanghai Cancer Center, Shanghai, CN, ²IEO, IRCCS, Milan, IT, ³National Cancer Center Hospital, Chuo-ku, JP, ⁴University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, US, ⁵Latin American Cooperative Oncology Group (LACOG), Porto Alegre, BR, ⁶Yonsei Cancer Center, Seoul, KR, ⁷Centre François Baclesse, Caen, FR, ⁸Institut du Cancer de Montpellier, Université de Montpellier, Montpellier, Cedex, FR, ⁹Showa University Hospital, Tokyo, JP, ¹⁰Szabolcs-Szatmár-Bereg County Hospital, Nyiregyhaza, HU, ¹¹IQVIA, Paris, FR, ¹²AstraZeneca, Gaithersburg, US, ¹³AstraZeneca, Cambridge, GB, ¹⁴National Cancer Centre Singapore, Singapore, SG



09:15 - 09:20

345MO - IBI354 (anti-HER2 antibody-drug conjugate [ADC]) in patients (pts) with advanced solid tumors and breast cancer (BC): Results from a phase I study

C. Lemech¹, Y. Sun², A. Nagrial³, X. Wu⁴, M. Morris⁵, F. Ning⁶, J. Yang⁷, Y. Pan⁸, J. Cai⁹, P. Lu¹⁰, T. Zhang¹¹, F. Qiu¹², C. Hu¹³, M. Zhang¹⁴, Z. Liu¹⁵, G. Han¹⁶, J. Nie¹⁷, C. Teng¹, H. Zhou¹⁸, D. Day¹⁹,
¹Scientia Clinical Research, Randwick, AU, ²Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, CN, ³Westmead Hospital, Westmead, AU, ⁴Hubei Cancer Hospital, wuhan, CN, ⁵Sunshine Coast University Hospital, Birtinya, AU, ⁶Binzhou Medical College, Yantai, CN, ⁷The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, CN, ⁸Anhui Provincial Hospital, Hefei, CN, ⁹Jingzhou First People's Hospital, Jingzhou City, CN, ¹⁰The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, CN, ¹¹The First Affiliated Hospital of Chongqing Medical University, Chongqing, CN, ¹²The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang, CN, ¹³Anhui Provincial Cancer Hospital, Hefei, CN, ¹⁴The Second Affiliated Hospital of Anhui Medical University, Hefei, CN, ¹⁵Dongguan People's Hospital, Dongguan, CN, ¹⁶Shanxi Cancer Hospital, Taiyuan, CN, ¹⁷Yunnan Cancer Hospital, Kunming, CN, ¹⁸Innovent Biologics, Inc., Beijing, CN, ¹⁹Monash Health, Clayton, AU

09:20 - 09:25

346MO - Trastuzumab deruxtecan (T-DXd) associated interstitial lung disease (ILD) in a large real-world French cohort of patients with HER2-driven breast cancer and other malignancies

A. Canellas¹, L. Elu¹, P. Du Rusquec², M.-A. Bendorra³, L. Drouin⁴, I. Cojean-Zelek⁵, A. Vozy⁶, E. Assaf⁷, A. Teillet Benmaziane⁸, J. Medioni⁹, R. Cohen¹⁰, L. Zelek¹¹, M. Wislez¹², J. Gligorov¹³, P.Y. Brillet¹¹, N. Girard², K. Bihan¹⁴, J. Cadranel¹⁵, ¹Hopital Tenon AP-HP, Paris, Cedex, FR, ²Institut Curie, Paris, FR, ³Institut Universitaire de Cancérologie AP-HP Sorbonne Université, Paris, FR, ⁴Hopital Saint Louis AP-HP, Paris, FR, ⁵Centre Hospitalier Intercommunal de Créteil, Créteil, FR, ⁶Hopital Pitié-Salpêtrière AP-HP, Paris, FR, ⁷Centre Hospitalier Universitaire Henri-Mondor AP-HP, Créteil, FR, ⁸Hopital Foch, Suresnes, FR, ⁹HEGP - Hopital Europeen Georges-Pompidou - AP-HP, Paris, FR, ¹⁰Hopital Saint-Antoine, Paris, FR, ¹¹Hopital Avicenne AP-HP, Bobigny, FR, ¹²Hopital Cochin AP-HP, Paris, FR, ¹³Institut Universitaire de Cancérologie AP-HP. Sorbonne Université, Hôpital Tenon, Paris, FR, ¹⁴Hopital Pitié Salpêtrière AP-HP, Paris, FR, ¹⁵Assistance Publique des Hôpitaux de Paris, Hôpital Tenon, Paris, FR

09:25 - 09:40

Invited Discussant 344MO, LBA22, 345MO and 346MO

P. Lorusso, Yale School of Medicine - Radiology and Biomedical Imaging, New Haven, US

08:30 - 10:00

Type: Educational session

Madrid Auditorium - Hall 2

Title: Antibody drug conjugates (ADCs) in lung cancer: Ready for prime time?

Chair(s): Alona Zer, IL; Anne-Marie Dingemans, NL

08:30 - 08:50

Resistance and sequencing to ADCs

L. Ellisen, MGH - Massachusetts General Hospital, Boston, US

08:50 - 09:10

Agnostic ADCs (TROP2 and other combinations)

P. Bironzo, Azienda Ospedaliera Universitaria San Luigi Gonzaga, Orbassano, IT



09:10 - 09:30 **Specific ADCs: HER2, HER3, CEACAM5, MET**
D. Planchard, Institut Gustave Roussy, Villejuif, Cedex, FR

09:30 - 09:50 **Toxicity of ADCs**
A.-M. Dingemans, Erasmus MC - University Medical Center, Rotterdam, NL

09:50 - 10:00 **Q&A and discussion**

08:30 - 10:00 **Type: Proffered Paper session** **Sevilla Auditorium - Hall 2**
Title: Proffered paper session 1: GI tumours, lower
 Chair(s): Jenny Seligmann, GB; Julien Taieb, FR

08:30 - 08:40 **5070 - Impact of lean body mass-based oxaliplatin dosage on neurotoxicity in adjuvant treatment of stage III colorectal cancer: Final results of the phase II randomized multicenter LEANOX trial**
E. Assenat¹, M. Ben Abdelghani², S. Gourgou³, H. Perrier⁴, F. Khemissa Akouz⁵, R. Desgrippes⁶, M.P. Galais⁷, C. Janiszewski¹, Y. Rinaldi⁸, C. Lepage⁹, R. Tetreau¹, P. Senesse¹, ¹ICM - Institut du Cancer de Montpellier, Montpellier, Cedex, FR, ²ICANS - Institut de Cancérologie Strasbourg Europe, Strasbourg, FR, ³ICM - Institut régional du Cancer de Montpellier, Val d'Aurelle, Montpellier, Cedex, FR, ⁴Fondation Hôpital Saint Joseph, Marseille, FR, ⁵Centre Hospitalier de Perpignan - Hôpital Saint Jean, Perpignan, Cedex, FR, ⁶Saint Malo hospital, Saint Malo, FR, ⁷Centre Francois Baclesse, Caen, Cedex, FR, ⁸Hopital Européen Marseille, Marseille, FR, ⁹CHU Dijon, Dijon, FR

08:40 - 08:50 **5120 - Adjuvant aspirin treatment in PIK3CA mutated colon cancer patients: The phase III, prospective-randomized placebo-controlled multicenter SAKK 41/13 trial**
U. Güller¹, S. Hayoz², D. Horber³, S. De Dosso⁴, D. Koeberle⁵, S. Schacher Kaufmann⁶, R. Inauen⁷, M. Stahl⁸, T. Delaunoy⁹, T. Ettrich¹⁰, G.M. Bodoky¹¹, P. Michel¹², T. Kössler¹³, K. Rothgiesser², S. Calmonte², M. Joerger³, ¹Spital STS AG - Onkologiezentrum Thun-Berner Oberland, Thun, CH, ²Swiss Group for Clinical Cancer Research (SAKK), Bern, CH, ³Cantonal Hospital St. Gallen, St. Gallen, CH, ⁴Oncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), Bellinzona, CH, ⁵St. Claraspital AG, Basel, CH, ⁶KSW - Kantonsspital Winterthur, Winterthur, CH, ⁷Spital Thurgau AG - Kantonsspital Muensterlingen, Muensterlingen, CH, ⁸KEM | Evang. Kliniken Essen-Mitte gGmbH, Essen, DE, ⁹Centre Hospitalier Jolimont-Lobbès, Haine-Saint-Paul, BE, ¹⁰Ulm University Hospital, Ulm, DE, ¹¹St. László Hospital, Budapest, HU, ¹²Rouen University Hospital, CHU Charles Nicolle, Rouen, FR, ¹³Hôpitaux Universitaires de Genève, Geneva, CH

08:50 - 09:00 **Invited Discussant 5070 and 5120**
S. Stintzing, Charité - Universitätsmedizin Berlin, Berlin, DE

09:00 - 09:10 **Q&A**



09:10 - 09:20

LBA24 - Neoadjuvant immunotherapy in locally advanced MMR-deficient colon cancer: 3-year disease-free survival from NICHE-2

M. Chalabi¹, L. Van Den Dungen¹, Y. Verschoor¹, S. Balduzzi¹, P. De Gooyer¹, N. Kok¹, E. Kerver², C. Grootsholten¹, E. Voest¹, J. Burger³, E. Hendriks⁴, T. De Wijkerslooth¹, T. Tin⁵, T. Aukema⁶, S. Oosterling⁷, A. Aalbers¹, J. Van Den Berg¹, M. Van Leerdam¹, T. Schumacher¹, J. Haanen¹, ¹NKI - Netherlands Cancer Institute, Amsterdam, NL, ²OLVG Hospital, Amsterdam, NL, ³Catharina Hospital Eindhoven, Eindhoven, NL, ⁴Tergooi Hospital, Hilversum, NL, ⁵Inc., Austin, US, ⁶Haga Hospital, Den Haag, NL, ⁷Spaarne Hospital Haarlem & Hoofddorp, Hoofddorp, NL

09:20 - 09:30

5030 - Neoadjuvant nivolumab (nivo) plus relatlimab (rela) in MMR-deficient colon cancer: Results of the NICHE-3 study

P. De Gooyer¹, Y. Verschoor¹, L. Van Den Dungen¹, S. Balduzzi¹, A. Lent², C. Grootsholten¹, S. Dokter¹, A. Den Hartog¹, J. Burger³, W. Verbeek¹, T. Aukema⁴, E. Hendriks⁵, S. Oosterling⁶, R. Beets-Tan¹, T. Schumacher¹, J. Haanen¹, K. Kuhlmann¹, M. Van Leerdam¹, J. Van Den Berg¹, M. Chalabi¹, ¹NKI - Netherlands Cancer Institute, Amsterdam, NL, ²OLVG Hospital, Amsterdam, NL, ³Catharina Hospital Eindhoven, Eindhoven, NL, ⁴Haga Hospital, Den Haag, NL, ⁵Tergooi MC, Hilversum, NL, ⁶Spaarne Hospital Haarlem & Hoofddorp, Hoofddorp, NL

09:30 - 09:40

5040 - IMHOTEP Phase II trial of neoadjuvant pembrolizumab in dMMR/MSI tumors: Results of the colorectal cancer cohort

C. De La Fouchardiere¹, A. Zaanan², R. Cohen³, S. Le Sourd⁴, D. Tougeron⁵, E. Soularue⁶, O. Dubreuil⁷, N. Williet⁸, E. Samalin-Scalzi⁹, G. Piessen¹⁰, V. Hautefeuille¹¹, M. Jary¹², M. Ben Abdelghani¹³, L. Evesque¹⁴, P. Rochigneux¹⁵, E. Blanc¹, F. Bibeau¹⁶, A. Demontfort¹, C. Coutzac¹, ¹Centre Léon Bérard, Lyon, FR, ²Hopital Europeen Georges-Pompidou - AP-HP, Paris, FR, ³Hopital Saint-Antoine, Paris, FR, ⁴Centre Eugene - Marquis, Rennes, FR, ⁵CHU Poitiers - Jean Bernard Hôpital, Poitiers, FR, ⁶Institut mutualiste Montsouris, PARIS, FR, ⁷Gh Diaconesses Croix Saint-Simon, Paris, FR, ⁸Hopital Nord, St Priest En Jarez, FR, ⁹ICM - Institut du Cancer de Montpellier, Montpellier, Cedex, FR, ¹⁰C.H.U. Claude Huriez, Lille, FR, ¹¹CHU Amiens-Picardie - Site Nord, Amiens, FR, ¹²CHU de Clermont-Ferrand - Site Estaing, Clermont-Ferrand, Cedex, FR, ¹³ICANS - Institut de Cancérologie Strasbourg Europe, Strasbourg, FR, ¹⁴Centre Anticancer Antoine Lacassagne, Nice, FR, ¹⁵IPC - Institut Paoli-Calmettes, Marseille, Cedex, FR, ¹⁶CHU de Besançon, Besançon, FR

09:40 - 09:50

Invited Discussant LBA24, 5030 and 5040

J. Seligmann, The University of Leeds, Leeds, GB

09:50 - 10:00

Q&A



08:30 - 10:00

Type: Mini Oral session

Bilbao Auditorium - Hall 2

Title: Mini oral session: GU tumours, non-prostate

Chair(s): Maria De Santis, DE; Camillo Guglielmo Porta, IT; Aristotelis Bamias, GR

08:30 - 08:35

LBA85 - TAR-200 & cetrelimab (CET) and CET alone in patients (pts) with bacillus Calmette-Guérin-unresponsive (BCG UR) high-risk non-muscle-invasive bladder cancer (HR NMIBC): Updated results from SunRISe-1 (SR-1)

M. Van Der Heijden¹, G. Simone², M. Boegemann³, E. Xylinas⁴, M. Roumiguié⁵, F. Guerrero-Ramos⁶, A. Necchi⁷, S. Daneshmand⁸, C. Van Praet⁹, P. Spiegelhalder¹⁰, K. Decaestecker¹¹, H. Arentsen¹², D. Zainfeld¹³, S. Hampras¹⁴, C. Cutie¹⁵, H. Sweiti¹⁶, K. Stromberg¹⁴, J. Martin¹⁷, A. Shukla¹⁵, J. Jacob¹⁸, ¹Netherlands Cancer Institute, Amsterdam, NL, ²'Regina Elena' National Cancer Institute, Rome, IT, ³University Hospital Münster, Münster, DE, ⁴Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris, Université de Paris Cité, Paris, FR, ⁵Toulouse Hospital, Toulouse, FR, ⁶University Hospital 12 de Octubre, Madrid, ES, ⁷IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, IT, ⁸University of Southern California Norris Comprehensive Cancer Center, Los Angeles, US, ⁹ERN Accredited Center, Ghent University Hospital, Ghent, BE, ¹⁰Urologie Neandertal, Gemeinschaftspraxis für Urologie, Mettmann, DE, ¹¹AZ Maria Middelaes, Gent, BE, ¹²AZ Sint-Jan Hospital Brugge-Oostende, Oostende, BE, ¹³Urology San Antonio, San Antonio, US, ¹⁴Janssen Research & Development, Raritan, US, ¹⁵Janssen Research & Development, Lexington, US, ¹⁶Janssen Research & Development, Spring House, US, ¹⁷Janssen Research & Development, High Wycombe, GB, ¹⁸Upstate Medical University, Syracuse, US

08:35 - 08:40

1964MO - Alliance A031501: AMBASSADOR study of adjuvant pembrolizumab (Pembro) in muscle-invasive urothelial carcinoma (MIUC) vs observation (Obs): Extended follow-up disease-free survival (DFS) results and metastatic (met) disease recurrence distribution

A. Apolo¹, K. Ballman², G. Sonpavde³, S. Berg⁴, W. Kim⁵, R. Parikh⁶, M.Y. Teo⁷, R. Sweis⁸, D. Geynisman⁹, P. Grivas¹⁰, G. Chatta¹¹, Z. Reichert¹², J. Kim¹³, M. Bilen¹⁴, B. McGregor¹⁵, S. Srinivas¹⁶, S. Halabi¹⁷, G. Perez Burbano¹⁸, M. Morris⁷, J. Rosenberg⁷, ¹National Cancer Institute, Bethesda, US, ²Mayo Clinic Cancer Center, Rochester, US, ³AdventHealth Cancer Institute, Orlando, US, ⁴Dana-Farber Cancer Institute, Boston, US, ⁵UNC Lineberger Comprehensive Cancer Center, Chapel Hill, US, ⁶KUMC - University of Kansas Medical Center, Kansas City, US, ⁷Memorial Sloan Kettering Cancer Center, New York, US, ⁸The University of Chicago, Chicago, US, ⁹Fox Chase Cancer Center - Main Campus, Philadelphia, US, ¹⁰University of Washington, Seattle, US, ¹¹Roswell Park Comprehensive Cancer Center, Buffalo, US, ¹²University of Michigan, Ann Arbor, US, ¹³Yale University School of Medicine - Yale Cancer Center, New Haven, US, ¹⁴Winship Cancer Institute of Emory University, Atlanta, US, ¹⁵Dana Farber Cancer Institute, Boston, US, ¹⁶Stanford Comprehensive Cancer Institute, Stanford, US, ¹⁷Duke University Medical Center, Durham, US, ¹⁸Mayo Clinic - Rochester, Rochester, US



08:40 - 08:45

1970MO - Circulating tumor DNA (ctDNA) clearance with neoadjuvant durvalumab (D) + tremelimumab (T) + enfortumab vedotin (EV) for cisplatin-ineligible muscle-invasive bladder cancer (MIBC) from the safety run-in cohort of the phase III VOLGA trial

A. Drakaki¹, T. Powles², Y. Wang³, M. Bupathi⁴, M. Joshi⁵, M. Fleming⁶, A. Gomez De Liano Lista⁷, R. Morales Barrera⁸, R. Pili⁹, S. Boulos¹⁰, Y. Shrestha¹¹, ¹David Geffen School of Medicine, Los Angeles, US, ²Barts Cancer Institute, Queen Mary University of London, London, GB, ³AstraZeneca, Waltham, US, ⁴Rocky Mountain Cancer Centers, Littleton, US, ⁵Penn State Cancer Institute, Hershey, US, ⁶Virginia Oncology Associates, Norfolk, US, ⁷Complejo Hospitalario Universitario Insular-Materno Infantil, Las Palmas, ES, ⁸Vall d'Hebron Institute of Oncology and University Hospital, Universitat Autònoma de Barcelona,, Barcelona, ES, ⁹Jacobs School of Medicine and Biomedical Sciences, Buffalo, US, ¹⁰AstraZeneca, Cambridge, GB, ¹¹AstraZeneca USA, Gaithersburg, US

08:45 - 09:00

Invited Discussant LBA85, 1964MO and 1970MO

M. De Santis, Charité - Universitätsmedizin Berlin, Berlin, DE

09:00 - 09:05

LBA76 - Anlotinib in combined with anti-PD-L1 antibody Benmelstobart(TQB2450) versus sunitinib in first-line treatment of advanced renal cell carcinoma (RCC): A randomized, open-label, phase III study (ETER100)

X. Sheng¹, P. Shen², W. Qu³, Z. Wang⁴, Y. Li⁵, X. Ren⁶, S. Jiang⁷, G. Li⁸, C. Fu⁹, W. Qin¹⁰, J. Wu¹¹, P. Chen¹², H. Guo¹³, F. Zhou¹⁴, Z. Ji¹⁵, A. Yang¹⁶, K. Chen¹⁶, L. Li¹⁶, A. Zhou³, J. Guo¹, ¹Peking University Cancer Hospital and Institute, Beijing, CN, ²SCU - Sichuan University - Huaxi Campus, Chengdu, CN, ³National Cancer Center/National Clinical Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN, ⁴Jiangsu Province Hospital/The First Affiliated Hospital of Nanjing Medical University, Nanjing, CN, ⁵Chongqing University Cancer Hospital, Chongqing, CN, ⁶Tianjin Cancer Hospital, Tianjin, CN, ⁷Hunan Cancer Hospital, Changsha, CN, ⁸The Second Hospital of Tianjin Medical University, Tianjin, CN, ⁹Liaoning Cancer Hospital & Institute, Shenyang, CN, ¹⁰The First Affiliated Hospital of the Chinese People's Liberation Army Air Force Medical University, Xian, CN, ¹¹Harbin Medical University Affiliated Cancer Hospital, Harbin, CN, ¹²Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, CN, ¹³The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, CN, ¹⁴Sun Yat-sen University Cancer Center, Guangzhou, CN, ¹⁵Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, Beijing, CN, ¹⁶CTTQ - Chia Tai Tianqing Pharmaceutical Group Co., Ltd. - Nanjing Site, Nanjing, CN



09:05 - 09:10

LBA77 - Fecal microbiota transplantation (FMT) versus placebo in patients receiving pembrolizumab plus axitinib for metastatic renal cell carcinoma: Preliminary results of the randomized phase II TACITO trial

C. Ciccarese¹, S. Porcari², S. Buti³, G. Fornarini⁴, F. Primi⁵, G.C. Giudice⁶, A. Damassi⁷, J.R. Giron Berrios⁵, L. Stumbo⁸, D. Arduini¹, A. Severino⁹, D. Rondinella⁹, L. Masucci⁹, M. Sanguinetti⁹, A. Gasbarrini¹⁰, G. Cammarota², N. Segata¹¹, G. Tortora¹, G. Ianaro⁹, R. Iacovelli², ¹Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT, ²Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT, ³Medical Oncology Unit, University Hospital of Parma, Parma, IT, ⁴IRCCS Ospedale Policlinico San Martino, Genova, IT, ⁵Ospedale Belcolle - ASL Viterbo, Viterbo, IT, ⁶Università di Parma, Parma, IT, ⁷Asl3 genovese, Genova, Genova, IT, ⁸Azienda Ospedaliera Universitaria S. Andrea, Rome, IT, ⁹Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, IT, ¹⁰Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, IT, ¹¹University of Trento - Cellular, Computational and Integrative Biology (CIBIO), Povo, IT

09:10 - 09:15

1694MO - Novel serum glycoproteomic biomarkers predict response to nivolumab plus cabozantinib (NIVO+CABO) versus sunitinib (SUN) in advanced RCC (aRCC): Analysis from CheckMate 9ER

D. Braun¹, Y. Wang², A. Yu², C. Pickering³, D. Serie⁴, T. Choueiri⁵, W. Xu⁵, M. Sun⁵, S.V. Vemula², S. Gupta², ¹Yale University School of Medicine - Yale Cancer Center, New Haven, US, ²Bristol-Myers Squibb, Lawrenceville, US, ³InterVenn Biosciences, South San Francisco, US, ⁴InterVenn Bioscience, South San Francisco, US, ⁵Dana Farber Cancer Institute, Boston, US

09:15 - 09:30

Invited Discussant LBA76, LBA77 and 1694MO

C.G. Porta, Università degli Studi di Bari Aldo Moro, Bari, IT

09:30 - 09:35

1965MO - Phase II study of futibatinib plus pembrolizumab in patients (pts) with advanced/metastatic urothelial carcinoma (mUC): Final analysis of efficacy and safety

V. Koshkin¹, P. Barthelemy², G. Gravis³, O. Goodman⁴, I. Duran⁵, R. Girones Sarrio⁶, C. Hwang⁷, J. Garcia-Donas⁸, R. Morales Barrera⁹, S. Zanetta¹⁰, M. Chisamore¹¹, M. Liu¹², M. Gil¹², G. Tomlinson¹², H. Elsayed¹², Y. Loriot¹³, ¹UCSF Medical Center at Mission Bay, San Francisco, US, ²Institut de Cancérologie Strasbourg Europe, Strasbourg, FR, ³IPC - Institut Paoli-Calmettes, Marseille, Cedex, FR, ⁴Comprehensive Cancer Centers of Nevada - Southwest, Las Vegas, US, ⁵Hospital Universitario Marques de Valdecilla, Santander, ES, ⁶Hospital Universitario y Politécnico la Fe de Valencia, Valencia, ES, ⁷Henry Ford Cancer Institute-Henry Ford Health, Detroit, US, ⁸Hospital Madrid Norte San Chinarro - Centro Integral Oncológico Clara Campal, Madrid, ES, ⁹Vall d'Hebron University Hospital, Barcelona, ES, ¹⁰Centre Georges-François Leclerc (Dijon), Dijon, FR, ¹¹Merck & Co., Inc., Rahway, US, ¹²Taiho Oncology, Inc., Princeton, US, ¹³Institut Gustave Roussy, Villejuif, Cedex, FR



09:35 - 09:40

1966MO - EV-302: Exploratory analysis of nectin-4 expression and response to 1L enfortumab vedotin (EV) + pembrolizumab (P) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC)

T. Powles¹, M. Van Der Heijden², S. Gupta³, B. Perez Valderrama⁴, M. Galsky⁵, J. Bedke⁶, E. Kikuchi⁷, J. Hoffman-Censits⁸, J.P. Maroto Rey⁹, C. Vulsteke¹⁰, G. Iyer¹¹, U. Swami¹², S.J. Shin¹³, A. Rodriguez-Vida¹⁴, M. Wozniak¹⁵, B. Homet Moreno¹⁶, J. Lu¹⁷, C. Yu¹⁷, L. Hogdal¹⁷, Y. Lorient¹⁸, ¹QMUL, London, GB, ²Netherlands Cancer Institute, Amsterdam, NL, ³The Cleveland Clinic, Cleveland, US, ⁴Hospital Universitario Virgen del Rocio, Seville, ES, ⁵Mount Sinai Medical Center, New York, US, ⁶Klinikum Stuttgart, Stuttgart, DE, ⁷St. Marianna University School of Medicine, Kawasaki, JP, ⁸Johns Hopkins Medical Center, Baltimore, US, ⁹Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ¹⁰Antwerp University, Antwerp, BE, ¹¹Memorial Sloan Kettering Cancer Center, New York, US, ¹²University of Utah, Salt Lake City, US, ¹³Yonsei University Health System, Seoul, KR, ¹⁴Hospital del Mar, Barcelona, ES, ¹⁵Astellas Pharma, Inc., Northbrook, US, ¹⁶Merck & Co., Inc., Rahway, US, ¹⁷Pfizer Inc., San Diego, US, ¹⁸Institut Gustave Roussy, Villejuif, Cedex, FR

09:40 - 09:45

1967MO - Preliminary efficacy and safety of disitamab vedotin (DV) with pembrolizumab (P) in treatment (Tx)-naive HER2-expressing, locally advanced or metastatic urothelial carcinoma (la/mUC): RC48G001 cohort C

M. Galsky¹, V. Koshkin², M. Campbell³, A. Drakaki⁴, I. Bowman⁵, A. Rose⁶, J. Brown⁷, J. Aragon-Ching⁸, S. Gadde⁹, A. Harandi¹⁰, J. Rosenberg¹¹, N. Matsubara¹², K. Sokolowski¹³, M. Ichimaru¹³, S. Chan¹⁴, S. Franco¹⁵, T. Powles¹⁶, ¹Mount Sinai Medical Center, New York, US, ²UCSF Medical Center at Mission Bay, San Francisco, US, ³The M. D. Anderson Cancer Center, Houston, US, ⁴David Geffen School of Medicine, Los Angeles, US, ⁵Banner MD Anderson Cancer Center, Gilbert, US, ⁶Jewish General Hospital McGill University, Montreal, CA, ⁷Case Western Reserve University / University Hospitals, Cleveland, US, ⁸Inova Schar Cancer Institute, Fairfax, US, ⁹UT - The University of Tennessee Medical Center, Knoxville, US, ¹⁰Florida Cancer Specialists, Fort Myers, US, ¹¹MSKCC - Memorial Sloan Kettering Cancer Center, New York, US, ¹²National Cancer Center Hospital East, Kashiwa, JP, ¹³Pfizer Inc., South San Francisco, US, ¹⁴Pfizer Inc., Bothell, US, ¹⁵Merck & Co. Inc, Rahway, US, ¹⁶Barts Cancer Institute, Queen Mary University of London, London, GB

09:45 - 10:00

Invited Discussant 1965MO, 1966MO and 1967MO

A. Bamias, National & Kapodistrian University of Athens, Athens, GR

08:30 - 10:00

Type: Educational session

Granada Auditorium - Hall 6

Title: Non-cutaneous melanoma and non-melanoma skin cancers: There is much more we can do

Chair(s): Mathilde Jalving, NL; Caroline Robert, FR

08:30 - 08:55

Uveal melanoma

J.M. Piulats Rodriguez, ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), Hospitalet de Llobregat, ES

08:55 - 09:20

Cutaneous squamous cell carcinoma

M. Jalving, UMCG - University Medical Center Groningen, Groningen, NL



09:20 - 09:45 **Novel targets in Merkel cell carcinoma**
J. Becker, DKFZ - German Cancer Research Center, Heidelberg, DE

09:45 - 10:00 **Q&A and discussion**

08:30 - 10:00	Type: Mini Oral session Title: Mini oral session 1: Gynaecological cancers Chair(s): Alexandra Leary, FR; Robert Coleman, US	Burgos Auditorium - Hall 5
----------------------	--	-----------------------------------

08:30 - 08:35 **710MO - Induction chemotherapy followed by chemoradiation in locally advanced cervical cancer: Quality of life outcomes of the GCIG INTERLACE trial**

G. Eminowicz¹, S. Vaja², D. Gallardo³, C. Kent⁴, M. Panades⁵, A. Anand⁶, M. Persic⁷, J. Forrest⁸, R. Bhana⁹, M. Adusumalli¹⁰, A. Chan², A.M. Hacker², A. Hackshaw², J. Ledermann², M. McCormack¹,
¹UCLH - University College London Hospitals NHS Foundation Trust, London, GB, ²UCL - University College London, London, GB, ³IMSS - Centro Medico Nacional Siglo XXI - Hospital de Oncologia, Ciudad de Mexico, MX, ⁴Leicester Royal Infirmary - University Hospitals of Leicester NHS Trust, Leicester, GB, ⁵United Lincolnshire Hospitals - Lincoln County Hospital, Lincoln, GB, ⁶Nottingham City Hospital, Nottingham, GB, ⁷Royal Derby Hospital - University Hospitals of Derby and Burton NHS Foundation Trust, Derby, GB, ⁸Royal Devon and Exeter NHS Hospital (Wonford) - Royal Devon and Exeter Foundation Trust, Exeter, GB, ⁹Royal Stoke University Hospital, Stoke-on-Trent, GB, ¹⁰The James Cook University Hospital, Middlesbrough, GB

08:35 - 08:40 **LBA33 - ICON9: International phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy**

S. Nicum¹, J. Ledermann², L. Mileskin³, G. Jayson⁴, C. Gourley⁵, A. Michael⁶, R. Lord⁷, H. Mackay⁸, M. Hall⁹, L. Tookman¹⁰, S. Banerjee¹¹, P. Harnett¹², I. Macdonald¹³, Y.C. Lee¹⁴, O. Elyashiv¹³, K. Wilkinson¹³, L. Farrelly¹⁵, N. Counsell¹³, ¹UCL Cancer Institute, London, GB, ²UCL Cancer Institute - UCL - London's Global University, London, GB, ³Peter MacCallum Cancer Center, Melbourne, AU, ⁴The Christie NHS Foundation Trust, Manchester, GB, ⁵Cancer Research UK Edinburgh Centre, Edinburgh, GB, ⁶University of Surrey - Faculty of Health and Medical Sciences, Guildford, GB, ⁷The Clatterbridge Cancer Centre, Liverpool, GB, ⁸Sunnybrook Health Sciences Centre - Odette Cancer Centre, Toronto, CA, ⁹Mount Vernon Cancer Centre, Northwood, GB, ¹⁰Imperial College London - Hammersmith Campus, London, GB, ¹¹The Royal Marsden Hospital - Chelsea, London, GB, ¹²Crown Princess Mary Cancer Centre Westmead, Westmead, AU, ¹³Cancer Research UK & University College London Cancer Trials Centre, London, GB, ¹⁴The University of Sydney, Camperdown, AU, ¹⁵UCL - University College London, London, GB



08:40 - 08:45

LBA34 - ENGOT-ov48/EUDARIO: European trial on enhanced DNA repair inhibition in ovarian cancer

N. Concin¹, T. Van Gorp², D. Lorusso³, I. Ray-Coquard⁴, A. Laenen⁵, C. Zamagni⁶, P. Harter⁷, J. Sehouli⁸, F. Raspagliesi⁹, A. Zeimet¹, J.-P. Lotz¹⁰, V. Salutari¹¹, O. Tredan⁴, R. Zeillinger¹², M. Dobbels¹³, U. Moll¹³, D. Kramer¹³, E. Obermayr¹², I. Braicu⁸, I. Vergote², ¹Medical University of Innsbruck, Innsbruck, AT, ²UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ³Fondazione Policlinico Universitario A. Gemelli IRCCS and Catholic University of the Sacred Heart, Rome, IT, ⁴Centre Léon Bérard, Lyon, FR, ⁵KU Leuven, Leuven, BE, ⁶AOU Universitaria Policlinico S. Orsola-Malpighi, F. Addarii, Bologna, IT, ⁷KEM | Evang. Kliniken Essen-Mitte gGmbH, Essen, DE, ⁸Charité Universitätsmedizin Berlin, Berlin, DE, ⁹Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ¹⁰Hopital Tenon, APHP Sorbonne Université, Paris, Cedex, FR, ¹¹Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT, ¹²Medical University of Vienna, Vienna, AT, ¹³Georg-August-Universität Göttingen, Göttingen, DE

08:45 - 09:00

Invited Discussant 710MO, LBA33 and LBA34

A. Leary, Institut Gustave Roussy, Villejuif, Cedex, FR

09:00 - 09:05

712MO - Final overall survival (OS) from the phase III ATALANTE/ENGOT-ov29 trial evaluating atezolizumab (Atz) versus placebo with standard chemotherapy (Cx) plus bevacizumab (bev) in ovarian cancer (OC) patients (pts) with platinum-sensitive relapse (PSR)

J.E. Kurtz¹, E. Pujade-Lauraine², A. Oaknin³, L. Belin⁴, C. Grimm⁵, R. Kocian⁶, H. Denys⁷, O. Rosengarten⁸, P. Follana⁹, J. Sehouli¹⁰, J. Martinez-Garcia¹¹, J. Alexandre¹², A.-C. Hardy-Bessard¹³, J.-S. Frenel¹⁴, R. Sabatier¹⁵, L. Gladieff¹⁶, T. De La Motte Rouge¹⁷, N. Bonichon Lamichhane¹⁸, E. Kalbacher¹⁹, F. Heitz²⁰, ¹ICANS - Institut de Cancérologie Strasbourg Europe & GINECO, Strasbourg, FR, ²ARCAGY-GINECO, Paris, FR, ³Vall d'Hebron Institute of Oncology, Vall d'Hebron Barcelona Hospital Campus & GEICO, Barcelona, ES, ⁴INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié Salpêtrière, Paris, FR, ⁵Medical University of Vienna, Vienna General Hospital Währinger Gürtel & AGO Austria, Vienna, AT, ⁶General University Hospital in Prague, First Faculty of Medicine, Charles University & CEEGOG, Prague, CZ, ⁷University hospital Ghent, Corneel Heymanslaan & BGOG, Gent, BE, ⁸Shaare Zedek Medical Center & ISGO, Jerusalem, IL, ⁹Centre Anticancer Antoine Lacassagne & GINECO, Nice, FR, ¹⁰Charité - Universitaetsmedizin Berlin & AGO Study Group, Berlin, DE, ¹¹Hospital Universitario Virgen de la Arrixaca, Biomedical Research Institute of Murcia & GEICO, El Palmar, ES, ¹²Université de Paris Cité, AP-HP, Cochin Port-Royal & GINECO, Paris, FR, ¹³CARIO - Centre Armoricaïn de Radiothérapie, d'Imagerie Médicale et d'Oncologie & GINECO, Plérin, FR, ¹⁴ICO - Institut de Cancerologie de l'Ouest René Gauducheau & GINECO, Saint-Herblain, FR, ¹⁵IPC - Institut Paoli-Calmettes & GINECO, Marseille, Cedex, FR, ¹⁶Institut Universitaire du Cancer - Toulouse- Oncopole & GINECO, Toulouse, FR, ¹⁷Centre Eugene - Marquis & GINECO, Rennes, FR, ¹⁸Tivoli Ducos Clinique & GINECO, Bordeaux, FR, ¹⁹CHRU Jean Minjot & GINECO, Besancon, FR, ²⁰Evang. Kliniken Essen-Mitte gGmbH & AGO Study Group, Essen, DE



09:05 - 09:10

713MO - Nivolumab and ipilimumab combination treatment in advanced gynaecological clear cell cancers: Results from the phase II MoST-CIRCUIT trial

O. Klein¹, M. Carlino², M. Michael³, C. Underhill⁴, J. So⁵, D. Kee¹, Y. Antill⁶, W.-S. Lam⁷, H. Chan⁸, R. Harrup⁹, A. Hamilton¹⁰, J. Palmer¹¹, D. Thomas¹², K. Wilkie¹¹, J. Cebon¹³, B. Gao¹⁴, ¹Austin Health - Austin Hospital, Heidelberg, AU, ²Crown Princess Mary Cancer Centre Westmead, Westmead, AU, ³Peter MacCallum Cancer Centre, Melbourne, AU, ⁴Border Medical Oncology Murray Valley Private Hospital, Wodonga, AU, ⁵Auckland City Hospital, Auckland, NZ, ⁶Royal Melbourne Hospital, Melbourne, AU, ⁷Fiona Stanley Hospital, Perth, AU, ⁸Calvary Mater Hospital Newcastle, Waratah, AU, ⁹RHH - Royal Hobart Hospital, Hobart, AU, ¹⁰Peter MacCallum Cancer Centre, East Melbourne, AU, ¹¹Olivia Newton-John Cancer Research Institute, Heidelberg, AU, ¹²Garvan Institute of Medical Research, Darlinghurst, AU, ¹³Olivia Newton-John Cancer Wellness & Research Centre, Heidelberg, AU, ¹⁴Blacktown Hospital, Blacktown, AU

09:10 - 09:15

LBA32 - A randomized, phase II, dose optimization of gotistobart, a pH-sensitive anti-CTLA-4, in combination with standard dose pembrolizumab in platinum-resistant recurrent ovarian cancer: Safety, efficacy and dose optimization (PRESERVE-004/GOG-3081)

J. Barlin¹, P. Lim², J. Thomes Pepin³, E. Hopp⁴, N. Cloven⁵, C. Lee⁶, H. Eshed⁷, D. Black⁸, H. Cottrill⁹, L. Hand¹⁰, D. O'Malley¹¹, L. Chuang¹², L. Willmott¹³, M. Chisamore¹⁴, S. Shpyro¹⁵, J. Durbin¹⁶, P. Zheng¹⁶, Y. Liu¹⁶, B. Monk¹⁷, ¹Women's Cancer Care Associates, Albany, US, ²Center of Hope Reno, Reno, US, ³Minnesota Oncology, Minneapolis, US, ⁴Froedtert Hospital & Medical College of Wisconsin, Milwaukee, US, ⁵Texas Oncology, Fort Worth, US, ⁶Texas Oncology - The Woodlands, Houston, US, ⁷Texas Oncology - Austin North, Austin, US, ⁸LSU Health Shreveport, Shreveport, US, ⁹Baptist Health, Lexington, US, ¹⁰Baptist Health Jacksonville, Jacksonville, US, ¹¹OSUCCC - The Ohio State University Comprehensive Cancer Center - James, Columbus, US, ¹²Danbury Hospital, part of Nuvance Health, Danbury, US, ¹³Arizona Center for Cancer Care, Phoenix, US, ¹⁴Merck & Co., Inc., Rahway, US, ¹⁵BioNTech SE, Mainz, DE, ¹⁶OncoC4, Inc., Rockville, US, ¹⁷Florida Cancer Specialists and Research Institute, West Palm Beach, US

09:15 - 09:30

Invited Discussant 712MO, 713MO and LBA32

R. Coleman, The US Oncology Network, The Woodlands, US

08:30 - 10:00

Type: Mini Oral session

Title: Mini oral session: CNS tumours

Salamanca Auditorium - Hall 5

Chair(s): Giuseppe Lombardi, IT; Dieta Brandsma, NL; Roger Stupp, US

08:30 - 08:35

445MO - Dual inhibition of post-radiogenic angio-vasculogenesis in glioblastoma: Results of the phase I/II GLORIA trial

F. Giordano¹, J.P. Layer², L.L. Friker³, R. Turiello², T. Zeyen³, B. Pregler³, O. Mirallas⁴, S. Kebir⁵, M. Renovanz⁶, P. Hambsch⁷, T. Pietsch³, E. Gkika², M. Platten¹, M. Schneider³, O. Grauer⁸, G. Tabatabai⁶, M. Glas⁵, C. Seidel⁷, U. Herrlinger⁹, M. Hölzel², ¹Heidelberg University - Faculty of Medicine in Mannheim, Mannheim, DE, ²UKB - Universitätsklinikum Bonn, Bonn, DE, ³University Hospital Bonn, Bonn, DE, ⁴VHIO - Vall d'Hebron Institute of Oncology, Barcelona, ES, ⁵University Hospital Essen, Essen, DE, ⁶Universität Tübingen, Tübingen, DE, ⁷University Hospital Leipzig, Leipzig, DE, ⁸UKM - University Hospital Muenster, Muenster, DE, ⁹Institute of Experimental Immunology - UKB University of Bonn, Bonn, DE



- 08:35 - 08:40 **446MO - SYHA1813, a vascular endothelial growth factor receptor (VEGFR) 1-3/colony-stimulating factor 1 receptor (CSF1R) inhibitor, in patients with recurrent glioblastoma**
W. Li¹, Z. Kang¹, F. Chen¹, S. Li¹, B. Zhang¹, M. Huang¹, X. Yang², F. She², S. Xiang², G. Liu², M. Liu², ¹Beijing Tiantan Hospital, Capital Medical University, Beijing, CN, ²CSPC Pharmaceutical Group Limited, Shijiazhuang, CN
- 08:40 - 08:45 **447MO - A clinical study of the safety and efficacy of anlotinib hydrochloride combined with temozolomide dose density scheme for the treatment of recurrent high grade glioma**
Y. Zhai, L. Wang, P. Ji, Y. Wang, J. Liu, S. Guo, The Second Affiliate Hospital of Air Force Medical University/Tangdu Hospital, Xi'an, CN
- 08:45 - 09:00 **Invited Discussant 445MO, 446MO and 447MO**
G. Lombardi, IOV - Istituto Oncologico Veneto IRCCS, Padova, IT
- 09:00 - 09:05 **448MO - A clinical study of the safety and efficacy of toripalimab in combination with anlotinib for the treatment of recurrent glioblastoma (GBM)**
L. Wang, Y. Zhai, P. Ji, Y. Wang, J. Liu, S. Guo, The Second Affiliate Hospital of Air Force Medical University/Tangdu Hospital, Xi'an, CN
- 09:05 - 09:10 **449MO - Macrophage derived immunotherapy in glioblastoma: Phase I TEM-GBM-001 results**
F. Ciceri¹, F. Farina¹, B. Gentner², M. Eoli³, M. Barcella⁴, E. Anghileri³, Q.G. D'Alessandris⁵, V. Ferla¹, A. Franzin⁶, F. Gagliardi¹, F. Legnani³, A. Capotondo⁷, S. Mazzoleni⁷, A. Olivi⁵, R. Pallini⁵, M. Saini³, S. Snider¹, L. Naldini⁴, C. Russo⁸, G. Finocchiaro¹, ¹IRCCS Ospedale San Raffaele, Milano, IT, ²UNIL CHUV Ludwig Institute for Cancer Research, Lausanne, CH, ³Fondazione IRCCS - Istituto Neurologico Carlo Besta, Milano, IT, ⁴San Raffaele Telethon Institute for Gene Therapy, Milano, IT, ⁵Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, IT, ⁶Fondazione Poliambulanza Istituto Ospedaliero, Brescia, IT, ⁷Genenta Science Spa, Milano, IT, ⁸Genenta Science, New York, US
- 09:10 - 09:15 **450MO - Characterization of tumor-infiltrating lymphocytes and tumor-associated macrophages within the tumor microenvironment of primary tumors and matched brain metastases**
M. Kleinberger¹, D. Cifci², C. Paiato¹, E. Tomasich¹, M. Mair¹, A. Steindl¹, Z. Carrero³, L. Berchtold¹, J. Hainfellner⁴, L. Müllauer⁴, G. Heller¹, M. Preusser¹, J. Kather⁵, A.S. Berghoff¹, ¹Medical University of Vienna, Vienna, AT, ²University Hospital RWTH Aachen, Aachen, DE, ³Medical Faculty Carl Gustav Carus, Technical University Dresden, Dresden, DE, ⁴Medical University Vienna, Vienna, AT, ⁵Technische Universität Dresden - Carl Gustav Carus Faculty of Medicine, Dresden, DE
- 09:15 - 09:30 **Invited Discussant 448MO, 449MO and 450MO**
D. Brandsma, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL



- 09:30 - 09:35 **451MO - Final results of glasdegib in combination with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma: Phase Ib/II GEINO 1602 trial**
M.A. Vaz Salgado¹, S. Del Barco², J.M. Sepúlveda³, M. Alonso⁴, E. Pineda⁵, C. Balana⁶, M. Martínez-García⁷, R. Gironés⁸, S. López-Muñoz⁹, ¹Hospital Universitario Ramón y Cajal, Madrid, ES, ²Institut Català d'Oncologia Girona, Girona, ES, ³Hospital Universitario 12 de Octubre, Madrid, ES, ⁴Hospital Virgen del Rocío, Sevilla, ES, ⁵Hospital Clínic de Barcelona, Barcelona, ES, ⁶Institut Català d'Oncologia, Badalona, ES, ⁷Hospital del Mar, Barcelona, ES, ⁸Hospital Universitario y Politécnico La Fe, Valencia, ES, ⁹Hospital Universitario Rey Juan Carlos, Mostoles, ES
- 09:35 - 09:40 **452MO - Early experience with azeliragon, a RAGE inhibitor, in combination with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma: Phase Ib/II CAN-201 NDG trial**
E. Pineda¹, J.M. Sepúlveda², M. Valiente³, M.Á. Vaz-Salgado⁴, M. Martínez-García⁵, M. Ruiz Vico², G. Velilla², M.A. Mazariegos-Rubi¹, I. Valduvico¹, M. Castro-Henriques⁵, L. Cano⁵, S.G. Marcus⁶, ¹Hospital Clínic de Barcelona, Barcelona, ES, ²Hospital Universitario 12 de Octubre, Madrid, ES, ³Spanish National Cancer Research Center (CNIO), Madrid, ES, ⁴Hospital Universitario Ramón y Cajal, Madrid, ES, ⁵Hospital del Mar, Barcelona, ES, ⁶Pharmaceuticals, Inc., Florida, US
- 09:40 - 09:45 **453MO - A phase I study for safety, tolerability, pharmacokinetics, and anti-tumor activity of ABM-1310 in patients (pts) with BRAF V600 mutated recurrent primary brain tumours: Interim result**
W. Li¹, Z. Kang¹, S. Li¹, F. Chen¹, B. Zhang¹, M. Huang¹, Z. Yang², C. Chen², Z. Yang³, ¹Beijing Tiantan Hospital, Capital Medical University, Beijing, CN, ²ABM, Shanghai, CN, ³ABM, Irvine, US
- 09:45 - 10:00 **Invited Discussant 451MO, 452MO and 453MO**
R. Stupp, Northwestern University Feinberg School of Medicine, Chicago, US
- 08:30 - 10:00** **Type: Special symposium** **Santander Auditorium - Hall 5**
Title: Next generation of combinations in early clinical trials
 Chair(s): Fernanda Herrera, CH; Elena Garraalda, ES
- 08:30 - 08:35 **Introduction and scientific background**
F. Herrera, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH
- 08:35 - 08:50 **AI guided combinations using targeted therapy**
U. Banerji, The Institute of Cancer Research and Royal Marsden Hospital, Sutton, GB
- 08:50 - 09:05 **How to exploit radiation-induced tumour microenvironment vulnerabilities?**
F. Herrera, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH
- 09:05 - 09:20 **Moving on from PD-1-CTLA-4 blockade**
S.Y.N. Wong, NCCS - National Cancer Centre Singapore, Singapore, SG



09:20 - 09:35 **DDR inhibitor combinations**
T.A. Yap, The University of Texas MD Anderson Cancer Center - Main Building, Houston, US

09:35 - 09:55 **Q&A and discussion**

09:55 - 10:00 **Conclusions and perspectives**
E. Garralda, Vall d'Hebron University Hospital, Barcelona, ES

08:30 - 10:00 **Type: Mini Oral session** **Oviedo Auditorium - Hall 3**
Title: Mini oral session 2: Haematological malignancies
 Chair(s): Won Seog Kim, KR; Annarita Conconi, IT

08:30 - 08:35 **809MO - Efficacy and safety results from the phase II study of Timdarpaccept in combination with tislelizumab, in prior anti-PD-1 failed classical Hodgkin lymphoma**
Y. Song¹, K. Zhou², S. Hou³, Y. Zhang⁴, F. Li⁵, W. Yang⁶, T. Yi⁷, N. Lin¹, X. Liu⁸, W. Meng⁹, Z. Wang⁹, Q. Lu⁹, W. Tian⁹, J. Zhu¹, ¹Peking University Cancer Hospital & Institute, Beijing, CN, ²Henan Cancer Hospital, Zhengzhou, CN, ³Shanxi Bethune Hospital, Taiyuan, CN, ⁴Shandong Cancer Hospital Affiliated to Shandong University, Jinan, CN, ⁵The First Affiliated Hospital of Nanchang University, Nanchang, CN, ⁶Shengjing Hospital affiliated to China Medical University, Shenyang, CN, ⁷Xiangyang Central Hospital, Xiangyang, CN, ⁸Henan Cancer Hospital, Zhengzhou, CN, ⁹ImmuneOnco Biopharmaceuticals (Shanghai) Inc., Shanghai, CN

08:35 - 08:40 **810MO - Combination of mitoxantrone hydrochloride liposome with chidamide in patients with relapsed or refractory peripheral T cell lymphoma: A phase I/II study**
Z. Li¹, P. Sun², H. Yang³, B. Zhang⁴, Y. Wang³, ¹State Key Laboratory of Oncology in South China & Collaborative Innovation Center for Cancer Medicine Sun Yat-sen University Cancer Centre, Guangzhou, CN, ²Sun Yat-sen University Cancer Center, Guangzhou, CN, ³Sun Yat-sen University Cancer Center, Guangzhou, CN, ⁴GDPU - Guangdong Pharmaceutical University, Guangzhou, CN

08:40 - 08:45 **811MO - An exploratory study to assess the safety, immunogenicity, and preliminary anti-tumor activity of the EBV mRNA vaccine (WGc-043 injection) in patients with NK/T cell lymphoma**
 X. Peng¹, J. Ji², M. Jing², W. Zhang¹, H. Huang³, Y. Chen¹, X. Li³, H. Zheng³, J. Chen³, Y. Wei¹, X. Song¹, ¹Sichuan University, Chengdu, CN, ²West China Hospital, Sichuan University, Chengdu, CN, ³WestGene Biopharma Co., Ltd, Chengdu, CN

08:45 - 08:50 **812MO - Initial results of the multicenter phase II trial of a novel hypofractionated low-dose radiotherapy for indolent non-Hodgkin lymphoma**
X. Wang¹, L.-R. Gao¹, L. Wang², X. Zhang³, K. Chen⁴, X. Feng⁵, R. Zheng⁵, Y.-X. Li¹, S. Qi¹, ¹National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN, ²Beijing Tongren Hospital, Capital Medical University, Beijing, CN, ³Tianjin Medical University Cancer Institute and Hospital, Tianjin, CN, ⁴The Affiliated People's Hospital of Ningbo University, Ningbo, CN, ⁵National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN

- 08:50 - 09:05 **Invited Discussant 809MO, 810MO, 811MO and 812MO**
W.S. Kim, Samsung Medical Center (SMC), Seoul, KR
- 09:05 - 09:10 **813MO - Phase I trial of a personalized multi-peptide vaccine combined with the TLR1/2 ligand XS15 under Bruton-Tyrosine-Kinase inhibitor (BTKi) treatment in chronic lymphocytic leukemia (CLL) patients**
C. Hackenbruch¹, J.S. Heitmann¹, S. Jung¹, Y. Maringer², M. Wacker², A. Nelde², M. Marconato¹, L. Zieschang², C. Kammer², M. Özbek², M. Richter², M. Denk², H. Salih¹, J. Walz¹, ¹University Hospital Tübingen, German Cancer Consortium (DKTK), Tübingen, DE, ²University and University Hospital Tübingen, Tübingen, DE
- 09:10 - 09:15 **814MO - Molecular biology study of primary immuno-privileged lymphomas**
C. Zhang¹, Y. Song², J. Deng², L. Mi², ¹Peking University Cancer Hospital and Institute, Beijing, CN, ²Peking University Cancer Hospital & Institute, Beijing, CN
- 09:15 - 09:20 **815MO - A prospective study of orelabrutinib plus obinutuzumab (O2) in treatment-naïve marginal zone lymphoma (MZL): Preliminary analysis on efficacy and safety**
J.-D. Xu, L.-Y. Cheng, J. Li, J.-L. Zhuang, Z.-X. Cheng, Y.-H. Ren, Y.-A. Zhang, Y. Wang, P. Liu, ZhongShan Hospital Fudan University, Shanghai, CN
- 09:20 - 09:25 **816MO - Two hematological precursors and their impact on hematological malignancies**
N. Boddicker¹, R. Griffin¹, E. Franke¹, S. Achenbach¹, K. Rabe¹, J. Olson¹, D. O'Brien¹, A. Norman¹, T. Ma¹, T. Call¹, M. Hoel¹, E. Braggio², P. Hampel¹, C. Hanson¹, J. Cerhan¹, C. Vachon¹, S. Parikh¹, T. Shanafelt³, S. Slager¹, ¹Mayo Clinic - Rochester, Rochester, US, ²Mayo Clinic, Phoenix, US, ³Stanford University Medical Center, Stanford, US
- 09:25 - 09:40 **Invited Discussant 813MO, 814MO, 815MO and 816MO**
A. Conconi, AOU Maggiore della Carità di Novara, Novara, IT

08:30 - 10:00 **Type: Special session** **Zaragoza Auditorium - CC5**
Title: POWG 2: Optimal perioperative systemic treatment in different tumours
 Chair(s): Alberto Cunquero Tomas, ES; Benedetta Pellegrino, IT

08:30 - 08:50 **Complexity of perioperative decisions in the era of novel therapies**
A. Indini, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT

08:50 - 09:10 **Breast cancer**
J. Gligorov, Institut Universitaire de Cancérologie AP-HP. Sorbonne Université, Hôpital Tenon, Paris, FR

09:10 - 09:30 **Bladder cancer**
L. Popovic, Oncology Institute of Vojvodina, Sremska Kamenica, RS



09:30 - 09:50 **Rectal cancer**
E. Van Cutsem, UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE

09:50 - 10:00 **Q&A and discussion**

08:30 - 10:00 **Type: EONS session** **Ronda Auditorium - Hall 7**
Title: Cancer patients and advocacy
 Chair(s): Merel van Klinken, NL; Fernanda Conceição, PT

08:30 - 08:50 **Difference between patient-centred and person-centred care: Patient advocate perspective**
R. Giles, VHL Europa, Vlaardingen, NL

08:50 - 09:10 **EU-CAYAS-NET IDE toolkit: Youth Cancer Europe**
K. Rizvi, YCE - Youth Cancer Europe, Cluj-Napoca, RO

09:10 - 09:30 **Policy and advocacy at the European and member state level: A collaborative approach**
A. Cardone, Cancer Patients Europe, Brussels, BE

09:30 - 09:40 **CN65 - Quality of endometrial cancer care from the patients' perspective: A cross-sectional study**
C. Olsson¹, M. Larsson¹, E. Holmberg², K. Ståhlberg³, C. Sköld⁴, A. Floter-Radestad⁵, M. Bjurberg⁶, P. Dahm-Kähler⁷, K. Hellman⁸, P. Kjolhede⁹, B. Wilde Larsson¹, E. Avall-Lundqvist¹⁰, C. Borgfeldt¹¹, ¹Karlstad University, Karlstad, SE, ²Region Västra Götaland, Göteborg, SE, ³Uppsala University, Uppsala, SE, ⁴University Hospital Uppsala/Akademiska Sjukhuset, Uppsala, SE, ⁵Karolinska Institutet, Stockholm, SE, ⁶Skane University Hospital, Malmö, SE, ⁷Institute of Clinical Sciences, Sahlgrenska Academy, Gothenburg, SE, ⁸Karolinska University Hospital, Stockholm, SE, ⁹Linköping University Linköping, Linköping, SE, ¹⁰LiU - Linköping University, Linköping, SE, ¹¹Linköping University, Linköping, SE

09:40 - 09:50 **CN66 - Healthcare needs, experiences of cancer care, and attitudes towards cancer among ethnic Chinese immigrants in Scotland**
L. Cheng¹, G. Kotronoulas¹, D. Cairns¹, W.-P. Sham², ¹University of Glasgow, Glasgow, GB, ²Chinese Association for Cancer Care, Surrey, GB

09:50 - 10:00 **Q&A and discussion**

08:30 - 10:00 **Type: EONS Industry Satellite Symposium** **Segovia Auditorium - Hall 7**
Title: Roche - Integration of subcutaneous therapies in cancer care
 Chair(s): Silvija Piskorjanac, HR

08:30 - 08:35 **Welcome and introduction**
S. Piskorjanac, KBC Osijek - Clinical Medical Center Osijek, Osijek, HR



- 08:35 - 08:50 **Current trends in subcutaneous therapy**
S. Gomes, Instituto Portugues Oncologia de Coimbra Francisco Gentil E. P. E. (IPO Coimbra), Coimbra, PT
- 08:50 - 09:05 **Mastering the art: Nursing excellence in subcutaneous therapies**
M. Hellberg-Naegele, Kantonsspital St. Gallen, St. Gallen, CH
- 09:05 - 09:20 **Personalizing care delivery options for people with cancer**
C. Ghione Mastry, Ghione Consulting, Vilassar De Mar, ES
- 09:20 - 09:55 **Panel discussion and Q&A**
A. Silverio Pons¹, M.E. Moreno Martinez², ¹VHIR - Vall d'Hebron Institut de Recerca, Barcelona, ES, ²Hospital de la Santa Creu i Sant Pau, Barcelona, ES
- 09:55 - 10:00 **Key takeaways**
S. Gomes, Instituto Portugues Oncologia de Coimbra Francisco Gentil E. P. E. (IPO Coimbra), Coimbra, PT

09:00 - 09:45 **Type: Challenge your Expert** **Valencia Auditorium - Hall 5**
Title: Radioligand theranostics in prostate cancer: Status quo and new developments
 Chair(s): Arun Azad, AU

09:00 - 09:20 **Presentation by Expert**
K. Herrmann, WTZ - Westdeutsches Tumorzentrum Essen, Essen, DE

09:20 - 09:45 **Discussion led by Chair**
A. Azad, Peter MacCallum Cancer Centre, Melbourne, AU

09:00 - 09:45 **Type: Challenge your Expert** **Pamplona Auditorium - Hall 3**
Title: Advances in cancer vaccines
 Chair(s): Lillian Siu, CA

09:00 - 09:20 **Presentation by Expert**
I. Melero, CCUN - Cancer Center Clinica Universidad de Navarra, Pamplona, ES

09:20 - 09:45 **Discussion led by Chair**
L. Siu, Princess Margaret Cancer Centre, Toronto, CA

09:00 - 09:45 **Type: Challenge your Expert** **Toledo Auditorium - Hall 3**
Title: Advanced thyroid cancer
 Chair(s): Laura Locati, IT

09:00 - 09:20 **Presentation by Expert**
M. Brose, Sidney Kimmel Cancer Center - Thomas Jefferson University, Philadelphia, US

09:20 - 09:45 **Discussion led by Chair**
L. Locati, University of Pavia, Pavia, IT

10:00 - 11:00 **Type: Special session** **Tarragona Auditorium - Hall 7**
Title: ESMO Resilience Task Force Special Open Forum: Sustaining the oncology workforce: How to create a culture change to protect our health, well-being and boost resilience
 Chair(s): Susana Banerjee, GB

10:00 - 10:10 **Introduction**
S. Banerjee, The Royal Marsden Hospital - Chelsea, London, GB

10:10 - 11:00 **Moderated discussion and Q&A**
M. Lambertini¹, H. Linardou², J.-Y. Blay³, K.H.J. Lim⁴, K. Kamposioras⁵, M.E. Elez Fernandez⁶,
¹IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT,
²Metropolitan Hospital, Athens, GR, ³Centre Léon Bérard, Lyon, FR, ⁴The Francis Crick Institute, London, GB, ⁵The Christie NHS Foundation Trust, Manchester, GB, ⁶Vall d'Hebron University Hospital, Barcelona, ES

10:15 - 11:45 **Type: Educational session** **Barcelona Auditorium - Hall 2**
Title: Neoadjuvant treatment for colon cancer: Building upon the existing data
 Chair(s): Eva Angenete, SE; Myriam Chalabi, NL

10:15 - 10:35 **Rationale for neoadjuvant treatment of localised cancer: Biological insights**
D. Pardoll, Johns Hopkins University School of Medicine, Baltimore, US

10:35 - 10:55 **Neoadjuvant chemotherapy in colon cancer: Who, what and for how long?**
J. Seligmann, The University of Leeds, Leeds, GB

10:55 - 11:15 **Neoadjuvant immunotherapy in colon cancer: Are we there yet?**
M. Chalabi, Netherlands Cancer Institute, Amsterdam, NL

11:15 - 11:35 **What's next? Clinical and translational opportunities in the neoadjuvant setting**
J. Taieb, Hopital European George Pompidou, Paris, FR

11:35 - 11:45 **Q&A and discussion**



10:15 - 11:30	Type: Mini Oral session Title: Mini oral session 1: Non-metastatic NSCLC Chair(s): Céline Mascaux, FR; Antonio Calles Blanco, ES; Jia Wu, US	Madrid Auditorium - Hall 2
10:15 - 10:20	LBA50 - Perioperative nivolumab (NIVO) v placebo (PBO) in patients (pts) with resectable NSCLC: Clinical update from the phase III CheckMate 77T study M. Provencio Pulla¹, M. Awad², T. Cascone³, J. Spicer⁴, J. He⁵, S. Lu⁶, A. Alexandru⁷, Y. Watanabe⁸, R. Cornelissen⁹, L. Koch¹⁰, J. Kuzdza¹¹, J.-L. Pujol¹², P. Hoffknecht¹³, J.E. Gray¹⁴, C. Coronado Erdmann¹⁵, J. Neely¹⁵, V. Devas¹⁵, S. Bhatia¹⁵, F. Tanaka¹⁶, ¹Hospital Universitario Puerta de Hierro, Madrid, ES, ²Dana-Farber Cancer Institute, Boston, US, ³The University of Texas MD Anderson Cancer Center, Houston, US, ⁴McGill University Health Centre, Montreal, CA, ⁵National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN, ⁶Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, CN, ⁷Institutul Oncologic Bucuresti Prof. Dr. Alexandru Trestioreanu, Bucharest, RO, ⁸Saitama Cancer Center, Saitama, JP, ⁹Erasmus MC Cancer Institute, Rotterdam, NL, ¹⁰Hospital Israelita Albert Einstein, Sao Paulo, BR, ¹¹Jagiellonian University Collegium Medicum, John Paul II Hospital, Krakow, PL, ¹²Montpellier Regional University Hospital, Montpellier, FR, ¹³Franziskus-Hospital Harderberg, Niels-Stensen-Kliniken, Georgsmarienhutte, DE, ¹⁴Moffitt Cancer Center, Tampa, US, ¹⁵Bristol Myers Squibb, Princeton, US, ¹⁶University of Occupational and Environmental Health, Kitakyushu, JP	
10:20 - 10:25	1209MO - Neoadjuvant nivolumab and nivolumab&#x2b;ipilimumab in resectable non-small cell lung cancer: Combined analysis of 5-year outcomes from NEOSTAR and CA209-159 J. Reuss¹, C.H. Leung², S. Rosner¹, N. Zhou³, A. Weissferdt⁴, A. Pataer⁵, W. Nassib William Junior⁶, J. Taube¹, S. Broderick¹, J. Spicer⁷, D. Jones⁸, D. Gibbons⁹, J. Heymach⁵, V. Anagnostou¹, H. Lin³, J.J. Lee³, B. Sepesi¹⁰, J. Chaff⁸, P. Forde¹, T. Cascone¹¹, ¹Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, US, ²The University of Texas MD Anderson Cancer Center, Houston, US, ³University of Texas MD Anderson Cancer Center, Houston, US, ⁴The University of Texas M. D. Anderson Cancer Center, Houston, US, ⁵MD Anderson Cancer Center, Houston, US, ⁶Grupo Oncoclínicas, Sao Paulo, BR, ⁷McGill University, Montreal, CA, ⁸MSKCC - Memorial Sloan Kettering Cancer Center, New York, US, ⁹UT MD Anderson Cancer Center, Houston, US, ¹⁰Sarah Cannon Institute at Swedish Medical Center, Englewood, US, ¹¹The University of Texas MD Anderson Cancer Center - Main Building, Houston, US	
10:25 - 10:40	Invited Discussant LBA50 and 1209MO C. Mascaux, Hopitaux Universitaires de Strasbourg - Nouvel Hopital Civil, Strasbourg, FR	



10:40 - 10:45

LBA49 - Associations of ctDNA clearance (CL) during neoadjuvant Tx with pathological response and event-free survival (EFS) in pts with resectable NSCLC (R-NSCLC): Expanded analyses from AEGEAN

M. Reck¹, D. Gale², Z. Zhu³, D. Harpole⁴, J. Taube⁵, T. Mitsudomi⁶, D. Van Luong⁷, M. Hochmair⁸, K.-Y. Lee⁹, Y. Horio¹⁰, L. Urban¹¹, H. Akamatsu¹², B. Biswas¹³, L. Antonuzzo¹⁴, Z. Szalai¹⁵, R. Stewart², Z. Lai¹⁶, D. Hodgson², G. Doherty², J. Heymach¹⁷, ¹Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, DE, ²AstraZeneca, Cambridge, GB, ³AstraZeneca, Gaithersburg, US, ⁴Duke University Medical Center, Durham, US, ⁵Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Kimmel Cancer Center, Baltimore, US, ⁶Kindai University Faculty of Medicine, Osaka-Sayama, JP, ⁷Vietnam National Lung Hospital, Hanoi, VN, ⁸Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna, AT, ⁹Shuang Ho Hospital, Taipei Medical University, New Taipei City, TW, ¹⁰Aichi Cancer Center Hospital, Aichi, JP, ¹¹Mátraháza University and Teaching Hospital, Matrahaza, HU, ¹²Wakayama Medical University, Wakayama, JP, ¹³Tata Medical Center, Kolkata, IN, ¹⁴Careggi University Hospital, Department of Experimental and Clinical Medicine, University of Florence, Florence, IT, ¹⁵Aladar Petz University Teaching Hospital, Győr, HU, ¹⁶AstraZeneca, Waltham, US, ¹⁷The University of Texas, M.D. Anderson Cancer Center, Houston, US

10:45 - 10:50

LBA51 - Circulating tumor DNA (ctDNA) dynamics and treatment responses in chemotherapy-ineligible patients (pts) with unresectable stage III NSCLC from the phase II DUART trial

A.R. Filippi¹, M.R. Garcia-Campelo², J.-B. Paoli³, D. Kowalski⁴, C. Bennati⁵, P. Borghetti⁶, D. Cortinovis⁷, A. Delmonte⁸, C. Genova⁹, R. Mroz¹⁰, S. Nawrocki¹¹, I. Toledano¹², G. Tonini¹³, R. Stewart¹⁴, Z. Zhu¹⁵, G. Wetherill¹⁴, N. Georgoulia¹⁵, I. Diaz Perez¹⁵, R. Dziadziuszko¹⁶, ¹University of Milan and Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT, ²University Hospital A Coruña, A Coruña, ES, ³Hôpital Privé Clairval, Marseille, FR, ⁴Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, PL, ⁵S Maria delle Croci Hospital, AUSL della Romagna, Ravenna, IT, ⁶ASST Spedali Civili and University of Brescia, Brescia, IT, ⁷Fondazione IRCCS San Gerardo dei Tintori Monza, Monza, IT, ⁸IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST), Meldola, IT, ⁹IRCCS Ospedale Policlinico San Martino/University of Genoa, Genova, IT, ¹⁰Medical University of Białystok, Białystok, PL, ¹¹University of Warmia and Mazury in Olsztyn, Olsztyn, PL, ¹²CCGM, Clinique Clémentville, Montpellier, FR, ¹³Fondazione Policlinico Universitario Campus Bio-Medico/Università Campus Bio-Medico di Roma, Rome, IT, ¹⁴AstraZeneca, Cambridge, GB, ¹⁵AstraZeneca, Gaithersburg, US, ¹⁶Medical University of Gdansk, Gdansk, PL

10:50 - 11:05

Invited Discussant LBA49 and LBA51

A. Calles Blanco, Hospital General Universitario Gregorio Marañón, Madrid, ES



11:05 - 11:10	1910MO - ARTIMES: Automated response evaluation to treatment in mesothelioma <u>K. Groot Lipman</u>¹, R. Wittenberg¹, M. De Oliveira Taveira², I. Smesseim¹, A. Schmitz¹, T. Boellaard¹, K. Chupetlovska¹, M. Abdelatty Elsayed¹, L. Petrychenko¹, N. Jain¹, F. Arico¹, A. Bajaj³, D. Fennell⁴, A. Curioni-Fontecedro⁵, T.D.L. Nguyen-Kim⁶, R. Tissier¹, P. Baas¹, S. Burgers¹, D. De Gooijer¹, S. Trebeschi¹, ¹NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ²MSKCC - Memorial Sloan Kettering Cancer Center, New York, US, ³University Hospitals of Leicester, Leicester, GB, ⁴Leicester Royal Infirmary, Leicester, GB, ⁵Cantonal Hospital Fribourg, Villar sur Glane, CH, ⁶Stadtspital Zürich, Zurich, CH
11:10 - 11:15	1240MO - Quantitative radiomics for the detection of symptomatic pneumonitis following chemoradiotherapy in patients with stage III unresectable NSCLC <u>J. Naidoo</u>¹, V. Haakensen², J. Bar³, F. Belmans⁴, A. Corsi⁵, M. Flechet⁵, L. Libert⁵, C. C. Meca⁵, N. Tsoutzidis⁵, P. Chander⁶, K. Patwardhan⁷, J. Faria⁸, D. De Ruysscher⁹, ¹Beaumont Hospital, Dublin, IE, ²Oslo University Hospital, Oslo, NO, ³Sheba Medical Center and Tel Aviv University, Ramat Gan/Tel Aviv, IL, ⁴Radiomics.bio and KU Leuven, Liège/Leuven, BE, ⁵Radiomics.bio, Liège, BE, ⁶AstraZeneca, Gaithersburg, US, ⁷AstraZeneca, Waltham, US, ⁸AstraZeneca, Cambridge, GB, ⁹Stichting Maastricht Radiation Oncology, ("MAASTRO"), Maastricht, NL
11:15 - 11:30	Invited Discussant 1910MO and 1240MO <u>J. Wu</u>, MD Anderson Cancer Center, Houston, US
10:15 - 11:45	Type: Educational session Title: Focus on rare GU cancers: A common challenge Chair(s): Eva Comperat, AT; Andrea Necchi, IT Sevilla Auditorium - Hall 2
10:15 - 10:35	Histology subtypes (variants) of bladder cancer <u>S. Hussain</u>, University of Sheffield Medical School, Sheffield, GB
10:35 - 10:55	Controversies in testis cancer <u>A. Terbuch</u>, LKH-Universitaetsklinikum Graz - Universitaetsklinik für Innere Medizin (UKIM), Graz, AT
10:55 - 11:15	Updates in penile cancer <u>A. Necchi</u>, IRCCS Ospedale San Raffaele, Milan, IT
11:15 - 11:35	Non-clear cell RCC <u>P.M. Coelho Barata</u>, University Hospitals Seidman Cancer Center, Cleveland, US
11:35 - 11:45	Q&A and discussion



10:15 - 11:45	Type: Special symposium Title: Management of oligometastatic gastroesophageal cancer Chair(s): Trevor Leong, AU; Radka Obermannova, CZ	Bilbao Auditorium - Hall 2
10:15 - 10:20	Introduction and scientific background <u>T. Leong</u> , Peter MacCallum Cancer Centre, Melbourne, AU	
10:20 - 10:35	The OMEC project <u>H. Van Laarhoven</u> , Academic Medical Center, University of Amsterdam, Amsterdam, NL	
10:35 - 10:50	The role of the surgeon in resecting oligometastases <u>S. Mönig</u> , HUG - Hopitaux Universitaires de Geneve, Geneva, CH	
10:50 - 11:05	Peritoneal metastases beyond surgery <u>J. So</u> , NCIS - National University Cancer Institute Singapore, Singapore, SG	
11:05 - 11:20	The role of the radiation oncologist in treating oligometastases <u>D. Chang</u> , Michigan Medicine University of Michigan, Ann Arbor, US	
11:20 - 11:40	Q&A and discussion	
11:40 - 11:45	Conclusions and perspectives <u>R. Obermannova</u> , Masaryk Memorial Cancer Institute, Brno, CZ	
10:15 - 11:45	Type: Special session Title: ESMO Clinical Practice Guidelines 1 Chair(s): Elizabeth Smyth, GB; Emanuela Romano, FR	Granada Auditorium - Hall 6
10:15 - 10:30	Epithelial ovarian cancer: Case presentation <u>M. Kfoury</u> , IPC - Institut Paoli-Calmettes, Marseille, Cedex 09, FR	
10:30 - 10:45	Epithelial ovarian cancer: Discussion <u>A. González-Martín</u> , Clinica Universidad de Navarra, Madrid, ES	
10:45 - 11:00	Epithelial ovarian cancer: Q&A	
11:00 - 11:15	Metastatic colorectal cancer: Case presentation <u>D.C. Guven</u> , Hacettepe University Oncology Hospital, Ankara, TR	
11:15 - 11:30	Metastatic colorectal cancer: Discussion <u>E. Martinelli</u> , Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT	
11:30 - 11:45	Metastatic colorectal cancer: Q&A	

10:15 - 11:45	Type: Educational session Title: Systemic treatment of anti PD-1 resistance in advanced melanoma Chair(s): Ana Maria Arance, ES; Inge Marie Svane, DK	Burgos Auditorium - Hall 5
10:15 - 10:40	Leads for treating PD1 resistance <u>A. Ribas</u> , Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, US	
10:40 - 11:05	Cellular therapies <u>I.M. Svane</u> , Herlev Hospital - National Center for Cancer Immune Therapy (CCIT-DK), Herlev, DK	
11:05 - 11:30	Non-cellular therapies <u>O. Michielin</u> , HUG - Hopitaux Universitaires de Geneve, Geneva, CH	
11:30 - 11:45	Q&A and discussion	
10:15 - 11:45	Type: Educational session Title: Deciphering the dark matter of the non-coding genome Chair(s): Ana Vivancos, ES; Daniel Schramek, CA	Santander Auditorium - Hall 5
10:15 - 10:40	Identification of non-coding cancer driver mutations <u>E. Rheinbay</u> , Harvard Medical School, Boston, US	
10:40 - 11:05	Recurrent UV-damage signatures in protein binding regulatory regions <u>K. Elliott</u> , Gothenburg University, Gothenburg, SE	
11:05 - 11:30	Mouse models to study functional effects of non-coding mutations <u>D. Schramek</u> , University of Toronto, Toronto, CA	
11:30 - 11:45	Q&A and discussion	
10:15 - 11:45	Type: Proffered Paper session Title: Proffered paper session: Head and neck cancer Chair(s): Sjoukje Oosting, NL; Hisham Mehanna, GB	Valencia Auditorium - Hall 5
10:15 - 10:25	8470 - Sequential chemoradiotherapy versus induction chemotherapy plus concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: A multicentre, open-label, non-inferiority, randomised, phase III trial <u>C. Hu</u> ¹ , F. Xue ¹ , D. Ou ¹ , C. Xie ² , S. Lin ³ , J. Li ⁴ , X. Chen ⁵ , F. Zhang ⁶ , H. Ying ¹ , X. Lu ¹ , C. Shen ¹ , T. Xu ¹ , X. Ou ¹ , W. Li ¹ , X. Zhou ¹ , C. Du ¹ , X. He ¹ , ¹ Fudan University Shanghai Cancer Center, Shanghai, CN, ² The First Affiliated Hospital of Wenzhou Medical University - Gongyuanlu Site, Wenzhou, CN, ³ Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Fuzhou, CN, ⁴ Jiangxi Provincial Cancer Hospital, Nanchang, CN, ⁵ Cancer Hospital of the University of Chinese Academy of Sciences/ Zhejiang Cancer Hospital, Hangzhou, CN, ⁶ Affiliated Hospital of Jiangnan University (Wuxi Fourth People's Hospital), Wuxi, CN	



10:25 - 10:35

LBA35 - Primary results from TACTI-003: A randomized phase IIb trial comparing eftilagimod alpha (soluble LAG-3) plus pembrolizumab versus pembrolizumab alone in first-line recurrent or metastatic head and neck squamous cell carcinoma with CPS ≥1

C. Kristensen¹, R. Metcalf², I. Braña³, S. Laban⁴, A. Soria Rivas⁵, D. Grose⁶, J. Rubio Casadevall⁷, V. Cheshuk⁸, S. Dieter⁹, A. Lopez Pousa¹⁰, S. Kasper-Virchow¹¹, B. Doger De Spéville¹², M. Covela¹³, F. Vogl¹⁴, C. Mueller¹⁵, F. Triebel¹⁶, ¹Rigshospitalet, Copenhagen, DK, ²The Christie NHS Foundation Trust, Manchester, GB, ³Vall d'Hebron Institute of Oncology, Barcelona, ES, ⁴Ulm University Medical Center, Ulm, DE, ⁵Hospital Universitario Ramon y Cajal, Madrid, ES, ⁶Institute of Cancer Science - Beatson West of Scotland Cancer Centre, Glasgow, GB, ⁷Institut Català d'Oncologia - Hospital Universitari de Girona, Girona, ES, ⁸ARENSIA Exploratory Medicine LLC, Kiev, UA, ⁹Nationales Centrum für Tumorerkrankungen Heidelberg, Heidelberg, DE, ¹⁰Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ¹¹University Hospital Essen, Essen, DE, ¹²University Hospital Fundacion Jimenez Diaz, Madrid, ES, ¹³Hospital Universitario Lucus Augusti (HULA), Lugo, ES, ¹⁴Immutep GmbH, Berlin, DE, ¹⁵Immutep GmbH - Berlin, Berlin, DE, ¹⁶Immutep, SAINT-AUBIN, FR

10:35 - 10:50

Invited Discussant 847O and LBA35

H. Mehanna, The University of Birmingham - Institute for Cancer Studies, Birmingham, GB

10:50 - 11:00

Q&A

11:00 - 11:10

849O - Phase II study of trastuzumab deruxtecan in patients with HER2-positive recurrent/metastatic salivary gland cancer: Results from the MYTHOS trial

I. Kinoshita¹, S. Kano¹, Y. Honma², N. Kiyota³, M. Tahara⁴, S. Takahashi⁵, Y. Ito¹, Y. Hatanaka¹, Y. Matsuno¹, H. Dosaka-Akita¹, ¹Hokkaido University Hospital, Sapporo, JP, ²National Cancer Center Hospital, Tokyo, JP, ³Kobe University Hospital, Kobe, JP, ⁴National Cancer Center Hospital East, Kashiwa, JP, ⁵The Cancer Institute Hospital of JFCR, Tokyo, JP

11:10 - 11:20

LBA36 - A randomised phase II study to evaluate the efficacy and safety of androgen deprivation therapy (ADT) vs chemotherapy (CT) in patients with recurrent and/or metastatic, androgen receptor (AR) expressing, salivary gland cancers

L. Licitra¹, L. Locati², L. Digue³, C. Even⁴, A. Psyrri⁵, P. Clement⁶, S. Ochsenreither⁷, J.-P. Delord⁸, C. Moro⁹, J.-P. Machiels¹⁰, T. Fuereder¹¹, A.-S. Govaerts¹², P. Quattrone¹³, L. De Cecco¹⁴, F. Perrone¹⁵, M. Rasschaert¹⁶, A. Nzokiranteve¹², A. Joaquim¹², E. Venslovaite¹², C. Fortpiéd Lefevre¹², ¹Fondazione IRCCS - Istituto Nazionale dei Tumori and University of Milan, Italy, Milan, IT, ²University of Pavia, Pavia, IT, ³CHU Bordeaux - Hopital St. André, Bordeaux, FR, ⁴Institut Gustave Roussy, Villejuif, Cedex, FR, ⁵Attikon University Hospital, Haidari, GR, ⁶UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ⁷Charité - Universitätsmedizin Berlin, Berlin, DE, ⁸IUCT - Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, FR, ⁹ASST Papa Giovanni XXIII, Bergamo, IT, ¹⁰Cliniques Universitaires Saint-Luc (UCLouvain Saint-Luc), Woluwe-Saint-Lambert, BE, ¹¹Universitätskliniken der MedUni Wien - AKH Wien, Vienna, AT, ¹²EORTC AISBL/IVZW - European Organisation for Research and Treatment of Cancer, Brussels, BE, ¹³Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT, ¹⁴Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ¹⁵Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ¹⁶UZA - University Hospital Antwerp, Edegem, BE

11:20 - 11:35 **Invited Discussant 8490 and LBA36**
A. Spreafico, UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA

11:35 - 11:45 **Q&A**

10:15 - 11:45 **Type: Special session** **Oviedo Auditorium - Hall 3**
Title: Session in collaboration with ASCO: Novel pathways for development of precision therapeutics in molecular oncology
 Chair(s): Andres Cervantes, ES; Robin Zon, US

10:15 - 10:20 **Introduction**
A. Cervantes, Hospital Clinico Universitario de Valencia, Valencia, ES

10:20 - 10:40 **The promise of patient-derived organoids (PDOs) in functional precision oncology**
E. Jaulin, Institut Gustave Roussy, Villejuif, FR

10:40 - 11:00 **Tumour-agnostic, biomarker-driven drug development: How and how often?**
V. Subbiah, Sarah Cannon Research Institute, Nashville, US

11:00 - 11:20 **Novel AI-enabled strategies in biomarker-informed clinical trials**
R. Fehrmann, UMCG - University Medical Center Groningen, Groningen, NL

11:20 - 11:40 **Regulatory sandboxes: How to synchronize safe, timely regulation with scientific breakthroughs in molecular 'niches'**
J. Gralow, American Society of Clinical Oncology (ASCO), Alexandria, US

11:40 - 11:45 **Conclusions**
R. Zon, American Society of Clinical Oncology (ASCO), Alexandria, US



10:15 - 11:45	Type: Mini Oral session Title: Mini oral session: Supportive and palliative care Chair(s): Shani Paluch-Shimon, IL; Anne Letsch, DE; Florian Scotté, FR	Toledo Auditorium - Hall 3
10:15 - 10:20	1817MO - Effect of a weight loss intervention (WLI) on exercise behaviors in women with breast cancer: Results from the breast cancer weight loss (BWEL) trial J. Ligibel¹, K. Ballman², L. McCall³, P. Goodwin⁴, A.C. Weiss⁵, T. Crane⁶, M. Irwin⁷, C. Thomson⁸, O. Hahn⁹, P. Spears¹⁰, D. Hershman¹¹, E. Paskett¹², J. Hopkins¹, V. Bernstein¹³, V. Stearns¹⁴, J. White¹⁵, T. Wadden¹⁶, E. Winer¹, L. Carey¹⁷, A.H. Partridge¹, ¹Dana Farber Cancer Institute, Boston, US, ²Mayo Clinic Cancer Center, Rochester, US, ³Duke University Medical Center, Durham, US, ⁴Sinai Health System, Toronto, CA, ⁵University of Rochester Cancer Center, Rochester, US, ⁶University of Miami, Sylvester Comprehensive Cancer Center, Deerfield Beach, US, ⁷Yale University School of Medicine - Yale Cancer Center, New Haven, US, ⁸University of Arizona Cancer Center, Tucson, US, ⁹University of Chicago Department of Medicine - Section of Hematology/Oncology, Chicago, US, ¹⁰UNC - Lineberger Cancer Center, Chapel Hill, US, ¹¹Columbia University Medical Center College of Physicians & Surgeons - New York Presbyterian Hospital, New York, US, ¹²James Cancer Hospital, The Ohio State University, Columbus, US, ¹³BC Cancer Agency - Victoria, Victoria, CA, ¹⁴Weill Cornell Medical Center, New York, US, ¹⁵Kansas University Medical Center, Kansas City, US, ¹⁶University of Pennsylvania, Philadelphia, US, ¹⁷UNC - The University of North Carolina at Chapel Hill - School of Medicine, Chapel Hill, US	
10:20 - 10:25	1818MO - Development and validation of a predictive model of aromatase inhibitor musculoskeletal toxicity (AIMT) among patients (pts) with early breast cancer (EBC) P. Lapidari¹, M. Lustberg², J. Havas¹, M. Pagliuca³, C. Bousrih³, C. Jouannaud⁴, M. Fournier⁵, W. Jacot⁶, L. Vanlemmens⁷, C. Kaderbhai⁸, O. Tredan⁹, C. Levy¹⁰, A.-L. Martin¹¹, C. Gaudin¹¹, G. Menvielle¹, M.A. Franzoi³, I. Vaz Luis³, A. Di Meglio³, ¹Institut Gustave Roussy - INSERM UMR 981, Villejuif, FR, ²Yale University School of Medicine, New Heaven, US, ³Institut Gustave Roussy, Villejuif, Cedex, FR, ⁴Institut Jean Godinot, Reims, FR, ⁵Institute Bergonié - Centre Régional de Lutte Contre le Cancer (CLCC), Bordeaux, FR, ⁶ICM - Institut du Cancer de Montpellier, Montpellier, Cedex, FR, ⁷Centre Oscar Lambret, Lille, FR, ⁸Centre Georges Francois Leclerc, Dijon, FR, ⁹Centre Léon Bérard, Lyon, FR, ¹⁰Centre Francois Baclesse, Caen, FR, ¹¹Unicancer, Paris, Cedex, FR	
10:25 - 10:40	Invited Discussant 1817MO and 1818MO S. Paluch-Shimon, Hadassah University Hospital - Ein Kerem, Jerusalem, IL	



- 10:40 - 10:45 **1819MO - Systemic inflammation, unhealthy behaviors, and cancer-related fatigue (CRF) among survivors of breast cancer (BC)**
A. Di Meglio¹, J. Havas², M. Pagliuca¹, M.A. Franzoi¹, D. Soldato², B. Pistilli¹, F. Joly Lobbedez³, P. Cottu⁴, O. Tredan⁵, A. Bertaut⁶, P. Ganz⁷, J. Bower⁸, A.H. Partridge⁹, A.-L. Martin¹⁰, S. Everhard¹¹, S. Boyault⁵, S. Broutin¹², S. Michiels¹, C. Sarre-Pradon¹², I. Vaz Luis¹, ¹Institut Gustave Roussy, Villejuif, Cedex, FR, ²Institut Gustave Roussy - INSERM UMR 981, Villejuif, FR, ³Centre Francois Baclesse, Caen, Cedex, FR, ⁴Institut Curie, Paris, FR, ⁵Centre Léon Bérard, Lyon, FR, ⁶Centre Georges-François Leclerc (Dijon), Dijon, FR, ⁷Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, US, ⁸UCLA - David Geffen School of Medicine, Los Angeles, US, ⁹Dana Farber Cancer Institute, Boston, US, ¹⁰Unicancer, Paris, Cedex, FR, ¹¹UNICANCER, Paris, FR, ¹²Gustave Roussy - Cancer Campus, Villejuif, FR
- 10:45 - 10:50 **1820MO - Predisposition, clinical characteristics and management of immune checkpoint inhibitor-induced nephritis: A series of 190 cases**
A. Olsson-Brown¹, D. Aje², N. Garbutt³, J. Sacco⁴, ¹Sussex Cancer Centre - University Hospitals Sussex, Liverpool, GB, ²University of Liverpool - School of Medicine, Worthing, GB, ³The Clatterbridge Cancer Centre - Liverpool, Liverpool, GB, ⁴Clatterbridge Cancer Center - NHS Foundation Trust, Wirral, GB
- 10:50 - 11:05 **Invited Discussant 1819MO and 1820MO**
A. Letsch, Universitätsklinikum Schleswig Holstein Campus Kiel II, Kiel, DE
- 11:05 - 11:10 **1477MO - A multicenter, randomized controlled trial (RCT) on the efficacy of specialized rehabilitation using the Op-reha guide for terminal cancer patients in palliative care units (PCUs)**
N. Nishiyama¹, Y. Matsuda², N. Fujiwara³, N. Nakajima⁴, K. Narita⁵, S. Oyamada⁶, K. Ariyoshi⁶, K. Ichimaru⁷, T. Kosugi⁷, K. Kushi⁸, I. Owan⁸, ¹Osaka Metropolitan University, Habikino, JP, ²NHO Kinki Chuo Chest Medical Center, Sakai, JP, ³IMSUT Hospital of the Institute of Medical Science, The University of Tokyo, Tokyo, JP, ⁴University of the Ryukyus Hospital, Okinawa, JP, ⁵Kyoto University, Kyoto, JP, ⁶JORTC Data Center, Tokyo, JP, ⁷Saga-Ken Medical Centre Koseikan, Saga, JP, ⁸NHO Okinawa Hospital, Okinawa, JP
- 11:10 - 11:15 **1821MO - Predictive biomarkers of dyspnea response to dexamethasone in cancer patients: A secondary analysis of the Alleviating Breathlessness in Cancer Patients with Dyspnea (ABCD) trial**
D. Hui¹, S. Hanneman², K. Jennings¹, A. Ontai¹, S. Cron², E. Bruera¹, ¹The University of Texas MD Anderson Cancer Center, Houston, US, ²The University of Texas Health Science Center at Houston, Houston, US
- 11:15 - 11:30 **Invited Discussant 1477MO and 1821MO**
E. Scotté, Institut Gustave Roussy, Villejuif, FR



10:15 - 11:45	Type: Educational session Title: Rare cancers Chair(s): Winette Van Der Graaf, NL; Paolo G. Casali, IT	Zaragoza Auditorium - CC5
10:15 - 10:40	What has been done at the EU level: Cancer Mission and the EU Beating Plan <u>J. Arabadjiev</u> , Acibadem City Clinic Tokuda Hospital, Sofia, BG	
10:40 - 11:05	What is missing? The physician point of view <u>W. Van Der Graaf</u> , NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL	
11:05 - 11:30	What is missing? The patient point of view <u>K. Rizvi</u> , YCE - Youth Cancer Europe, Cluj-Napoca, RO	
11:30 - 11:45	Q&A and discussion	
10:15 - 11:45	Type: EONS session Title: Symptom management Chair(s): Karin Dieperink, DK; Remziye Semerci, TR	Ronda Auditorium - Hall 7
10:15 - 10:35	Quality of life and symptoms in cancer patients more than 80 years of age <u>E. Beisland</u> , Western Norway University of Applied Sciences, Bergen, NO	
10:35 - 10:55	Prevention and treatment of chronic pain in breast cancer survivors: A transmural perspective <u>Y. Slaghuyllder</u> , Universiteit Gent, Gent, Belgium, BE	
10:55 - 11:05	CN68 - From surviving cancer to getting on with life: Adult testicular germ cell tumor survivors&#x2019; perspectives on transition from follow-up care to long-term survivorship <u>S. Van Geel-Weda</u> ¹ , D. Zweers ² , B. Suelmann ² , R. Meijer ² , S. Vervoort ³ , ¹ HU University of Applied Sciences Utrecht,, Utrecht, NL, ² UMC - University Medical Center Utrecht, Utrecht, NL, ³ UMC- University Medical Center Utrecht, Utrecht, NL	
11:05 - 11:15	CN84 - Nursing intervention for self-management of symptoms in people undergoing chemotherapy: Feasibility and acceptability test <u>G.M. Carrillo González</u> , L. Corredor Parra, J.E. García Forero, Universidad Nacional de Colombia, Bogota, CO	
11:15 - 11:25	CN67 - Health literacy and self-management behaviours among prostate cancer survivors: A systematic review <u>S. Sheehan</u> ¹ , L. Bernués Caudillio ² , A. De Brún ³ , A. Drury ¹ , ¹ DCU - Dublin City University, Dublin, IE, ² Instituto de Salud Carlos III (ISCIII), Madrid, ES, ³ University College Dublin, Dublin, IE	

11:25 - 11:35 **CN85 - Empowering patient education to enhance self-care of nutritional side-effects during the chemotherapy**

L. Tuominen, University of Turku, Turku, FI

11:35 - 11:45 **Q&A and discussion**

10:15 - 11:00 **Type: EONS Industry Satellite Symposium** **Segovia Auditorium - Hall 7**
Title: Paxman - Achieving successful scalp cooling – the importance of nursing in chemotherapy side effect management
 Chair(s): Annie Young, GB

10:15 - 10:17 **Welcome and introduction**

A. Young, University of Warwick, Coventry, GB

10:17 - 10:27 **Clinical research and data on scalp cooling: Retention and regrowth**

C. Van Den Hurk, IKNL - Netherlands Comprehensive Cancer Organisation, Utrecht, NL

10:27 - 10:37 **Cancer nursing interventions: The importance of the role of nursing in successful scalp cooling**

A. Burke¹, L. Marqués Jiménez², ¹UPMC Beacon Hospital, Dublin, IE, ²IOB - Insititute of Oncology - Hospital Quironsalud Barcelona, Barcelona, ES

10:37 - 10:47 **The patient perspective: The power of scalp cooling**

B. Parrado, Paxman Coolers Ltd, Huddersfield, GB

10:47 - 10:57 **Discussion and Q&A**

A. Young¹, C. Van Den Hurk², A. Burke³, L. Marqués Jiménez⁴, B. Parrado⁵, ¹University of Warwick, Coventry, GB, ²IKNL - Netherlands Comprehensive Cancer Organisation, Utrecht, NL, ³UPMC Beacon Hospital, Dublin, IE, ⁴IOB - Insititute of Oncology - Hospital Quironsalud Barcelona, Barcelona, ES, ⁵Paxman Coolers Ltd, Huddersfield, GB

10:57 - 11:00 **Conclusion remarks**

A. Young, University of Warwick, Coventry, GB

10:45 - 11:30 **Type: Challenge your Expert** **Salamanca Auditorium - Hall 5**
Title: Escalating and descalating strategies with immunotherapies in NSCLC
 Chair(s): Benjamin Besse, FR

10:45 - 11:05 **Presentation by Expert**

N. Reguart Aransay, Hospital Clinic y Provincial de Barcelona, Barcelona, ES

11:05 - 11:30 **Discussion led by Chair**

B. Besse, Institut Gustave Roussy, Villejuif, Cedex, FR

10:45 - 11:30	Type: Challenge your Expert Title: How to treat very young patients with ER+, node positive BC? Chair(s): Sibylle Loibl, DE	Pamplona Auditorium - Hall 3
10:45 - 11:05	Presentation by Expert <u>A.H. Partridge</u> , Dana Farber Cancer Institute, Boston, US	
11:05 - 11:30	Discussion led by Chair <u>S. Loibl</u> , German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE	
10:45 - 11:30	Type: Young Oncologists session Title: YO Brunch 2 Chair(s): Pawel Sobczuk, PL	Cartagena Auditorium - Hall 7
10:45 - 10:45	Molecular profiling from panel NGS to WGS: Do YOs need special training? <u>C.B. Westphalen</u> , LMU Klinikum der Universität München, Munich, DE	
12:00 - 12:35	Type: Keynote lecture Title: How AI will transform cancer care Chair(s): Thomas Powles, GB	Madrid Auditorium - Hall 2
12:00 - 12:05	Introduction <u>T. Powles</u> , St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB	
12:05 - 12:20	Applications of artificial intelligence in precision oncology <u>J. Kather</u> , Technische Universität Dresden - Carl Gustav Carus Faculty of Medicine, Dresden, DE	
12:20 - 12:35	Implementing artificial intelligence in oncology at scale <u>A. Abernethy</u> , Verily Life Sciences, South San Francisco, US	
12:00 - 13:30	Type: EONS Industry Satellite Symposium Title: BMS - Subcutaneous administration of immunotherapy in different care settings Chair(s): Lena Sharp, SE	Ronda Auditorium - Hall 7
12:00 - 12:05	Welcome and introduction <u>L. Sharp</u> , RCC - Regionalt cancercentrum Stockholm - Gotland, Stockholm, SE	
12:05 - 12:25	Use, benefits, and barriers of subcutaneous immunotherapy applications <u>G.A. De Velasco Oria</u> , Hospital Universitario 12 de Octubre, Madrid, ES	
12:25 - 12:45	Safe administration of subcutaneous immunotherapy: Operating procedures for nurses <u>Z. O'neil</u> , University Hospital Coventry - University Hospitals Coventry and Warwickshire NHS Trust, Coventry, GB	



12:45 - 13:05 **Medication safety and management of side-effects in across care settings, including home**
E. Muñoz-Couselo, Vall d'Hebron University Hospital, Barcelona, ES

13:05 - 13:25 **Discussion and Q&A**
L. Sharp¹, G.A. De Velasco Oria², Z. O'neil³, E. Muñoz-Couselo⁴, ¹RCC - Regionalt cancercentrum Stockholm - Gotland, Stockholm, SE, ²Hospital Universitario 12 de Octubre, Madrid, ES, ³University Hospital Coventry - University Hospitals Coventry and Warwickshire NHS Trust, Coventry, GB, ⁴Vall d'Hebron University Hospital, Barcelona, ES

13:25 - 13:30 **Conclusion remarks**
L. Sharp, RCC - Regionalt cancercentrum Stockholm - Gotland, Stockholm, SE

12:00 - 13:00 **Type: EONS session** **Segovia Auditorium - Hall 7**
Title: EONS Rapid-fire session 2
 Chair(s): Amanda Drury, IE

12:00 - 12:10 **Opening remarks and instructions**
A. Drury, DCU - Dublin City University, Dublin, IE

12:10 - 12:15 **CN50 - Predictors of safe handling precautions amongst cancer nurses in the UK: A cross sectional survey**
K. Campbell, Edinburgh Napier University, Edinburgh, GB

12:15 - 12:20 **CN51 - A scoping review of interventions to enhance cancer nurses' psychological well-being, occupational health and resilience**
N. Dodlek¹, R. Semerci², A. Charalambous³, G. Kotronoulas⁴, C. Díez De Los Ríos De La Serna⁴, D. Protogiros⁵, S. Islamcevic⁶, V. Sulosaari⁷, ¹Cyprus University of Technology, Limassol, Cyprus, CY, ²Koc University Hospital, Istanbul, TR, ³Cyprus University of Technology - Nursing Science, Limassol, CY, ⁴University of Glasgow, Glasgow, GB, ⁵Ministry of Health, Athens, GR, ⁶University Clinical Center Zagreb - Gynecological Cancer Center, Zagreb, HR, ⁷TUAS - Turku University of Applied Sciences, Turku, FI

12:20 - 12:25 **CN22 - Remote patient monitoring using mHealth technology in cancer care and research: Patients' perspectives, willingness, and current use**
D. Stuijt¹, M. Kos², E. Van Doeveren³, I. Dingemans⁴, C. Richel⁴, M. Eversdijk³, J. Bosch¹, A. Bins², M. Bak³, M. Van Oijen⁵, ¹CHDR - Centre for Human Drug Research, Leiden, NL, ²Academic Medical Center, University of Amsterdam, Amsterdam, NL, ³Amsterdam UMC, locatie VUmc, Amsterdam, NL, ⁴NFK - Dutch Federation of Cancer Patient Organisations, Utrecht, NL, ⁵Amsterdam University Medical Center (UMC) locatie Academic Medical Center (AMC), Amsterdam, NL

12:25 - 12:30 **CN52 - Nurses' communication barriers about fertility preservation: An integrative review**
C. Mazzega Fabbro¹, A. Coden¹, S. Libriani², ¹CRO Aviano - Centro di Riferimento Oncologico - IRCCS, Aviano, IT, ²Università degli Studi di Udine, Udine, IT



- 12:30 - 12:35 **CN91 - Toxicities in breast cancer patients undergoing neoadjuvant immune checkpoint inhibitor therapy: Insights from a nurse practitioner perspective**
A.B. Rodriguez Garcia¹, Y. Torralba², B. Walbaum¹, E. Segui Solis¹, O. Martinez Saez³, N. Bartolome², M. Alatamirano², E. Carcelero¹, G. Riu², F. Schettini⁴, I. García-Fructuoso¹, R. Gómez Bravo³, P. Rivera², T. Pascual¹, B. Adamo¹, M.J. Vidal Losada³, M. Munoz³, A. Prat¹, A. Domenech², ¹Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ²Hospital Clinic de Barcelona, Barcelona, ES, ³Hospital Clinic of Barcelona, Barcelona, ES, ⁴Translational Genomics and Targeted Therapies in Solid Tumors Group, August Pi I Sunyer Biomedical Research Institute (IDIBAPS) and Medical Oncology Department, Hospital Clinic of Barcelona, Barcelona, Spain, Barcelona, ES
- 12:35 - 12:40 **CN53 - Healthcare professionals' wellbeing in post-pandemic oncology settings: A cross-sectional multisite study**
G. Catania¹, M. Zanini¹, M.E. Musio¹, L. Aiken², L. Sasso¹, A. Bagnasco¹, ¹University of Genova, Genova, IT, ²University of Pennsylvania, Philadelphia, US
- 12:40 - 12:45 **CN102 - Health-related quality of life of Brazilian cancer patients with an indication for chemotherapy and associated factors**
E.J.C.D.S. Minarini, R.M. Pessanha, N.S. D'agostini, T.B. Santos, W.R. Grippa, L.C. Lopes-Júnior, Universidade Federal do Espírito Santo, Campus de Maruípe, Vitoria, BR
- 12:45 - 12:50 **CN73 - The impact of mindfulness-based meditation and yoga on stress, body image, self-esteem and sexual adjustment in breast cancer patients undergoing modified radical mastectomy: A randomized controlled trial**
M. Pehlivan¹, S. Eyi², ¹Kutahya Health Science University, Kutahya, TR, ²ESOGÜ - Eskisehir Osmangazi University, Eskisehir, TR
- 12:50 - 12:55 **CN92 - Pain monitoring and assessment in oncology: A best practice implementation project**
H. Martins¹, A. Pimenta², D. Martins², M. Martins², M. Belchior², P. Cabrita², S. Caldeira³, R. Rodrigues⁴, ¹Polytechnical Institute of Beja, Beja, PT, ²Centro Hospitalar Universitário do Algarve - Hospital de Faro EPE-SNS, Faro, PT, ³Universidade Católica Portuguesa, Lisbon, PT, ⁴Escola Superior de Enfermagem de Coimbra, Portugal, Coimbra, PT
- 12:55 - 13:00 **CN54 - The empowering leadership approach in oncology nursing according to work experience**
E. Vitale¹, R. Mea², G. Micallo³, C. Mazzega Fabbro⁴, M.G. D'Alonzo⁵, ¹IRCCS Istituto Tumori "Giovanni Paolo II", Bari, IT, ²San Carlo Hospital, Potenza, IT, ³Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Napoli, IT, ⁴CRO Aviano - Centro di Riferimento Oncologico - IRCCS, Aviano, IT, ⁵IRCCS Istituto Tumori Giovanni Paolo II, Bari, IT



12:30 - 14:00	Type: Patient Advocacy session Title: Immunotherapy: New indications, hopes and perspectives Chair(s): Anne-Marie Baird, IE; Agata Polinska, PL	Zaragoza Auditorium - CC5
12:30 - 12:45	Understanding resistance in immunotherapy <u>J. Naidoo</u> , Beaumont Hospital, Dublin, IE	
12:45 - 13:00	Patients' involvement in immunotherapy trials design <u>A.-M. Baird</u> , St. James's Hospital, Dublin, IE	
13:00 - 13:15	New indications for immunotherapies and the difference they deliver: Lung, breast, and other cancers. Does it work for all? <u>J.-P. Machiels</u> , Cliniques Universitaires Saint-Luc (UCLouvain Saint-Luc), Woluwe-Saint-Lambert, BE	
13:15 - 13:30	Side effects of immunotherapy, and how to deal with patients' health problems <u>M. Jarzab</u> , National Oncology Institute Maria Skłodowskiej-Curie National Research Institute, Gliwice Branch, Gliwice, PL	
13:30 - 13:45	Access to immunotherapies in Poland and in Spain based on EMA and ESMO guidance <u>A. Polinska</u> , Alivia - Fundacja Onkologiczna Osób Młodych (Alivia - Young People Cancer Foundation), Warsaw, PL	
13:45 - 14:00	Discussion	
13:00 - 14:30	Type: Industry Satellite Symposium Title: Medscape Global Oncology - Milestones and Horizons in Hepatobiliary Carcinomas: The Unfolding Story of Immunotherapy Chair(s): Bruno Sangro, ES	Burgos Auditorium - Hall 5
13:00 - 13:05	Welcome and Introduction <u>B. Sangro</u> , Clinica Universidad de Navarra, Pamplona, ES	
13:05 - 13:15	Evolving Standards: Maximizing Outcomes in Advanced HCC with Immunotherapy <u>L. Rimassa</u> , IRCCS Humanitas Research Hospital, Rozzano, IT	
13:15 - 13:30	Crafting the Future: Emerging Multimodal Strategies for Embolization-Eligible HCC <u>B. Sangro</u> , Clinica Universidad de Navarra, Pamplona, ES	
13:30 - 13:45	Raising the Bar: Optimizing Curative Opportunities in Early HCC <u>S. Chan</u> , The Chinese University of Hong Kong - Sino Building, Sha Tin, HK	
13:45 - 14:00	Maximizing Potential: Integrating Immunotherapy into the Management of BTC <u>A. Vogel</u> , MHH - Medizinische Hochschule Hannover, Hannover, DE	

14:00 - 14:20 **The Art and Science of Immunotherapy in Clinical Practice: A Case-Based Discussion**
B. Sangro¹, L. Rimassa², S. Chan³, A. Vogel⁴, ¹Clinica Universidad de Navarra, Pamplona, ES,
²IRCCS Humanitas Research Hospital, Rozzano, IT, ³The Chinese University of Hong Kong - Sino
 Building, Sha Tin, HK, ⁴MHH - Medizinische Hochschule Hannover, Hannover, DE

14:20 - 14:30 **Q&A and Concluding Remarks**
B. Sangro, Clinica Universidad de Navarra, Pamplona, ES

13:00 - 14:30 **Type: Industry Satellite Symposium** **Salamanca Auditorium - Hall**
Title: Novartis - The Evolution of HR+/HER2- Early Breast 5
Cancer Clinical Practice: Broadening the Impact of CDK4/6 Inhibitors
 Chair(s): César A. Rodríguez, ES

13:00 - 13:05 **Welcome and Introduction**
C.A. Rodríguez, University Hospital of Salamanca, Salamanca, ES

13:05 - 13:15 **Risk of Recurrence in Patients With HR+/HER2- Early Breast Cancer**
C.A. Rodríguez, University Hospital of Salamanca, Salamanca, ES

13:15 - 13:45 **Efficacy of CDK4/6 inhibitors in Patients With HR+/HER2- Early Breast Cancer**
S. Tolaney, Dana Farber Cancer Institute, Boston, US

13:45 - 14:20 **Patient Management Considerations in HR+/HER2- Early Breast Cancer**
P.A. Fasching, University Hospital Erlangen, Erlangen, DE

14:20 - 14:30 **Live Q&A and Closing**
C.A. Rodríguez¹, P.A. Fasching², S. Tolaney³, ¹University Hospital of Salamanca, Salamanca, ES,
²University Hospital Erlangen, Erlangen, DE, ³Dana Farber Cancer Institute, Boston, US

13:00 - 14:30 **Type: Industry Satellite Symposium** **Santander Auditorium - Hall 5**
Title: Johnson & Johnson - Driving EGFR-mutant NSCLC care forward
 Chair(s): Noemi Reguart Aransay, ES; Antonio Passaro, IT

13:00 - 13:10 **Welcome and introductions**
N. Reguart Aransay, Hospital Clinic y Provincial de Barcelona, Barcelona, ES

13:10 - 13:25 **A new era for treatment-naïve patients with common EGFR mutations**
A. Spira, Virginia Cancer Specialist, Fairfax, US

13:25 - 13:40 **Breaking barriers upon EGFR treatment resistance**
S. Popat, The Royal Marsden Hospital - NHS Foundation Trust, London, GB



13:40 - 13:55 **Discussion**
N. Reguart Aransay¹, A. Passaro², S. Popat³, A. Spira⁴, E. Felip⁵, ¹Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ²IEO - Istituto Europeo di Oncologia IRCCS, Milan, IT, ³The Royal Marsden Hospital - NHS Foundation Trust, London, GB, ⁴Virginia Cancer Specialist, Fairfax, US, ⁵Vall d'Hebron University Hospital, Barcelona, ES

13:55 - 14:10 **The evolving management of patients with EGFR exon20insertion mutations**
E. Felip, Vall d'Hebron University Hospital, Barcelona, ES

14:10 - 14:25 **Discussion**
N. Reguart Aransay¹, A. Passaro², S. Popat³, A. Spira⁴, E. Felip⁵, ¹Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ²IEO - Istituto Europeo di Oncologia IRCCS, Milan, IT, ³The Royal Marsden Hospital - NHS Foundation Trust, London, GB, ⁴Virginia Cancer Specialist, Fairfax, US, ⁵Vall d'Hebron University Hospital, Barcelona, ES

14:25 - 14:30 **Closing remarks**
A. Passaro, IEO - Istituto Europeo di Oncologia IRCCS, Milan, IT

13:00 - 14:30 **Type: Industry Satellite Symposium** **Valencia Auditorium - Hall 5**
Title: Astellas - NEW HORIZONS: Priorities for Treatment Intensification in Managing HSPC
 Chair(s): Eleni Efsthathiou, US

13:00 - 13:05 **Welcome and introduction**
E. Efsthathiou, Houston Methodist, houston, US

13:05 - 13:25 **The importance of early treatment intensification in patients with nmHSPC with high-risk BCR**
S. Freedland, Prostate Cancer and Prostatic Diseases, New York, US

13:25 - 13:40 **Practical considerations when selecting patients with high-risk BCR**
E. Efsthathiou¹, S. Freedland², A. Rodriguez-Vida³, T. Steuber⁴, ¹Houston Methodist, houston, US, ²Prostate Cancer and Prostatic Diseases, New York, US, ³Hospital del Mar - Parc de Salut Mar, Barcelona, ES, ⁴UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE

13:40 - 14:05 **The importance of early treatment intensification in patients with mHSPC**
A. Rodriguez-Vida, Hospital del Mar - Parc de Salut Mar, Barcelona, ES

14:05 - 14:25 **Maximising QoL for patients with HSPC**
T. Steuber, UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE

14:25 - 14:30 **Summary and meeting close**
E. Efsthathiou, Houston Methodist, houston, US



13:00 - 14:30	Type: Industry Satellite Symposium Title: PeerVoice - Staying at the Forefront of HER2- and TROP2-Directed Antibody-Drug Conjugate (ADC) Advances in Breast Cancer Chair(s): Peter Schmid, GB	Alicante Auditorium - Hall 3
13:00 - 13:05	Welcome and Introduction <u>P. Schmid</u>, Cancer Research UK Barts Centre - Barts and The London School of Medicine and Dentistry, London, GB	
13:05 - 13:20	Treating HER2- and HR-Positive Breast Cancers: An Era of Impressive Advances <u>P. Schmid</u>, Cancer Research UK Barts Centre - Barts and The London School of Medicine and Dentistry, London, GB	
13:20 - 13:40	The Next Advances in ADC Strategies for HER2-Positive Metastatic Breast Cancer <u>C. Saura Manich</u>, Vall d'Hebron University Hospital, Barcelona, ES	
13:40 - 14:00	HR-Positive Metastatic Breast Cancer: The Latest Updates and Clinical Implications of HER2- and TROP2-Directed ADCs <u>A. Bardia</u>, UCLA - David Geffen School of Medicine, Los Angeles, US	
14:00 - 14:10	ADCs for High-Risk Early HER2-Positive Breast Cancer: Are the Data Showing Potential? <u>P. Schmid</u>¹, <u>C. Saura Manich</u>², <u>A. Bardia</u>³, ¹Cancer Research UK Barts Centre - Barts and The London School of Medicine and Dentistry, London, GB, ²Vall d'Hebron University Hospital, Barcelona, ES, ³UCLA - David Geffen School of Medicine, Los Angeles, US	
14:10 - 14:30	Ask-the-Faculty Roundtable Discussion and Take-Home Messages <u>P. Schmid</u>¹, <u>C. Saura Manich</u>², <u>A. Bardia</u>³, ¹Cancer Research UK Barts Centre - Barts and The London School of Medicine and Dentistry, London, GB, ²Vall d'Hebron University Hospital, Barcelona, ES, ³UCLA - David Geffen School of Medicine, Los Angeles, US	
13:00 - 14:30	Type: Industry Satellite Symposium Title: F. Hoffmann - La Roche - Patient Matters: Innovation in Lung Cancer Chair(s): Ben Solomon, AU	Pamplona Auditorium - Hall 3
13:00 - 13:05	Welcome and introduction <u>B. Solomon</u>, Peter MacCallum Cancer Center, Melbourne, AU	
13:05 - 13:20	Detecting targets early: biomarkers and testing in lung cancer <u>F. Lopez-Rios</u>, Hospital Universitario 12 de Octubre, Madrid, ES	
13:20 - 13:45	Targeting NSCLC: new developments in ALK+ and KRAS G12C NSCLC <u>B. Solomon</u>¹, <u>J. Naidoo</u>², ¹Peter MacCallum Cancer Center, Melbourne, AU, ²Beaumont Hospital, Dublin, IE	



13:45 - 14:15	Treatment experience matters: integration of subcutaneous immunotherapy in the clinic <u>M. Majem</u>¹, <u>J. Naidoo</u>², ¹Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ²Beaumont Hospital, Dublin, IE
14:15 - 14:25	Panel discussion and Q& <u>B. Solomon</u>¹, <u>F. Lopez-Rios</u>², <u>J. Naidoo</u>³, <u>M. Majem</u>⁴, ¹Peter MacCallum Cancer Center, Melbourne, AU, ²Hospital Universitario 12 de Octubre, Madrid, ES, ³Beaumont Hospital, Dublin, IE, ⁴Hospital de la Santa Creu i Sant Pau, Barcelona, ES
14:25 - 14:30	Meeting close <u>B. Solomon</u>, Peter MacCallum Cancer Center, Melbourne, AU
13:00 - 14:30	Type: Industry Satellite Symposium Oviedo Auditorium - Hall 3 Title: Amgen - Innovation in lung cancer treatment: unlocking the potential of precision medicine Chair(s): Ernest Nadal, ES
13:00 - 13:05	Precision medicine in lung cancer today <u>E. Nadal</u>, ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), L'Hospitalet de Llobregat, ES
13:05 - 13:20	KRASG12C inhibitors: expanding outcomes from clinical studies to real-world patient populations <u>M. Johnson</u>, Sarah Cannon Research Institute-Cancer Centre, Nashville, US
13:20 - 13:40	Engaging T cells in SCLC: the DLL3-targeted approach <u>A.-M. Dingemans</u>, Erasmus MC - University Medical Center, Rotterdam, NL
13:40 - 14:00	Expert perspectives: optimising care for patients receiving DLL3 T-cell engagers <u>M. Pérol</u>, Centre Léon Bérard, Lyon, FR
14:00 - 14:10	Advancing lung cancer treatment: emerging targets and novel therapies <u>E. Nadal</u>, ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), L'Hospitalet de Llobregat, ES
14:10 - 14:25	Panel discussion and Q&A <u>E. Nadal</u>¹, <u>M. Johnson</u>², <u>A.-M. Dingemans</u>³, <u>M. Pérol</u>⁴, ¹ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), L'Hospitalet de Llobregat, ES, ²Sarah Cannon Research Institute-Cancer Centre, Nashville, US, ³Erasmus MC - University Medical Center, Rotterdam, NL, ⁴Centre Léon Bérard, Lyon, FR
14:25 - 14:30	Summary and close <u>E. Nadal</u>, ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), L'Hospitalet de Llobregat, ES

13:00 - 14:30	Type: Industry Satellite Symposium Title: Bayer - Managing menopausal symptoms in patients undergoing endocrine therapy due to hormone-receptor positive breast cancer	Toledo Auditorium - Hall 3
13:00 - 13:10	Welcome and introduction: Addressing menopause symptoms following treatment for breast cancer <u>S. Loibl</u> , German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE	
13:10 - 13:25	The burden of induced menopause symptoms on women's health <u>M. Kiechle</u> , Klinikum Rechts der Isar - Technische Universitaet Muenchen, Munich, DE	
13:25 - 13:45	KNDy neurons and the science behind menopause <u>V. Navarro</u> , Harvard Medical School, Boston, US	
13:45 - 14:00	Options for symptoms management and unmet needs <u>D. Brennan</u> , The Mater Misericordiae University Hospital, Dublin, IE	
14:00 - 14:25	Round table discussion and Q&A <u>S. Loibl</u> ¹ , <u>M. Kiechle</u> ² , <u>V. Navarro</u> ³ , <u>D. Brennan</u> ⁴ , ¹ German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE, ² Klinikum Rechts der Isar - Technische Universitaet Muenchen, Munich, DE, ³ Harvard Medical School, Boston, US, ⁴ The Mater Misericordiae University Hospital, Dublin, IE	
14:25 - 14:30	Close <u>S. Loibl</u> , German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE	



14:45 - 16:15

Type: Proffered Paper session

Madrid Auditorium - Hall 2

Title: Proffered paper session 2: GI tumours, lower

Chair(s): Michel Ducreux, FR; Chiara Cremolini, IT

14:45 - 14:55

LBA25 - Randomized phase III trial of ramucirumab in combination with TAS102 (Trifluridin/Tipiracil) vs. TAS102 monotherapy in heavily pretreated metastatic colorectal cancer: The RAMTAS/IKF643 trial of the German AIO (AIO-KRK-0316)

S. Kasper-Virchow¹, R.D. Hofheinz², S. Stintzing³, T. Dechow⁴, T. Ettrich⁵, M. Sinn⁶, C. Roderburg⁷, L. Fischer Von Weikersthal⁸, U. Graeven⁹, C. Mueller¹⁰, J. Meiler¹¹, A. Stein¹², D. Modest¹³, C. Pauligk¹⁴, I. Virchow¹⁵, J. Siveke¹⁶, S.-E. Al-Batran¹⁷, M. Schuler¹⁶, T. Goetze¹⁸, ¹WTZ - Westdeutsches Tumorzentrum Essen, Essen, DE, ²UMM - Universitätsklinikum Mannheim, Mannheim, DE, ³Charité - Universitätsmedizin Berlin, Berlin, DE, ⁴Onkologie Hamatologie Ravensburg, Ravensburg, DE, ⁵University Hospital Of Ulm - Oberer Eselsberg, Ulm, DE, ⁶University Medical Center Hamburg-Eppendorf, Hamburg, DE, ⁷UKD - Universitätsklinikum Düsseldorf, Düsseldorf, DE, ⁸St. Marien Hospital, Amberg, Amberg, DE, ⁹Kliniken Maria Hilf GmbH - Klinik für Haematologie, Onkologie und Gastroenterologie, Mönchengladbach, DE, ¹⁰Kliniken Essen Mitte Evang. Huysens-Stiftung, Essen, DE, ¹¹Klinik Dr. Hancken GmbH, Stade, DE, ¹²Hematology Oncology Practice Hamburg, Hamburg, DE, ¹³Charité - Universitätsmedizin Berlin, Berlin, DE, ¹⁴Hospital Northwest, UCT-University Cancer Center, Frankfurt am Main, DE, ¹⁵West German Cancer Center, University Hospital Essen, Essen, DE, ¹⁶Universitätsklinikum Essen, Essen, DE, ¹⁷Nordwest-Krankenhaus, Frankfurt am Main, DE, ¹⁸IKF - Institut für Klinische Krebsforschung GmbH, Frankfurt am Main, DE

14:55 - 15:05

5020 - Pembrolizumab in combination with CAPOX and bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: Preliminary results of FFCD 1703 POCHI trial

D. Tougeron¹, J.-F. Emile², A. Bodere³, E. Barbier⁴, J. Bez⁴, L.M. Dourthe⁵, H. Perrier⁶, S. Corbinais⁷, V. Le Brun-Ly⁸, K. Bideau⁹, B. Chibaudel¹⁰, F. Khemissa Akouz¹¹, J. Hartwig¹², M. Laly¹³, A. Lievre¹⁴, C. Toullec¹⁵, N. Lomenie¹⁶, P. Laurent-Puig¹⁶, C. Lepage¹⁷, J. Taieb¹⁸, ¹CHU Poitiers - Jean Bernard Hôpital, Poitiers, FR, ²Ambroise-Paré Hospital, APHP, Paris-Saclay University, Versailles SQY University, Boulogne, FR, ³CH Saint Malo, Saint-Malo, FR, ⁴Fédération Francophone de Cancérologie Digestive, Dijon, FR, ⁵Clinique de l'Orangerie, Strasbourg, FR, ⁶Fondation Hôpital Saint Joseph, Marseille, FR, ⁷Centre Francois Baclesse, Caen, FR, ⁸CHU Limoges - Hopital Dupuytren, Limoges, FR, ⁹Centre Hospitalier de Cornouaille - Site de Laennec, Quimper, Cedex, FR, ¹⁰HFB - Hopital Franco-Britannique - Fondation Cognacq-Jay, Levallois-Perret, FR, ¹¹Centre Hospitalier de Perpignan - Hôpital Saint Jean, Perpignan, Cedex, FR, ¹²Infirmierie Protestante, Caluire et Cuire, FR, ¹³CHD Vendee - Hopital Les Oudairies, La Roche-sur-Yon, FR, ¹⁴CHU de Rennes - Hopital Pontchaillou, Rennes, Cedex, FR, ¹⁵Institut Sainte-Catherine, Avignon, FR, ¹⁶Université Paris Cité, Paris, FR, ¹⁷CHU Dijon, Dijon, FR, ¹⁸Hopital European George Pompidou, Paris, FR



15:05 - 15:15

5050 - Sotorasib (soto), panitumumab (pani) and FOLFIRI in the first-line (1L) setting for KRAS G12C–mutated metastatic colorectal cancer (mCRC): Safety and efficacy analysis from the phase Ib CodeBreak 101 study

S. Siena¹, K. Yamaguchi², J. Ruffinelli Rodriguez³, E. Corral De La Fuente⁴, Y. Kuboki⁵, C. Cremolini⁶, I. Victoria Ruiz⁷, M.E. Elez Fernandez⁸, J. Strickler⁹, M. Furqan¹⁰, B. Bashir¹¹, C. Nduka¹², J. Hippenmeyer¹³, E. Chan¹⁴, C. Xia¹⁴, T. Masuishi¹⁵, ¹Università degli Studi di Milano and Grande Ospedale Metropolitano Niguarda, Milan, IT, ²The Cancer Institute Hospital of JFCR, Koto-ku, JP, ³ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), Barcelona, ES, ⁴Hospital Universitario Ramon y Cajal, Madrid, ES, ⁵National Cancer Center Hospital East, Kashiwa, JP, ⁶University of Pisa, Pisa, IT, ⁷Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ⁸Vall d'Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, ES, ⁹Duke Cancer Center, Durham, US, ¹⁰University of Iowa Hospitals and Clinics, Iowa City, US, ¹¹Sidney Kimmel Cancer Center - Thomas Jefferson University, Philadelphia, US, ¹²Amgen - UK Uxbridge, Uxbridge, GB, ¹³Amgen (Europe) GmbH, Rotkreuz, CH, ¹⁴AMGEN (Headquarters) - USA, Thousand Oaks, US, ¹⁵Aichi Cancer Center Hospital, Nagoya, JP

15:15 - 15:25

Invited Discussant LBA25, 5020 and 5050

C. Montagut Viladot, Hospital del Mar - Parc de Salut Mar, Barcelona, ES

15:25 - 15:35

Q&A

15:35 - 15:45

LBA26 - SOLARIS (Alliance A021703): A multicenter double-blind phase III randomized clinical trial (RCT) of vitamin D (VitD) combined with standard chemotherapy plus bevacizumab (bev) in patients (pts) with previously untreated metastatic colorectal cancer (mCRC)

K. Ng¹, F.-S. Ou², T. Zemla², N. Mccleary³, A. Kalyan⁴, M. Shusterman⁵, N. Vijayvergia⁶, C. Wu⁷, S. Cohen⁸, S. Pulsipher², A. Shergill⁹, L. Schwartz¹⁰, D. Zuckerman¹¹, E. O'Reilly¹², J. Meyerhardt¹, ¹Dana Farber Cancer Institute, Boston, US, ²Mayo Clinic - Rochester, Rochester, US, ³Dana-Farber Cancer Institute, Boston, US, ⁴Northwestern University Feinberg School of Medicine, Chicago, US, ⁵NYU Langone Medical Center and School of Medicine, New York, US, ⁶Fox Chase Cancer Center - Main Campus, Philadelphia, US, ⁷Mayo Clinic Cancer Center, Phoenix, US, ⁸University of Washington, Seattle, US, ⁹University of Chicago Department of Medicine - Section of Hematology/Oncology, Chicago, US, ¹⁰MSKCC - Memorial Sloan Kettering Westchester, West Harrison, US, ¹¹St. Luke's Cancer Insitute, Boise, US, ¹²Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US

15:45 - 15:55 **506O - Evaluation of risk of disease progression in first-line therapy of unresected metastatic colorectal cancer to guide intervals of radiological assessment: An analysis of eleven randomized trials by AIO and GONO**

M. Germani¹, V. Heinemann², D. Rossini³, L. Fischer Von Weikersthal⁴, F. Morano⁵, K. Heinrich⁶, A. Stahler⁷, F. Bergamo⁸, F. Kaiser⁹, T. Decker¹⁰, L. Salvatore¹¹, L. Weiss¹², A. Russo⁵, M. Fuchs¹³, A. Prete⁸, C. Antoniotti¹⁴, G. Masi¹⁵, S. Stintzing¹⁶, C. Cremolini¹⁵, D. Modest⁷,
¹University of Pisa and Charité - Universitaetsmedizin Berlin, Pisa - Berlin, IT, ²LMU Klinikum der Universität München, Munich, DE, ³University of Florence, Firenze, IT, ⁴Klinikum St. Marien Amberg, Amberg, DE, ⁵Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ⁶Hospital Munich Grosshadern - Ludwig-Maximilians-University (LMU), Munich, DE, ⁷Charité - Universitaetsmedizin Berlin, Berlin, DE, ⁸IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, ⁹VK&K, Landshut, DE, ¹⁰Onkologie Hamatologie Ravensburg, Ravensburg, DE, ¹¹Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT, ¹²LMU University Hospital, LMU Munich, Munich, DE, ¹³München Klinikum Bogenhausen, Munich, DE, ¹⁴AOU Pisana - Stabilimento di Santa Chiara, Pisa, IT, ¹⁵University of Pisa, Pisa, IT, ¹⁶Charité - Universitätsmedizin Berlin, Berlin, DE

15:55 - 16:05 **Invited Discussant LBA26 and 506O**

M. Ducreux, Gustave Roussy - Cancer Campus, Villejuif, FR

16:05 - 16:15 **Q&A**

14:45 - 16:15 **Type: Educational session** **Sevilla Auditorium - Hall 2**
Title: Incorporating novel treatment insights for ER+ early BC patients
 Chair(s): Stephen Johnston, GB; Petra Tesarova, CZ

14:45 - 15:10 **CDK4/6 inhibitors for early breast cancer: State-of-the-art**

S. Johnston, The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, GB

15:10 - 15:35 **Prognostic and predictive factors for clinical decision making**

N. Harbeck, Ludwig Maximilians University - Grosshadern, Munich, DE

15:35 - 16:00 **Optimal treatment for elderly ER+ BC patients**

E. Brain, Hopital René Huguenin - Institut Curie, Saint-Cloud, FR

16:00 - 16:15 **Q&A and discussion**

14:45 - 16:15 **Type: Educational session** **Bilbao Auditorium - Hall 2**
Title: Personalisation of surgical and systemic approaches in 2024: Optimising cure and quality of life in gastroesophageal cancer
 Chair(s): Yelena Janjigian, US; Sheraz Markar, GB

14:45 - 15:10 **To operate or not operate: Personalised surgical approaches in the curative setting**

G. Piessen, C.H.U. Claude Huriez, Lille, FR

15:10 - 15:35 **Personalised systemic approaches to improve survivorship and cure**
Y. Janjigian, MSKCC - Memorial Sloan Kettering Cancer Center, New York, US

15:35 - 16:00 **How does surgery with curative intent impact quality of life?**
J. Elliott, Trinity College Dublin, Dublin, IE

16:00 - 16:15 **Q&A and discussion**

14:45 - 16:15 **Type: Special session** **Granada Auditorium - Hall 6**
Title: ESMO Clinical Practice Guidelines 2
 Chair(s): Elizabeth Smyth, GB; Emanuela Romano, FR

14:45 - 15:00 **Renal-cell carcinoma: Case presentation**
C. Messina, Ospedale Civico (A.R.N.A.S.), Palermo, IT

15:00 - 15:15 **Renal-cell carcinoma: Discussion**
T. Powles, St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB

15:15 - 15:30 **Renal-cell carcinoma: Q&A**

15:30 - 15:45 **Management of venous thromboembolism: Case presentation**
R. Sanchez Bayona, Hospital Universitario 12 de Octubre, Madrid, ES

15:45 - 16:00 **Management of venous thromboembolism: Discussion**
G. Gerotziafas, Institut Universitaire de Cancérologie AP-HP. Sorbonne Université, Hôpital Tenon, Paris, FR

16:00 - 16:15 **Management of venous thromboembolism: Q&A**

14:45 - 16:15 **Type: Educational session** **Burgos Auditorium - Hall 5**
Title: Gene modified T cells and new players
 Chair(s): Marcus Butler, CA; Katy Rezvani, US

14:45 - 15:10 **Moving CAR-T beyond haemato-oncology**
E. Locatelli, Ospedale Pediatrico Bambino Gesù, Rome, IT

15:10 - 15:35 **CAR NK cells**
K. Rezvani, The University of Texas MD Anderson Cancer Center - Main Building, Houston, US

15:35 - 16:00 **Bispecifics**
E. Calvo, CIOCC - Centro Integral Oncológico Clara Campal, Hospital Universitario HM Sanchinarro, Madrid, ES

16:00 - 16:15 **Q&A and discussion**



14:45 - 16:15 **Type: Proffered Paper session** **Salamanca Auditorium - Hall 5**
Title: Proffered paper session 2: Developmental therapeutics

Chair(s): Alexander Drilon, US; Neeltje Steeghs, NL

14:45 - 14:55 **608O - Preliminary safety and clinical activity of ASP3082, a first-in-class, KRAS G12D selective protein degrader in adults with advanced pancreatic (PC), colorectal (CRC), and non-small cell lung cancer (NSCLC)**

W. Park¹, A. Kasi², A. Spira³, J. Berlin⁴, J. Wang⁵, B. Herzberg⁶, Y. Kuboki⁷, S. Kitano⁸, M. Pelster⁹, J. Goldman¹⁰, D. Morgensztern¹¹, S. Kondo¹², P.A. Jänne¹³, H. Fujii¹⁴, H.-J. Lee¹⁵, S. Gill¹⁶, A. Saci¹⁷, P. Lorusso¹⁸, A. Tolcher¹⁹, ¹Memorial Sloan Kettering Cancer Center, New York, US, ²University of Kansas Medical Center, Westwood, US, ³Virginia Cancer Specialists Research Institute, Fairfax, US, ⁴Vanderbilt-Ingram Cancer Center, Nashville, US, ⁵Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, US, ⁶Herbert Irving Comprehensive Cancer Center, New York, NY, USA, New York, US, ⁷National Cancer Center Hospital East, Kashiwa, JP, ⁸The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto-ku, JP, ⁹Sarah Cannon Research Institute, Nashville, US, ¹⁰David Geffen School of Medicine, Los Angeles, US, ¹¹Washington University School of Medicine in St. Louis, St. Louis, US, ¹²National Cancer Center - Tsukiji Campus, Chuo-ku, JP, ¹³Dana Farber Cancer Institute, Boston, US, ¹⁴Astellas Pharma USA, Northbrook, US, ¹⁵Astellas Pharma Inc., Northbrook, US, ¹⁶Astellas Pharma Global Development, Inc, Northbrook, US, ¹⁷Astellas Pharma Global Development, Inc., Deerfield, US, ¹⁸Yale School of Medicine - Radiology and Biomedical Imaging, New Haven, US, ¹⁹South Texas Accelerated Research Therapeutics, San Antonio, US

14:55 - 15:05 **LBA27 - First-in-human results of STX-478, a mutant-selective PI3Ka inhibitor, in advanced solid tumor patients**

A. Montero¹, A. Giordano², K. Jhaveri³, P. Munster⁴, J. Rodon⁵, P. Lorusso⁶, D. Orr⁷, J. Bartolomé Arcilla⁸, A. Italiano⁹, A. Elias¹⁰, A. Soyano¹¹, M. De Miguel¹², B. Doger De Spéville¹³, G. Daniele¹⁴, J. O'Shaughnessy¹⁵, T. Hernandez Guerrero¹⁶, R. Wesolowski¹⁷, C. Saura Manich¹⁸, M. Chao¹⁹, D. Juric²⁰, ¹Case Western Reserve University / University Hospitals, Cleveland, US, ²Dana-Farber Cancer Institute, Boston, US, ³Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US, ⁴University of California, San Francisco, San Francisco, US, ⁵University of Texas MD Anderson Cancer Center, Houston, US, ⁶Yale School of Medicine, New Haven, US, ⁷Mary Crowley Cancer Research, Dallas, US, ⁸Hospital Clinico Universitario San Carlos, Madrid, ES, ⁹Institute Bergonié, Bordeaux, FR, ¹⁰University Of Colorado Faculty, Aurora, US, ¹¹H. Lee Moffitt Cancer Center & Research Institute - Magnolia Campus, Tampa, US, ¹²CIOCC - Centro Integral Oncológico Clara Campal, Hospital Universitario HM Sanchinarro, Madrid, ES, ¹³START Madrid-FJD and Hospital Universitario Fundacion Jimenez Diaz, Madrid, ES, ¹⁴Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT, ¹⁵Texas Oncology - Baylor Sammons Cancer Center, Dallas, US, ¹⁶START Barcelona Delfos, HM Nou, Madrid, ES, ¹⁷Ohio State University Medical Center, Columbus, US, ¹⁸Vall d'Hebron Institute of Oncology, Barcelona, ES, ¹⁹Scorpion Therapeutics, Boston, US, ²⁰Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, US

15:05 - 15:15 **Invited Discussant 608O and LBA27**

A. Drilon, Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US



15:15 - 15:25

Q&A

15:25 - 15:35

6090 - CLDN18.2 targeted antibody-drug conjugate (ADC), SHR-A1904, in patients (pts) with gastric/gastroesophageal junction cancer (GC/GEJC): A phase I study

R.-H. Xu¹, D. Ruan¹, S. Luo², X. Liang³, Z. Niu⁴, Q. Dang⁴, Z. Pan⁵, Y. Zhang⁶, X. Li⁷, H. Li⁵, X. Xiao⁸, S. Cai⁹, Y. Dong⁹, J. Zhang¹⁰, Z. Li¹⁰, H. Lan¹¹, H. Lu¹², S. Wang¹³, Q. Wu¹³, J. Xie¹³, ¹Sun Yat-Sen University Cancer Center, Guangzhou, CN, ²Henan Cancer Hospital, Zhengzhou, CN, ³Hubei Cancer Hospital, Wuhan, CN, ⁴Shandong First Medical University Affiliated Tumor Hospital, Jinan, CN, ⁵Tianjin Medical University Cancer Institute Hospital, Tianjin, CN, ⁶Harbin Medical University Cancer Hospital, Harbin, CN, ⁷The First Affiliated Hospital of Zhengzhou University, Zhengzhou, CN, ⁸Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, CN, ⁹The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, CN, ¹⁰Zhujiang Hospital of Southern Medical University, Guangzhou, CN, ¹¹Sichuan Academy of Medical Sciences Sichuan Provincial People's Hospital, Chengdu, CN, ¹²Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, CN, ¹³Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, CN

15:35 - 15:45

6100 - Preliminary results from a phase I, first-in-human study of DS-9606a, a claudin 6 (CLDN6)-directed antibody-drug conjugate (ADC), in patients (pts) with tumor types known to express CLDN6

M. Patel¹, E. Hamilton², S. Piha-Paul³, J. Henry⁴, U. Banerji⁵, M.N. Al-Hallak⁶, H. Okada⁷, M. Qian⁷, X. Zhang⁷, N. Said⁷, V. Chatikhine⁷, E. Fontana⁸, ¹Florida Cancer Specialists, Sarasota, US, ²Sarah Cannon Research Institute, Nashville, US, ³The University of Texas MD Anderson Cancer Center, Houston, US, ⁴Sarah Cannon Research Institute at HealthOne, Denver, US, ⁵The Institute of Cancer Research and Royal Marsden Hospital, London, GB, ⁶Karmanos Cancer Institute, Detroit, US, ⁷Daiichi Sankyo, Inc., Basking Ridge, US, ⁸Sarah Cannon Research Institute SCRI UK, London, GB

15:45 - 15:55

6110 - Updated results from BNT211-01 (NCT04503278), an ongoing, first-in-human, phase I study evaluating safety and efficacy of CLDN6 CAR T cells and a CLDN6-encoding mRNA vaccine in patients with relapsed/refractory CLDN6⁺ solid tumors

J. Haanen¹, A. Mackensen², C. Schultze-Florey³, W. Alsdorf⁴, E. Wagner-Drouet⁵, D. Heudobler⁶, P. Borchmann⁷, A. Busse⁸, S. Mielke⁹, S. Bins¹⁰, G. Ungerechts¹¹, C. Bokemeyer⁴, S. Klobuch¹, N. Kutsch⁷, F. Müller², A. Desuki⁵, W. Zhong¹², L. Preussner¹³, Ö. Türeci¹³, U. Sahin¹³, ¹Netherlands Cancer Institute, Amsterdam, NL, ²University Hospital Erlangen, Erlangen, DE, ³Hannover Medical School, Hannover, DE, ⁴University Medical Center Hamburg-Eppendorf, Hamburg, DE, ⁵University Medical Center Mainz, Mainz, DE, ⁶University Hospital Regensburg, Regensburg, DE, ⁷University Hospital of Cologne, Köln, DE, ⁸Charité-Universitätsmedizin Berlin, Berlin, DE, ⁹Karolinska Institutet and University Hospital, Stockholm, SE, ¹⁰Erasmus MC Cancer Institute, Rotterdam, NL, ¹¹Heidelberg University Hospital, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, DE, ¹²BioNTech US, Cambridge, US, ¹³BioNTech SE, BioNTech Cell & Gene Therapies GmbH, Mainz, DE



15:55 - 16:05 **Invited Discussant 6090, 6100 and 6110**

C. Hierro Carbo, Catalan Institute of Oncology (ICO- Badalona) Germans Trias i Pujol University Hospital, Badalona, ES

16:05 - 16:15 **Q&A**

14:45 - 16:15

Type: Mini Oral session

Santander Auditorium - Hall 5

Title: Mini oral session 2: Gynaecological cancers

Chair(s): Kathleen Moore, US; Antonio González-Martín, ES; Jean Emmanuel Kurtz, FR

14:45 - 14:50

714MO - Datopotamab deruxtecan (Dato-DXd) in patients with endometrial (EC) or ovarian cancer (OC): Results from the phase II TROPION-PanTumor03 study

A. Oaknin¹, J.E. Ang², S.Y. Rha³, K. Yonemori⁴, R. Kristeleit⁵, C.-C. Lin⁶, T. Satoh⁷, P. Estevez Garcia⁸, M.A.N. Sendur⁹, L. Medina Rodríguez¹⁰, A. Italiano¹¹, I. Lugowska¹², I. Ray-Coquard¹³, A. Oza¹⁴, J. Zhao¹⁵, S. Gajavelli¹⁵, J. Filant¹⁶, S. Bodla¹⁷, Y. Janjigian¹⁸, F. Meric-Bernstam¹⁹, ¹Vall d'Hebron University Hospital, Barcelona, ES, ²Cambridge University Hospitals NHS Foundation Trust, Cambridge, GB, ³Yonsei University College of Medicine, Seoul, KR, ⁴National Cancer Center Hospital, Tokyo, JP, ⁵Guy's and St Thomas' NHS Foundation Trust, London, GB, ⁶National Taiwan University Hospital, Taipei, TW, ⁷Osaka University Hospital, Suita, JP, ⁸Hospital Universitario Virgen del Rocio, Seville, ES, ⁹Ankara City Hospital, Oncology Hospital, Ankara, TR, ¹⁰Regional and Virgen de la Victoria University Hospitals, IBIMA, Malaga, ES, ¹¹Institute Bergonié, Bordeaux, FR, ¹²Maria Sklodowska-Curie Institute-Oncology Center, Warsaw, PL, ¹³Centre Léon Bérard, Lyon, FR, ¹⁴Princess Margaret Cancer Centre, Toronto, CA, ¹⁵AstraZeneca, New York, US, ¹⁶AstraZeneca, Warsaw, PL, ¹⁷AstraZeneca, Cambridge, GB, ¹⁸Memorial Sloan Kettering Cancer Center, New York, US, ¹⁹MD Anderson Cancer Center, University of Texas, Houston, US

14:50 - 14:55

715MO - Safety and efficacy of sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced endometrial carcinoma (EC) and ovarian cancer (OC) from a phase II study

D. Wang¹, K. Wang², R. An³, G. Yu⁴, K. Zhang⁵, D. Wang⁶, K. Jiang⁷, Y. Gao⁸, Y. Cheng⁹, Y. Liu¹⁰, H. Qiu¹¹, X. Wang¹², T. Liu¹³, B. Akala¹⁴, E. Chartash¹⁴, Y. Li¹⁵, X. Li¹⁵, X. Jin¹⁵, J. Ge¹⁵, J. Li¹⁶, ¹Liaoning Cancer Hospital, Shenyang, CN, ²Tianjin Medical University Cancer Institute & Hospital, Tianjin, CN, ³The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, CN, ⁴Weifang People's Hospital, Weifang, CN, ⁵Hunan Cancer Hospital, Changsha, CN, ⁶Chongqing University Cancer Hospital, Chongqing, CN, ⁷The Second Hospital of Dalian Medical University, Dalian, CN, ⁸Beijing Cancer Hospital, Beijing, CN, ⁹Jilin Cancer Hospital, Changchun, CN, ¹⁰The First Hospital of China Medical University, Shenyang, CN, ¹¹Zhongnan Hospital of Wuhan University, Wuhan, CN, ¹²Xuzhou Central Hospital, Xuzhou, CN, ¹³Zhongshan Hospital, Fudan University, Shanghai, CN, ¹⁴Merck & Co., Inc., Rahway, US, ¹⁵Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., Chengdu, CN, ¹⁶Shanghai Gobroad Cancer Hospital, Shanghai, CN



14:55 - 15:00

716MO - Efficacy and safety of sacituzumab tirumotecan (sac-TMT) plus pembrolizumab in patients with recurrent or metastatic cervical cancer

J. Wang¹, R. An², Y. Huang³, J. Zhang⁴, J. Goh⁵, K. Jiang⁶, G. Yu⁷, L. Chen⁸, D. Provencher⁹, Y. Tang¹⁰, G. Li¹¹, H. Qiu¹², B. Akala¹³, E. Chartash¹³, Y. Zhou¹⁴, X. Jin¹⁴, J. Ge¹⁵, X. Wu¹⁶, ¹The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, CN, ²The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, CN, ³Hubei Cancer Hospital, Wuhan, CN, ⁴Guangxi Medical University Cancer Hospital, Nanning, CN, ⁵Icon Cancer Centre Wesley, Chermside, AU, ⁶The Second Hospital of Dalian Medical University, Dalian, CN, ⁷Weifang People's Hospital, Weifang, CN, ⁸Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, CN, ⁹CHUM - Centre Hospitalier de l'Université de Montréal, Montreal, CA, ¹⁰Chongqing University Cancer Hospital, Chongqing, CN, ¹¹Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CN, ¹²Zhongnan Hospital of Wuhan University, Wuhan, CN, ¹³Merck & Co., Inc., Rahway, US, ¹⁴Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., Chengdu, CN, ¹⁵Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., CHENGDU, CN, ¹⁶Fudan University Shanghai Cancer Center, Shanghai, CN

15:00 - 15:05

717MO - SHR-A1921 in platinum-resistant ovarian cancer (PROC): data from a first-in-human (FIH) phase I study

Z. Song¹, L. Chen², Q. Dang², D. Tang³, T. Liu⁴, L. Wang⁵, J. Wang⁶, C. Liu⁷, X. Qu⁸, X. Li⁹, J. Zhong¹⁰, S. Zhang¹¹, N. Xing¹², Y. Li¹³, Y. Wu¹⁴, Z. Lin¹⁴, Z. Zhang¹⁴, S. Wang¹⁴, ¹Zhejiang Cancer Hospital, Hangzhou, CN, ²The First Affiliated Oncology Hospital of Shandong Medical University, Jinan, CN, ³Hunan Cancer Hospital, Changsha, CN, ⁴Zhongshan Hospital Fudan University, Shanghai, CN, ⁵Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, CN, ⁶National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Beijing, CN, ⁷Shengjing Hospital of China Medical University, Shenyang, CN, ⁸The First Hospital of China Medical University, Shenyang, CN, ⁹The First Affiliated Hospital of Zhengzhou University, Zhengzhou, CN, ¹⁰The First Affiliated Hospital of Guangxi Medical University, Nanning, CN, ¹¹Sichuan Cancer Hospital, Chengdu, CN, ¹²Shanxi Provincial Cancer Hospital, Taiyuan, CN, ¹³The First Affiliated Hospital of Nanchang University, Nanchang, CN, ¹⁴Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, CN

15:05 - 15:20

Invited Discussant 714MO, 715MO, 716MO and 717MO

K. Moore, Stephenson Cancer Center/University of Oklahoma, Oklahoma City, US



15:20 - 15:25

718MO - Mirvetuximab soravtansine (MIRV) in recurrent platinum-sensitive ovarian cancer (PSOC) with high folate receptor-alpha (FR α) expression: Results from the PICCOLO trial

A. Secord¹, B. Corr², S. Lewin³, E. Diver⁴, S.-M. Ayuk⁴, Y. Wang⁴, C. Murphy⁵, V. Salutari⁶, A. Barquin Garcia⁷, F. Galvez Montosa⁸, I. Ray-Coquard⁹, C. Mathews¹⁰, G. Konecny¹¹, A. Oaknin¹², M.J. Rubio Pérez¹³, A. Bonaventura¹⁴, S. Pignata¹⁵, ¹Duke University Hospital - Health System, Durham, US, ²University of Colorado Cancer Center, Aurora, US, ³Holy Name Medical Center, Teaneck, US, ⁴ImmunoGen, Inc., Waltham, US, ⁵Bon Secours Hospital, Cork, IE, ⁶Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT, ⁷HM University Sanchinarro Hospital, Madrid, ES, ⁸Hospital Universitario de Jaén, Jaén, ES, ⁹Centre Léon Bérard, Lyon, FR, ¹⁰Women and Infants Hospital of Rhode Island, Providence, US, ¹¹UCLA Westwood Oncology Hematology - Oncology Community Practice Group, Los Angeles, US, ¹²Vall d'Hebron Institute of Oncology, Vall d'Hebron Barcelona Hospital Campus, Barcelona, ES, ¹³Hospital Universitario Reina Sofía, Cordoba, ES, ¹⁴Newcastle Private Hospital, Newcastle, AU, ¹⁵Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Napoli, IT

15:25 - 15:30

719MO - A phase I/II study of rinatabart sesutecan (Rina-S) in patients with advanced ovarian or endometrial cancer

E. Lee¹, O. Yeku², I. Winer³, E. Hamilton⁴, D. Richardson⁵, J. Zhang⁶, G. Konecny⁷, I. Anderson⁸, X. Wu⁶, D. Orr⁹, S. Patel¹⁰, A. Jewell¹¹, J. Wang¹², A. Spira¹³, A. Melnyk¹⁴, L. Seamon¹⁵, E. Kavalierchik¹⁶, Z. Chen¹⁶, E. Song¹⁶, J. Call¹⁷, ¹Dana-Farber Cancer Institute, Boston, US, ²Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, US, ³Wayne State University and Karmanos Cancer Institute, Detroit, US, ⁴Sarah Cannon Research Institute at Tennessee Oncology, Nashville, US, ⁵Stephenson Cancer Center/University of Oklahoma, Oklahoma City, US, ⁶Fudan University Shanghai Cancer Center, Shanghai, CN, ⁷University of California Los Angeles, Los Angeles, US, ⁸Providence Medical Group, Santa Rosa, US, ⁹Mary Crowley Cancer Research, Dallas, US, ¹⁰University of California San Diego, San Diego, US, ¹¹University of Kansas Medical Center, Westwood, US, ¹²Hunan Cancer Hospital, Changsha, CN, ¹³Virginia Cancer Specialist, Fairfax, US, ¹⁴Texas Oncology-Abilene, Abilene, US, ¹⁵START Midwest, Grand Rapids, US, ¹⁶ProfoundBio, Seattle, US, ¹⁷START Mountain Region, West Valley City, US

15:30 - 15:45

Invited Discussant 718MO and 719MO

A. González-Martín, Clínica Universidad de Navarra, Madrid, ES



15:45 - 15:50

720MO - IBI354 (anti-HER2 antibody-drug conjugate [ADC]) in patients (pts) with advanced gynecological cancers (Gynecol C): Results from a phase I study

J. Shu¹, T. Zhu², Y. Huang³, Q. Xu⁴, R. Guo⁵, H. Liu⁶, H. Zhao⁷, L. Zhu⁸, X. Wang⁹, X. Xu¹⁰, W. Cheng¹¹, J. Tang¹², Q. Zhu¹³, X. Chen¹⁴, R. An¹⁵, J. Gao¹⁶, G. Li¹⁷, Z. Zhang¹⁸, H. Zhou¹⁹, Q. Zhou¹,
¹Affiliated Cancer Hospital of Chongqing University, Chongqing, CN, ²Zhejiang Cancer Hospital, Hangzhou, CN, ³Hubei Cancer Hospital, Wuhan, CN, ⁴Fujian Provincial Cancer Hospital, Fuzhou, CN, ⁵The First Affiliated Hospital of Zhengzhou University, Zhengzhou, CN, ⁶Gansu Provincial Hospital, Lanzhou, CN, ⁷Shanxi Cancer Hospital, Taiyuan, CN, ⁸Nanjing Drum Tower Hospital - Nanjing University, School Of Medicine, Nanjing, CN, ⁹The Affiliated Hospital of Xuzhou Medical University, Xuzhou, CN, ¹⁰Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, CN, ¹¹Jiangsu Province Hospital, Nanjing, CN, ¹²Hunan Cancer Hospital, Changsha, CN, ¹³Jiangxi Maternal and Child Health Care Hospital, Nanchang, CN, ¹⁴Obstetrics & Gynecology Hospital of Fudan University, Shanghai, CN, ¹⁵The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, CN, ¹⁶Jiangxi Cancer Hospital, Nanchang, CN, ¹⁷Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CN, ¹⁸The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, CN, ¹⁹Innovent Biologics (Suzhou) Co., Ltd., Suzhou, CN

15:50 - 15:55

721MO - Phase I, two-part, multicenter first-in-human (FIH) study of TORL-1-23: A novel claudin 6 (CLDN6) targeting antibody drug conjugate (ADC) in patient with advanced solid tumors

G. Konecny¹, A. Wahner Hendrickson², B. Winterhoff³, A.A. Adjei⁴, A. Kung⁵, L.-L. Miller⁵, M. Press⁶, I. Qazi⁵, N. Scholler⁵, H. Dokainish⁵, S. Letrent⁵, D. Slamon⁷, ¹UCLA Westwood Oncology Hematology - Oncology Community Practice Group, Los Angeles, US, ²Mayo Clinic, Rochester, US, ³University of Minnesota, Minneapolis, US, ⁴Cleveland Clinic Main Campus, Cleveland, US, ⁵TORL Biotherapeutics, LLC, Culver City, US, ⁶Keck School of Medicine - University of Southern California USC, Los Angeles, US, ⁷UCLA - David Geffen School of Medicine, Los Angeles, US

15:55 - 16:10

Invited Discussant 720MO and 721MO

J.E. Kurtz, ICANS - Institut de Cancérologie Strasbourg Europe, Strasbourg, FR



14:45 - 16:15	Type: Proffered Paper session Title: Proffered paper session: GU tumours, prostate Chair(s): Elena Castro, ES; Rana McKay, US	Valencia Auditorium - Hall 5
14:45 - 14:55	LBA65 - Efficacy of 177Lu-PNT2002 in PSMA-positive mCRPC following progression on an androgen-receptor pathway inhibitor (ARPI) (SPLASH) <u>O. Sartor</u>¹, D.M. Jiang², M. Smoragiewicz³, M. Zibelman⁴, A. Flechon⁵, G. El-Haddad⁶, G. Abikhzer⁷, F. Saad⁸, R. Tutrone⁹, S. Tagawa¹⁰, U. Metser¹¹, J. Calais¹², A. Hansen¹¹, W. Wu¹³, J. Jensen¹³, C. Trieu¹³, N. Fleshner¹³, I. Teslenko¹⁴, J.-C. Provost¹⁵, K.N. Chi¹⁶, ¹Mayo Clinic - Rochester, Rochester, US, ²University Health Network - Princess Margaret Cancer Center, Toronto, CA, ³Canadian Cancer Trials Group, Kingston, CA, ⁴Fox Chase Cancer Center - Main Campus, Philadelphia, US, ⁵Centre Leon Berard, Lyon, FR, ⁶H. Lee Moffitt Cancer Center & Research Institute - Magnolia Campus, Tampa, US, ⁷Jewish General Hospital McGill University, Montreal, CA, ⁸Centre Hospitalier de Université to Montréal (CHUM), Montreal, CA, ⁹Carolina Urologic Research Center, LLC, Myrtle Beach, US, ¹⁰NewYork-Presbyterian Hospital/ Weill Cornell Medical Center, New York, US, ¹¹Princess Margaret Cancer Centre, Toronto, CA, ¹²UCLA, Los Angeles, US, ¹³POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company, Indianapolis, US, ¹⁴Lantheus Holdings, Inc., Bedford, US, ¹⁵Lantheus, Bedford, US, ¹⁶BC Cancer Agency - Vancouver, Vancouver, CA	
14:55 - 15:05	LBA66 - UpFrontPSMA: A randomised phase II study of sequential 177Lu-PSMA-617 and docetaxel (D) versus docetaxel in metastatic hormone-sensitive prostate cancer (mHSPC) <u>A. Azad</u>¹, M. Bressel², H. Tan³, M. Voskoboinik⁴, A. Suder⁵, A. Weickhardt⁶, A. Guminski⁷, R. Francis⁸, J. Saghebi¹, N. Dhiantravan⁹, A. Joshua¹⁰, L. Emmett¹¹, D. Murphy², E. Hsiao⁷, S.T. Lee¹², D. Pattison⁹, D. Nadebaum⁴, I. Kirkwood¹³, M. Hofman², ¹Peter MacCallum Cancer Centre, Melbourne, AU, ²Peter MacCallum Cancer Center, Melbourne, AU, ³Royal Adelaide Hospital, Adelaide, AU, ⁴Alfred Hospital, Melbourne, AU, ⁵University of Queensland, Brisbane, AU, ⁶Olivia Newton-John Cancer Wellness & Research Centre, Heidelberg, AU, ⁷RNSH - Royal North Shore Hospital, St Leonards, AU, ⁸University of Western Australia, Perth, AU, ⁹Royal Brisbane and Women's Hospital, Herston, AU, ¹⁰The Kinghorn Cancer Centre, Sydney, AU, ¹¹St. Vincent's Hospital, Darlinghurst, AU, ¹²Austin Health - Austin Hospital, Heidelberg, AU, ¹³RAH - Royal Adelaide Hospital, Adelaide, AU	
15:05 - 15:15	Invited Discussant LBA65 and LBA66 <u>I. Burger</u>, KSB - Kantonsspital Baden, Baden, CH	
15:15 - 15:30	Q&A	



15:30 - 15:40

LBA67 - Cabozantinib (C) plus atezolizumab (A) versus 2nd novel hormonal therapy (NHT) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC): Final overall survival (OS) results of the phase III, randomized, CONTACT-02 study

N. Agarwal¹, A. Azad², J.C. Galceran³, N. Matsubara⁴, S. Oudard⁵, F. Saad⁶, A. Merseburger⁷, A. Soares⁸, B. McGregor⁹, B. Zurawski¹⁰, M. Tsiatas¹¹, S. North¹², E. Bournakis¹³, L. Antonuzzo¹⁴, D. Williamson¹⁵, L. Evilevitch¹⁵, A. Simmons¹⁵, R. Ferraldeschi¹⁶, P. Nandoskar¹⁷, S. Pal¹⁸,
¹University of Utah Health - Huntsman Cancer Institute, Salt Lake City, US, ²Peter MacCallum Cancer Centre, Melbourne, AU, ³Vall d'Hebron University Hospital, Barcelona, ES, ⁴National Cancer Center Hospital East, Kashiwa, JP, ⁵Georges Pompidou European Hospital and University Paris Cité, Paris, FR, ⁶Centre Hospitalier de Université to Montréal (CHUM), Montreal, CA, ⁷University Hospital Schleswig-Holstein, Campus Lübeck Schleswig-Holstein - Campus Lübeck, Lübeck, DE, ⁸Centro Paulista de Oncologia/Oncoclínicas and Hospital Israelita Albert Einstein, Sao Paulo, BR, ⁹Dana Farber Cancer Institute, Boston, US, ¹⁰Ambulatorium Chemioterapii, Bydgoszcz, PL, ¹¹Athens Medical Center, Marousi, GR, ¹²University of Alberta Cross Cancer Institute, Edmonton, CA, ¹³Metropolitan General Hospital, Cholgargos, GR, ¹⁴Clinical Oncology Unit, Careggi University Hospitalro-Universitaria Careggi, Firenze, IT, ¹⁵Exelixis, Inc., Alameda, US, ¹⁶F. Hoffmann-La Roche AG, Basel, CH, ¹⁷Exelixis, Inc., South San Francisco, US, ¹⁸City of Hope Comprehensive Cancer Center, Duarte, US

15:40 - 15:50

1596O - Decipher mRNA score for prediction of survival benefit from docetaxel at start of androgen deprivation therapy (ADT) for advanced prostate cancer (PC): An ancillary study of the STAMPEDE docetaxel trials

E. Grist¹, P. Dutey-Magni², L. Mendes³, M.A. Parry¹, A. Sachdeva⁴, J. Proudfoot⁵, A. Hamid⁶, C. Amos⁷, W. Cross⁸, S. Gillissen⁹, D. Berney¹⁰, M. Sydes¹¹, M. Parmar¹¹, F. Feng¹², N. Clarke¹³, E. Davicioni⁵, C. Sweeney¹⁴, N. James¹⁵, L. Brown², G. Attard¹⁶,
¹UCL Cancer Institute, London, GB, ²MRC - Medical Research Council Clinical Trials Unit - University College London (UCL), London, GB, ³UCL - University College London, London, GB, ⁴The University of Manchester, Manchester, GB, ⁵Veracyte, Inc. - Headquarters, South San Francisco, US, ⁶Memorial Sloan Cancer Center, New York, US, ⁷MRC Clinical Trials Unit at University College London, Institute of Clinical Trials and Methodology, University College London; London, UK, London, GB, ⁸University of Leeds - Leeds Institute of Molecular Medicine (LIMM), Leeds, GB, ⁹EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, CH, ¹⁰QMUL - Queen Mary University of London - Charterhouse Square, London, GB, ¹¹MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London, GB, ¹²UCSF Medical Center at Mission Bay, San Francisco, US, ¹³The Christie and Salford Royal NHS Foundation Trusts, Manchester, GB, ¹⁴The University of Adelaide, Adelaide, AU, ¹⁵ICR - Institute of Cancer Research, London, GB, ¹⁶University College London, London, GB

15:50 - 16:00

Invited Discussant LBA67 and 1596O

R. McKay, University of California San Diego - UCSD, La Jolla, US

16:00 - 16:15

Q&A



14:45 - 16:00	Type: Multidisciplinary session Title: Management and diagnostics of meningioma Chair(s): Emeline Tabouret, FR; Gelareh Zadeh, CA	Pamplona Auditorium - Hall 3
----------------------	---	-------------------------------------

14:45 - 14:50	Presentation of case/condition <u>E. Tabouret</u> , CHU La Timone Adultes, Marseille, FR	
14:50 - 15:10	Molecular characteristics in meningioma <u>F. Sahm</u> , University Hospital of Heidelberg, Heidelberg, DE	
15:10 - 15:30	Treatment changes of meningioma <u>G. Zadeh</u> , University of Toronto, Toronto, CA	
15:30 - 15:50	Controversies in radiotherapy for meningioma <u>S. Short</u> , UL - University of Leeds, Leeds, GB	
15:50 - 16:00	Discussion	

14:45 - 16:15	Type: Mini Oral session Title: Mini oral session: Melanoma and other skin tumours Chair(s): Jessica Hassel, DE; James Larkin, GB; Bart Neyns, BE	Oviedo Auditorium - Hall 3
----------------------	--	-----------------------------------

14:45 - 14:50	LBA43 - 10-y survival outcomes from the phase III CheckMate 067 trial of nivolumab plus ipilimumab in advanced melanoma <u>J. Larkin</u> ¹ , V. Chiarion Sileni ² , C. Gaudy Marqueste ³ , P. Rutkowski ⁴ , T. Medina ⁵ , C. Lao ⁶ , C.L. Cowey ⁷ , D. Schadendorf ⁸ , J. Wagstaff ⁹ , R. Dummer ¹⁰ , P. Queirolo ¹¹ , J. Walker ¹² , M. Butler ¹³ , A. Hill ¹⁴ , I. Marquez-Rodas ¹⁵ , J. Haanen ¹⁶ , A. Nassar ¹⁷ , M. Askelson ¹⁷ , F.S. Hodi ¹⁸ , J. Wolchok ¹⁹ , ¹ The Royal Marsden Hospital, London, GB, ² Veneto Institute of Oncology IOV-IRCCS, Padova, IT, ³ Timone Hospital, Aix-Marseille University, Marseille, FR, ⁴ Curie National Institute of Oncology, Warsaw, PL, ⁵ University of Colorado Cancer Center, Aurora, US, ⁶ University of Michigan, Rogel Cancer Center (current affiliation is Bristol Myers Squibb), Ann Arbor, US, ⁷ Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, US, ⁸ University Hospital Essen and the German Cancer Consortium, Essen, DE, ⁹ The College of Medicine, Swansea University, Swansea, GB, ¹⁰ University of Zurich, Zurich, CH, ¹¹ European Institute of Oncology IRCCS, Milan, IT, ¹² University of Alberta, Cross Cancer Institute, Edmonton, CA, ¹³ UHN Princess Margaret Cancer Centre, Toronto, CA, ¹⁴ Tasman Oncology Research, Southport, AU, ¹⁵ Hospital General Universitario Gregorio Marañón, Madrid, ES, ¹⁶ Netherlands Cancer Institute, Amsterdam, NL, ¹⁷ Bristol Myers Squibb, Princeton, US, ¹⁸ Dana-Farber Cancer Institute, Boston, US, ¹⁹ Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, US	
---------------	--	--



14:50 - 14:55

LBA44 - Pembrolizumab vs ipilimumab in advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study

C. Robert¹, M. Carlino², C. Mcneil³, A. Ribas⁴, J. Schachter⁵, M. Nyakas⁶, D. Kee⁷, T. Petrella⁸, A. Blaustein⁹, M. Lotem¹⁰, A.M. Arance¹¹, A. Daud¹², O. Hamid¹³, J. Larkin¹⁴, L. Yao¹⁵, R. Singh¹⁵, R. Lal¹⁵, G. Long¹⁶, ¹Gustave Roussy and Paris-Sud University, Villejuif, Cedex, FR, ²Melanoma Institute Australia, The University of Sydney, and Westmead and Blacktown Hospitals, Sydney, AU, ³Chris O'Brien Lifecare, Camperdown, AU, ⁴Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, US, ⁵Sheba Medical Center-Tel HaShomer, Ramat Gan, IL, ⁶Oslo University Hospital, Oslo, NO, ⁷Austin Health, Heidelberg, AU, ⁸Sunnybrook Health Sciences Centre - Odette Cancer Centre, Toronto, CA, ⁹Mount Sinai Medical Center Comprehensive Cancer Center, Miami Beach, US, ¹⁰Sharett Institute of Oncology, Hadassah University Hospital Ein Kerem, Jerusalem, IL, ¹¹Hospital Clinic Barcelona and IDIBAPS, Barcelona, ES, ¹²University of California San Francisco, San Francisco, US, ¹³The Angeles Clinic and Research Institute, a Cedars-Sinai Affiliate, Los Angeles, US, ¹⁴The Royal Marsden Hospital - Chelsea, London, GB, ¹⁵Merck & Co., Inc., Rahway, US, ¹⁶Melanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, AU

14:55 - 15:00

LBA45 - Early switch from targeted to immunotherapy in advanced BRAFV600-positive melanoma: Long-term OS and final PFS results of the randomized phase II ImmunoCobiVem trial

D. Schadendorf¹, H. Gogas², L. Kandolf Sekulovic³, F. Meier⁴, T. Eigentler⁵, M. Ziemer⁶, P. Terheyden⁷, A. Gesierich⁸, R. Herbst⁹, K. Kähler¹⁰, D. Ziogas¹¹, Ž. Mijušković³, M. Garzarolli¹², C. Garbe¹³, A. Roesch¹, S. Ugurel-Becker¹⁴, R. Gutzmer¹⁵, J.J. Grob¹⁶, L. Zimmer¹⁷, E. Livingstone¹⁸, ¹WTZ - Westdeutsches Tumorzentrum Essen, Essen, DE, ²National and Kapodistrian University of Athens - School of Medicine, Athens, GR, ³Military Medical Academy VMA, Belgrade, RS, ⁴Universitätsklinikum Carl Gustav Carus Dresden, Dresden, DE, ⁵Charité - Universitätsmedizin Berlin, Berlin, DE, ⁶Universitätsklinikum Leipzig - Klinik und Poliklinik für Frauenheilkunde, Leipzig, DE, ⁷UKSH - Universitätsklinikum Schleswig-Holstein - Campus Lübeck, Lübeck, DE, ⁸UKW - University Hospital Würzburg, Würzburg, DE, ⁹Helios Klinikum Erfurt, Erfurt, DE, ¹⁰UKSH - Universitätsklinikum Schleswig-Holstein - Campus Kiel, Kiel, DE, ¹¹Laiko General Hospital of Athens, Athens, GR, ¹²NCT / UCC - National Center for Tumor Diseases Dresden, Dresden, DE, ¹³Universitäts-Hautklinik Tuebingen, Tuebingen, DE, ¹⁴Uniklinikum Essen, Essen, DE, ¹⁵Ruhr University Bochum Medizinische Universitätsklinik, Bochum, DE, ¹⁶Hopital St. Marguerite Assistance Publique Hopitaux de Marseille, Marseille, FR, ¹⁷Universitätsklinikum Essen, Essen, DE, ¹⁸University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE

15:00 - 15:15

Invited Discussant LBA43, LBA44 and LBA45

J. Hassel, NCT - Nationales Zentrum für Tumorerkrankungen, Heidelberg, DE



15:15 - 15:20

1077MO - Adjuvant nivolumab v placebo in stage IIB/C melanoma: 3-year results from CheckMate 76K

G. Long¹, M. Del Vecchio², C. Hoeller³, J. Weber⁴, J.J. Grob⁵, P. Mohr⁶, S. Grabbe⁷, C. Dutriaux⁸, V. Chiarion Sileni⁹, J. Mackiewicz¹⁰, P. Rutkowski¹¹, P. Arenberger¹², G. Quereux¹³, T. Meniawy¹⁴, P. Ascierto¹⁵, J. Taube¹⁶, A. Nassar¹⁷, W. Wang¹⁷, J. Kirkwood¹⁸, ¹Melanoma Institute Australia, University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, AU, ²Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT, ³Medizinische Universität Wien, Vienna, AT, ⁴NYU Langone Medical Center, New York City, US, ⁵Hôpital de la Timone, Marseille, FR, ⁶Elbe Kliniken Buxtehude, Buxtehude, DE, ⁷JGU - Johannes Gutenberg University, Mainz, DE, ⁸Hôpital Saint-André, Bordeaux, FR, ⁹Istituto Oncologico Veneto IRCCS, Padova, IT, ¹⁰Poznan University of Medical Sciences, Poznan, PL, ¹¹Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, PL, ¹²Charles University Third Faculty of Medicine and University Hospital of Královské Vinohrady, Prague, CZ, ¹³Nantes University Hospital, Nantes, FR, ¹⁴Sir Charles Gairdner Hospital, Perth, AU, ¹⁵Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', Naples, IT, ¹⁶Johns Hopkins Medical Institutions, Baltimore, US, ¹⁷Bristol-Myers Squibb, Princeton, US, ¹⁸UPMC Hillman Cancer Center, Pittsburgh, US

15:20 - 15:25

1078MO - Pembrolizumab (pembro) vs placebo as adjuvant therapy for high-risk stage II melanoma: Long-term follow-up, rechallenge, and crossover in KEYNOTE-716

J. Luke¹, P. Ascierto², M. Khattak³, P. Rutkowski⁴, M. Del Vecchio⁵, F. Spagnolo⁶, J. Mackiewicz⁷, L. De La Cruz Merino⁸, V. Chiarion Sileni⁹, J. Kirkwood¹⁰, C. Robert¹¹, D. Schadendorf¹², F. De Galitiis¹³, M. Carlino¹⁴, A. Odeleye-Ajakaye¹⁵, M. Kalabis¹⁶, C. Krepler¹⁷, A. Eggermont¹⁸, G. Long¹⁹, ¹UPMC Hillman Cancer Center and University of Pittsburgh, Pittsburgh, US, ²Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Napoli, IT, ³Fiona Stanley Hospital, Perth, AU, ⁴Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, PL, ⁵Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT, ⁶IRCCS Ospedale Policlinico San Martino & Università degli Studi di Genova, Genova, IT, ⁷Poznan University of Medical Sciences; Greater Poland Cancer Center, Poznan, PL, ⁸Hospital Universitario Virgen Macarena, Seville, ES, ⁹Istituto Oncologico Veneto, IOV-IRCCS, Padova, IT, ¹⁰UPMC Hillman Cancer Center, Pittsburgh, US, ¹¹Institut Gustave Roussy, Villejuif, Cedex, FR, ¹²WTZ - Westdeutsches Tumorzentrum Essen, Essen, DE, ¹³IDI - Istituto dermatologico dell'immacolata - IRCCS, Rome, IT, ¹⁴Crown Princess Mary Cancer Centre Westmead, Westmead, AU, ¹⁵Merck & Co., Inc., Rahway, US, ¹⁶Merck & Co., Inc., North Wales, US, ¹⁷Merck & Co. Inc., North Wales, US, ¹⁸University Medical Center Utrecht & Comprehensive Cancer Center Munich or the Technical University Munich and Ludwig Maximilian University, Utrecht, NL, ¹⁹Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, AU

15:25 - 15:30

1079MO - Survival before and after the introduction of adjuvant treatment in stage III melanoma: A nationwide registry-based study

H. Helgadottir¹, L. Ny², G. Ullenhag³, J. Falkenius⁴, R. Mikiver⁵, R. Olofsson Bagge⁶, K. Isaksson⁷, ¹Karolinska Institutet - Cancer Center Karolinska (CCK), Stockholm, SE, ²Sahlgrenska University Hospital, Göteborg, SE, ³University Hospital Uppsala/Akademiska Sjukhuset, Uppsala, SE, ⁴Karolinska Institute, Stockholm, SE, ⁵LiU - Linköping University, Linköping, SE, ⁶University of Gothenburg - The Sahlgrenska Academy, Göteborg, SE, ⁷Lund University, Lund, SE



15:30 - 15:45

Invited Discussant 1077MO, 1078MO and 1079MO

J. Larkin, The Royal Marsden Hospital - Chelsea, London, GB

15:45 - 15:50

LBA46 - Primary efficacy, safety, and survival data from the registration-intended cohort of patients with anti-PD-1/anti-CTLA-4 failed melanoma from the IGNYTE clinical trial with RP1 combined with nivolumab

C. Robert¹, M. Milhem², J. Sacco³, J. Michels⁴, G. In⁵, E. Muñoz-Couselo⁶, D. Schadendorf⁷, G. Beasley⁸, J. Niu⁹, B. Chmielowski¹⁰, T. Wise-Draper¹¹, T. Bowles¹², K. Tsai¹³, C. Lebbe¹⁴, C. Gaudy Marqueste¹⁵, M. Middleton¹⁶, A. Samson¹⁷, J. Zhu¹⁸, M. Viana¹⁸, M.K.K. Wong¹⁹, ¹Gustave Roussy and Paris-Saclay University, Villejuif, FR, ²Holden Comprehensive Cancer Center, University of Iowa, Iowa City, US, ³The Clatterbridge Cancer Centre and University of Liverpool, Wirral, GB, ⁴Gustave Roussy, Villejuif, Cedex, FR, ⁵USC Norris Comprehensive Cancer Center, Los Angeles, US, ⁶Vall d'Hebron Institute of Oncology (VHIO) and Vall d'Hebron Hospital, Barcelona, ES, ⁷West German Cancer Center, University Hospital Essen, Essen, DE, ⁸Duke Cancer Institute, Duke University, Durham, US, ⁹Banner MD Anderson Cancer Center - Main Campus, Gilbert, US, ¹⁰Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, US, ¹¹University of Cincinnati Cancer Center, University of Cincinnati, Cincinnati, US, ¹²Intermountain Medical Center, Murray, US, ¹³Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, US, ¹⁴Université Paris Cité, AP-HP Dermato-Oncology and CIC, Cancer Institute APHP. Nord-Université Paris Cité, INSERM U976, Saint Louis Hospital, Paris, FR, ¹⁵Aix-Marseille Université, APHM, Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM, U1068, CNRS, UMR7258, UM105, Hôpital Timone, CEPCM, Marseille, FR, ¹⁶Churchill Hospital and University of Oxford, Oxford, GB, ¹⁷Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, GB, ¹⁸Replimune, Inc., Woburn, US, ¹⁹University of Texas MD Anderson Cancer Center, Houston, US

15:50 - 15:55

1080MO - Sitravatinib plus tislelizumab for metastatic uveal melanoma with liver metastasis: The open-label, multicenter, phase II GEM-2101 trial

L. Del Carpio Huerta¹, E. Espinosa², L. De La Cruz Merino³, A. Berrocal-Jaime⁴, J.M. Piulats¹, ¹Catalan Institute of Cancer (ICO), L'Hospitalet de Llobregat, Barcelona, Spain. Cancer Immunotherapy Group (CIT), Bellvitge Biomedical Research Institute IDIBELL—OncoBell, L'Hospitalet de Llobregat, ES, ²Hospital Universitario La Paz - CIBERONC, Madrid, ES, ³Hospital Universitario Virgen Macarena, Department of Medicine, Universidad de Sevilla, Sevilla, ES, ⁴Complejo Hospitalario General Universitario de Valencia, Valencia, ES



15:55 - 16:00

1081MO - Phase I study of WNT974 in combination with spartalizumab in patients with cutaneous melanoma

P. Ascierto¹, J. Rodon², F. De Vos³, V. Gambardella⁴, M. De Miguel⁵, I. Marquez-Rodas⁶, M. Gil Martín⁷, C. Robert⁸, M. Del Vecchio⁹, V. Moreno Garcia¹⁰, D. Schadendorf¹¹, R. Jamal¹², S. Sloan¹³, M. McLaughlin¹⁴, S. Murray¹⁴, B. Gomez-Carrillo Ruiz¹⁵, E. Hsiue¹⁴, S. Moody¹⁴, A.M. Arance¹⁶, ¹Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Napoli, IT, ²The University of Texas MD Anderson Cancer Center - Main Building, Houston, US, ³UMC - University Medical Center Utrecht, Utrecht, NL, ⁴Hospital Clinico Universitario de Valencia, Valencia, ES, ⁵CIOCC HM Sanchinarro, Madrid, ES, ⁶Hospital Gregorio Marañon, Madrid, ES, ⁷L'Hospitalet-Barcelona, Hospitalet de Llobregat, ES, ⁸Saclay University, Villejuif, FR, ⁹Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ¹⁰University Hospital, Madrid, ES, ¹¹University Hospital Essen and German Cancer Consortium Partner Site, Essen, DE, ¹²CHUM - Centre Hospitalier de l'Université de Montréal, Montreal, CA, ¹³Novartis, Basel, CH, ¹⁴Novartis, Boston, US, ¹⁵Novartis, CA, US, ¹⁶Hospital Clínic and IDIBAPS, Barcelona, ES

16:00 - 16:05

LBA47 - Nivolumab plus ipilimumab and ASTX727 or nivolumab plus ipilimumab in PD-1 resistant metastatic melanoma: Primary analysis of the randomized phase II NIBIT-ML1 study

A. Di Giacomo¹, E. Simonetti², L. Calabro³, V. Vegni⁴, F. Santangelo⁵, R. Depenni⁶, M. Colucci², M. Valente⁵, R. Grifoni⁷, M.F. Lofiego², G. Amato⁵, H. Keer⁸, A. Oganessian⁸, D. Chan⁹, D. Giannarelli¹⁰, M. Altomonte⁵, M. Ceccarelli¹¹, A. Anichini¹², A. Covre², M. Maio¹, ¹University of Siena, Center for Immuno-Oncology, University Hospital of Siena, NIBIT Foundation Onlus, Siena, IT, ²University of Siena, Siena, IT, ³University of Ferrara, Ferrara, IT, ⁴NIBIT Foundation Onlus, Siena, IT, ⁵Center for Immuno-Oncology, University Hospital of Siena, Siena, IT, ⁶University of Modena, Modena, IT, ⁷Azienda USL Toscana Centro, Firenze, IT, ⁸Taiho Pharmaceuticals Inc., Pleasanton, US, ⁹Taiho Pharmaceuticals Inc., Pleasanton, US, ¹⁰Fondazione Policlinico A. Gemelli, Rome, IT, ¹¹Sylvester Comprehensive Cancer Center, and Department of Public Health Sciences, Miller School of Medicine, University of Miami, Miami, US, ¹²Human Tumors Immunobiology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT

16:05 - 16:20

Invited Discussant LBA46, 1080MO, 1081MO and LBA47

B. Neyns, Vrije Universiteit Brussel - Faculty of Medicine & Pharmacy, Brussels, BE

14:45 - 16:15

Type: Special session

Toledo Auditorium - Hall 3

Title: ESMO in collaboration with the MASCC: Shedding light on the hidden microbiota

Chair(s): Matteo Lambertini, IT; Florian Scotté, FR

14:45 - 15:05

What is the microbiota-gut-brain-axis?

J. Bowen, The University of Adelaide, Adelaide, AU

15:05 - 15:25

The gut microbiota & immune related adverse events

C. Ruhlmann, OUH - Odense University Hospital, Odense, DK

15:25 - 15:45

The gut microbiota & neurocognitive functioning in patients with cancer

L. Derosa, Institut Gustave Roussy, Villejuif, FR

15:45 - 16:05 **Pre-habilitation interventions to improve outcomes in patients with cancer. What is the evidence?**

L. Buffart, Radboud University Medical Center, Nijmegen, Nijmegen, NL

16:05 - 16:15 **Panel discussion / Q&A**

14:45 - 16:15 **Type: Patient Advocacy session** **Zaragoza Auditorium - CC5**
Title: The future of cancer via patient expertise in research & innovation projects
 Chair(s): Tanja Spanic, SI; André Deschamps, BE

14:45 - 15:00 **How patient-centred research and innovation drives improved cancer care**
J.W. Van De Loo, European Commission - CDMA - DG Research & Innovation, Ixelles, BE

15:00 - 15:15 **Real world experience & patients' participation in multidisciplinary consortiums**
B. Ryll, Melanoma Patient Network Europe MPNE, Uppsala, SE

15:15 - 15:30 **The European Cancer Patient Digital Centre**
P. Gunther, European Commission, Stockholm, SE

15:30 - 15:45 **Understanding patient engagement in EU funded projects**
K. Beyer, Erasmus University Rotterdam - School of Health Policy & Management, Rotterdam, NL

15:45 - 16:00 **Can artificial intelligence improve early detection of cardiotoxicity after breast cancer treatment**
T. Spanic, Europa Donna - Slovensko zdruzenje za boj proti raku dojk, Ljubljana, SI

16:00 - 16:15 **Discussion**

14:45 - 17:45 **Type: Young Oncologists session** **Cartagena Auditorium - Hall 7**
Title: YO Masterclass: Designing v2.0 clinical trials
 Chair(s): Rille Pihlak, GB; Rodrigo Sanchez Bayona, ES

14:45 - 15:10 **New approaches to trial design to minimise costs and maximise benefit: The oncologists perspective**
R. Plummer, Newcastle University, Newcastle upon Tyne, GB

15:10 - 15:25 **Discussion**

15:25 - 15:50 **Are adaptive trial design and platform studies widely applicable? Tips from statistician**
S. Litiere, EORTC AISBL/IVZW - European Organisation for Research and Treatment of Cancer, Brussels, BE

15:50 - 16:05 **Discussion**

16:05 - 16:25	Coffee break	
16:25 - 16:50	Integrating digital technologies into clinical trials <u>I. Vaz Luis</u> , Institut Gustave Roussy, Villejuif, Cedex, FR	
16:50 - 17:05	Discussion	
17:05 - 17:30	Integrating translational research into clinical trials: Understanding models and their readouts <u>C. Sotiriou</u> , Institute Jules Bordet, Brussels, BE	
17:30 - 17:45	Discussion	
15:00 - 15:45	Type: Challenge your Expert Title: New directions in liquid biopsy for monitoring early stage NSCLC Chair(s): Enriqueta Felip, ES	Alicante Auditorium - Hall 3
15:00 - 15:20	Presentation by Expert <u>M. Diehn</u> , Stanford University, Stanford, US	
15:20 - 15:45	Discussion led by Chair <u>E. Felip</u> , Vall d'Hebron University Hospital, Barcelona, ES	
15:00 - 16:30	Type: EONS session Title: Advance care planning and palliative care Chair(s): Hazal Özdemir Koyu, TR; Wendy Mcinally, GB	Ronda Auditorium - Hall 7
15:00 - 15:15	Providing palliative care in a hospital setting <u>H. Berghenoltz</u> , University Hospital Sjællands Roskilde, Roskilde, DK	
15:15 - 15:30	What is your last wish? A volunteer project led by an oncology nurse <u>S. Gomes</u> , Instituto Portugues Oncologia de Coimbra Francisco Gentil E. P. E. (IPO Coimbra), Coimbra, PT	
15:30 - 15:45	A targeted discharge pathway to reduce hospital readmissions and dying in hospital in cancer patients at the end of life <u>M. Van Klinken</u> , Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (NKI-AVL), Amsterdam, NL	
15:45 - 15:55	CN1 - Nurses' emotional affect when caring for cancer patients undergoing deep sedation: Findings from a meta-synthesis <u>L. Cadarin</u> ¹ , E. Boccalon ² , ¹ CRO Aviano - Centro di Riferimento Oncologico - IRCCS, Aviano, IT, ² Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy, Aviano, IT	

15:55 - 16:05 **CN2 - An updated evidence on the effects of spiritual interventions in cancer: A systematic review with meta-analysis**

Z. Gok Metin¹, N. Izgu¹, H. Eroglu², R. Semerci³, H. Pars⁴, ¹Hacettepe University - Faculty of Nursing, Ankara, TR, ²Lokman Hekim University, Ankara, TR, ³Koc University Hospital, Istanbul, TR, ⁴Hacettepe University Health Sciences Institute, Ankara, TR

16:05 - 16:15 **CN3 - Existential distress in head-and-neck male cancer patients: A comprehensive study of demographic factors**

L. Sanz Monge¹, J. Garrido Gallego¹, P. Palao Contell¹, P.J. Gomez Garcia¹, C. Pertusa Gomez¹, L. Santa Cruz Ramis¹, A. Cunquero Tomas¹, A. Berrocal², ¹CHGUV - Consorcio Hospital General Universitario de Valencia, Valencia, ES, ²Hospital General Universitario Valencia, Valencia, ES

16:15 - 16:30 **Q&A and discussion**

15:00 - 16:30 **Type: EONS Industry Satellite Symposium** **Segovia Auditorium - Hall 7**
Title: Daiichi-Sankyo & AstraZeneca - The guiding hand in patient care: Managing Antibody-Drug Conjugate (ADC) related adverse events
 Chair(s): Andreas Charalambous, CY

15:00 - 15:05 **Welcome and introduction**

A. Charalambous, Cyprus University of Technology - Nursing Science, Limassol, CY

15:05 - 15:20 **The current context and use of ADC in metastatic breast cancer**

C. Saura Manich, Vall d'Hebron University Hospital, Barcelona, ES

15:20 - 15:40 **Managing ADC-related adverse events: How nurses contribute to improving patient outcomes**

D. Dohnal-Suvajac, Landeskrankenhaus LK Thermenregion Moedling, Moedling, AT

15:40 - 16:00 **Working together: Multidisciplinary management of real-world metastatic breast cancer cases**

M. Lapuente, St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB

16:00 - 16:30 **Panel discussion and Q&A**

A. Charalambous¹, C. Saura Manich², D. Dohnal-Suvajac³, M. Lapuente⁴, ¹Cyprus University of Technology - Nursing Science, Limassol, CY, ²Vall d'Hebron University Hospital, Barcelona, ES, ³Landeskrankenhaus LK Thermenregion Moedling, Moedling, AT, ⁴St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB



16:30 - 17:50	Type: Proffered Paper session Title: Presidential Symposium II: Practice-changing trials Chair(s): Solange Peters, CH; Rebecca Dent, SG	Barcelona Auditorium - Hall 2
16:30 - 16:42	LBA4 - Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: Overall survival results from the phase III KEYNOTE-522 study <u>P. Schmid</u>¹, J. Cortés², R. Dent³, H. Mcarthur⁴, L. Pusztai⁵, S. Kummel⁶, C. Denkert⁷, Y.H. Park⁸, R. Hui⁹, N. Harbeck¹⁰, M. Takahashi¹¹, S.-A. Im¹², M. Untch¹³, P.A. Fasching¹⁴, F. Cardoso¹⁵, J. Zhao¹⁶, X. Zhou¹⁶, K. Tryfonidis¹⁶, G. Aktan¹⁶, J. O'Shaughnessy¹⁷, ¹Barts Cancer Institute, Queen Mary University, London, GB, ²Faculty of Biomedical and Health Sciences, Department of Medicine, Universidad Europea de Madrid, Madrid, ES, ³Duke – National University of Singapore Medical School, Singapore, SG, ⁴University of Texas Southwestern Medical Center, Dallas, US, ⁵Yale Cancer Center, New Haven, US, ⁶Department of Gynecology with Breast Center, Berlin, DE, ⁷Philipps-University Marburg and University Hospital Marburg, Marburg, DE, ⁸Sungkyunkwan University School of Medicine, Seoul, KR, ⁹School of Clinical Medicine, University of Hong Kong, Hong Kong, HK, ¹⁰LMU University Hospital, Munich, DE, ¹¹Hokkaido University Hospital, Sapporo, JP, ¹²Cancer Research Institute, Seoul National University, Seoul, KR, ¹³Helios Klinikum Berlin-Buch, Berlin, DE, ¹⁴Comprehensive Cancer Center Erlangen-EMN, Erlangen, DE, ¹⁵Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, PT, ¹⁶Merck & Co., Inc., Rahway, US, ¹⁷Sarah Cannon Research Institute, Dallas, US	
16:42 - 16:52	Invited Discussant LBA4 <u>M. Kok</u>, Netherlands Cancer Institute, Amsterdam, NL	
16:52 - 17:04	2310 - Locoregional hypo vs normofractionated RT in early breast cancer: 5 years results of the HypoG-01 phase III UNICANCER trial <u>S. Rivera</u>¹, R. Ghodssighassemabadi², T. Brion³, Y. Kirova⁴, S. Racadot⁵, M. Benchalal⁶, J.B. Clavier⁷, C. Brunaud⁸, M.-E. Fouche-Chand⁹, D. Argo Leignel¹⁰, K. Peignaux-Casasnovas¹¹, A. Benyoucef¹², D. Pasquier¹³, P. Guilbert¹⁴, J. Blanchecotte¹⁵, G. Phothirath¹⁶, A. Lamrani-Ghaouti¹⁶, M. Bergeaud¹⁶, G. Auzac³, S. Michiels¹, ¹Institut Gustave Roussy, Villejuif, Cedex, FR, ²Gustave Roussy INSERM 1018, Villejuif, FR, ³Gustave Rousy, Villejuif, FR, ⁴Institut Curie, Paris, FR, ⁵Center Leon Berard, Lyon, FR, ⁶Centre Eugene - Marquis, Rennes, FR, ⁷ICANS - Institut de Cancérologie Strasbourg Europe, Strasbourg, FR, ⁸Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre-lès-Nancy, FR, ⁹CLCC - Centre Antoine Lacassagne, Nice, FR, ¹⁰Hôpital du Scorff, Lorient, FR, ¹¹Centre Georges François Leclerc, Dijon, FR, ¹²Centre Henri Becquerel, Rouen, FR, ¹³Centre Oscar Lambret, Lille, FR, ¹⁴Institut Jean Godinot, Reims, FR, ¹⁵ICO - Institut de Cancerologie de l'Ouest - Site Paul Papin, Angers, Cedex, FR, ¹⁶Unicancer, Paris, Cedex, FR	
17:04 - 17:14	Invited Discussant 2310 <u>C. Coles</u>, University of Cambridge - Clinical Oncology - R block (R4), Cambridge, GB	



17:14 - 17:26

LBA5 - A randomized phase III trial of neoadjuvant durvalumab plus chemotherapy followed by radical cystectomy and adjuvant durvalumab in muscle-invasive bladder cancer (NIAGARA)

T. Powles¹, M. Van Der Heijden², M. Galsky³, H. Al-Ahmadie⁴, J. Meeks⁵, H. Nishiyama⁶, T. Vu⁷, L. Antonuzzo⁸, P. Wiechno⁹, V. Atduev¹⁰, A. Kann¹¹, T.-H. Kim¹², C. Suarez Rodriguez¹³, C.-H. Chang¹⁴, F. Roghmann¹⁵, M. Ozguroglu¹⁶, J. Armstrong¹⁷, S. Ho¹⁸, S. Hois¹⁸, J. Catto¹⁹, ¹Barts Cancer Institute, Queen Mary University of London, London, GB, ²Netherlands Cancer Institute, Amsterdam, NL, ³Icahn School of Medicine at Mount Sinai, New York, US, ⁴Memorial Sloan Kettering Cancer Center, New York, US, ⁵Northwestern University, Feinberg School of Medicine, Chicago, US, ⁶University of Tsukuba, Tsukuba, JP, ⁷Vietnam National Cancer Hospital, Hanoi, VN, ⁸Universitaria Careggi, Florence, IT, ⁹Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, PL, ¹⁰Volga District Medical Center, Nizhny Novgorod, RU, ¹¹Hospital Alemão Oswaldo Cruz, Sao Paulo, BR, ¹²Kyungpook National University School of Medicine, Daegu, KR, ¹³Vall d' Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d' Hebron, Vall d' Hebron Barcelona Hospital Campus, Barcelona, ES, ¹⁴China Medical University and Hospital, Taichung, TW, ¹⁵University Hospital of Ruhr-University Bochum, Marien Hospital, Herne, DE, ¹⁶Istanbul University-Cerrahpaşa, Cerrahpaşa School of Medicine, Istanbul, TR, ¹⁷AstraZeneca, Cambridge, GB, ¹⁸AstraZeneca, Gaithersburg, US, ¹⁹School of Medicine & Population Health, University of Sheffield, and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, GB

17:26 - 17:36

Invited Discussant LBA5

P. Grivas, University of Washington, Seattle, US

17:36 - 17:50

Q&A and discussion

16:30 - 18:00

Type: Educational session

Granada Auditorium - Hall 6

Title: What we know and what we should know on immunotherapy and endometrial cancer (EC)

Chair(s): Ana Oaknin, ES; Isabelle Ray-Coquard, FR

16:30 - 16:50

Should IO be considered the new standard of care in advanced EC?

A. Oaknin, Vall d'Hebron University Hospital, Barcelona, ES

16:50 - 17:10

Digging into the biology: Who are the responders?

X. Matias-Guiu, IDIBELL - Bellvitge Biomedical Research Institute, Hospitalet de Llobregat, ES

17:10 - 17:30

Enhancing the checkpoints' activity in pMMR

V. Makker, Memorial Sloan-Kettering Cancer Center, New York City, US

17:30 - 17:50

Overcoming the resistance to IO: What can we do?

E. Marmé, UMM - Universitaetsklinikum Mannheim - Medizinische Fakultät, Mannheim, DE

17:50 - 18:00

Q&A and discussion



16:30 - 17:45 **Type: Multidisciplinary session** **Santander Auditorium - Hall 5**
Title: Definition and clinical implication of response in localised sarcomas
 Chair(s): Aisha Miah, GB; Kjetil Boye, NO

16:30 - 16:35 **Presentation of case/condition**
A. Miah, The Royal Marsden Hospital - Chelsea, London, GB

16:35 - 16:50 **How to define pathologic response?**
J. Bovée, LUMC-Leiden University Medical Center, Leiden, NL

16:50 - 17:05 **The radiologist point of view**
W. Kunz, LMU - Ludwig Maximilians University of Munich, Munich, DE

17:05 - 17:20 **Impact on surgery: Extremities and other sites**
S. Bonvalot, Institut Curie, Paris, FR

17:20 - 17:35 **Impact on surgery: Other tumour locations**
W. Van Houdt, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL

17:35 - 17:45 **Discussion**

16:30 - 18:00 **Type: Special session** **Pamplona Auditorium - Hall 3**
Title: Current advances in clinical pharmacology within oncology, and its relevance for daily practice
 Chair(s): Ron Mathijssen, NL; Emiliano Calvo, ES

16:30 - 16:35 **Introduction**
E. Calvo, CIOCC - Centro Integral Oncológico Clara Campal, Hospital Universitario HM Sanchinarro, Madrid, ES

16:35 - 16:55 **Implementation in clinical practice of therapeutic drug monitoring (TDM) of kinase inhibitors anno 2024**
R. Mathijssen, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL

16:55 - 17:15 **The advantages of boosting studies to increase drug exposure of anticancer drugs**
N. Van Erp, Radboud University Medical Center, Nijmegen, Nijmegen, NL

17:15 - 17:35 **Cost-effectiveness of optimized immunotherapy dosing**
M. Del Re, UniCamillus International Medical University in Rome, Rome, IT



17:35 - 17:55 **Pharmacology and dose-selection of ADCs**
E. Calvo, CIOCC - Centro Integral Oncológico Clara Campal, Hospital Universitario HM Sanchinarro, Madrid, ES

17:55 - 18:00 **Conclusions**
R. Mathijssen, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL

16:30 - 18:00 **Type: Proffered Paper session** **Zaragoza Auditorium - CC5**
Title: Proffered paper session: Policy and preventive strategies
 Chair(s): Dario Trapani, IT; Suzette Delalogue, FR

16:30 - 16:40 **15350 - Cost and value of EMA-registered checkpoint inhibitors for solid tumours in the Netherlands**
A. Huisman¹, S. Koole², M. Wymenga³, A. Pisters⁴, H. Gelderblom¹, S. Van Waalwijk Van Doorn-Khosrovani⁵, ¹Leiden University Medical Center, Leiden, NL, ²Zilveren Kruis Health Insurance, Zeist, NL, ³MST - Medisch Spectrum Twente, Enschede, NL, ⁴CZ, Tilburg, NL, ⁵LUMC - Leiden University Medical Center, Leiden, NL

16:40 - 16:50 **15360 - Indication-specific pricing and weighted-average pricing: Estimated price and cost savings for cancer drugs**
D. Michaeli¹, C. Michaeli², ¹National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg, DE, ²UMM - Universitätsklinikum Mannheim, Mannheim, DE

16:50 - 17:00 **15370 - Value of immune checkpoint blockade (ICB) in microsatellite stable/mismatch repair proficient (MSS/pMMR) metastatic colorectal cancer (mCRC)**
B. Geisler¹, S. Meltzer¹, E. Burger², E. Aas², A. Ree¹, ¹Akershus University Hospital HF, Lorenskog, NO, ²University of Oslo, Oslo, NO

17:00 - 17:10 **Invited Discussant 15350, 15360 and 15370**
D. Trapani, Università degli Studi di Milano, Milan, IT

17:10 - 17:20 **Q&A**

17:20 - 17:30 **15380 - Environmental pollutants and molecular alterations in non-small cell lung cancer: Insights from the KBP-2020 cohort study**
A. Cortot¹, M. Genin¹, F. Occelli², L. Dauchet², V. Leblanc², E. Auvray³, M. Sabatini⁴, F. Goupil⁵, C. Dussopt⁶, S. Thierry⁷, P. Masson⁸, M. Jaafar⁹, C. Marthy¹⁰, C. Maurer¹¹, S. Dehette¹², E. Wasielewski¹, A. Hamroun¹, D. Debieuvre¹³, S. Leblanc¹, ¹CHU Lille - Centre Hospitalier Régional Universitaire de Lille, Lille, FR, ²Univ. Lille, Lille, FR, ³CH Aix-les-Bains, Aix-les-Bains, FR, ⁴Centre Hospitalier de la Côte Basque, Bayonne, FR, ⁵Hospital Center- Le Mans, Le Mans, FR, ⁶L'Hopital Nord Ouest - Villefranche-Sur-Saone, Villefranche-Sur-Saone, FR, ⁷Centre Hospitalier d'Arras, Amilly, FR, ⁸CH Cholet, Cholet, FR, ⁹CH Eure-Seine Evreux, Evreux, CEDEX, FR, ¹⁰CH Saint-Nazaire, Saint-Nazaire, FR, ¹¹Groupe Hospitalier Intercommunal Le Raincy Montfermeil, Montfermeil, FR, ¹²Centre Hospitalier de Cannes, Cannes, FR, ¹³GHRMSA, Mulhouse, FR



17:30 - 17:40 **Invited Discussant 15380**
S. Delaloge, Institut Gustave Roussy, Villejuif, Cedex, FR

17:40 - 17:50 **Q&A**

16:45 - 17:45 **Type: EONS session** **Ronda Auditorium - Hall 7**
Title: MASCC-EONS collaborative session: Nursing researchers' role in supportive care implementation
 Chair(s): Matthew Fowler, GB; Carlos Fernandes Cargaleiro, GB

16:45 - 17:00 **Cancer nursing research priorities on supportive care in Europe: Results of a mixed methods study**
M. Dowling, NUI - National University of Ireland Galway, Galway, IE

17:00 - 17:15 **The role of cancer nurse scientists in advancing supportive care implementation**
G. Kotronoulas, University of Glasgow, Glasgow, GB

17:15 - 17:25 **CN29 - Short term effects of self-care behaviours on quality of life for patients on oral anticancer agents**
M. Di Nitto¹, F. Lacarbonara², S. Ucciero², T. Bolgeo³, V. Damico⁴, G. Ghizzardi⁵, S.R. Zerulo⁶, R. Alvaro², F. Torino⁷, E. Vellone², ¹University of Genoa, Genoa, IT, ²University of Rome Tor Vergata - School of Medicine and Surgery, Rome, IT, ³Azienda Ospedaliero Universitaria SS Antonio e Biagio e Cesare Arrigo, Alessandria, IT, ⁴Azienda Socio-Sanitaria Territoriale di Lecco, Lecco, IT, ⁵Azienda Socio Sanitaria Territoriale di Lodi, Lodi, IT, ⁶Azienda Ospedaliero Universitaria - Ospedali Riuniti Foggia, Foggia, IT, ⁷University of Rome Tor Vergata, Rome, IT

17:25 - 17:35 **CN47 - Consensus research priorities for cancer nursing in Europe: A Delphi study**
A. Drury¹, M. Dowling², S. Colomer-Lahiguera³, N. Efstathiou⁴, C. Semple⁵, P. Fernández Ortega⁶, K. Dieperink⁷, E. Pape⁸, G. Kotronoulas⁹, S. Miguel¹⁰, G. Bagcivan¹¹, ¹DCU - Dublin City University, Dublin, IE, ²NUI - National University of Ireland Galway, Galway, IE, ³Institute of Higher Education and Research in Healthcare - IUFRS, CHUV, Lausanne, CH, ⁴The University of Birmingham - Medical School, Birmingham, GB, ⁵Ulster Hospital - South Eastern Health and Social Care Trust, Dundonald, GB, ⁶ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), L'Hospitalet de Llobregat, ES, ⁷Odense University Hospital, Odense C, DK, ⁸UZ Gent - Universitair Ziekenhuis Gent, Gent, BE, ⁹University of Glasgow, Glasgow, GB, ¹⁰Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E. (IPO Lisboa), Lisbon, PT, ¹¹Koc University - School of Nursing, Istanbul, TR

17:35 - 17:45 **Q&A and discussion**



17:00 - 17:45	Type: Challenge your Expert Title: New horizons in T cell lymphoma: From classification to clinic Chair(s): Francesco D'Amore, DK	Oviedo Auditorium - Hall 3
17:00 - 17:20	Presentation by Expert <u>W.S. Kim</u> , Samsung Medical Center (SMC), Seoul, KR	
17:20 - 17:45	Discussion led by Chair <u>F. D'Amore</u> , Aarhus University Hospital, Aarhus, DK	
18:30 - 20:00	Type: Industry Satellite Symposium Title: Exact Sciences - Tools to guide treatment decisions in early breast cancer: Genomic testing and emerging role of MRD Chair(s): Nicholas Turner, GB	Burgos Auditorium - Hall 5
18:30 - 18:35	Opening / Welcome <u>N. Turner</u> , The Royal Marsden Hospital - Chelsea, London, GB	
18:35 - 18:55	Tissue-based genomics to guide adjuvant therapy decisions <u>J. Walshe</u> , St Vincent's University Hospital, Dublin, IE	
18:55 - 19:10	Evolving role of genomic assays in early breast cancer <u>M. Martin Jimenez</u> , Hospital General Universitario Gregorio Marañón, Madrid, ES	
19:10 - 19:20	Introduction to MRD in breast cancer <u>N. Turner</u> , The Royal Marsden Hospital - Chelsea, London, GB	
19:20 - 19:40	Evolving role of MRD guided decision making in early breast cancer <u>S. Loi</u> , Peter MacCallum Cancer Centre, Melbourne, AU	
19:40 - 19:50	Optimizing the approach to MRD assay development <u>R. Baehner</u> , Exact Sciences Corporation, Madison, US	
19:50 - 20:00	Panel discussion <u>N. Turner</u> ¹ , <u>M. Martin Jimenez</u> ² , <u>S. Loi</u> ³ , <u>J. Walshe</u> ⁴ , <u>R. Baehner</u> ⁵ , ¹ The Royal Marsden Hospital - Chelsea, London, GB, ² Hospital General Universitario Gregorio Marañón, Madrid, ES, ³ Peter MacCallum Cancer Centre, Melbourne, AU, ⁴ St Vincent's University Hospital, Dublin, IE, ⁵ Exact Sciences Corporation, Madison, US	



18:30 - 20:00 **Type: Industry Satellite Symposium** **Salamanca Auditorium - Hall 5**
Title: PeerVoice - Innovation and Individualisation in mHSPC and nmCRPC: Optimising Patient Outcomes and Experiences
 Chair(s): Elena Castro, ES

18:30 - 18:33 **Welcome and Introduction**

E. Castro, Hospital Universitario 12 de Octubre, Madrid, ES

18:33 - 19:18 **Individualising Treatment Intensification in mHSPC: Why We Should and How We Can**

E. Castro¹, F. Saad², M. Boegemann³, ¹Hospital Universitario 12 de Octubre, Madrid, ES, ²Centre Hospitalier de Université to Montréal (CHUM), Montreal, CA, ³UKM - University Hospital Muenster, Muenster, DE

19:18 - 19:30 **Audience Q&A: Seeking Solutions to Current Challenges in mHSPC**

E. Castro¹, F. Saad², M. Boegemann³, ¹Hospital Universitario 12 de Octubre, Madrid, ES, ²Centre Hospitalier de Université to Montréal (CHUM), Montreal, CA, ³UKM - University Hospital Muenster, Muenster, DE

19:30 - 19:45 **Improving Patient Outcomes While Prioritising the Patient Experience in nmCRPC: Can We Do Both?**

E. Castro¹, F. Saad², M. Boegemann³, ¹Hospital Universitario 12 de Octubre, Madrid, ES, ²Centre Hospitalier de Université to Montréal (CHUM), Montreal, CA, ³UKM - University Hospital Muenster, Muenster, DE

19:45 - 19:57 **Audience Q&A: Expert Insights on Your Inquiries in nmCRPC**

E. Castro¹, F. Saad², M. Boegemann³, ¹Hospital Universitario 12 de Octubre, Madrid, ES, ²Centre Hospitalier de Université to Montréal (CHUM), Montreal, CA, ³UKM - University Hospital Muenster, Muenster, DE

19:57 - 20:00 **Final Remarks, Conclusions, and Closing**

E. Castro, Hospital Universitario 12 de Octubre, Madrid, ES

18:30 - 20:00 **Type: Industry Satellite Symposium** **Santander Auditorium - Hall 5**
Title: Pfizer Oncology - Setting a new benchmark for ALK+ aNSCLC targeted therapy
 Chair(s): Tony S.K. Mok, HK

18:30 - 18:35 **Welcome and introduction**

T.S.K. Mok, Prince of Wales Hospital - Li Ka Shing Specialist Clinics, Sha Tin, HK

18:35 - 19:00 **Latest data in the 1L ALK+ aNSCLC treatment landscape**

J. Gainor, MGH - Massachusetts General Hospital, Boston, US

19:00 - 19:20 **Optimising 1L treatment in clinical practice**

T.S.K. Mok, Prince of Wales Hospital - Li Ka Shing Specialist Clinics, Sha Tin, HK



- 19:20 - 19:40 **Practical strategies for managing adverse events**
E. Felip, Vall d'Hebron University Hospital, Barcelona, ES
- 19:40 - 19:55 **ALK+ aNSCLC treatment expectations now and in the future**
T.S.K. Mok, Prince of Wales Hospital - Li Ka Shing Specialist Clinics, Sha Tin, HK
- 19:55 - 20:00 **Meeting close**
T.S.K. Mok, Prince of Wales Hospital - Li Ka Shing Specialist Clinics, Sha Tin, HK

18:30 - 20:00 **Type: Industry Satellite Symposium** **Valencia Auditorium - Hall 5**
Title: MSD - Advancements in Women's Health: Innovations in HPV Vaccination, Cervical Cancer, and Endometrial Cancer Treatment
 Chair(s): Ana Oaknin, ES

- 18:30 - 18:35 **Introductions and Objectives**
A. Oaknin, Vall d'Hebron University Hospital, Barcelona, ES
- 18:35 - 18:50 **Innovations in Cervical Cancer and Endometrial Cancer: Current Treatment Landscape**
A. Oaknin, Vall d'Hebron University Hospital, Barcelona, ES
- 18:50 - 19:00 **Prevention: HPV Immunization and Cervical Cancer Elimination**
M. Del Pino Saldrigues, Universitat de Barcelona - Facultat de Medicina, Barcelona, ES
- 19:00 - 19:20 **Advancements in Cervical Cancer Management: Comprehensive Strategies for Locally Advanced and First-line Metastatic Disease**
D. Lorusso, Humanitas San Pio X, Milan, IT
- 19:20 - 19:40 **Advancing the Frontiers: State-of-the-Art Approaches in Endometrial Cancer Treatment**
R. Eskander, University of California San Diego - UCSD, La Jolla, US
- 19:40 - 19:50 **Q&A**
A. Oaknin¹, D. Lorusso², R. Eskander³, M. Del Pino Saldrigues⁴, ¹Vall d'Hebron University Hospital, Barcelona, ES, ²Humanitas San Pio X, Milan, IT, ³University of California San Diego - UCSD, La Jolla, US, ⁴Universitat de Barcelona - Facultat de Medicina, Barcelona, ES
- 19:50 - 20:00 **Closing**
A. Oaknin, Vall d'Hebron University Hospital, Barcelona, ES

18:30 - 20:00 **Type: Industry Satellite Symposium** **Alicante Auditorium - Hall 3**
Title: Boehringer Ingelheim - Emerging therapies in clinical practice: What are the patient perspectives on the future of lung cancer treatment?
 Chair(s): Martin Wermke, DE

- 18:30 - 18:35 **Welcome & Introduction**
M. Wermke, Dresden University, Dresden, DE

- 18:35 - 18:50 **Unmet needs and future perspectives for treatment of lung cancer**
G. Ruiter, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL
- 18:50 - 19:10 **Emerging targeted therapies in lung cancers of neuroendocrine origin: DLL3**
M. Wermke, Dresden University, Dresden, DE
- 19:10 - 19:40 **Selectively targeting HER2 in NSCLC**
J. Zugazagoitia, Hospital Universitario 12 de Octubre, Madrid, ES
- 19:40 - 19:55 **Panel discussion and audience Q&A**
M. Wermke¹, G. Ruiter², J. Zugazagoitia³, ¹Dresden University, Dresden, DE, ²NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ³Hospital Universitario 12 de Octubre, Madrid, ES
- 19:55 - 20:00 **Chair's closing remarks**
M. Wermke, Dresden University, Dresden, DE

18:30 - 20:00 **Type: Industry Satellite Symposium** **Pamplona Auditorium - Hall 3**
Title: Illumina - Liquid biopsy-based biomarkers for cancer profiling and monitoring: current and future applications
 Chair(s): Umberto Malapelle, IT

- 18:30 - 18:35 **Welcome**
U. Malapelle, Università degli Studi di Napoli Federico II - Scuola di Medicina e Chirurgia, Napoli, IT
- 18:35 - 18:50 **Introduction to the value of liquid biopsy testing in oncology**
U. Malapelle, Università degli Studi di Napoli Federico II - Scuola di Medicina e Chirurgia, Napoli, IT
- 18:50 - 19:05 **National implementation of Liquid Biopsy testing for Non Small Cell Lung Cancer - QuicDNA**
M. Meissner, Velindre Cancer Centre - Velindre NHS University Trust - NHS Wales, Cardiff, GB
- 19:05 - 19:20 **Added value of Liquid Biopsy testing in advanced cancer - IMPRESS NORWAY**
Å. Helland, Oslo University Hospital - The Norwegian Radium Hospital, Oslo, NO



19:20 - 19:35 **The Value of Liquid Biopsy Testing in Colorectal Cancer: The Patient Advocacy Perspective**
S. Rowley, Inspire2Live, Amsterdam, NL

19:35 - 20:00 **Panel discuss**
U. Malapelle¹, M. Meissner², A. Helland³, S. Rowley⁴, ¹Università degli Studi di Napoli Federico II - Scuola di Medicina e Chirurgia, Napoli, IT, ²Velindre Cancer Centre - Velindre NHS University Trust - NHS Wales, Cardiff, GB, ³Oslo University Hospital - The Norwegian Radium Hospital, Oslo, NO, ⁴Inspire2Live, Amsterdam, NL

18:30 - 20:00 **Type: Industry Satellite Symposium** **Oviedo Auditorium - Hall 3**
Title: Bristol Myers Squibb - Developments in Genitourinary Cancer
Management: Joint Decision Making in MIUC and Advanced RCC
 Chair(s): Michael Jewett, CA; Andrea Necchi, IT; Laurence Albiges, FR

18:30 - 18:40 **Welcome and Introduction**
M. Jewett, University of Toronto - St. George Campus, Toronto, CA

18:40 - 19:00 **Clinical Considerations in Early Stages of Cancer: the MIUC Experience**
A. Necchi, IRCCS Ospedale San Raffaele, Milan, IT

19:00 - 19:20 **Role of Long-term Efficacy, Safety Outcomes and Different Routes of Administration in the Advance Disease Setting: the RCC Experience**
L. Albiges, Institut Gustave Roussy, Villejuif, Cedex, FR

19:20 - 19:40 **Improving Joint Decision Making in Genitourinary Cancers**
M. Jewett, University of Toronto - St. George Campus, Toronto, CA

19:40 - 19:55 **Q&A Session**
M. Jewett¹, A. Necchi², L. Albiges³, ¹University of Toronto - St. George Campus, Toronto, CA, ²IRCCS Ospedale San Raffaele, Milan, IT, ³Institut Gustave Roussy, Villejuif, Cedex, FR

19:55 - 20:00 **Closing Remarks**
L. Albiges, Institut Gustave Roussy, Villejuif, Cedex, FR

18:30 - 20:00 **Type: Industry Satellite Symposium** **Toledo Auditorium - Hall 3**
Title: Merck Healthcare KGaA - Shaping the Future: Breakthroughs and challenges in mCRC
 Chair(s): Gerald Prager, AT

18:30 - 18:35 **Welcome and opening**
G. Prager¹, C. Parseghian², ¹Universitätskliniken der MedUni Wien - AKH Wien, Vienna, AT, ²MD Anderson Cancer Center, Houston, US

18:35 - 18:50 **Which treatment for which patient? Exploring selection in the RAS wt setting**
M. Scartozzi, University of Cagliari, Cagliari, IT

- 18:50 - 19:05 **Does age matter? Assessing treatment options for older and younger patients in the adjuvant and metastatic settings**
D. Papamichael, Bank of Cyprus Oncology Centre, Nicosia, CY
- 19:05 - 19:20 **Can we improve outcomes for KRAS mt and BRAF mt disease?**
C. Parseghian, MD Anderson Cancer Center, Houston, US
- 19:20 - 19:35 **Looking ahead: Exploring novel strategies with ongoing clinical trials**
G. Prager, Universitätskliniken der MedUni Wien - AKH Wien, Vienna, AT
- 19:35 - 19:55 **Time to ask your questions! Panel discussion**
G. Prager¹, M. Scartozzi², C. Parseghian³, D. Papamichael⁴, ¹Universitätskliniken der MedUni Wien - AKH Wien, Vienna, AT, ²University of Cagliari, Cagliari, IT, ³MD Anderson Cancer Center, Houston, US, ⁴Bank of Cyprus Oncology Centre, Nicosia, CY
- 19:55 - 20:00 **Meeting Close**
G. Prager¹, C. Parseghian², ¹Universitätskliniken der MedUni Wien - AKH Wien, Vienna, AT, ²MD Anderson Cancer Center, Houston, US



16.09.2024

08:30 - 10:00

Type: Mini Oral session

Barcelona Auditorium - Hall 2

Title: Mini oral session 2: Breast cancer, metastatic

Chair(s): Carmen Criscitiello, IT; Sandra Ximena Franco Millan, CO

08:30 - 08:35

347MO - The safety and efficacy of ivonescimab in combination with chemotherapy as first-line (1L) treatment for triple-negative breast cancer (TNBC)

Q. Ouyang¹, X. Wang², C. Tian¹, X. Shao², J. Huang², Z.-H. Chen², Y. Wang³, T. Sun⁴, T. Yi⁵, X. Yu⁶, Z.M. Wang⁶, B. Li⁶, Y. Xia⁶, ¹Hunan Cancer Hospital, Changsha, CN, ²Zhejiang Cancer Hospital, Hangzhou, CN, ³Affiliated Cancer Hospital of Shandong First Medical University, Jinan, CN, ⁴Liaoning Cancer Hospital & Institute, Shenyang, CN, ⁵Xiangyang Central Hospital, Xiangyang, CN, ⁶Akeso Biopharma Inc., Zhongshan, CN

08:35 - 08:40

348MO - A phase Ib/II study to assess the safety and efficacy of PM8002/BNT327 in combination with nab-paclitaxel for first-line treatment of locally advanced or metastatic triple-negative breast cancer

J. Wu¹, J. Zhang², Z. Tong³, Q. Zhang⁴, Y. Wang⁵, Q. Cheng⁶, X. Chen⁷, Z. Li⁸, Y. Yin⁹, Y. Du², Y. Meng², ¹Fudan University Cancer Institute, Shanghai, CN, ²Fudan University Shanghai Cancer Center, Shanghai, CN, ³TMUCIH - Tianjin Medical University Cancer Institute and Hospital, Tianjin, CN, ⁴Harbin Medical University Cancer Hospital, Harbin, CN, ⁵Shandong Cancer Hospital, Shandong University, Jinan, CN, ⁶The First Affiliated Hospital of Chongqing Medical University, Chongqing, CN, ⁷Yibin Second People's Hospital, Yibin, CN, ⁸Jiangxi Medical College of Nanchang University - Donghu Campus, Nanchang, CN, ⁹Jiangsu Province Hospital/The First Affiliated Hospital of Nanjing Medical University, Nanjing, CN

08:40 - 08:45

349MO - Results from a phase Ia/Ib Study of ESG401, a novel Trop2 antibody-drug conjugate, in patients with different subtypes of metastatic breast cancer

E. Ma¹, F. Qiu², Z. Tong³, J. Wang⁴, Y. Shi³, Y. Zhang⁵, G. Yu⁶, H. Shi⁷, X. Wu⁸, A. Liu⁹, Y. Zhang¹⁰, H. Wang¹¹, Y. Cheng¹², H. Yang¹³, H. Li¹⁴, J. Chang¹⁵, X. Xing¹⁶, ¹Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, Beijing, CN, ²The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang, CN, ³TMUCIH - Tianjin Medical University Cancer Institute and Hospital, Tianjin, CN, ⁴Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN, ⁵The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, CN, ⁶WEIFANG PEOPLE'S HOSPITAL, Weifang, CN, ⁷First Affiliated Hospital of Gannan Medical university, Ganzhou, CN, ⁸Hubei Cancer Hospital, wuhan, CN, ⁹The Second Affiliated Hospital of Nanchang University, Nanchang, CN, ¹⁰Beijing Hospital, Beijing, CN, ¹¹Nanchang People's Hospital Affiliated of Nanchang Medical College, Nanchang, CN, ¹²Jilin Cancer Hospital, Changchun, CN, ¹³Affiliated Hospital of Hebei University, Baoding, CN, ¹⁴Peking University Cancer Hospital and Institute, Beijing, CN, ¹⁵THE AFFILIATED HOSPITAL OF GUIZHOU MEDICAL UNIVERSITY, guizhou, CN, ¹⁶Shanghai Escugen Biotechnology Co., Ltd, Shanghai, CN

08:45 - 09:00

Invited Discussant 347MO, 348MO and 349MO

C. Criscitiello, IEO - Istituto Europeo di Oncologia IRCCS, Milan, IT



09:00 - 09:20

LBA23 - ABIGAIL: Randomized phase II study of abemaciclib plus endocrine therapy (ET) with or without a short course of induction paclitaxel in patients (pts) with previously untreated HR-positive/HER2-negative advanced breast cancer (HR⁺/HER2⁻ ABC) with aggressive disease criteria

J. De La Haba Rodriguez¹, J. Cortés², S. Di Cosimo³, I. Blancas López-Barajas⁴, S.P. Cortez Castedo⁵, A. López⁶, E. López-Miranda⁷, H. Pla Juher⁸, C. Albacar Miro⁹, J. Ponce¹⁰, V. Carañana Ballerini¹¹, L. Paris Bouzas¹², M. Valero Arbizu¹³, M. Ruiz Borrego¹⁴, V. Iranzo¹⁵, A. Garrido¹⁶, D. Alcalá-López¹⁶, L. Mina¹⁷, J.J. Garcia Mosquera¹⁸, A. Llombart Cussac¹¹, ¹Hospital Universitario Reina Sofía, Cordoba, ES, ²INTERNATIONAL BREAST CANCER CENTER, IBCC, Barcelona, ES, ³Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ⁴Hospital Clinico San Cecilio, Granada, ES, ⁵Complejo Hospitalario Ruber Juan Bravo, Madrid, ES, ⁶Complejo Asistencial Universitario de León - Hospital de León, León, ES, ⁷Hospital Universitario Ramon y Cajal, Madrid, ES, ⁸ICO Girona - Institut Català d'Oncologia Girona, Girona, ES, ⁹Hospital Universitari Sant Joan de Reus, Reus, ES, ¹⁰Hospital General Universitario Dr. Balmis, Alicante, ES, ¹¹Hospital Arnau de Vilanova, Valencia, ES, ¹²CHUAC - Complejo Hospitalario Universitario A Coruña, A Coruña, ES, ¹³Hospital Quironsalud Sagrado Corazón, Seville, ES, ¹⁴Hospital Universitario Virgen del Rocío, Seville, ES, ¹⁵CHGUV - Consorcio Hospital General Universitario de Valencia, Valencia, ES, ¹⁶MEDSIR - Medica Scientia Innovation Research, Barcelona, ES, ¹⁷MedSIR - Medica Scientia Innovation Research, Barcelona, ES, ¹⁸IOR - Instituto Oncológico Dr. Rosell, Barcelona, ES

09:20 - 09:25

320MO - Tibremciclib (BPI-16350) plus fulvestrant in patients with HR⁺/HER2⁻ advanced breast cancer after progressing on endocrine therapy: A randomized, multicenter, double-blind, phase III study

X. Hu¹, Z. Tao¹, S. Wang², J. Zhang¹, Q. Zheng², Y. Wang³, L. Cai⁴, H. Xu⁵, X. Xu⁶, X. Kong⁷, S. Ding⁸, C. Hao⁹, H. Wang¹⁰, H. Zong¹¹, X. Jin¹², X. Wang¹³, Y. Li¹⁴, X. Yang¹⁵, L. Ding¹⁶, P. Li¹⁶, ¹Fudan University Shanghai Cancer Center, Shanghai, CN, ²Sun Yat-sen University Cancer Center, Guangzhou, CN, ³Shandong Cancer Hospital, Jinan, CN, ⁴Harbin Medical University Cancer Hospital, Harbin, CN, ⁵Weihai Municipal Hospital, Weihai, CN, ⁶Yichang Central People's Hospital, Yichang, CN, ⁷Xingtai People's Hospital, Xingtai, CN, ⁸The Central Hospital of Yongzhou, Yongzhou, CN, ⁹Tianjin Medical University Cancer Institute and Hospital, Tianjin, CN, ¹⁰Sichuan Cancer Hospital, Chengdu, CN, ¹¹The First Affiliated Hospital of Zhengzhou University, Zhengzhou, CN, ¹²The First Affiliated Hospital of Bengbu Medical College, Bengbu, CN, ¹³The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, CN, ¹⁴The First Affiliated Hospital of Guangxi Medical University, Nanning, CN, ¹⁵The First Affiliated Hospital of Nanyang Medical College, Nanyang, CN, ¹⁶Betta Pharmaceuticals Co., Ltd., Hangzhou, CN



09:25 - 09:30

350MO - Omission of chemotherapy and addition of the CDK4/6 inhibitor ribociclib in HER2-positive and hormone-receptor positive metastatic breast cancer – Second interim efficacy analysis of the randomized phase III DETECT V trial

W. Janni¹, T. Fehm², V. Mueller³, A. De Gregorio⁴, T. Decker⁵, A. Hartkopf⁶, M. Just⁷, J. Sagasser⁸, M. Schmidt⁹, P. Wimberger¹⁰, T. Engler⁶, M. Banys- Paluchowski¹¹, P.A. Fasching¹², B. Rack¹, A. Schneeweiss¹³, J.-U. Blohmer¹⁴, J. Huober¹⁵, K. Pantel¹⁶, T. Friedl¹, F. Schochter¹⁷, ¹Ulm University Hospital, Ulm, DE, ²UKD - Universitätsklinikum Düsseldorf, Düsseldorf, DE, ³UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE, ⁴SLK Kliniken, Heilbronn, DE, ⁵Onkologie Hamatologie Ravensburg, Ravensburg, DE, ⁶University Hospital of Tübingen, Tuebingen, DE, ⁷Onkologische Schwerpunktpraxis, Bielefeld, DE, ⁸University Hospital Augsburg, Augsburg, DE, ⁹Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, DE, ¹⁰Universitaetsklinikum Carl Gustav Carus Dresden, Dresden, DE, ¹¹UKSH - Universitätsklinikum Schleswig-Holstein - Campus Lübeck, Lübeck, DE, ¹²University Hospital Erlangen, Erlangen, DE, ¹³German Cancer Research Center - National Center for Tumor Diseases (NCT), Heidelberg, DE, ¹⁴Charité – Universitätsmedizin Berlin, Berlin, DE, ¹⁵Kantonsspital St. Gallen, St. Gallen, CH, ¹⁶University Medical Center Hamburg-Eppendorf, Hamburg, DE, ¹⁷Universitätsklinikum Ulm, Ulm, DE

09:30 - 09:45

Invited Discussant LBA23, 320MO and 350MO

S.X. Franco Millan, CTIC Centro de Tratamiento e Investigacion Sobre Cancer, Bogota, CO

08:30 - 09:45

Type: Multidisciplinary session

Madrid Auditorium - Hall 2

Title: Improving outcome in long-term survivors with metastatic NSCLC

Chair(s): Silvia Novello, IT; Adrian Sacher, CA

08:30 - 08:35

Presentation of case/condition

M. Gemelli, IRCCS MultiMedica, Milan, IT

08:35 - 08:55

Radionecrosis

L. Hendriks, Maastricht University Medical Center (MUMC), Maastricht, NL

08:55 - 09:15

Consolidation in oligo-persistent

M. Guckenberger, USZ - University Hospital Zürich, Zurich, CH

09:15 - 09:35

Quality of life

S. Novello, Università Degli Studi Di Torino - Orbassano, Orbassano, IT

09:35 - 09:45

Discussion



08:30 - 10:00	Type: Proffered Paper session Title: Proffered Paper session 2: GU, non-prostate Chair(s): Shilpa Gupta, US; Maria De Santis, DE	Sevilla Auditorium - Hall 2
---------------	--	-----------------------------

08:30 - 08:40	19630 - JCOG1019: An open-label, non-inferiority, randomised phase III study comparing the effectiveness of watchful waiting (WW) and intravesical Bacillus Calmette-Guérin (BCG) in patients (Pts) with high-grade pT1 (HGT1) bladder cancer with pT0 on the second transurethral resection (TUR) specimen <u>H. Kitamura</u>¹, J. Mizusawa², T. Shibata², K. Sasaki², K. Hashine³, K. Fujimoto⁴, K. Hashimoto⁵, T. Kobayashi⁶, S. Narita⁷, T. Kimura⁸, M. Sugimoto⁹, Y. Matsui¹⁰, S. Hatakeyama¹¹, M. Eto¹², H. Nishiyama¹³, ¹University of Toyama, Toyama, JP, ²National Cancer Center Hospital, Tokyo, JP, ³NHO Shikoku Cancer Center, Matsuyama, JP, ⁴Nara Medical University, Nara, JP, ⁵Sapporo Medical University School of Medicine, Sapporo, JP, ⁶Kyoto University Graduate School of Medicine, Kyoto, JP, ⁷Akita University Hospital, Akita, JP, ⁸Jikei University School of Medicine, Tokyo, JP, ⁹Kagawa University Faculty of Medicine/Graduate School of Medicine, Miki, JP, ¹⁰NCCH - National Cancer Center Hospital-Tsukiji Campus, Chuo-ku, JP, ¹¹Hirosaki University Graduate School of Medicine, Hirosaki, JP, ¹²Kyushu University - Graduate School of Medical Sciences - Faculty of Medical Sciences, Fukuoka, JP, ¹³University of Tsukuba, Tsukuba, JP	
08:40 - 08:50	19600 - Identification of bladder cancer patients that could benefit from early post-cystectomy immunotherapy based on serial circulating tumour DNA (ctDNA) testing: Preliminary results from the TOMBOLA trial <u>J. Bjerggaard Jensen</u>¹, K. Birkenkamp-Demtröder¹, I. Nordentoft¹, R.V. Milling¹, S.K. Körner¹, S.B. Brandt¹, M. Knudsen¹, G.W. Lam², L. Dohn², K. Fabrin³, A. Carus³, A. Petersen³, U.N. Joensen⁴, H. Pappot⁴, P.S. Holt⁵, N.V. Jensen⁵, M. Agerbæk⁶, L. Dyrskjot¹, ¹Aarhus University Hospital, Aarhus N, DK, ²Herlev and Gentofte Hospital, Herlev, DK, ³Aalborg University Hospital, Aalborg, DK, ⁴Rigshospitalet, Copenhagen, DK, ⁵OUH - Odense University Hospital, Odense, DK, ⁶Aarhus University Hospital, Aarhus, DK	
08:50 - 09:00	LBA84 - TAR-200 plus cetrelimab (CET) or CET alone as neoadjuvant therapy in patients (pts) with muscle-invasive bladder cancer (MIBC) who are ineligible for or refuse neoadjuvant cisplatin-based chemotherapy (NAC): Interim analysis of SunRISe-4 (SR-4) <u>A. Necchi</u>¹, F. Guerrero-Ramos², P.L. Crispen³, B. Herrera Imbroda⁴, R. Garje⁵, T. Powles⁶, C.C. Peyton⁷, B. Pradere⁸, J.H. Ku⁹, N. Shore¹⁰, M. Boegemann¹¹, M. Preston¹², E. Xylinas¹³, C. Gong¹⁴, S. Najmi¹⁵, M. Hasan¹⁵, H. Stitou¹⁶, S. Bhanvadia¹⁵, H. Sweiti¹⁵, S. Psutka¹⁷, ¹IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, IT, ²University Hospital 12 de Octubre, Madrid, ES, ³University of Florida, Gainesville, US, ⁴Hospital Universitario Virgen de la Victoria, Malaga, ES, ⁵Miami Cancer Institute, Miami, US, ⁶Barts Cancer Centre; The Royal Free London NHS Foundation Trust, London, GB, ⁷University of Alabama at Birmingham, Birmingham, US, ⁸UROSUD, La Croix Du Sud Hospital, Tours, FR, ⁹Seoul National University Hospital, Seoul, KR, ¹⁰Carolina Urologic Research Center, Myrtle Beach, US, ¹¹Münster University Hospital, Muenster, DE, ¹²Brigham & Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, US, ¹³Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris, Université de Paris Cité, Paris, FR, ¹⁴Janssen Research & Development, Raritan, US, ¹⁵Janssen Research & Development, Spring House, US, ¹⁶Janssen-Cilag, Issy-les-Moulineaux, Cedex, FR, ¹⁷University of Washington, Fred Hutchinson Cancer Center, Seattle, US	



- 09:00 - 09:10 **Invited Discussant 19630, 19600 and LBA84**
B. Schmidt, University of Utah Health - Huntsman Cancer Institute, Salt Lake City, US
- 09:10 - 09:20 **Q&A**
- 09:20 - 09:30 **19610 - Nivolumab plus chemoradiotherapy in patients with non-metastatic muscle-invasive bladder cancer (nmMIBC), not undergoing cystectomy: A phase II, randomized study by the Hellenic GU Cancer Group**
A. Kougioumtzopoulou¹, K. Koutsoukos², R. Zakopoulou¹, K. Tzannis³, A. Kyriazoglou¹, A. Damatopoulou⁴, M. Lontos⁵, M. Pispirigkou⁶, K. Ntoumas⁷, K. Stravodimos⁸, D. Mitropoulos⁸, A. Dellis⁹, A. Papatsoris¹⁰, M. Chrisofos¹¹, D. Kardamakis⁶, A. Zygianni¹², Z. Liakouli⁴, G. Pissakas⁴, A. Bamias¹³, V. Kouloulis¹⁴, ¹Attikon University Hospital, Haidari, GR, ²Metropolitan Hospital, Athens, GR, ³2nd Propaedeutic Department of Internal Medicine, Athens, GR, ⁴General Hospital of Athens Alexandra, Athens, Greece, Athens, GR, ⁵Alexandra Hospital, Athens, GR, ⁶University Hospital Patras, Patras, GR, ⁷General Hospital of Athens G.N.A. G. Gennimatas, Athens, GR, ⁸National & Kapodistrian University of Athens, Laiko Hospital, Athens, GR, ⁹School of Medicine, Aretaieion Hospital, National and Kapodistrian University of Athens, Athens, Greece, Athens, GR, ¹⁰School of Medicine, Sismanoglio Hospital, National and Kapodistrian University of Athens, Athens, GR, ¹¹Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens,, Athens, GR, ¹²1st Department of Radiology, Medical School, Aretaieion Hospital, National and Kapodistrian University of Athens, Athens, GR, ¹³National & Kapodistrian University of Athens, University Hospital Attikon, Athens, GR, ¹⁴Radiotherapy Unit, National and Kapodistrian University of Athens, Attikon University Hospital, School of Medicine, Athens, Greece, Athens, GR
- 09:30 - 09:40 **19620 - Health-related quality of life from the CheckMate 901 trial of nivolumab as first-line therapy for unresectable or metastatic urothelial carcinoma**
J. Bedke¹, W. Liao², L. Shi², S. Blum³, M. Patel³, T. Powles⁴, ¹Eberhard Karls University Tübingen, Tübingen, DE, ²Evidera, Bethesda, US, ³Bristol Myers Squibb, Princeton, US, ⁴Barts Cancer Institute, Queen Mary University of London, London, GB
- 09:40 - 09:50 **Invited Discussant 19610 and 19620**
S. Gupta, Taussig Cancer Center-Cleveland Clinic, Cleveland, US
- 09:50 - 10:00 **Q&A**



08:30 - 10:00	Type: Mini Oral session Title: Mini oral session: GI tumours, upper Chair(s): Radka Obermannova, CZ; Arndt Vogel, DE; James Harding, US	Bilbao Auditorium - Hall 2
08:30 - 08:35	LBA60 - Phase III study of SHR-1701 versus placebo in combination with chemo as first-line (1L) therapy for HER2-negative gastric/gastroesophageal junction adenocarcinoma (G/GEJA) Z. Peng¹, J. Wang², Y. Zhang³, H. Li⁴, Q. Zhao⁵, X. Zhu⁶, S. Wei⁷, Y. Cheng⁸, W. Yang⁹, J. Yao¹⁰, M. Zhang¹¹, L. Xie¹², X. Zhang¹³, P. Zhao¹⁴, C. Hu¹⁵, J. Zhang¹⁶, Z. Wang¹⁷, W. Wang¹⁷, H. Han¹⁷, L. Shen¹, ¹Peking University Cancer Hospital & Institute, Beijing, CN, ²Henan Cancer Hospital, Zhengzhou, CN, ³Harbin Medical University Cancer Hospital, Harbin, CN, ⁴Tianjin Medical University Cancer Institution & Hospital, Tianjin, CN, ⁵The Fourth Hospital of Hebei Medical University, Shijiazhuang, CN, ⁶Fudan University Shanghai Cancer Center, Shanghai, CN, ⁷Hubei Cancer Hospital, Wuhan, CN, ⁸Jilin Cancer Hospital, Changchun, CN, ⁹Shanxi Cancer Hospital, Taiyuan, CN, ¹⁰The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, CN, ¹¹The Second Hospital of Anhui medical university, Hefei, CN, ¹²Yunnan Cancer Hospital & Third Affiliated Hospital of Kunming Medical University, Kunming, CN, ¹³North Jiangsu People's Hospital, Yangzhou, CN, ¹⁴Sichuan Cancer Hospital, Chengdu, CN, ¹⁵Anhui Provincial Hospital, Hefei, CN, ¹⁶Liaoning Cancer Hospital and Institute, Shenyang, CN, ¹⁷Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, CN	
08:35 - 08:40	1402MO - An international study evaluating pathological response to guide adjuvant FLOT chemotherapy in gastroesophageal cancer D. Liu¹, K. Hall¹, D. Wong², M. Lee³, C. Duong¹, T. Bright⁴, A. Aly², D. Watson⁴, ¹Peter MacCallum Cancer Center, Melbourne, AU, ²Austin Health - Austin Hospital, Heidelberg, AU, ³Eastern Health Clinical School - Monash University, Box Hill, AU, ⁴FMC - Flinders Medical Centre, Bedford Park, AU	
08:40 - 08:55	Invited Discussant LBA60 and 1402MO <u>R. Obermannova</u>, Masaryk Memorial Cancer Institute, Brno, CZ	
08:55 - 09:00	LBA63 - A randomized phase I/II study of second line treatment with liposomal irinotecan and S-1 versus liposomal irinotecan and 5-fluorouracil in patients with metastatic pancreatic cancer following gemcitabine-based chemotherapy A. Gehrels¹, E. Pijnappel², E. Vandaalen³, S. Casalino⁴, C. Zecchetto⁵, A. Quinzii⁴, G. Prager⁶, J. De Vos-Geelen⁷, T. Macarulla Mercade⁸, D. Melisi⁴, H. Wilmink², ¹Academic Medical Center, University of Amsterdam, Amsterdam, NL, ²Amsterdam University Medical Center (UMC) - locatie Academic Medical Center (AMC), Amsterdam, NL, ³Amsterdam UMC, locatie VUmc, Amsterdam, NL, ⁴AOU Integrata di Verona - Ospedale Borgo Roma, Verona, IT, ⁵AOU Integrata Borgo Roma Verona, Verona, IT, ⁶Universitätskliniken der MedUni Wien - AKH Wien, Vienna, AT, ⁷Maastricht University Medical Center (MUMC), Maastricht, NL, ⁸Vall d'Hebron Institute of Oncology - Cellex Center, Barcelona, ES	



09:00 - 09:05

1504MO - Phase II trial of Pembrolizumab and OLApRib (POLAR) maintenance for select patients (pts) with metastatic pancreatic cancer (mPC) with (A) homologous recombination deficiency (HRD), (B) non-core HRD (ncHRD) and (C) exceptional response to platinum

W. Park¹, C. O'Connor², J. Chou³, C. Schwartz², M. Larsen⁴, A. Varghese⁵, K. Yu⁵, F. Balogun⁵, J. Yang², S. Katz⁶, D. Kelsen³, S. Umeda³, C. Bandlamudi², N. Riaz⁷, M. Berger², V. Balachandran⁸, D. Peer³, M. Capanu³, C. Iacobuzio-Donahue³, E. O'Reilly¹, ¹Memorial Sloan Kettering Cancer Center, David M. Rubenstein Center for Pancreatic Cancer Research, Weill Cornell Medical College, Parker Institute for Cancer Immunotherapy, New York, US, ²Memorial Sloan Kettering Cancer Center, New York, US, ³Memorial Sloan Kettering Cancer Center, David M. Rubenstein Center for Pancreatic Cancer Research, New York, US, ⁴Memorial Sloan Kettering Cancer Center, David M. Rubenstein Center for Pancreatic Cancer Research, New York, US, ⁵Memorial Sloan Kettering Cancer Center, David M. Rubenstein Center for Pancreatic Cancer Research, Weill Cornell Medical College, New York, US, ⁶MSKCC, New York, US, ⁷MSKCC - Memorial Sloan Kettering Cancer Center, New York, US, ⁸Memorial Sloan Kettering, David M. Rubenstein Center for Pancreatic Cancer Research, New York, US

09:05 - 09:20

Invited Discussant LBA63 and 1504MO

A. Vogel, MHH - Medizinische Hochschule Hannover, Hannover, DE

09:20 - 09:25

965MO - Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) treatment for unresectable hepatocellular carcinoma (uHCC): Expanded analyses from CheckMate 9DW

T. Decaens¹, T. Yau², M. Kudo³, B. Sangro⁴, S. Qin⁵, L. Da Fonseca⁶, H. Karachiwala⁷, J.-W. Park⁸, E. Gane⁹, M. Pinter¹⁰, D. Tai¹¹, A. Santoro¹², G. Pizarro¹³, C.-F. Chiu¹⁴, M. Schenker¹⁵, A.R. He¹⁶, Q. Wang¹⁷, T. Ogata¹⁷, J. Hreiki¹⁷, P. Galle¹⁸, ¹Univ. Grenoble Alpes, CHU Grenoble Alpes, Institute for Advanced Biosciences, CNRS UMR 5309-INSERM U1209, Grenoble, FR, ²Queen Mary Hospital, Pok Fu Lam, Hong Kong, HK, ³Kindai University Hospital, Osaka, JP, ⁴Clinica Universidad de Navarra and CIBEREHD, Pamplona, ES, ⁵The 81st Hospital of PLA, Nanjing, CN, ⁶Instituto do Cancer do Estado de São Paulo, ICESP, São Paulo, BR, ⁷Cross Cancer Institute, Edmonton, CA, ⁸National Cancer Center, Goyang, KR, ⁹Auckland City Hospital, Auckland, NZ, ¹⁰Medical University of Vienna, Vienna, AT, ¹¹National Cancer Centre, Singapore, SG, ¹²Humanitas University, Pieve Emanuele, and IRCCS Humanitas Research Hospital, Rozzano, Milan, IT, ¹³Bradford Hill Centro de Investigacion Clinica, Recoleta, CL, ¹⁴China Medical University Hospital, Taichung City, TW, ¹⁵Centrul de Oncologie Sf. Nectarie, Craiova, RO, ¹⁶MedStar Georgetown University, Washington, DC, US, ¹⁷Bristol Myers Squibb, Princeton, US, ¹⁸University Medical Center, Mainz, DE



09:25 - 09:30

947MO - Five-year overall survival (OS) and OS by tumour response measures from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)

L. Rimassa¹, S. Chan², B. Sangro³, G. Lau⁴, M. Kudo⁵, V. Breder⁶, M. Varela⁷, O. Crysler⁸, M. Bouattour⁹, V.T. Dao¹⁰, A. Faccio¹¹, J. Furuse¹², L.-B. Jeng¹³, Y.-K. Kang¹⁴, R.K. Kelley¹⁵, M. Paskow¹⁶, M. Makowsky¹⁶, D. Ran¹⁶, A. Negro¹⁶, G. Abou-Alfa¹⁷, ¹Humanitas University, Pieve Emanuele and Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, IT, ²Sir Yue-Kong Pao Center for Cancer, The Chinese University of Hong Kong, Hong Kong SAR, CN, ³Clínica Universidad de Navarra and CIBEREHD, Pamplona, ES, ⁴Humanity and Health Medical Group, Hong Kong SAR, CN, ⁵Kindai University Faculty of Medicine, Osaka, JP, ⁶N. N. Blokhin National Medical Research Center of Oncology, Moscow, RU, ⁷Hospital Universitario Central de Asturias, IUOPA, ISPA, FINBA, Universidad de Oviedo, Oviedo, ES, ⁸University of Michigan, Ann Arbor, US, ⁹Liver Cancer Unit, Paris, FR, ¹⁰Department of Optimal Therapy, National Cancer Hospital, Hanoi, VN, ¹¹CEON – Centro Especializado em Oncologia, Ribeirao Preto, BR, ¹²Kanagawa Cancer Center, Yokohama, JP, ¹³China Medical University and Hospital, Taichung, TW, ¹⁴University of Ulsan College of Medicine, Asan Medical Center, Seoul, KR, ¹⁵University of California, San Francisco, US, ¹⁶AstraZeneca, Gaithersburg, US, ¹⁷Memorial Sloan Kettering Cancer Center and Weill Medical College, Cornell University, New York, US

09:30 - 09:45

Invited Discussant 965MO and 947MO

J. Harding, Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US

08:30 - 10:00

Type: Educational session

Granada Auditorium - Hall 6

Title: Protein degradation as a novel approach for cancer therapy

Chair(s): Sophie Postel-Vinay, FR; Alex A. Adjei, US

08:30 - 08:55

Targeted protein degradation: Pharmacological aspects

J. Rodon, The University of Texas MD Anderson Cancer Center - Main Building, Houston, US

08:55 - 09:20

Designing protein degraders for cancer treatment

Z. Rankovic, ICR - The Institute of Cancer Research - North Site, Sutton, GB

09:20 - 09:45

Degraders and molecular glues: Where are we in the clinic now?

S. Postel-Vinay, Institut Gustave Roussy, Villejuif, FR

09:45 - 10:00

Q&A and discussion

08:30 - 09:45

Type: Multidisciplinary session

Burgos Auditorium - Hall 5

Title: Survivors of advanced melanoma: Management and support

Chair(s): Karijn Suijkerbuijk, NL; Mora Guardamagna, FR

08:30 - 08:35

Case presentation

M. Guardamagna, Institut Gustave Roussy, Villejuif, Cedex, FR

08:35 - 08:55 **Managing long-term treatment sequelae**
C. Nardin, CHRU Besancon - Hopital Jean Minjoz, Besancon, FR

08:55 - 09:15 **Psychological support and resilience**
M. Van Der Lee, Helen Dowling Institute, Bilthoven, NL

09:15 - 09:35 **Neuro-cognitive remediation in case of permanent neurological deficits**
A. Rogiers, UZ Brussel - Universitair Ziekenhuis Brussel, Jette, BE

09:35 - 09:45 **Discussion**

08:30 - 10:00 **Type: Mini Oral session** **Valencia Auditorium - Hall 5**
Title: Mini oral session: Basic science & Translational research
 Chair(s): Angela George, GB; Göran Jönsson, SE; Daniela Thommen, NL

08:30 - 08:35 **69MO - Organ-specific performance of a multi-analyte, multi-cancer early detection (MCED) blood test in a prospectively-collected cohort**
C. Douville¹, V. Gainullin², K. Arvai², M. Gray², M. Kumar², M. Manesse², X. Chen², P. Uren², G. Cerqueira², G. Silvestri³, D. Chesla⁴, R. Given⁵, A. Mazloom², J. Garces², T. Beer², F. Diehl²,
¹Johns Hopkins University, Baltimore, US, ²Exact Sciences Corporation, Madison, US, ³Medical University of South Carolina, Charleston, US, ⁴Corewell Health, Grand Rapids, US, ⁵Urology of Virginia, Virginia Beach, US

08:35 - 08:40 **70MO - Cell-free DNA indicates potential preclinical detectability of cancer signals up to 30 months prior to diagnosis**
C. Vachon¹, R. Jiang², J. Youngren², E. Fung², E. Hubbell², O. Venn², X. Hou², K. Giridhar¹, F. Couch¹, B. Rybicki³, R. Korn⁴, Z. Alhilli⁵, D. Kurbegov⁶, ¹Mayo Clinic - Rochester, Rochester, US, ²GRAIL, LLC, Menlo Park, US, ³Henry Ford Health & Michigan State University, Detroit, US, ⁴Southwest Medical Imaging, Scottsdale, US, ⁵Cleveland Clinic, Cleveland, US, ⁶Sarah Cannon Research Institute, Nashville, US

08:40 - 08:45 **1171MO - AI-derived diagnostic criteria for early lung cancer screening using primary care health records**
A. Houston, S. Williams, W. Ricketts, C. Gutteridge, J. Conibear, Barts Health NHS Trust, London, GB

08:45 - 09:00 **Invited Discussant 69MO, 70MO and 1171MO**
A. George, The Institute of Cancer Research and Royal Marsden Hospital, Sutton, GB



09:00 - 09:05

71MO - Clinical and biomarker analyses of intratumoral CD40 agonist sotigalimab in combination with pembrolizumab in metastatic melanoma: A phase I/II trial

S.-E. Bentebibel¹, D. Mcgrail², R. Abdel Wahab¹, V. Kochat¹, E. Arslan¹, B. Pazdrak¹, N.H. Tahon¹, R. Amaria¹, I. Glitza¹, S. Patel¹, M.K.K. Wong¹, H. Tawbi¹, J. Mcquade¹, M. Davies¹, C. Bernatchez¹, J. Burks³, K. Rai¹, S. Ekmekcioglu¹, L. Lizée¹, A. Diab¹, ¹The University of Texas MD Anderson Cancer Center, Houston, US, ²University of Texas MD Anderson Cancer Center, Houston, US, ³The University of Texas MD Anderson Cancer, Houston, Texas, USA., Houston, US

09:05 - 09:10

72MO - Concurrent BRAF targeted therapy (TT) with dabrafenib and trametinib and anti-PD-1 agent pembrolizumab (PD1) increased B cell signalling and inflammatory pathways more effectively than when given sequentially or with anti-PD-1 alone

J. Braden¹, J. Conway¹, A. Ramanathan¹, L. Smith¹, A. Menzies², M. Carlino³, G. Au-Yeung⁴, R. Rawson⁵, K. Shannon⁶, T. Pennington⁶, S. Ch'Ng⁶, R. Saw⁷, A. Spillane⁶, D. Gyokri⁴, J. Howle⁸, J. Wilmott¹, R. Scolyer⁶, G. Long⁹, I. Pires Da Silva¹⁰, ¹The University of Sydney, Camperdown, AU, ²Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, AU, ³Melanoma Institute Australia and Westmead Hospital, Sydney, AU, ⁴Peter MacCallum Cancer Centre, Melbourne, AU, ⁵Melanoma Institute Australia, Sydney, AU, ⁶Melanoma Institute Australia, Wollstonecraft, AU, ⁷Royal Prince Alfred Hospital, Camperdown, AU, ⁸Crown Princess Mary Cancer Centre Westmead, Westmead, AU, ⁹Melanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, AU, ¹⁰Melanoma Institute Australia, The University of Sydney, Sydney, AU

09:10 - 09:15

73MO - Longitudinal probing of combinatorial immunotherapy (anti-VEGF/anti-PD1) response in advanced nasopharyngeal carcinoma, at single cell resolution

S.-M. Chia¹, N. Shirgaonkar¹, Y.C. Lim², J.K. Tay³, W.Q. Chong⁴, J.L. Low⁴, K. Sooi⁵, R. Soo⁵, H.L. Teo⁶, J. Samol⁶, G. Goh², L.R. Kong², A. Gopinathan⁷, D. Eu³, R. Tsang³, K.-S. Loh³, B.C. Tai⁸, H.C. Toh⁹, B.-C. Goh⁴, R. Dasgupta¹, ¹A*STAR - Genome Institute of Singapore (GIS), Singapore, SG, ²Cancer Science Institute (CSI) - National University of Singapore (NUS), Singapore, SG, ³NUS - National University of Singapore, Singapore, SG, ⁴National University Cancer Institute Singapore, Singapore, SG, ⁵NCIS - National University Cancer Institute Singapore, Singapore, SG, ⁶National Healthcare Group - Tan Tock Seng Hospital, Singapore, SG, ⁷NUH - National University Hospital (S) Pte. Ltd., Singapore, SG, ⁸National University of Singapore (NUS), Singapore, SG, ⁹NCCS - National Cancer Centre Singapore, Singapore, SG

09:15 - 09:30

Invited Discussant 71MO, 72MO and 73MO

G. Jönsson, Lund University, Lund, SE

- 09:30 - 09:35 **74MO - Impact of MTAP loss on prognosis and efficacy of immune check point inhibitors across advanced solid tumors: SCRUM-Japan MONSTAR-SCREEN-1**
K. Seguchi¹, T. Fujisawa¹, S. Ikeda², Y. Oyama³, S. Kadowaki⁴, C. Morizane⁵, M. Ueno⁶, E. Oki⁷, W. Yamagami⁸, S. Yuki⁹, N. Nonomura¹⁰, H. Iwata⁴, H. Watari⁹, S. Okano¹, K. Namikawa¹¹, H. Bando¹, T. Yoshino¹, Y. Nakamura¹, ¹National Cancer Center Hospital East, Kashiwa, JP, ²Tokyo Medical and Dental University, Tokyo, JP, ³Kameda Medical Center, Kamogawa, JP, ⁴Aichi Cancer Center Hospital, Nagoya, JP, ⁵NCCH - National Cancer Center Hospital-Tsukiji Campus, Chuo-ku, JP, ⁶Kanagawa Cancer Center, Yokohama, JP, ⁷Kyushu University - Graduate School of Medical Sciences - Faculty of Medical Sciences, Fukuoka, JP, ⁸Keio University School of Medicine, Shinjuku-ku, JP, ⁹Hokkaido University Hospital, Sapporo, JP, ¹⁰Graduate School of Medicine / Faculty of Medicine, Osaka University, Suita, JP, ¹¹NCCH - National Cancer Center Hospital, Chuo-ku, JP
- 09:35 - 09:40 **75MO - Atlas of tertiary lymphoid structures in solid tumors: Genomic features and prediction of response to immunotherapy**
A. Italiano¹, J. Trent², G. Sledge³, J. Xiu³, E. Antonarakis⁴, G. D'Amato⁵, D. Hsieh⁶, A. Elliott⁷, ¹Institute Bergonié - Centre Régional de Lutte Contre le Cancer (CLCC), Bordeaux, FR, ²Sylvester Comprehensive Cancer Center, Miami, US, ³Caris Life Sciences, Phoenix, US, ⁴Masonic Cancer Center - University of Minnesota, Minneapolis, US, ⁵Sylvester Comprehensive Cancer Center - University of Miami, Miami, US, ⁶UCI - University Of California Irvine - Health Manchester Pavilion, Orange, US, ⁷Caris Life Sciences - Headquarters, Irving, US
- 09:40 - 09:55 **Invited Discussant 74MO and 75MO**
D. Thommen, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL

08:30 - 10:00 **Type: Special session** **Toledo Auditorium - Hall 3**
Title: ESMO-SIOG: Working together in the era of personalized care for older adults with cancer
 Chair(s): Ravindran Kanesvaran, SG; Rabia Boulahssass, FR

- 08:30 - 08:31 **Introduction**
R. Kanesvaran, NCCS - National Cancer Centre Singapore, Singapore, SG
- 08:31 - 08:31 **MDT: Breast cancer - Case of an older adult with metastatic breast cancer**
- 08:31 - 08:46 **Case study and principles of GA (Geriatric Assessment)**
E. Brain, Hopital René Huguenin - Institut Curie, Saint-Cloud, FR
- 08:46 - 08:56 **Geriatrician perspective**
R. Boulahssass, Centre Anticancer Antoine Lacassagne, Nice, FR
- 08:56 - 09:11 **Medical oncologist perspective**
L. Biganzoli, Nuovo Ospedale di Prato Santo Stefano - Azienda Usl Toscana Centro, Prato, IT

09:11 - 09:15	Q&A and discussion	
09:15 - 09:15	MDT: Prostate cancer - Case of an older adult with metastatic prostate cancer	
09:15 - 09:30	Case study and principles of GA <u>R. Kanesvaran</u> , NCCS - National Cancer Centre Singapore, Singapore, SG	
09:30 - 09:45	Urologist perspective <u>A. Merseburger</u> , UKSH - Universitätsklinikum Schleswig-Holstein - Campus Lübeck, Lübeck, DE	
09:45 - 09:55	Geriatrician perspective <u>R. Boulahssass</u> , Centre Anticancer Antoine Lacassagne, Nice, FR	
09:55 - 09:59	Q&A and discussion	
09:59 - 10:00	Summary and close <u>E. Brain</u> , Hopital René Huguenin - Institut Curie, Saint-Cloud, FR	
08:30 - 10:00	Type: Educational session Title: ESMO-CDDF – Regulatory challenges in clinical cancer drug development Chair(s): Teresa Amaral, DE; Ruth Plummer, GB	Zaragoza Auditorium - CC5
08:30 - 08:50	Specifics of CHMP assessment of cancer drugs <u>A. Sosa Mejia</u> , Danish Medicines Agency, Copenhagen, DK	
08:50 - 09:10	Current status and implications of the In Vitro Diagnostics regulation <u>A. Wolf</u> , EFPIA - European Federation of Pharmaceutical Industries and Associations, Brussels, BE	
09:10 - 09:30	Initiatives for a joint EU HTA assessment <u>M. Guardian</u> , Dierks + Company, Berlin, DE	
09:30 - 10:00	Q&A and discussion	
08:30 - 10:00	Type: Young Oncologists session Title: YO Forum - Finding your “X-factor”: Skills for professional development Chair(s): Elene Mariamidze, GE; Hongcheng Zhu, CN	Cartagena Auditorium - Hall 7
08:30 - 08:50	What makes you stand out? <u>E. De Azambuja</u> , Institute Jules Bordet, Brussels, BE	
08:50 - 09:10	Understanding the support you need to build your career <u>A. Lamarca</u> , Hospital Universitario Fundacion Jimenez Diaz, Madrid, ES	

09:10 - 09:30 **Do you need to be more assertive: How to benefit from opportunities in a competitive environment?**

S. Peters, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH

09:30 - 09:50 **Tips and techniques for people management at work**

C. Hardy, Lancaster University Division of Health Research, Lancaster, GB

09:50 - 10:00 **Discussion**

08:30 - 10:00	Type: EONS session Title: Rehabilitation and survivorship care Chair(s): Karin Dieperink, DK; Hazal Özdemir Koyu, TR	Ronda Auditorium - Hall 7
----------------------	--	----------------------------------

08:30 - 08:45 **Optimizing cancer survivorship care plans: Empowering long-term survivors and families beyond treatment**

C. García-Vivar, Universidad de Navarra - Campus Pamplona, Pamplona, ES

08:45 - 09:00 **A cent: A model for person-centered care in allogeneic stem cell transplantation**

J. Winterling, Karolinska Institutet, Huddinge, SE

09:00 - 09:15 **Rehabilitation in radiotherapy**

S. Faithfull, Trinity College Dublin, Dublin, IE

09:15 - 09:25 **CN48 - Pilot evaluation of RCC4Nurses to enhance nursing education and practice in survivorship care of people with advanced renal cell carcinoma in Europe**

G. Kotronoulas¹, C. Díez De Los Ríos De La Serna¹, D. Kelly², A. Drury³, W. Oldenmenger⁴, C. Papadopoulou⁵, T. Wiseman⁶, ¹University of Glasgow, Glasgow, GB, ²Cardiff University - School of Healthcare Sciences, Cardiff, GB, ³DCU - Dublin City University, Dublin, IE, ⁴Erasmus MC Cancer Institute, Rotterdam, NL, ⁵University of the West of Scotland-UWS Paisley, Paisley, GB, ⁶The Royal Marsden Hospital - NHS Foundation Trust, London, GB

09:25 - 09:35 **CN69 - The effect of an empowerment program on ruminative thoughts, fatigue and psychological resilience of cancer survivors: A randomized controlled trial**

S. Öcalan¹, S. Üzar-Özçetin², O. Dizdar³, C. Gürel⁴, ¹Hacettepe University - Faculty of Nursing, Ankara, TR, ²University College Dublin, Dublin, IE, ³Hacettepe University - Faculty of Medicine, Ankara, TR, ⁴Hacettepe University Faculty of Medicine Department of Mental Health and Diseases, Ankara, TR

09:35 - 09:45 **CN86 - Review of nursing interventions for the management of psychosocial problems in adults after hematopoietic stem cell transplantation: A systematic review**

A. Cetin Uceriz¹, G. Bagcivan², ¹Department of Nursing, Halic University, Faculty of Health Sciences; Koc University Graduate School of Health Sciences, Istanbul, TR, ²Koc University - School of Nursing, Istanbul, TR

09:45 - 10:00 **Q&A and discussion**



08:30 - 10:00 **Type: EONS Industry Satellite Symposium** **Segovia Auditorium - Hall 7**
Title: Johnson & Johnson - Safeguarding Skin Health in NSCLC with EGFR-targeted agents
 Chair(s): Helena Ullgren, SE

08:30 - 08:35 **Welcome and introduction**
H. Ullgren, Karolinska University Hospital-Solna, Solna, SE

08:35 - 08:55 **Use of EGFR targeted agents in lung cancer, now and future**
P. Garrido Lopez, Hospital Universitario Ramon y Cajal, Madrid, ES

08:55 - 09:15 **Management of skin toxicity with EGFR targeted agents – a patient's perspective**
G. Harrison, EGFR Positive UK, Croydon, GB

09:15 - 09:35 **Nursing care of patients with EGFR targeted agents: challenging side-effects**
E. Nildén, Karolinska University Hospital, Helsingborg, SE

09:35 - 09:55 **Panel discussion and Q&A**
H. Ullgren¹, A. Terry², E. Nildén³, P. Garrido Lopez⁴, ¹Karolinska University Hospital-Solna, Solna, SE, ²EGFR Positive UK, London, GB, ³Karolinska University Hospital, Helsingborg, SE, ⁴Hospital Universitario Ramon y Cajal, Madrid, ES

09:55 - 10:00 **Conclusion remarks**
H. Ullgren, Karolinska University Hospital-Solna, Solna, SE

09:00 - 09:45 **Type: Challenge your Expert** **Salamanca Auditorium - Hall 5**
Title: New first-line ovarian cancer data: How this will impact first line and relapse treatment?
 Chair(s): Nicoletta Colombo, IT

09:00 - 09:20 **Presentation by Expert**
I. Ray-Coquard, Centre Léon Bérard, Lyon, FR

09:20 - 09:45 **Discussion led by Chair**
N. Colombo, IEO - Istituto Europeo di Oncologia, Milan, IT

09:00 - 09:45 **Type: Challenge your Expert** **Pamplona Auditorium - Hall 3**
Title: How to handle challenging patient factors in the treatment of head and neck cancer
 Chair(s): Sjoukje Oosting, NL

09:00 - 09:20 **Presentation by Expert**
P. Szturcz, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH

09:20 - 09:45 **Discussion led by Chair**
S. Oosting, UMCG - University Medical Center Groningen, Groningen, NL



09:00 - 09:45	Type: Challenge your Expert Title: Implementing and disseminating guidelines in supportive and palliative care: Can technology/AI help? Chair(s): Karin Jordan, DE	Oviedo Auditorium - Hall 3
09:00 - 09:20	Presentation by Expert <u>M. Lustberg</u> , Yale University School of Medicine, New Heaven, US	
09:20 - 09:45	Discussion led by Chair <u>K. Jordan</u> , Ernst von Bergmann Klinikum Potsdam, Potsdam, DE	
10:15 - 11:45	Type: Proffered Paper session Title: Proffered paper session: Breast cancer, early stage Chair(s): Ann H. Partridge, US; Elgene Lim, AU	Barcelona Auditorium - Hall 2
10:15 - 10:25	LBA12 - eMouvoir: Randomised phase III trial evaluating the impact of a personalized and remote physical activity (PA) for breast cancer survivors (BCS). Results on the quality of life (QoL) <u>L. Vanlemmens</u> ¹ , C. Lefeuvre-Plesse ² , J. Thery ¹ , E. Bogart ¹ , E. Aymes ³ , M.-A. Brochard ⁴ , F. Le Gall ⁴ , M. Belmimoun ¹ , L. Rotsaert ¹ , H. Mocaer ¹ , J.B. Prevost ⁵ , D. Chocteau ⁶ , H. Rhliouch ⁷ , G. Lauridant Philippin ⁸ , T. Mulliez ⁹ , A. Najem ¹⁰ , A.-C. Hardy-Bessard ¹¹ , E. Lartigau ¹ , A. Anota ¹² , M.-C. Le Deley ¹ , ¹ Centre Oscar Lambret, Lille, FR, ² Centre Eugene - Marquis, Rennes, FR, ³ CHU Lille - Centre Hospitalier Régional Universitaire de Lille, Lille, FR, ⁴ Stimulab, Nantes, FR, ⁵ Centre Pierre Curie, Beuvry, FR, ⁶ Hôpital privé du Confluent, Nantes, FR, ⁷ Centre Marie Curie Arras, Arras, FR, ⁸ Cancer Centre les Dentellieres, Valenciennes, FR, ⁹ Centre Hospitalier de Dunkerque, Dunkerque, FR, ¹⁰ Centre Hospitalier Boulogne-Sur-Mer, Boulogne sur Mer, FR, ¹¹ CARIO - Centre Armoricaïn de Radiothérapie, d'Imagerie Médicale et d'Oncologie, Plérin, FR, ¹² Centre Léon Bérard, Lyon, FR	
10:25 - 10:35	2320 - Effects of a high-intensity exercise intervention on recurrence and survival: The OptiTrain breast cancer trial <u>H. Rundqvist</u> ¹ , M. Rietz ¹ , S. Mijwel ¹ , L. Lindström ² , Y. Wengström ¹ , ¹ Karolinska Institutet, Huddinge, SE, ² Karolinska Institute, Stockholm, SE	
10:35 - 10:45	Invited Discussant LBA12 and 2320 <u>J. Ligibel</u> , Dana Farber Cancer Institute, Boston, US	
10:45 - 10:55	Q&A	



10:55 - 11:05

LBA10 - Primary endpoint results of the Neo-CheckRay phase II trial evaluating stereotactic body radiation therapy (SBRT) +/- durvalumab (durva) +/- oleclumab (ole) combined with neo-adjuvant chemotherapy (NACT) for early-stage, high risk ER+/HER2- breast cancer (BC)

A. De Caluwe¹, I. Desmoulins², K. Cao³, V. Remouchamps⁴, A. Baten⁵, E. Longton⁶, K. Peignaux-Casasnovas², G. Nader-Marta⁷, L. Arecco¹, E. Agostinetti¹, P. Kristanto⁸, X. Catteau¹, D. Larsimont¹, R. Salgado⁹, C. Sotiriou¹⁰, P. Poortmans¹¹, M. Piccart¹, M. Ignatiadis¹, E. Romano³, L. Buisseret¹, ¹Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Brussels, BE, ²Centre Georges-François Leclerc (Dijon), Dijon, FR, ³Institut Curie, Paris, FR, ⁴CHU-UCL-Namur - Site Sainte-Elisabeth, Namur, BE, ⁵UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ⁶Cliniques Universitaires Saint-Luc (UCLouvain Saint-Luc), Woluwe-Saint-Lambert, BE, ⁷Dana-Farber Cancer Institute, Boston, US, ⁸ULB - Université Libre de Bruxelles - Faculté de Médecine, Brussels, BE, ⁹ZAS Hospitals, Antwerp, BE, ¹⁰Institute Jules Bordet, Brussels, BE, ¹¹AZ Sint-Augustinus - Oncologisch Centrum GZA - Iridium Kankernetwerk, Antwerpen, BE

11:05 - 11:15

LBA11 - Neoadjuvant nivolumab/relatlimab or nivolumab/ipilimumab in triple negative breast cancer with high tumor-infiltrating lymphocytes (TILs)

I. Nederlof¹, A. Rolfes¹, R. Gielen¹, G. Awada², M. Dongen³, H. Horlings¹, K. Van De Vijver⁴, C. Drukker⁵, F. Van Duijnhoven⁵, M. Lopez-Yurda⁵, I. Mandjes⁵, R. Mann¹, C. Loo¹, C. Blank³, T. Schumacher⁶, R. Salgado⁷, M. Kok³, ¹NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ²UZ Brussel - Universitair Ziekenhuis Brussel, Jette, BE, ³Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, NL, ⁴UZ Gent - Universitair Ziekenhuis Gent, Gent, BE, ⁵Netherlands Cancer Institute, Amsterdam, NL, ⁶NKI - Netherlands Cancer Institute, Amsterdam, NL, ⁷ZAS Hospitals, Antwerp, BE



11:15 - 11:25

LBA13 - Adjuvant ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in patients (Pts) with HR⁺/HER2⁺ early breast cancer (EBC): 4-year outcomes from the NATALEE trial

P.A. Fasching¹, D. Stroyakovskiy², D. Yardley³, C.-S. Huang⁴, J. Crown⁵, A. Bardia⁶, S. Chia⁷, S.-A. Im⁸, M. Martin Jimenez⁹, B. Xu¹⁰, S. Loi¹¹, C. Barrios¹², M. Untch¹³, R. Moroosse¹⁴, F. Visco¹⁵, G. Hortobagyi¹⁶, D. Slamon⁶, Y. Oviedo¹⁷, S. Waters¹⁸, S. Hurvitz¹⁹, ¹University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, DE, ²Moscow City Oncology Hospital No. 62 of Moscow Healthcare Department, Istra, RU, ³Sarah Cannon Research Institute, Nashville, US, ⁴National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei City, TW, ⁵St. Vincent's University Hospital, Dublin, IE, ⁶David Geffen School of Medicine at UCLA, Los Angeles, US, ⁷British Columbia Cancer Agency, Vancouver, CA, ⁸Cancer Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, KR, ⁹Instituto de Investigación Sanitaria Gregorio Marañón, Centro de Investigación Biomédica en Red de Cáncer, Grupo Español de Investigación en Cáncer de Mama, Universidad Complutense de Madrid, Madrid, ES, ¹⁰Chinese Academy of Medical Sciences (CAMS) & Peking Union Medical College (PUMC), Beijing, CN, ¹¹Peter MacCallum Cancer Centre, Melbourne, AU, ¹²Latin American Cooperative Oncology Group (LACOG), Porto Alegre, BR, ¹³Interdisciplinary Breast Cancer Center, Helios Klinikum Berlin-Buch, Berlin, DE, ¹⁴Orlando Health Cancer Institute, Orlando, US, ¹⁵National Breast Cancer Coalition (NBCC), Washington DC, US, ¹⁶The University of Texas MD Anderson Cancer Center, Houston, US, ¹⁷Translational Research in Oncology (TRIO), Montevideo, UY, ¹⁸Novartis Ireland Limited, Dublin, IE, ¹⁹Fred Hutchinson Cancer Center, University of Washington, Seattle, US

11:25 - 11:35

Invited Discussant LBA10, LBA11 and LBA13

E. Lim, Garvan Institute of Medical Research, Darlinghurst, AU

11:35 - 11:45

Q&A

10:15 - 11:45

Type: Mini Oral session

Madrid Auditorium - Hall 2

Title: Mini oral session: GU tumours, prostate

Chair(s): Niven Mehra, NL; Deborah Mukherji, AE; Christopher Sweeney, AU

10:15 - 10:20

1595MO - Phenotypic and genomic characterization of de novo metastatic prostate cancer: An ancillary study of the PEACE-1 phase III trial

C. Pobel¹, C. Bargain², J. Scoazec¹, E. Rouleau², G. Roubaud³, P. Ronchin⁴, S. Supiot⁵, A. Hasbini⁶, M. Silva⁷, A. Flechon⁸, B. Laguerre⁹, S. Abadie Lacourtoisie¹⁰, C. El Kouri¹¹, L. Mourey¹², T. Maurina¹³, E. Martin¹⁴, H. Ribault¹⁵, S. Foulon², K. Fizazi¹⁶, Y. Loriot¹⁶, ¹Institut Gustave Roussy, Villejuif, FR, ²Gustave Roussy - Cancer Campus, Villejuif, FR, ³Institute Bergonié, Bordeaux, FR, ⁴Centre Azuréen de Cancérologie, Mougins, FR, ⁵ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, ⁶Clinique Pasteur, Brest, FR, ⁷Centre Francois Baclesse, Caen, Cedex, FR, ⁸Centre Leon Berard, Lyon, FR, ⁹Centre Eugene - Marquis, Rennes, FR, ¹⁰Centre Paul Papin, Angers, FR, ¹¹Centre Catherine de Sienne, Nantes, FR, ¹²IUCT - Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, FR, ¹³CHRU Besancon - Hopital Jean Minjot, Besancon, FR, ¹⁴Centre Georges-François Leclerc, Dijon, FR, ¹⁵Unicancer, Paris, FR, ¹⁶Institut Gustave Roussy, Villejuif, Cedex, FR



10:20 - 10:25

LBA68 - Efficacy and safety of darolutamide plus androgen-deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the phase III ARANOTE trial

E. Saad¹, E. Vjaters², N. Shore³, D. Olmos⁴, N. Xing⁵, A.J. Gomes⁶, A.C. Mota⁷, P. Salman⁸, M. Jievaltas⁹, A. Ulys¹⁰, M. Jakubovskis¹¹, E. Kopyltsov¹², W. Han¹³, L. Nevalaita¹⁴, I. Testa¹⁵, M.-A. Le Berre¹⁶, I. Kuss¹⁷, H. Kunhiparambath¹⁸, ¹Centre Hospitalier de l'Université de Montréal, University of Montreal, Montreal, CA, ²P. Stradinš Clinical University Hospital, Riga, LV, ³Carolina Urologic Research Center and AUC Urology Specialists, Myrtle Beach, US, ⁴Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (Imas12), Madrid, ES, ⁵National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN, ⁶Liga Norte Riograndense Contra O Cancer, Natal, BR, ⁷Instituto ETICA – Clinica AMO/DASA, Salvador, BR, ⁸Oncovida Research, Santiago, CL, ⁹Lithuanian University of Health Sciences, Medical Academy, Kaunas, LT, ¹⁰National Cancer Institute, Vilnius University, Vilnius, LT, ¹¹Clinic of Urology and Oncological Urology, Riga East University Hospital, Riga, LV, ¹²Clinical Oncological Dispensary of Omsk Region, Omsk, RU, ¹³The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Hunan Cancer Center, Changsha, Hunan, CN, ¹⁴Orion Pharma, Espoo, FI, ¹⁵Bayer S.p.A., Milan, IT, ¹⁶Bayer Healthcare SAS, Lille, FR, ¹⁷Bayer AG, Berlin, DE, ¹⁸All India Institute of Medical Sciences, New Delhi, IN

10:25 - 10:30

LBA69 - Prostate cancer efficacy results from a randomised phase III evaluation of transdermal oestradiol (tE2) versus luteinising hormone releasing hormone agonists (LHRHa) for androgen suppression in non-metastatic (M0) prostate cancer

R. Langley¹, M. Nankivell¹, D. Gilbert¹, E. Bourmpaki¹, S. Mangar², H. Rush¹, S. Rosen³, A. Alhasso⁴, R. Kockelbergh⁵, J. Marshall¹, A. Griffiths¹, K.H.Y. Chan¹, W. Mohamed⁶, N. Dallas⁷, S. Brown⁸, N. Clarke⁹, N. James¹⁰, M. Parmar¹, ¹Institute of Clinical Trials and Methodology, London, GB, ²Charing Cross Hospital - Imperial College Healthcare NHS Trust, London, GB, ³National Heart & Lung Institute - Imperial College, London, GB, ⁴BWSSC - Beatson West of Scotland Cancer Centre, Glasgow, GB, ⁵University Hospital of Leicester NHS Trust, Leicester, GB, ⁶Singleton Hospital - Swansea Bay UHB, Swansea, GB, ⁷Royal Berkshire Hospital, Reading, GB, ⁸Airedale General Hospital, Keighley, GB, ⁹The Christie and Salford Royal NHS Foundation Trusts, Manchester, GB, ¹⁰ICR - Institute of Cancer Research, London, GB

10:30 - 10:45

Invited Discussant 1595MO, LBA68 and LBA69

N. Mehra, Radboud University Medical Center, Nijmegen, Nijmegen, NL



10:45 - 10:50

LBA70 - Adding metformin to androgen deprivation therapy (ADT) for patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC): Overall survival (OS) results from the multi-arm, multi-stage randomised platform trial STAMPEDE

S. Gillessen¹, L. Murphy², N. James³, A. Sachdeva⁴, G. Attard², R. Jones⁵, A. Adler⁶, O. El-Taji⁷, M. Varughese⁸, J. Gale⁹, S. Brown¹⁰, N.N. Srihari¹¹, R. Millman², D. Matheson¹², C. Amos², C. Murphy², C. Mcalpine², M. Parmar², L. Brown², N. Clarke¹³, ¹EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, CH, ²University College London, London, GB, ³ICR - Institute of Cancer Research, London, GB, ⁴The University of Manchester, Manchester, GB, ⁵MVLS - Medical, Veterinary and Life Sciences College - University of Glasgow, Glasgow, GB, ⁶University of Oxford, Oxford, GB, ⁷The Christie NHS Foundation Trust, Manchester, GB, ⁸Royal Devon University Hospitals NHS Trust, Exeter, GB, ⁹St. Mary's Hospital Portsmouth Oncology Centre, Portsmouth, GB, ¹⁰Airedale General Hospital, Keighley, GB, ¹¹Royal Shrewsbury Hospital Shrewsbury, Shrewsbury, GB, ¹²University Of Wolverhampton - Walsall Campus, Walsall, GB, ¹³The Christie and Salford Royal NHS Foundation Trusts, Manchester, GB

10:50 - 10:55

LBA71 - Open-label, multicentre randomised trial of Radium223-docetaxel versus docetaxel-Radium223 sequence in metastatic castration resistant prostate cancer (mCRPC) with prospective biomarker evaluation (RAPSON study)

V. Conteduca¹, N. Brighi², G. Gurioli², D. Wetterskog³, E. Giunta², C. Lolli², G. Schepisi², V.E. Chiuri⁴, D. Gasparro⁵, P. Zucali⁶, A. Virga², I. Bondi⁷, B. Vertogen⁷, V. Di Iorio², M. Sansovini², S. Severi², E. Scarpi⁷, M. Urbini², G. Attard³, U. De Giorgi², ¹University of Foggia, Foggia, IT, ²IRST - Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRCCS S.r.l., Meldola, IT, ³University College London, London, GB, ⁴Ospedale "Sacro Cuore di Gesù", Gallipoli, Italy., Gallipoli, IT, ⁵Ospedal Maggiore di Parma, Parma, IT, ⁶Istituto Clinico Humanitas, Rozzano, IT, ⁷IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l., Meldola, IT

10:55 - 11:10

Invited Discussant LBA70 and LBA71

D. Mukherji, Clemenceau Medical Center, Dubai, AE

11:10 - 11:15

1597MO - Clinical activity of BMS-986365 (CC-94676), a dual androgen receptor (AR) ligand-directed degrader and antagonist, in heavily pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

D. Rathkopf¹, M. Patel², A.D. Choudhury³, D. Rasco⁴, N. Lakhani⁵, J. Hawley⁶, S. Srinivas⁷, A. Aparicio⁸, V. Narayan⁹, K. Runcie¹⁰, H. Enamekhoo¹¹, Z. Reichert¹², H. Nguyen¹³, A. Wells¹⁴, R. Kandimalla¹³, S. Suryawanshi¹³, J. Wu¹³, V. Arora¹³, M. Pourdehnad¹⁴, A. Armstrong¹⁵, ¹MSKCC - Memorial Sloan Kettering Cancer Center, New York, US, ²Florida Cancer Specialists, Fort Myers, US, ³Dana-Farber Cancer Institute, Boston, US, ⁴The START Center for Cancer Care, San Antonio, US, ⁵START Midwest, Grand Rapids, US, ⁶UW Division of Medical Oncology, Seattle, US, ⁷Stanford Comprehensive Cancer Institute, Stanford, US, ⁸The University of Texas MD Anderson Cancer Center, Houston, US, ⁹Abramson Cancer Center and Perelman School of Medicine, Philadelphia, US, ¹⁰New York-Presbyterian/Columbia University Medical Center, New York, US, ¹¹University of Wisconsin Carbone Cancer Center, Madison, US, ¹²University of Michigan Medical School, Ann Arbor, US, ¹³Bristol Myers Squibb, Princeton, US, ¹⁴Bristol Myers Squibb, San Francisco, US, ¹⁵Duke Cancer Center, Durham, US

11:15 - 11:20 **LBA72 - Nivolumab 3mg/kg and ipilimumab 1mg/kg (nivo3/ipi1) in molecularly selected patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)**
N. Mehra¹, S. Van Wilpe¹, H. Westdorp¹, I. Kloots¹, P. Slootbeek¹, M. Den Brok¹, M. Franken¹, M. Coskuntürk¹, H. Bloemendaal¹, J. Nagarajah², J. Van Ipenburg¹, L. Kroeze¹, M. Ligtenberg¹, J. Schalken¹, W. Gerritsen¹, ¹Radboud University Medical Center, Nijmegen, Nijmegen, NL, ²Radboud University Medical Center, Nijmegen, NL

11:20 - 11:35 **Invited Discussant 1597MO and LBA72**
C. Sweeney, The University of Adelaide, Adelaide, AU

10:15 - 11:30 **Type: Multidisciplinary session** **Sevilla Auditorium - Hall 2**
Title: Management of adjuvant/neoadjuvant HCC in 2024
 Chair(s): Lorenza Rimassa, IT; Angela Lamarca, ES

10:15 - 10:20 **Presentation of case/condition**
A. Saborowski, MHH - Medizinische Hochschule Hannover, Hannover, DE

10:20 - 10:40 **Update on adjuvant treatment**
T. Meyer, UCL Cancer Institute - Paul O'Gorman Building, London, GB

10:40 - 11:00 **How are locoregional therapies evolving in HCC?**
B. Sangro, Clinica Universidad de Navarra, Pamplona, ES

11:00 - 11:20 **How to select first-line and what to do after progression to immunotherapy**
L. Rimassa, IRCCS Humanitas Research Hospital, Rozzano, IT

11:20 - 11:30 **Discussion**

10:15 - 11:30 **Type: Multidisciplinary session** **Bilbao Auditorium - Hall 2**
Title: Updates in the management of advanced renal cell carcinoma
 Chair(s): Camillo Guglielmo Porta, IT; Cristina Suarez Rodriguez, ES

10:15 - 10:20 **Presentation of case/condition**
C. Suarez Rodriguez, Vall d'Hebron University Hospital, Barcelona, ES

10:20 - 10:40 **The role of cytoreductive nephrectomy in the immunotherapy era**
M.C. Mir Maresma, IVO - Fundación Instituto Valenciano de Oncología, Valencia, ES

10:40 - 11:00 **Is there a role for radiation therapy in advanced RCC?**
C. Tang, The University of Texas MD Anderson Cancer Center - Main Building, Houston, US



11:00 - 11:20 **Systemic treatment options**

T. Alonso Gordo, Hospital Universitario Ramon y Cajal, Madrid, ES

11:20 - 11:30 **Discussion**

10:15 - 11:45

Type: Mini Oral session

Granada Auditorium - Hall 6

Title: Mini oral session: Investigational immunotherapy

Chair(s): Akseli Hemminki, FI; John Haanen, NL; Anna Di Giacomo, IT

10:15 - 10:20

993MO - A phase I, open-label, multicenter, dose escalation safety and tolerability study of oncolytic virus OVV-01 in advanced solid tumors

Y. Hua¹, C. Wang¹, F. Li², Y. Han³, D. Zuo¹, Y. Lv¹, Y. Peng⁴, J. Chen⁵, R. Yuan⁶, F. Zhang⁷, Y. Wang⁸, H. Wu⁸, G. Zhou⁸, S. Wang³, N. Li⁹, Y. Lu¹⁰, Q. Lin¹¹, ¹First People's Hospital Affiliated with Shanghai Jiao Tong University / Shanghai general hospital, China, CN, ²GoBroad Medical(Hematology)Beijing Research Center / Beijing GoBroad Boren Hospital, Beijing, CN, ³National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, CN, ⁴Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, Beijing, CN, ⁵Massachusetts Institute of Technology, Cambridge, US, ⁶Dowlin Biomed, New Hampshire, US, ⁷2047 SE Duncan Dr, Hillsboro, US, ⁸Joint Biosciences (SH) Ltd, Shanghai, CN, ⁹National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN, ¹⁰The 302 medical Center of Peking University Health Science Center, Beijing, CN, ¹¹North China Petroleum Bureau General Hospital, Hebei Medical University, Hebei Province, CN

10:20 - 10:25

994MO - The updated report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/Rα payloads, in patients with advanced solid tumors

Y. Shen¹, S. Rahimian², A. Qin³, Y. Qiu³, T. Fang¹, X. Liang¹, Y. Li¹, Q. Tan³, R. Zhao³, X. Bai¹, T. Liang¹, ¹The First Affiliated Hospital, Zhejiang University School Of Medicine, Hangzhou, CN, ²Virogin Biotech, Jonesville, US, ³Virogin Biotech (Shanghai) Ltd, Shanghai, CN

10:25 - 10:30

995MO - Association of SARS-COV-2 mRNA vaccines with tumor PD-L1 expression and clinical responses to immune checkpoint blockade

A. Grippin¹, S. Copling¹, A. Kim¹, E. Young¹, R. Lohray¹, E. Chang¹, R. Kouzy¹, J. Lewis¹, X. Wei¹, W. Rinsurongkawong¹, J.J. Lee¹, D. Gibbons², A. Vaporciyan³, H. Tran², Y.S.B. Kim¹, J. Heymach², J. Zhang², E. Sayour⁴, W. Jiang¹, S.H. Lin¹, ¹University of Texas MD Anderson Cancer Center, Houston, US, ²UT MD Anderson Cancer Center, Houston, US, ³MD Anderson Cancer Center, Houston, US, ⁴University of Florida, Gainesville, US

10:30 - 10:45

Invited Discussant 993MO, 994MO and 995MO

A. Hemminki, University of Helsinki, Helsinki, FI



10:45 - 10:50

996MO - Dazostinag (TAK-676) alone and in combination with pembrolizumab (pembro) in patients (pts) with advanced/metastatic solid tumors: Data from phase I dose escalation

J. Luke¹, X. Gao², A. Olszanski³, R. Sanborn⁴, G. Falchook⁵, S. Patel⁶, P. Bedard⁷, D. Orr⁸, J.P. Gibbs⁹, C. Li⁹, Y.-C. Huang⁹, R. Gregory⁹, R. Ramesh⁹, R. Xu⁹, B. Wu⁹, K. Ding⁹, J. Raizer⁹, P. Lorusso¹⁰, ¹UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, US, ²Massachusetts General Hospital, Boston, US, ³Fox Chase Cancer Center, Philadelphia, US, ⁴Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, US, ⁵Sarah Cannon Research Institute at HealthONE, Denver, US, ⁶University of California San Diego Moores Cancer Center, La Jolla, US, ⁷University Health Network, Toronto, CA, ⁸Mary Crowley Cancer Research, Dallas, US, ⁹Takeda Development Center Americas, Inc. (TDCA), Lexington, US, ¹⁰Yale Cancer Center, New Haven, US

10:50 - 10:55

997MO - A first-in-human phase I/Ib study of ATG-037 monotherapy and combination therapy with pembrolizumab in patients with advanced solid tumors: STAMINA-01

G. Kichenadasse¹, J. Lombard², M.A. Khattak³, J. Lundy⁴, A. Tazbirkova⁵, Q. Zhou⁶, Y. Li⁷, A. Kudva⁸, H. Cui⁹, E. Hoe⁸, K. Lynch⁸, M. Chisamore¹⁰, Y.-L. Wu¹¹, ¹Southern Oncology Clinical Research Unit Pty Ltd, Adelaide, AU, ²Newcastle Private Hospital, New Lambton Heights, AU, ³One Clinical Research, Nedlands, AU, ⁴Peninsula Health, Frankston, AU, ⁵Pindara Private Hospital, Benowa, AU, ⁶Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, CN, ⁷Chongqing Cancer Hospital, Chongqing, CN, ⁸Antengene, Melbourne, AU, ⁹The First Affiliated Hospital of China Medical University, Shenyang, CN, ¹⁰Merck & Co., Inc. - Corporate Headquarters, Rahway, US, ¹¹Guangdong Provincial People's Hospital, Guangzhou, CN

10:55 - 11:00

998MO - Nivolumab and ipilimumab combination treatment in advanced dMMR/MSI-H noncolorectal cancers: Results from the phase II MoST-CIRCUIT study

O. Klein¹, B. Gao², H. Chan³, M. Michael⁴, R. Zielinski⁵, J. So⁶, S. Harris⁷, D. Kee¹, I.M. Collins⁸, W.-S. Lam⁹, M. Lyle¹⁰, C. Underhill¹¹, M. Brown¹², R. Harrup¹³, S.F. Wong¹⁴, J. Palmer¹⁵, D. Thomas¹⁶, K. Wilkie¹⁵, J. Cebon¹⁷, M. Carlino¹⁸, ¹Austin Health - Austin Hospital, Heidelberg, AU, ²Blacktown Hospital, Blacktown, AU, ³Calvary Mater Hospital Newcastle, Waratah, AU, ⁴Peter MacCallum Cancer Centre, Melbourne, AU, ⁵Orange Health Service, Orange, AU, ⁶Auckland City Hospital, Auckland, NZ, ⁷Bendigo Health, Bendigo, AU, ⁸South West Health Care, Warrnambool, AU, ⁹Fiona Stanley Hospital, Perth, AU, ¹⁰Cairns Base Hospital, Cairns, AU, ¹¹Border Medical Oncology Murray Valley Private Hospital, Wodonga, AU, ¹²Royal Adelaide Hospital RAH Cancer Centre, Adelaide, AU, ¹³RHH - Royal Hobart Hospital, Hobart, AU, ¹⁴Barwon Health - University Hospital Geelong, Geelong, AU, ¹⁵Olivia Newton-John Cancer Research Institute, Heidelberg, AU, ¹⁶University of New South Wales, Sydney, AU, ¹⁷Olivia Newton-John Cancer Wellness & Research Centre, Heidelberg, AU, ¹⁸Crown Princess Mary Cancer Centre Westmead, Westmead, AU

11:00 - 11:15

Invited Discussant 996MO, 997MO and 998MO

J. Haanen, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL



11:15 - 11:20

999MO - HARE-40: A phase I/II trial of therapeutic HPV vaccine (BNT113) in patients with HPV16 driven carcinoma

C. Ottensmeier¹, E. King², S. Crabb³, I. Karydis³, D. Graham⁴, K. Martin², I. Eberhart², S. Ewings², P. Lee², K. Mccann⁵, L. Chudley⁶, L. Berry⁷, J. Dias⁸, R. Das⁹, J. Furlanetto⁸, E. Johnson⁹, J. Setzer⁸, U. Sahin⁸, Ö. Türeci⁸, G. Griffiths², ¹University of Liverpool - School of Medicine, Liverpool, GB, ²University of Southampton, Southampton, GB, ³Southampton General Hospital, Southampton, GB, ⁴The Christie NHS Foundation Trust, Manchester, GB, ⁵University of Southampton - Cancer Research UK Centre, Southampton, GB, ⁶University of Liverpool, Liverpool, GB, ⁷University Hospital Southampton NHS Foundation Trust, Southampton, GB, ⁸BioNTech SE, Mainz, DE, ⁹BioNTech US, Cambridge, US

11:20 - 11:25

1000MO - A phase I/II, open-label study of the novel checkpoint IGSF8 inhibitor GV20-0251 in patients with advanced solid tumors

K. Wentzel¹, J. Peguero², S. Kummar³, P. Lorusso⁴, J. Mehnert⁵, A. Spira⁶, A. Naing⁷, O. Hamid⁸, I. Mehmi⁹, K. Benhadji¹⁰, L. Alland¹⁰, X. Hu¹⁰, H. Xiao¹⁰, X. Bao¹⁰, J. Chen¹⁰, Y. Gong¹⁰, X.S. Liu¹⁰, ¹The Angeles Clinic & Research Institute, Los Angeles, US, ²Oncology Consultants, Houston, US, ³OHSU Knight Cancer Institute - Center for Health and Healing Building 1 - South Waterfront, Portland, US, ⁴Yale School of Medicine - Radiology and Biomedical Imaging, New Haven, US, ⁵Laura and Isaac Perlmutter Cancer Center, New York, US, ⁶Virginia Cancer Specialists, Fairfax, US, ⁷The University of Texas M. D. Anderson Cancer Center, Houston, US, ⁸The Angeles Clinic and Research Institute, Los Angeles, US, ⁹The Angeles Clinic & Research Institute, Los Angeles, CA, USA, Santa Monica, US, ¹⁰GV20 Therapeutics, Cambridge, US

11:25 - 11:30

1001MO - Initial safety, pharmacokinetics, and anti-tumor activity data of TCER IMA401, a MAGEA4/8-directed half-life extended TCR bispecific, in phase I dose escalation

M. Wermke¹, S. Ochsenreither², M. Chatterjee³, S. Gröpper⁴, M.-F. Häring⁵, D. Heudobler⁶, D. Jäger⁷, A. Bleckmann⁸, S. Spoerl⁹, S. Knop¹⁰, J. Hecker¹¹, S. Bunk¹², N. Hilf¹², M. Hutt¹², A. Mayer-Mokler¹², S. Missel¹², O. Veremchuk¹², C. Britten¹³, C. Reinhardt¹³, ¹Dresden University, Dresden, DE, ²Charité - Universitätsmedizin Berlin, Berlin, DE, ³UKW - University Hospital Würzburg, Würzburg, DE, ⁴Marienhospital, Düsseldorf, DE, ⁵Medical University Tuebingen, Tuebingen, DE, ⁶UKR - University Hospital Regensburg, Regensburg, DE, ⁷NCT - Nationales Zentrum für Tumorerkrankungen, Heidelberg, DE, ⁸UKM - University Hospital Muenster, Muenster, DE, ⁹Uniklinikum Erlangen, Friedrich-Alexander University Erlangen-Nürnberg (FAU), Erlangen, DE, ¹⁰Nuremberg General Hospital, Nürnberg, DE, ¹¹Klinikum Rechts der Isar - Technische Universität München, Munich, DE, ¹²Immatics Biotechnologies GmbH, Tuebingen, DE, ¹³Immatics N.V., Tuebingen, DE

11:30 - 11:45

Invited Discussant 999MO, 1000MO and 1001MO

A. Di Giacomo, AOU Senese - Santa Maria delle Scotte, Siena, IT



10:15 - 11:45	Type: Educational session Title: Differential diagnosis and management of clinical syndromes Chair(s): Rachel Riechelmann, BR; Rocio Garcia-Carbonero, ES	Salamanca Auditorium - Hall 5
10:15 - 10:35	Carcinoid syndrome <u>R. Riechelmann</u> , A.C. Camargo Cancer Center - Unidade Antonio Prudente, Sao Paulo, BR	
10:35 - 10:55	Functional pancreatic NETs syndromes <u>G. Kaltsas</u> , National & Kapodistrian University of Athens (NKUA), Athens, GR	
10:55 - 11:15	Functioning paraganglioma and pheochromocytoma <u>S. Glasberg</u> , Hadassah University Hospital - Ein Kerem, Jerusalem, IL	
11:15 - 11:35	Ectopic cushing and neuroendocrine neoplasms <u>A. Grossman</u> , Churchill Hospital, Oxford, GB	
11:35 - 11:45	Q&A and discussion	
10:15 - 11:30	Type: Multidisciplinary session Title: Multidisciplinary team working in the management of anal cancer: Current perspectives Chair(s): Maria Antonietta Gambacorta, IT; Sheela Rao, GB	Valencia Auditorium - Hall 5
10:15 - 10:20	Presentation of case <u>A. Gilbert</u> , University of Leeds-Clinical Trials Research Unit, Leeds, GB	
10:20 - 10:35	Anal cancer: Biological classifications and current thinking <u>M.A. Gambacorta</u> , Università Cattolica del Sacro Cuore, Rome, IT	
10:35 - 10:50	The role of (chemo)radiotherapy <u>A. Gilbert</u> , University of Leeds-Clinical Trials Research Unit, Leeds, GB	
10:50 - 11:05	The role of surgery <u>E. Angenete</u> , Sahlgrenska University Hospital, Göteborg, SE	
11:05 - 11:20	The role of systemic treatment <u>S.P. Choo</u> , NCCS - National Cancer Centre Singapore, Singapore, SG	
11:20 - 11:30	Discussion	

10:15 - 11:15	Type: Special session Title: ESMO in collaboration with SIOPE / ESMO AYA: The greatest need for better outcome of Adolescent and Young Adult Cancer (AYA) with cancer Chair(s): Daniel Stark, GB; Ivana Bozovic Spasojevic, RS	Pamplona Auditorium - Hall 3
10:15 - 10:30	Delivering precision oncology to AYA patients with cancer <u>D. Thomas</u> , Garvan Institute of Medical Research, Darlinghurst, AU	
10:30 - 10:45	What clinicians need to successfully treat AYA patient with cancer <u>F. Peccatori</u> , IEO - Istituto Europeo di Oncologia IRCCS, Milan, IT	
10:45 - 11:00	Adolescent and Young Adult Cancer: Important messages from patient's perspectives <u>T. Spanic</u> , Europa Donna - Slovensko zdruzenje za boj proti raku dojk, Ljubljana, SI	
11:00 - 11:15	Q&A and discussion	
10:15 - 11:45	Type: Special symposium Title: Cancer neuroscience in brain tumours and beyond Chair(s): Frank Winkler, DE; Amélie Darlix, FR	Toledo Auditorium - Hall 3
10:15 - 10:20	Introduction and scientific background <u>A. Darlix</u> , ICM Regional Cancer Institute of Montpellier, Montpellier, FR	
10:20 - 10:35	Brain tumour cancer neuroscience <u>F. Winkler</u> , University Hospital of Heidelberg, Heidelberg, DE	
10:35 - 10:50	Neural influences on non-CNS malignancies <u>L. Li</u> , The Francis Crick Institute, London, GB	
10:50 - 11:05	Neural influences on immunotherapies <u>S. Talbot</u> , Queen's University, Kingston, CA	
11:05 - 11:20	Translation: Chances and challenges <u>U. Herrlinger</u> , Institute of Experimental Immunology - UKB University of Bonn, Bonn, DE	
11:20 - 11:40	Q&A and discussion	
11:40 - 11:45	Conclusions and perspectives <u>F. Winkler</u> , University Hospital of Heidelberg, Heidelberg, DE	



10:15 - 11:45	Type: Educational session Title: ESMO-IARC – Medical oncology and cancer prevention: The odd couple? Chair(s): Jean-Yves Blay, FR; Elisabete Weiderpass, FR	Zaragoza Auditorium - CC5
10:15 - 10:40	The vital role of medical oncologists in primary, secondary, and tertiary cancer prevention <u>N. Arber</u> , Tel Aviv Sourasky Medical Center-(Ichilov), Tel Aviv, IL	
10:40 - 11:05	The value of IARC's cancer prevention resources in daily clinical practice, and how ESMO is supporting them <u>E. Weiderpass</u> , International Agency for Research on Cancer, Lyon, FR	
11:05 - 11:30	Are you really up-to-date on cancer prevention? <u>J. Tabernero</u> , Vall d'Hebron University Hospital, Barcelona, ES	
11:30 - 11:45	Q&A and discussion	
10:15 - 11:45	Type: EONS session Title: eHealth and digital innovations Chair(s): Karen Campbell, GB; Carlos Fernandes Cargaleiro, GB	Ronda Auditorium - Hall 7
10:15 - 10:35	Designing and evaluation of a novel, theory-driven eLearning resource to equip professionals to support adults at end of life who have significant caregiving responsibilities for children < 18 years <u>C. Semple</u> , Ulster Hospital - South Eastern Health and Social Care Trust, Dundonald, GB	
10:35 - 10:55	Use of digital symptom reporting in haematological patients <u>R. Cordoba Mascunano</u> , Hospital Universitario Fundacion Jimenez Diaz, Madrid, ES	
10:55 - 11:05	CN12 - Efficacy of digital health intervention in smoking cessation: A systematic review and network meta-analysis of randomized controlled trials <u>S. Li</u> ¹ , <u>C. Xu</u> ² , <u>Y. Li</u> ³ , <u>S. Tao</u> ⁴ , <u>X. Ma</u> ¹ , ¹ West China School of Medicine/West China Hospital of Sichuan University, Chengdu, CN, ² West China School of Medicine, West China Hospital, Sichuan University, Chengdu, CN, ³ West China School of Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China, Chengdu, CN, ⁴ College of Biomass Science and Engineering, Sichuan University, Chengdu, China, Chengdu, CN	

11:05 - 11:15 **CN13 - Impact of AI clinical trial program on screening, matching, and enrollment of patients over 6 months**
D. Shepard¹, S. Mallahan², C. Osterman², D. Skelly², E. Patnaude², M. Weiss³, B. O'neil⁴, A. Rao⁵, N. Abdulla⁶, A. Zarzour⁷, K. Kumar Sankhala⁸, M. Goldstein⁹, B. Parsons¹⁰, P. La Porte¹¹, A. Franzen², E. Cohen², M. Cooney², ¹Taussig Cancer Center-Cleveland Clinic, Cleveland, US, ²Tempus AI, Inc., Chicago, US, ³Froedtert Hospital & Medical College of Wisconsin, Milwaukee, US, ⁴Community Health Network, Indianapolis, US, ⁵Orange Coast Medical Center - MemorialCare, Fountain Valley, US, ⁶Cancer & Blood Specialty Clinic, Los Alamitos, US, ⁷Toledo Clinic Cancer Centers, Toledo, US, ⁸Cedars-Sinai Comprehensive Cancer Center, Los Angeles, US, ⁹Center for Cancer and Blood Disorders, Bethesda, US, ¹⁰Gundersen Health System, La Crosse, US, ¹¹The Oncology Institute of Hope & Innovation, Cerritos, US

11:15 - 11:25 **CN14 - Innovative paths: A qualitative exploration of nurses' views on technology-based interventions in pediatric oncology care**
A. Ay¹, E.H. Savaş², A. Akça Sümengen³, I. Ercan Koyuncu⁴, M. Erku⁵, R. Semerci⁶, ¹Başkent University, Ankara, TR, ²Independent researcher, Istanbul, TR, ³The University of Alabama at Birmingham, Birmingham, US, ⁴Baskent University, Ankara, TR, ⁵Antalya Bilim University, Antalya, TR, ⁶Koc University Hospital, Istanbul, TR

11:25 - 11:35 **CN15 - Mobile application-based intervention study in improving treatment adherence and quality of life in cancer patients**
G. Prakash¹, S. Kumar D¹, K. Pk¹, V. Arun², D. Yadav¹, ¹JSS Academy Of Higher Education and Research, Mysore, IN, ²JSS Science and Technology University, Mysuru, IN

11:35 - 11:45 **Q&A and discussion**

10:15 - 11:45 **Type: EONS session** **Segovia Auditorium - Hall 7**
Title: ESMO-EONS collaborative session: Caring for the carers
 Chair(s): Fernanda Conceição, PT; Kok Haw Jonathan Lim, GB

10:15 - 10:35 **Optimising well-being and tackling burnout in oncology**
K.H.J. Lim, The Francis Crick Institute, London, GB

10:35 - 10:55 **Cancer is a family affair**
K. Dieperink, Odense University Hospital, Odense C, DK

10:55 - 11:05 **CN30 - Scoping review of the interventions for promoting dyadic adjustment in adult cancer patients and their partners**
R. Gürel¹, S. Kav¹, Y. Eskigulek¹, C. Akdag Topal¹, P. Fernández Ortega², ¹Baskent University, Ankara, TR, ²ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), L'Hospitalet de Llobregat, ES

11:05 - 11:15 **CN70 - Experiences and needs of carers of patients with head and neck cancer: A systematic review**
C. Semple¹, M. Tsai², G. Cherry³, J. Patterson⁴, S. Rogers⁵, ¹Ulster University / South Eastern Health and Social Care Trust, Northern Ireland, GB, ²Royal Brisbane and Women's Hospital, Brisbane, Brisbane, AU, ³University of Liverpool, Liverpool, GB, ⁴Liverpool Head and Neck Centre, School of Health Science, Liverpool, GB, ⁵Wirral University Teaching Hospital NHS Foundation Trust, Metropolitan Borough of Wirral, GB

11:15 - 11:25 **CN4 - Parents' lived experience of children with leukemia**
Q. Alnasser¹, A. Hussain², Y. Musleh³, M. Abuamarah³, ¹King Faisal Specialist Hospital and Research Center, Riyadh, SA, ²King Faisal Specialist Hospital & Research Centre - Riyadh (KFSHRC-R), Riyadh, SA, ³King Faisal Specialist Hospital & Research Centre - Riyadh (KFSHRC-RC), Riyadh, SA

11:25 - 11:45 **Q&A and discussion**

10:45 - 11:30 **Type: Challenge your Expert** **Alicante Auditorium - Hall 3**
Title: Unlocking the potential of mRNA therapeutics
 Chair(s): Kevin Harrington, GB

10:45 - 11:05 **Presentation by Expert**
V. Balachandran, MSKCC - Memorial Sloan Kettering Westchester, West Harrison, US

11:05 - 11:30 **Discussion led by Chair**
K. Harrington, ICR - Institute of Cancer Research - Chester Beatty Laboratories, London, GB

10:45 - 11:30 **Type: Challenge your Expert** **Oviedo Auditorium - Hall 3**
Title: Desmoid-type fibromatosis: To treat or not to treat?
 Chair(s): Alessandro Gronchi, IT

10:45 - 11:05 **Presentation by Expert**
B. Kasper, UMM - Universitaetsklinikum Mannheim, Mannheim, DE

11:05 - 11:30 **Discussion led by Chair**
A. Gronchi, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT

10:45 - 11:30 **Type: Young Oncologists session** **Cartagena Auditorium - Hall 7**
Title: YO Brunch 3
 Chair(s): Myrto Moutafi, GR; Hongcheng Zhu, CN

10:45 - 10:45 **Frailty assessments and its impact on treatment decisions: What YOs need to know?**
E. Brain, Hopital René Huguenin - Institut Curie, Saint-Cloud, FR

12:00 - 12:30	Type: Keynote lecture Title: The emerging global epidemic of young age- onset cancer: Nature or nurture? Chair(s): Irit Ben-Aharon, IL	Madrid Auditorium - Hall 2
12:00 - 12:05	Introduction <u>I. Ben-Aharon</u> , Rambam Health Care Campus, Haifa, IL	
12:05 - 12:30	The emerging global epidemic of young age- onset cancer: Nature or nurture? <u>S. Ogino</u> , Harvard Medical School, Boston, US	
12:00 - 12:45	Type: Challenge your Expert Title: Histology independent cancer drug development: Is it truly a game changer for patients and society? Chair(s): Nicolas Girard, FR	Zaragoza Auditorium - CC5
12:00 - 12:20	Presentation by Expert <u>R. Plummer</u> , Newcastle University, Newcastle upon Tyne, GB	
12:20 - 12:45	Discussion led by Chair <u>N. Girard</u> , Institut Curie, Paris, FR	
12:00 - 13:00	Type: EONS session Title: Celebrating 40 years of EONS Chair(s): Virpi Sulosaari, FI; Helena Ullgren, SE	Ronda Auditorium - Hall 7
12:00 - 12:15	European Cancer Nursing Index, 2022 update: The state of cancer nursing in Europe <u>M. Fowler</u> , Heartlands Hospital - University Hospitals Birmingham NHS Foundation Trust, Birmingham, GB	
12:15 - 13:00	40 years of EONS: Panel discussion <u>S. Faithfull</u> ¹ , <u>L. Sharp</u> ² , <u>J. De Munter</u> ³ , <u>J. Serra López</u> ⁴ , <u>A. Khmaladze</u> ⁵ , ¹ Trinity College Dublin, Dublin, IE, ² RCC - Regionalt cancercentrum Stockholm - Gotland, Stockholm, SE, ³ UZ Gent - Universitair Ziekenhuis Gent, Gent, BE, ⁴ Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ⁵ New Vision University Hospital, Tbilisi, GE	
12:00 - 13:30	Type: EONS Industry Satellite Symposium Title: Pfizer - Optimal biomarker testing in GU cancers Chair(s): Melanie Costin, GB	Segovia Auditorium - Hall 7
12:00 - 12:05	Welcome and introduction <u>M. Costin</u> , Fight Bladder Cancer, Chinnor, GB	
12:05 - 12:25	Where do we stand in biomarker for prostate- & bladder cancer <u>D. Demaeseneer</u> , UZ Gent - University Hospital Ghent, Gent, BE	

12:25 - 12:45 **Comprehensive nursing care for prostate cancer patients: From diagnosis to long-term outcomes**

M. Varandas, Fundação Champalimaud, Lisbon, PT

12:45 - 13:05 **Nursing management of late and long-term effects of bladder cancer**

B.T. Jensen, Institute of Clinical Medicine, Aarhus University Hospital Skejby, Aarhus, DK

13:05 - 13:25 **Discussion and Q&**

M. Costin¹, D. Demaeseneer², M. Varandas³, B.T. Jensen⁴, ¹Fight Bladder Cancer, Chinnor, GB, ²UZ Gent - University Hospital Ghent, Gent, BE, ³Fundação Champalimaud, Lisbon, PT, ⁴Institute of Clinical Medicine, Aarhus University Hospital Skejby, Aarhus, DK

13:25 - 13:30 **Conclusion remarks**

M. Costin, Fight Bladder Cancer, Chinnor, GB

12:00 - 13:30 **Type: Young Oncologists session** **Tarragona Auditorium - Hall 7**
Title: YO Fellowship session - Fellowships in Europe: Educational opportunities for Young Oncologists
 Chair(s): Teresa Amaral, DE

12:00 - 12:15 **Introduction**

T. Amaral, Skin Cancer Clinical Trials Center, University of Tuebingen, Tübingen, DE

12:15 - 12:35 **Best fellowship project 1**

L. Nguyen, Princess Margaret Cancer Centre, Toronto, CA

12:35 - 12:55 **Best fellowship project 2**

M. Strach, Chris O'Brien Lifecare, Camperdown, AU

12:55 - 13:30 **Awards: Presentation of the 2024 Fellows, 2023 Best Exam and 2024 Merit Travel Grants**

13:00 - 14:30 **Type: Industry Satellite Symposium** **Burgos Auditorium - Hall 5**
Title: MSD - Treatment Modalities in Early-Stage NSCLC
 Chair(s): Federico Cappuzzo, IT

13:00 - 13:15 **Opening Remarks and Current Treatment Landscape in Early-Stage NSCLC**

F. Cappuzzo, IRCCS Istituto Nazionale Tumori Regina Elena (IRE), Rome, IT

13:15 - 13:35 **Current Early-Stage Resectable Disease Data (neoadjuvant & perioperative)**

F. Cappuzzo, IRCCS Istituto Nazionale Tumori Regina Elena (IRE), Rome, IT

13:35 - 13:55 **Surgical considerations in Early-Stage Disease**

J. Spicer, McGill University, Montreal, CA



13:55 - 14:15 **Approaches to Treatment in the Medically Inoperable Patient**
S. Jabbour, Rutgers Cancer Institute of New Jersey, New Brunswick, US

14:15 - 14:30 **Panel Q&A and Closing**
F. Cappuzzo¹, J. Spicer², S. Jabbour³, ¹IRCCS Istituto Nazionale Tumori Regina Elena (IRE), Rome, IT, ²McGill University, Montreal, CA, ³Rutgers Cancer Institute of New Jersey, New Brunswick, US

13:00 - 14:30 **Type: Industry Satellite Symposium** **Salamanca Auditorium - Hall 5**
Title: Novartis - Radioligand therapy for advanced prostate cancer: are we on target?
 Chair(s): Kim Nguyen Chi, CA

13:00 - 13:05 **Welcome and Introduction**
K.N. Chi, BC Cancer Agency - Vancouver, Vancouver, CA

13:05 - 13:15 **Where do we stand? Current recommendations for radioligand therapy (RLT) in metastatic castration-resistant prostate cancer**
K.N. Chi¹, M. Eiber², J.C. Galceran³, J. Walz⁴, ¹BC Cancer Agency - Vancouver, Vancouver, CA, ²TUM - Technical University of Munich, Munich, DE, ³Vall d'Hebron University Hospital, Barcelona, ES, ⁴IPC - Institut Paoli-Calmettes, Marseille, Cedex 09, FR

13:15 - 14:05 **Who should we treat? Optimizing the impact of RLT in patients with metastatic castration resistant prostate cancer**
K.N. Chi¹, M. Eiber², J.C. Galceran³, J. Walz⁴, ¹BC Cancer Agency - Vancouver, Vancouver, CA, ²TUM - Technical University of Munich, Munich, DE, ³Vall d'Hebron University Hospital, Barcelona, ES, ⁴IPC - Institut Paoli-Calmettes, Marseille, Cedex 09, FR

14:05 - 14:25 **Where are we going? Discussing the future of RLT in patients with advanced prostate cancer**
K.N. Chi¹, M. Eiber², J.C. Galceran³, J. Walz⁴, ¹BC Cancer Agency - Vancouver, Vancouver, CA, ²TUM - Technical University of Munich, Munich, DE, ³Vall d'Hebron University Hospital, Barcelona, ES, ⁴IPC - Institut Paoli-Calmettes, Marseille, Cedex 09, FR

14:25 - 14:30 **Closing remarks**
K.N. Chi, BC Cancer Agency - Vancouver, Vancouver, CA

13:00 - 14:30 **Type: Industry Satellite Symposium** **Santander Auditorium - Hall 5**
Title: Daiichi Sankyo - Advance, Deliver, Challenge: ADCs and the potential future of mNSCLC
 Chair(s): Marina Garassino, US

13:00 - 13:05 **Welcome and Introductions**
M. Garassino, University of Chicago Department of Medicine - Section of Hematology/Oncology, Chicago, US



- 13:05 - 13:20 **ADC design and considerations for evolving clinical mNSCLC landscape**
M. Garassino, University of Chicago Department of Medicine - Section of Hematology/Oncology, Chicago, US
- 13:20 - 13:45 **ADCs' potential for non-AGA populations**
S. Liu, Lombardi Cancer Center Georgetown University, Washington, US
- 13:45 - 14:10 **Evolving applications of ADCs in NSCLC with AGAs**
B. Besse, Institut Gustave Roussy, Villejuif, Cedex, FR
- 14:10 - 14:25 **Audience Q&A and panel discussion**
M. Garassino¹, B. Besse², S. Liu³, ¹University of Chicago Department of Medicine - Section of Hematology/Oncology, Chicago, US, ²Institut Gustave Roussy, Villejuif, Cedex, FR, ³Lombardi Cancer Center Georgetown University, Washington, US
- 14:25 - 14:30 **Meeting close**
M. Garassino, University of Chicago Department of Medicine - Section of Hematology/Oncology, Chicago, US

13:00 - 14:30 Type: Industry Satellite Symposium Valencia Auditorium - Hall 5
Title: F. Hoffmann - La Roche Ltd - How can we PI3K the right treatment for every patient with HR+ breast cancer?
 Chair(s): Carlos Barrios, BR

- 13:00 - 13:05 **Welcome**
C. Barrios, Latin American Cooperative Oncology Group, Porto Alegre, BR
- 13:05 - 13:25 **PI3K: Unmet need has driven a succession of targeting attempts**
K. Kalinsky, Winship Cancer Institute of Emory University, Atlanta, US
- 13:25 - 13:50 **PI3Ki: Continued efforts are showing success**
K. Jhaveri, Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US
- 13:50 - 14:10 **PI3Ki: An evolving drug class with an exciting future**
C. Barrios, Latin American Cooperative Oncology Group, Porto Alegre, BR
- 14:10 - 14:25 **Q&A**
C. Barrios¹, K. Jhaveri², K. Kalinsky³, ¹Latin American Cooperative Oncology Group, Porto Alegre, BR, ²Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US, ³Winship Cancer Institute of Emory University, Atlanta, US
- 14:25 - 14:27 **Close**
K. Kalinsky, Winship Cancer Institute of Emory University, Atlanta, US



13:00 - 14:30 **Type: Industry Satellite Symposium** **Alicante Auditorium - Hall 3**
Title: MSD - Advancing Cancer Care: Immunotherapy in Early Stage Cancers
 Chair(s): Antonio Llombart Cussac, ES

13:00 - 13:05 **Welcome and Introductions**
A. Llombart Cussac, Hospital Arnau de Vilanova, Valencia, ES

13:05 - 13:25 **Enhancing IO Approaches for Early Stage Disease: Exploring Rationales, Recurrence Risks, and Lessons Learned**
A. Llombart Cussac, Hospital Arnau de Vilanova, Valencia, ES

13:25 - 13:40 **Synergistic Strategies for Early Stage Cancers: Integrating Radiotherapy in Multidisciplinary Tumor boards**
S. Senan, Amsterdam UMC - Vrije University Medical Centre (VUmc), Amsterdam, NL

13:40 - 13:55 **Unleashing the Power of Collaboration: The Role of Surgeons in Multidisciplinary Tumor boards**
J. Gschwend, Klinikum Rechts der Isar - Technische Universitaet Muenchen, Munich, DE

13:55 - 14:25 **Panel discussion**
A. Llombart Cussac¹, S. Senan², J. Gschwend³, ¹Hospital Arnau de Vilanova, Valencia, ES, ²Amsterdam UMC - Vrije University Medical Centre (VUmc), Amsterdam, NL, ³Klinikum Rechts der Isar - Technische Universitaet Muenchen, Munich, DE

14:25 - 14:30 **Closing remarks**
A. Llombart Cussac, Hospital Arnau de Vilanova, Valencia, ES

13:00 - 14:30 **Type: Industry Satellite Symposium** **Pamplona Auditorium - Hall 3**
Title: Pfizer - Three Moves Ahead: Strategic Sequencing Approaches for Patients With HER2+ MBC
 Chair(s): Eva Ciruelos, ES

13:00 - 13:05 **Welcome and Introduction**
E. Ciruelos, Hospital Universitario 12 de Octubre, Madrid, ES

13:05 - 13:15 **Opening Moves: How Has the Therapeutic Landscape Evolved for HER2+ MBC?**
E. Ciruelos, Hospital Universitario 12 de Octubre, Madrid, ES

13:15 - 13:35 **What Is Your Defence Strategy? Clinical Decision-Making Against CNS Involvement in HER2+ MBC**
H. Mcarthur¹, J.-S. Frene², ¹UTSW - University of Texas Southwestern Medical Center, Dallas, US, ²ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR



- 13:35 - 13:55 **What Is Your Strategic Move? Clinical Decision-Making in 3L HER2+ MBC**
H. McArthur¹, J.-S. Frene², ¹UTSW - University of Texas Southwestern Medical Center, Dallas, US,
²ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR
- 13:55 - 14:10 **Mastering Future Moves: Opportunities in HER2+ MBC**
G. Bianchini, IRCCS Ospedale San Raffaele, Milan, IT
- 14:10 - 14:25 **Panel Discussion and Audience Q&A**
E. Ciruelos¹, H. McArthur², J.-S. Frene³, G. Bianchini⁴, ¹Hospital Universitario 12 de Octubre, Madrid, ES, ²UTSW - University of Texas Southwestern Medical Center, Dallas, US, ³ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, ⁴IRCCS Ospedale San Raffaele, Milan, IT
- 14:25 - 14:30 **Closing Remarks**
E. Ciruelos, Hospital Universitario 12 de Octubre, Madrid, ES

13:00 - 14:30 **Type: ESMO Colloquium** **Oviedo Auditorium - Hall 3**
Title: ESMO Colloquium supported by Novocure - The role of alternating electric fields in the therapeutic management of patients with advanced non-small cell lung cancer
 Chair(s): Tician Leal, US; Gerben Borst, GB

- 13:00 - 13:10 **Welcome and introduction**
T. Leal, Emory University, Atlanta, US
- 13:10 - 13:25 **Alternating electric fields in cancer therapy: Mode of action and principles of cytotoxicity**
C. Hagemann, UKW - University Hospital Würzburg, Würzburg, DE
- 13:25 - 13:40 **Clinical evidence for efficacy & safety of electric fields therapeutic applications for patients with advanced non-small cell lung cancer**
T. Leal, Emory University, Atlanta, US
- 13:40 - 13:55 **Emerging clinical evidence on the efficacy of electric fields in controlling sanctuary metastatic site**
M. Mehta, Northwestern University Feinberg School of Medicine, Chicago, US
- 13:55 - 14:10 **Research insights in future developments of alternating electric field applications in oncology and potential for combination with systemic agents and irradiation**
G. Borst, The University of Manchester, Manchester, GB
- 14:10 - 14:25 **Q&A and discussion**
- 14:25 - 14:30 **Concluding remarks**
G. Borst, The University of Manchester, Manchester, GB



13:00 - 14:30	Type: Industry Satellite Symposium Title: BeiGene - A new comprehensive approach to lung cancer treatment Chair(s): Silvia Novello, IT; Tony S.K. Mok, HK	Toledo Auditorium - Hall 3
13:00 - 13:05	Welcome and Introduction <u>S. Novello</u> , Università Degli Studi Di Torino - Orbassano, Orbassano, IT	
13:05 - 13:20	Resectable NSCLC – neo-adjuvant/adjuvant <u>M. Provencio Pulla</u> , University Hospital Puerta de Hierro Majadahonda, Majadahonda, ES	
13:20 - 13:50	Single agent IO is the only treatment option for NSCLC with PD-L1 high expression (debate: PRO – M. Reck; CON – T. Mok) <u>T.S.K. Mok</u> ¹ , <u>M. Reck</u> ² , ¹ Prince of Wales Hospital - Li Ka Shing Specialist Clinics, Sha Tin, HK, ² LungenClinic Grosshansdorf, Grosshansdorf, DE	
13:50 - 14:05	What to do in NSCLC with low PD-L1 expression? <u>L. Paz-Ares</u> , Hospital Universitario 12 de Octubre, Madrid, ES	
14:05 - 14:20	1L SCLC <u>S. Novello</u> , Università Degli Studi Di Torino - Orbassano, Orbassano, IT	
14:20 - 14:29	General panel discussion / audience Q&A <u>S. Novello</u> ¹ , <u>M. Provencio Pulla</u> ² , <u>T.S.K. Mok</u> ³ , <u>M. Reck</u> ⁴ , <u>L. Paz-Ares</u> ⁵ , ¹ Università Degli Studi Di Torino - Orbassano, Orbassano, IT, ² University Hospital Puerta de Hierro Majadahonda, Majadahonda, ES, ³ Prince of Wales Hospital - Li Ka Shing Specialist Clinics, Sha Tin, HK, ⁴ LungenClinic Grosshansdorf, Grosshansdorf, DE, ⁵ Hospital Universitario 12 de Octubre, Madrid, ES	
14:29 - 14:30	Take-home messages and farewell <u>T.S.K. Mok</u> , Prince of Wales Hospital - Li Ka Shing Specialist Clinics, Sha Tin, HK	
13:15 - 14:15	Type: EONS session Title: Cancer care during exceptional circumstances Chair(s): Matthew Fowler, GB; Wendy Mcinally, GB	Ronda Auditorium - Hall 7
13:15 - 13:30	Experience from cancer nursing during earthquake: The impact on cancer care <u>R. Semerci</u> , Koc University Hospital, Istanbul, TR	
13:30 - 13:45	Experiences from the war in Ukraine from a patient perspective <u>N. Hrad</u> , Kyiv National Linguistic University, Kyiv, UA	
13:45 - 14:00	Nursing with limited resources during an ongoing conflict <u>T. Jafar</u> , Bethlehem Care Hospice & Trust, Bethlehem, PS	
14:00 - 14:15	Q&A and discussion	



14:30 - 15:30	Type: EONS session Title: SIOPE-EONS collaborative session Chair(s): Eugenia Trigos Arjona, ES; Johan De Munter, BE	Ronda Auditorium - Hall 7
14:30 - 14:45	Nurse as a transition leader: From paediatric to adults <u>E. Trigos Arjona</u> , Hospital Universitari i Politècnic La Fe, Valencia, ES	
14:45 - 15:00	It's skin cancer: A rollercoaster of a journey for young people and their significant other <u>W. Mcinally</u> , Open University, Edinburgh, GB	
15:00 - 15:10	CN5 - Journeying through the landscape of home-based pediatric cancer care: Needs and expectations from the insights of children and parents <u>H. Özdemir Koyu</u> , E. Kilcarslan, Gazi University - Faculty of Nursing, Ankara, TR	
15:10 - 15:20	CN16 - Effectiveness of technology-based intervention in symptom management in pediatric oncology patients: A systematic review and meta-analysis <u>E.H. Savaş</u> ¹ , A. Akça Sümengen ² , R. Semerci ³ , ¹ Independent researcher, Istanbul, TR, ² The University of Alabama at Birmingham, Birmingham, US, ³ Koc University Hospital, Istanbul, TR	
15:20 - 15:30	Q&A and discussion	
14:45 - 16:15	Type: Proffered Paper session Title: Proffered paper session 2: Basic science & Translational research Chair(s): Aurélien Marabelle, FR; Naureen Starling, GB	Madrid Auditorium - Hall 2
14:45 - 14:55	66O - Association of a blood T cell fitness gene signature with clinical benefit from ImmTAC bispecific T cell engagers <u>J. Sacco</u> ¹ , R. Carvajal ² , O. Hamid ³ , P. Kirk ⁴ , L. Collins ⁴ , M. Butler ⁵ , A. Shoushtari ⁶ , J. Hassel ⁷ , A. Ikeguchi ⁸ , L. Hernandez-Aya ⁹ , P. Nathan ¹⁰ , J.M. Piulats Rodriguez ¹¹ , H. Shaw ¹² , D. Davar ¹³ , C. Han ¹⁴ , M. Middleton ¹⁵ , F. Thistlethwaite ¹⁶ , F. Peck ⁴ , K. Ranade ¹⁷ , T. Sato ¹⁸ , ¹ The Clatterbridge Cancer Centre and University of Liverpool, Wirral, GB, ² Northwell Health Cancer Institute, New York, US, ³ The Angeles Clinic and Research Institute a Cedars-Sinai Affiliate, Los Angeles, US, ⁴ Immunocore Limited, Abingdon-on-Thames, GB, ⁵ Princess Margaret Cancer Center, Toronto, CA, ⁶ Memorial Sloan Kettering Cancer Center, New York, US, ⁷ University Hospital Heidelberg, Heidelberg, DE, ⁸ Stephenson Cancer Center/University of Oklahoma, Oklahoma City, US, ⁹ University of Miami Sylvester Comprehensive Cancer Center, Miami Beach, US, ¹⁰ Mount Vernon Cancer Centre, Northwood, GB, ¹¹ ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), Barcelona, ES, ¹² UCLH - University College London Hospitals NHS Foundation Trust, London, GB, ¹³ University of Pittsburgh Cancer Institute, Pittsburgh, US, ¹⁴ University of Auckland, Auckland, NZ, ¹⁵ University of Oxford, Oxford, GB, ¹⁶ The Christie NHS Foundation Trust, Manchester, GB, ¹⁷ Immunocore LLC, Rockville, US, ¹⁸ Jefferson University, Philadelphia, US	

- 14:55 - 15:05 **670 - Polygenic risk score associations with immune checkpoint inhibitors related endocrine toxicity**
C. Thorball¹, Z. Quandt², A. Saha³, L. Yao⁴, P. Midda⁵, Y. Xu⁴, C. Bejan⁴, F. Hodel¹, A. Stravodimou⁶, E. Shearer-Kang³, M. Aldrich⁴, E.J. Philips⁷, G. Liu⁸, A. Schoenfeld⁹, D. Johnson⁴, E. Ziv¹⁰, J. Fellay¹¹, R. Mohindra¹², J. Balko⁴, G.S. Chandler¹³, ¹Lausanne University Hospital and University of Lausanne, Lausanne, CH, ²UCSF, San Francisco, CH, ³Genentech, Inc., South San Francisco, US, ⁴Vanderbilt University Medical Center, Nashville, US, ⁵University of California, San Francisco, US, ⁶Lausanne University Hospital, Lausanne, CH, ⁷VUMC - Vanderbilt University Medical Center, Nashville, US, ⁸Princess Margaret Cancer Center, Toronto, CA, ⁹MSKCC - Memorial Sloan Kettering Cancer Center, New York, US, ¹⁰UCSF, San Francisco, US, ¹¹Lausanne University Hospital and University of Lausanne; Swiss Federal Institute of Technology, Lausanne, CH, ¹²F. Hoffmann-La Roche AG, Basel, CH, ¹³F. Hoffmann-La Roche Ltd, Basel, CH
- 15:05 - 15:15 **Invited Discussant 660 and 670**
A. Marabelle, Institut Gustave Roussy, Villejuif, FR
- 15:15 - 15:30 **Q&A**
- 15:30 - 15:40 **680 - Frequency of clinical acquired RAS-MAPK pathway resistance alterations in patients treated with KRASG12C inhibitors: An individual patient meta-analysis**
J. Riedl¹, F. Fece², B. Caughey², H. Matsubara¹, P. Patel¹, A. Varkaris², H. Barnes¹, S. Ehnstrom², J. Schwartz², J.J. Lin², A. Parikh², J. Gainor², A. Hata², R. Heist², R. Corcoran², ¹Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, US, ²MGH - Massachusetts General Hospital, Boston, US
- 15:40 - 15:50 **11720 - Akkermansia muciniphila-based multi-omic profiling in advanced non-small cell lung cancer**
L. Belluomini¹, A. Bonato², A. Almonte³, F. Gattazzo⁴, I. Lebhar³, R. Birebent³, C. Flament³, M. Xiberras³, M. Marques³, P. Ly³, C. Thelemaque³, C. Parisi⁵, J. Remon Masip⁵, B. Besse⁵, D. Planchard⁵, C. Alves Costa Silva³, F. Barlesi⁵, L. Zitvogel³, L. Derosa³, ¹University of Verona and University and Hospital Trust (AOUI) of Verona, Italy, Verona, IT, ²AOU Pisana - Stabilimento di Sanra Chiara, Pisa, IT, ³Gustave Roussy - Cancer Campus, Villejuif, FR, ⁴Università Cattolica del Sacro Cuore, Piacenza, IT, ⁵Institut Gustave Roussy, Villejuif, Cedex, FR
- 15:50 - 16:00 **Invited Discussant 680 and 11720**
B. Routy, CRCHUM - Centre de recherche du CHUM, Montreal, CA
- 16:00 - 16:15 **Q&A**



14:45 - 15:45

Type: Mini Oral session

Sevilla Auditorium - Hall 2

Title: Mini oral session 2: Non-metastatic NSCLC

Chair(s): Heather Wakelee, US; Kersti Oselin, EE

14:45 - 14:50

1241MO - Osimertinib (osi) after definitive chemoradiotherapy (CRT) in unresectable (UR) stg III EGFRm NSCLC: Analyses of CNS and distant progression from the phase III LAURA study

S. Lu¹, M.-J. Ahn², T. Baisamut³, M. Ozguroglu⁴, T. Kato⁵, J.C.-H. Yang⁶, M. Huang⁷, F. Fujiki⁸, T. Inoue⁹, V.Q. Le¹⁰, V. Sriuranpong¹¹, D. Vicente¹², C. Fuentes¹³, R.N. Darapureddi¹⁴, L. Poole¹⁴, E. Armenteros Monterroso¹⁴, T. Van Der Gronde¹⁵, Y. Rukazenzov¹⁴, S. Ramalingam¹⁶, ¹Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, CN, ²Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, ³Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, TH, ⁴Istanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, Istanbul, TR, ⁵Kanagawa Cancer Center, Yokohama, JP, ⁶National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, TW, ⁷Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, CN, ⁸Instituto do Câncer do Estado de São Paulo, São Paulo, BR, ⁹Osaka International Cancer Institute, Osaka, JP, ¹⁰Hanoi Medical University, Hanoi, VN, ¹¹Chulalongkorn University and the King Chulalongkorn Memorial Hospital, Bangkok, TH, ¹²Hospital Universitario Virgen de Macarena, Sevilla, ES, ¹³Centro Médico Dra. De Salvo, Buenos Aires, AR, ¹⁴AstraZeneca, Cambridge, GB, ¹⁵AstraZeneca, New York, US, ¹⁶Emory University School of Medicine, Winship Cancer Institute, Atlanta, US

14:50 - 14:55

1206MO - ALINA: Exploratory biomarker analyses in patients (pts) with resected ALK+ non-small cell lung cancer (NSCLC) treated with adjuvant alectinib vs chemotherapy (chemo)

B. Solomon¹, Y.-L. Wu², R. Dziadziuszko³, F. Barlesi⁴, M. Nishio⁵, J.S. Ahn⁶, H. Horinouchi⁷, M. Hochmair⁸, F. De Marinis⁹, M.R. Migliorino¹⁰, A. Kurochkin¹¹, H. Harputluoglu¹², D. Planchard⁴, K. Korphaisarn¹³, J.-Y. Han¹⁴, T. Lohmann¹⁵, A. Cardona Gavaldon¹⁵, V. Archer¹⁶, M. Nowicka¹⁵, J. Noe¹⁵, ¹Peter MacCallum Cancer Center, Melbourne, AU, ²Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, CN, ³Medical University of Gdańsk, Gdańsk, PL, ⁴University Paris Saclay & Gustave Roussy, Villejuif, FR, ⁵Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, JP, ⁶Samsung Medical Center, Seoul, KR, ⁷National Cancer Center Hospital, Tokyo, JP, ⁸Klinik Floridsdorf, Karl-Landsteiner-Institute for Lung Research and Pulmonary Oncology, Vienna, AT, ⁹European Institute of Oncology (IRCCS), Milan, IT, ¹⁰San Camillo Forlanini Hospital, Rome, IT, ¹¹RCI Sumy Regional Clinical Oncological Dispensary, Sumy Region, Kharkiv Governorate, UA, ¹²Inonu University Medical Faculty Turgut Ozal Medical Center, Malatya, TR, ¹³Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, TH, ¹⁴National Cancer Center, Goyang, KR, ¹⁵F. Hoffmann-La Roche Ltd, Basel, CH, ¹⁶Roche Products Limited, Welwyn Garden City, GB



- 14:55 - 15:00 **1207MO - Neoadjuvant nivolumab monotherapy for high-risk clinical stage I non-small cell lung cancer: A phase II POTENTIAL study**
Y. Tsutani¹, Y. Sakairi², N. Ikeda³, Y. Tanaka⁴, M. Tsuboi⁵, H. Ito⁶, K. Suzuki⁷, K. Kushitani⁸, K. Aokage⁵, K. Yoshimura⁹, K. Awai⁸, G. Ishii⁵, Y. Takeshima⁸, M. Okada², ¹Kindai University - Faculty of Medicine, Osaka, JP, ²Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, JP, ³Tokyo Medical University, Shinjuku-ku, JP, ⁴Kobe University Graduate School of Medicine, Kobe, JP, ⁵National Cancer Center Hospital East, Kashiwa, JP, ⁶Kanagawa Cancer Center, Yokohama, JP, ⁷Juntendo University Hospital, Bunkyo-ku, JP, ⁸Hiroshima University Hospital, Hiroshima, JP, ⁹Graduate School of Medical Sciences Medical School, Nagoya City University, Aichi, JP
- 15:00 - 15:15 **Invited Discussant 1241MO, 1206MO and 1207MO**
H. Wakelee, Stanford University, Stanford, US
- 15:15 - 15:20 **1208MO - Phase III trial of perioperative pirfenidone therapy for lung cancer with idiopathic pulmonary fibrosis (IPF): NEJ034 study**
Y. Goto¹, Y. Sakairi², I. Yoshino³, H. Suzuki⁴, M. Okada⁵, Y. Sato¹, M. Tsuboi⁶, T. Nakagawa⁷, T. Iwata², J. Okami⁸, H. Takei⁹, H. Suzuki¹⁰, N. Ikeda¹¹, Y. Sato¹², K. Kobayashi¹³, ¹University of Tsukuba, Tsukuba, JP, ²Chiba Cancer Center, Chiba, JP, ³International University of Health and Welfare School of Medicine, Chiba, JP, ⁴Chiba University, School of Medicine, Chiba, JP, ⁵Department of Hiroshima University Hospital, Hiroshima, JP, ⁶National Cancer Center Hospital East, Kashiwa, JP, ⁷Omagari Kosei Medical Center, Daisen, JP, ⁸Osaka International Cancer Institute, Osaka, JP, ⁹Showa University School of Medicine, Tokyo, JP, ¹⁰Fukushima Medical University, Fukushima, JP, ¹¹Tokyo Medical University, Shinjuku-ku, JP, ¹²Kitasato University Hospital, Sagami-hara, JP, ¹³Saitama Medical University International Medical Center, Saitama, JP
- 15:20 - 15:25 **1242MO - The addition of belomethason propionate inhalation to radical radiotherapy for patients with locally advanced non-small cell lung cancer: A randomized controlled, open-label phase II study**
J. Zhang¹, Q. Wu², H. Wu¹, W. Zhao², M. Shi¹, ¹Shanghai Pulmonary Hospital, Shanghai, CN, ²Shanghai Pulmonary Hospital - Tongji University School of Medicine, Shanghai, CN



15:25 - 15:30 **1243MO - A phase III study comparing weekly carboplatin plus nab-paclitaxel and daily low-dose carboplatin for concurrent chemoradiotherapy in elderly patients (≥75 years) with unresectable locally advanced NSCLC: JCOG1914**

S. Omori¹, H. Kenmotsu², T. Takahashi², S. Nomura³, H. Harada², S. Ishikura⁴, M. Ando⁵, H. Izumi⁶, Y. Shinno³, M. Oki⁷, T. Masuda⁸, T. Yokoyama⁹, Y. Hosomi¹⁰, T. Shimokawa¹¹, S. Murakami¹², T. Kurosaki¹³, H. Yoshioka¹⁴, N. Mitome³, H. Fukuda³, Y. Ohe³, ¹Oita University Hospital, Oita, JP, ²Shizuoka Cancer Center, Shizuoka, JP, ³National Cancer Center Hospital, Tokyo, JP, ⁴St. Luke's International Hospital, St. Luke's International University, Tokyo, JP, ⁵Nagoya University Hospital, Aichi, JP, ⁶National Cancer Center Hospital East, Chiba, JP, ⁷NHO Nagoya Medical Center, Aichi, JP, ⁸Hiroshima University Hospital, Hiroshima, JP, ⁹Kurashiki Central Hospital, Okayama, JP, ¹⁰Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, JP, ¹¹Yokohama Municipal Citizen's Hospital, Kanagawa, JP, ¹²Kanagawa Cancer Center, Kanagawa, JP, ¹³Kindai University Faculty of Medicine, Osaka, JP, ¹⁴Kansai Medical University Hospital, Osaka, JP

15:30 - 15:45 **Invited Discussant 1208MO, 1242MO and 1243MO**

K. Oselin, North Estonia Medical Centre Foundation (SA Pohja-Eesti Regionaalhaigla), Tallinn, EE

14:45 - 16:15 **Type: Special symposium** **Bilbao Auditorium - Hall 2**
Title: New technology, new ideas: What is on the horizon for colorectal cancer?
 Chair(s): Maria Elena Elez Fernandez, ES; Christopher Williams, GB

14:45 - 14:50 **Introduction and scientific background**

M.E. Elez Fernandez, Vall d'Hebron University Hospital, Barcelona, ES

14:50 - 15:05 **Microbiome in colorectal cancer: Ready for primetime?**

M. Giannakis, Dana Farber Cancer Institute, Boston, US

15:05 - 15:20 **Sex and gender: First steps towards tailored treatment**

K. Heinrich, Hospital Munich Grosshadern - Ludwig-Maximilians-University (LMU), Munich, DE

15:20 - 15:35 **Liquid profiling of molecular metastatic disease and impact on decision making**

N. Tarazona Llavero, Hospital Clinico Universitario de Valencia, Valencia, ES

15:35 - 15:50 **Novel systemic therapeutic approaches in mCRC**

M.E. Elez Fernandez, Vall d'Hebron University Hospital, Barcelona, ES

15:50 - 16:10 **Q&A and discussion**

16:10 - 16:15 **Conclusions and perspectives**

C. Williams, UL - University of Leeds, Leeds, GB



14:45 - 16:15 **Type: Special symposium** **Granada Auditorium - Hall 6**
Title: Management of oligoprogressive disease
 Chair(s): Lucia Del Mastro, IT; Karen Gelmon, CA

14:45 - 14:50 **Introduction and scientific background**
K. Gelmon, BC Cancer Agency - Vancouver, Vancouver, CA

14:50 - 15:05 **Leptomeningeal disease**
A. Fitzpatrick, King's College London, London, GB

15:05 - 15:20 **CNS disease**
N. Lin, Dana Farber Cancer Institute, Boston, US

15:20 - 15:35 **Patients with bone metastases**
R. Van Den Begin, Institute Jules Bordet, Anderlecht, BE

15:35 - 15:50 **Patients with liver metastases**
R. Adam, Hôpital Paul Brousse AP-HP, Villejuif, FR

15:50 - 16:10 **Q&A and discussion**

16:10 - 16:15 **Conclusions and perspectives**
L. Del Mastro, IRCCS Ospedale Policlinico San Martino, Genova, IT

14:45 - 16:00 **Type: Multidisciplinary session** **Burgos Auditorium - Hall 5**
Title: How can we best manage locally-advanced and persistent cervical cancers?
 Chair(s): Jack Chan, SG; Domenica Lorusso, IT

14:45 - 14:50 **Presentation of case/condition**
D. Najjari Jamal, ICO - Institut Català d'Oncologia - Hospital Duran i Reynals, Hospitalet de Llobregat, ES

14:50 - 15:10 **The role of chemotherapy in concurrent chemoradiation**
J. Chan, NCCS - National Cancer Centre Singapore, Singapore, SG

15:10 - 15:30 **The role of immunotherapy plus concurrent chemoradiation**
D. Najjari Jamal, ICO - Institut Català d'Oncologia - Hospital Duran i Reynals, Hospitalet de Llobregat, ES

15:30 - 15:50 **Surgery for persistent cervical cancer after chemoradiation**
N. Abu-Rustum, MSKCC - Memorial Sloan Kettering Cancer Center, New York, US

15:50 - 16:00 **Discussion**



14:45 - 16:00	Type: Multidisciplinary session Title: The evolving diagnostic landscape of early phase trials Chair(s): Alexander Drilon, US; Michal Bassani-Sternberg, CH	Salamanca Auditorium - Hall 5
----------------------	---	--------------------------------------

14:45 - 14:50	Presentation of case/condition <u>A. Drilon</u> , Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US	
14:50 - 15:05	Utility of more comprehensive sequencing to identify biomarkers for early phase clinical trials <u>M. Berger</u> , Memorial Sloan Kettering Cancer Center, New York, US	
15:05 - 15:20	Challenges of HLA, neoantigen, and immune biomarker testing for early phase immunomodulatory therapy trials <u>M. Bassani-Sternberg</u> , Ludwig Institute for Cancer Research, Lausanne - DOF - UNIL, Lausanne, CH	
15:20 - 15:35	Expanding proteome interrogation to identify early phase clinical trial biomarkers <u>J. Lehtiö</u> , Karolinska Institutet, Stockholm, SE	
15:35 - 15:50	AI and machine learning to identify early phase clinical trial biomarkers <u>J. Kather</u> , Technische Universität Dresden - Carl Gustav Carus Faculty of Medicine, Dresden, DE	
15:50 - 16:00	Q&A and discussion	

14:45 - 16:15	Type: Proffered Paper session Title: Proffered paper session: Sarcoma Chair(s): Bernd Kasper, DE; Silvia Stacchiotti, IT	Santander Auditorium - Hall 5
----------------------	--	--------------------------------------

14:45 - 14:55	17180 - EREMISS trial: A double-blind placebo (PBO)-controlled randomised trial assessing efficacy/safety of regorafenib (REGO) as maintenance therapy after 1st line doxorubicin-based chemotherapy in advanced soft-tissue sarcoma (ASTS) patients (pts) <u>N. Penel</u> ¹ , A. Italiano ² , J. Wallet ¹ , L. Chaigneau ³ , B. Verret ⁴ , N. Firmin ⁵ , S. Watson ⁶ , T. Valentin ⁷ , E. Bompas ⁸ , F. Bertucci ⁹ , M. Brahmi ¹⁰ , A. Le Cesne ¹¹ , A. Brunot ¹² , M. Spalato Ceruso ² , M. Vanseymortier ¹ , E. Decoupigny ¹ , S. Taieb ¹³ , M.-C. Le Deley ¹ , C. Perrin ¹² , J.-Y. Blay ¹⁰ , ¹ Centre Oscar Lambret, Lille, FR, ² Institute Bergonié - Centre Régional de Lutte Contre le Cancer (CLCC), Bordeaux, FR, ³ CHRU Besancon - Hopital Jean Minjot, Besancon, FR, ⁴ Institut Gustave Roussy, Villejuif, FR, ⁵ ICM Val D Aurelle, Montpellier, FR, ⁶ Institut Curie, Paris, FR, ⁷ Institut Universitaire du Cancer -Toulouse- Oncopole, Toulouse, FR, ⁸ ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, ⁹ IPC - Institut Paoli-Calmettes, Marseille, FR, ¹⁰ Centre Léon Bérard, Lyon, FR, ¹¹ Gustave Roussy - Cancer Campus, Villejuif, FR, ¹² Centre Eugene - Marquis, Rennes, FR, ¹³ CentreOscarLambret, Lille, FR	
---------------	--	--



14:55 - 15:05

17190 - Multisarc: A randomized precision medicine study in advanced soft-tissue sarcomas

B. Verret¹, C. Bellera², P. Boudou Rouquette³, E. Bompas⁴, S. Watson⁵, N. Penel⁶, J.E. Kurtz⁷, I. Desmoulins⁸, F. Bertucci⁹, E. Saada¹⁰, M. Brahmi¹¹, N. Isambert¹², J.-C. Thery¹³, P. Dubray-Longeras¹⁴, J.-Y. Blay¹¹, Y. Laizet², J.-F. Deleuze¹⁵, I. Soubeyran¹⁶, S. Mathoulin¹⁷, A. Italiano²,
¹Institut Gustave Roussy, Villejuif, FR, ²Institute Bergonié - Centre Régional de Lutte Contre le Cancer (CLCC), Bordeaux, FR, ³Hopital Cochin - Site Port-Royal AP-HP, Paris, FR, ⁴ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, ⁵Institut Curie, Paris, FR, ⁶Centre Oscar Lambret, Lille, FR, ⁷ICANS - Institut de Cancérologie Strasbourg Europe, Strasbourg, FR, ⁸Centre Georges-François Leclerc (Dijon), Dijon, FR, ⁹IPC - Institut Paoli-Calmettes, Marseille, FR, ¹⁰Centre Anticancer Antoine Lacassagne, Nice, FR, ¹¹Centre Léon Bérard, Lyon, FR, ¹²CHU Poitiers - Jean Bernard Hôpital, Poitiers, FR, ¹³Centre Henri Becquerel, Rouen, FR, ¹⁴Centre Jean PERRIN, Clermont-Ferrand, Cedex, FR, ¹⁵CNRGH - Centre National de Recherche en Génomique Humaine - CEA, Évry-Courcouronnes, Cedex, FR, ¹⁶Institute Bergonié, Bordeaux, FR, ¹⁷Univ. Bordeaux, Inserm, Bordeaux, FR

15:05 - 15:15

Invited Discussant 17180 and 17190

C.M. Valverde Morales, Vall d'Hebron University Hospital, Barcelona, ES

15:15 - 15:25

Q&A

15:25 - 15:35

LBA78 - Updated efficacy and safety of vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT): One-year follow-up from the MOTION phase III trial

H. Gelderblom¹, V. Bhadri², S. Stacchiotti³, S. Bauer⁴, A.J. Wagner⁵, M. Van De Sande¹, N.M. Bernthal⁶, A. Lopez Pousa⁷, A.R. Abdul Razak⁸, A. Italiano⁹, M. Ahmed¹⁰, A. Le Cesne¹¹, C. Tait¹², A. Saunders¹², B. Harrow¹², M.G. Sharma¹², R. Ruiz-Soto¹², M.L. Sherman¹², J.-Y. Blay¹³, W.D. Tap¹⁴,
¹Leiden University Medical Center, Leiden, NL, ²Chris O'Brien Lifehouse, Camperdown, AU, ³Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT, ⁴Sarcoma Center, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Germany and German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, DE, ⁵Dana-Farber Cancer Institute, Boston, US, ⁶University of California Los Angeles, Los Angeles, US, ⁷Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ⁸Princess Margaret Cancer Centre, Toronto, CA, ⁹Institute Bergonié, Bordeaux, FR, ¹⁰University College London Hospitals NHS Foundation Trust, London, GB, ¹¹Gustave Roussy, Villejuif, FR, ¹²Deciphera Pharmaceuticals, LLC, Waltham, US, ¹³Centre Léon Bérard, Lyon, FR, ¹⁴Memorial Sloan Kettering Cancer Center, New York, US



15:35 - 15:45 **LBA79 - LENVAGIST: A multicentre, comparative, placebo (P)-controlled, double-blinded, phase II study of the efficacy of Lenvatinib (L) in patients with advanced GIST after failure of imatinib and sunitinib**

A. Le Cesne¹, C. Cropet², M. Brahmi², R. Bahleda¹, E. Bompas³, T. Valentin⁴, A. Hervieu⁵, O. Bouche⁶, A. Dufresne², M. Toulmonde⁷, K. Bourcier⁷, F. Duffaud⁸, M. Pracht⁹, F. Bertucci¹⁰, L. Lebellec¹¹, A. Italiano⁷, C. Henon¹, J. Gautier², D. Perol², J.-Y. Blay², ¹Gustave Roussy - Cancer Campus, Villejuif, FR, ²Centre Léon Bérard, Lyon, FR, ³ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, ⁴Institut Universitaire du Cancer -Toulouse- Oncopole, Toulouse, FR, ⁵Centre Georges-François Leclerc (Dijon), Dijon, FR, ⁶Hopital Robert Debré - CHU de Reims, Reims, FR, ⁷Institute Bergonié - Centre Régional de Lutte Contre le Cancer (CLCC), Bordeaux, FR, ⁸CHU La Timone Adultes, Marseille, FR, ⁹Centre Eugene - Marquis, Rennes, FR, ¹⁰IPC - Institut Paoli-Calmettes, Marseille, FR, ¹¹Centre Oscar Lambret, Lille, FR

15:45 - 15:55 **Invited Discussant LBA78 and LBA79**
T.W.-W. Chen, NTU - National Taiwan University - College of Medicine, Taipei City, TW

15:55 - 16:05 **Q&A**

14:45 - 16:00 **Type: Multidisciplinary session** **Valencia Auditorium - Hall 5**
Title: Which patients should we treat beyond progression and when should we stop?
 Chair(s): Fiona Thistlethwaite, GB; Ignacio Melero, ES

14:45 - 14:50 **Presentation of case/condition**
F. Thistlethwaite, The Christie NHS Foundation Trust, Manchester, GB

14:50 - 15:10 **What are the types of progression?**
S. Champiat, The University of Texas MD Anderson Cancer Center, Houston, US

15:10 - 15:30 **Do we have clinical or radiological biomarkers to guide us?**
R. Ferrara, UniSR - Università Vita e Salute San Raffaele Milano, Milan, IT

15:30 - 15:50 **How do we manage patient progression?**
F. Thistlethwaite, The Christie NHS Foundation Trust, Manchester, GB

15:50 - 16:00 **Discussion**

14:45 - 16:15 **Type: Special session** **Alicante Auditorium - Hall 3**
Title: How Real World Data (RWD) are transforming oncology
 Chair(s): Miriam Koopman, NL; Suzette Delaloge, FR

14:45 - 15:05 **Predicting major outcomes from large cohorts: How is it actionable?**
A.K. Clift, University of Oxford, Oxford, GB



15:05 - 15:25 **How much do real world patients really differ from clinical trials?**

C. Yap, ICR - The Institute of Cancer Research - North Site, Sutton, GB

15:25 - 15:45 **How to overcome biases to build Real World Evidence**

A. Valachis, Örebro University Hospital (Universitetssjukhuset Örebro), Örebro, SE

15:45 - 16:00 **Future directions in the development and use of Real World Evidence**

M. Koopman, UMC - University Medical Center Utrecht, Utrecht, NL

16:00 - 16:15 **Q&A and discussion**

14:45 - 16:15

Type: Proffered Paper session

Pamplona Auditorium - Hall 3

Title: Proffered paper session: NETs and endocrine tumours

Chair(s): Chris Verslype, BE; Sara De Dosso, CH

14:45 - 14:55

11410 - Cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET Trial/Alliance A021602): Updated results including progression free-survival (PFS) by blinded independent central review (BICR) and subgroup analyses

J. Chan¹, S. Geyer², T. Zemla², M. Knopp³, S. Behr⁴, S. Pulsipher², J. Acoba⁵, A. Shergill⁶, E. Wolin⁷, T. Halfdanarson², B. Konda⁸, N. Trikalinos⁹, S. Shaheen¹⁰, N. Vijayvergia¹¹, N.A. Dasari¹², J. Strosberg¹³, E. Kohn¹⁴, M. Kulke¹⁵, E. O'Reilly¹⁶, J. Meyerhardt¹, ¹Dana-Farber Cancer Institute, Boston, US, ²Mayo Clinic, Rochester, US, ³University of Cincinnati, Cincinnati, US, ⁴University of California San Francisco, San Francisco, US, ⁵University of Hawaii Cancer Center, Honolulu, US, ⁶University of Chicago, Chicago, US, ⁷Icahn School of Medicine at Mount Sinai, New York, US, ⁸The Ohio State University Comprehensive Cancer Center, Columbus, US, ⁹Washington University School of Medicine in St. Louis - Siteman Cancer Center, St. Louis, US, ¹⁰Stanford Comprehensive Cancer Institute, Stanford, US, ¹¹Fox Chase Cancer Center - Main Campus, Philadelphia, US, ¹²MD Anderson Cancer Center, Houston, US, ¹³H. Lee Moffitt Cancer Center & Research Institute, Tampa, US, ¹⁴National Cancer Institute, Bethesda, US, ¹⁵Boston University and Boston Medical Center, Boston, US, ¹⁶Memorial Sloan Kettering Cancer Center, New York, US



14:55 - 15:05

11420 - Multivariable analysis of streptozotocin plus 5-fluorouracil and everolimus sequences in advanced pancreatic neuroendocrine tumor patients: The SEQTOR trial (GETNE-1206)

J. Capdevila Castillon¹, S. Tafuto², M. Krogh³, A. Teule⁴, R. Garcia-Carbonero⁵, H.J. Klumpen⁶, B. Cremer⁷, I. Sevilla⁸, B. Eriksson⁹, E. Mitkina Tabaksblat¹⁰, J.-P. Metges¹¹, N.S. Reed¹², J. Schrader¹³, S. Bozzarelli¹⁴, U. Knigge¹⁵, P. Jimenez-Fonseca¹⁶, M. Benavent Viñuales¹⁷, M. Venerito¹⁸, V. Navarro¹⁹, R. Salazar Soler⁴, ¹Vall Hebron University Hospital, Vall Hebron Institute of Oncology (VHIO), Barcelona, ES, ²Istituto Nazionale Tumori IRCCS, Fondazione "G.Pascale" Naples, Napoli, IT, ³Odense University Hospital, Odense, DK, ⁴Institut Català d'Oncologia Hospital Duran i Reynals, Departament de Ciències Clíniques, Campus Bellvitge, Universitat de Barcelona. CIBERONC, Barcelona, ES, ⁵Hospital 12 de Octubre, Ima12, UCM, Madrid, ES, ⁶Amsterdam UMC, University of Amsterdam, Amsterdam, NL, ⁷Köln Universitätsklinikum Köln (AöR), Köln, DE, ⁸Investigación Clínica y Traslacional en Cáncer / Instituto de Investigaciones Biomédicas de Málaga (IBIMA) / Hospitales Universitarios Regional y Virgen de la Victoria de Málaga, Málaga, ES, ⁹University Hospital, Uppsala, SE, ¹⁰Aarhus University Hospital, CoE, Aarhus, DK, ¹¹Brest Hôpital Augustin Morvan, Institut de Cancero-Hemato, Brest, FR, ¹²Beatson Oncology Centre, Glasgow, GB, ¹³Hamburg Medizinische Klinik und Poliklinik, Hamburg-Eppendorf, DE, ¹⁴Humanitas Cancer Center, Milano, IT, ¹⁵Rigshospitalet NET CoE, Copenhagen, DK, ¹⁶Hospital Universitario Central de Asturias, ISPA, Oviedo, ES, ¹⁷University Hospital Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS), Seville, ES, ¹⁸Hepatology and Infectious Diseases, Otto-von-Guericke University Magdeburg, Medical Faculty, Magdeburg, DE, ¹⁹Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat, Barcelona, ES

15:05 - 15:20

Invited Discussant 11410 and 11420

N. Fazio, IEO - Istituto Europeo di Oncologia IRCCS, Milan, IT

15:20 - 15:30

Q&A

15:30 - 15:40

11430 - Refining molecular classification of neuroendocrine tumors from diverse origins using multi-omic integration models: Unveiling novel neuroendocrine subtypes and their clinical implications

C. Carretero-Puche¹, B. Antón Pascual², A. Lens-Pardo³, M. Benavent Viñuales⁴, L. Gomez-Izquierdo⁴, P. Jimenez Fonseca⁵, A. Teijo³, Y. Rodríguez³, B. Rubio-Cuesta³, A. Lamas-Paz³, G. Gomez-Lopez⁶, B. Soldevilla¹, R. Garcia-Carbonero⁷, ¹Centro de Oncología experimental. Instituto de Investigación Sanitaria Hospital 12 de Octubre (i+12). CNIO, Madrid, ES, ²Doce de Octubre University Hospital, Madrid, ES, ³Instituto de Investigación Sanitaria Hospital 12 de Octubre (i+12), Madrid, ES, ⁴University Hospital Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS), Seville, ES, ⁵Hospital Universitario Central de Asturias, Oviedo, ES, ⁶CNIO - Centro Nacional de Investigaciones Oncológicas, Madrid, ES, ⁷University Hospital 12 De Octubre, Madrid, ES

15:40 - 15:50 **11440 - Osteopontin (OPN) predicts the efficacy of anti-angiogenic therapy with multikinase inhibitors (MKIs) in advanced neuroendocrine tumors (NETs): Underlying molecular mechanisms**
A. Lens-Pardo¹, C. Carretero-Puche¹, B. Antón Pascual², J. Capdevila Castillon³, M. Benavent Viñuales⁴, P. Jimenez Fonseca⁵, E. Grande⁶, C. Perna⁷, A. Caminoa⁷, B. Rubio-Cuesta¹, J. Sarmentero¹, B. Gil-Calderón¹, P. Llamas¹, B. Soldevilla¹, R. Garcia-Carbonero², ¹Centro de Oncología experimental. Instituto de Investigación Sanitaria Hospital 12 de Octubre (i+12). CNIO, Madrid, ES, ²Doce de Octubre University Hospital, Madrid, ES, ³Vall d'Hebron University Hospital. Vall d'Hebron Institute of Oncology (VHIO). Universitat Autònoma de Barcelona, Barcelona, ES, ⁴University Hospital Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS), Seville, ES, ⁵Hospital Universitario Central de Asturias. ISPA, Oviedo, ES, ⁶MD Anderson Cancer Center Madrid, Madrid, ES, ⁷Hospital Universitario Ramón y Cajal. IRYCIS. Universidad de Alcalá, Madrid, ES

15:50 - 16:05 **Invited Discussant 11430 and 11440**
T. Dayton, European Molecular Biology Laboratory, Barcelona, ES

16:05 - 16:15 **Q&A**

14:45 - 16:15 **Type: Educational session** **Oviedo Auditorium - Hall 3**
Title: Treatment of difficult lymphomas
 Chair(s): Cédric Rossi, FR; Maria Gomes da Silva, PT

14:45 - 15:05 **Relapsed refractory Hodgkin's lymphoma**
C. Rossi, CHU Dijon, Dijon, FR

15:05 - 15:25 **Primary CNS lymphoma**
A. Ferreri, IRCCS Ospedale San Raffaele, Milan, IT

15:25 - 15:45 **Mantle cell lymphoma**
G. Hess, JGU - Johannes Gutenberg University, Mainz, DE

15:45 - 16:05 **HIV lymphoma**
K. Hübel, Universitätsklinikum Köln (AÖR), Köln, DE

16:05 - 16:15 **Q&A and discussion**

14:45 - 16:15 **Type: Special symposium** **Toledo Auditorium - Hall 3**
Title: Improving the management of toxicities from immunotherapy
 Chair(s): Mario Mandalà, IT; Christina Ruhlmann, DK

14:45 - 14:50 **Introduction and scientific background**
M. Mandalà, Università degli Studi di Perugia, Perugia, IT



- 14:50 - 15:05 **Treatment beyond corticosteroids**
C. Ruhlmann, OUH - Odense University Hospital, Odense, DK
- 15:05 - 15:20 **Cardiovascular toxicities: Focus on myocarditis**
E. De Azambuja, Institute Jules Bordet, Brussels, BE
- 15:20 - 15:35 **Gastrointestinal disorders: Enterocolitis and beyond**
M. Mandalà, Università degli Studi di Perugia, Perugia, IT
- 15:35 - 15:50 **What about long-term toxicities?**
E. Ghisoni, UNIL - Ludwig Institute for Cancer Research - Lausanne Branch, Epalinges, CH
- 15:50 - 16:10 **Q&A and discussion**
- 16:10 - 16:15 **Conclusions and perspectives**
C. Ruhlmann, OUH - Odense University Hospital, Odense, DK

14:45 - 16:15 **Type: Mini Oral session** **Zaragoza Auditorium - CC5**
Title: Mini oral session: Policy and preventive strategies
Chair(s): Christine Chomienne, FR; Paolo G. Casali, IT; Judith Balmaña, ES

- 14:45 - 14:50 **1539MO - Oncologists' voices in time of crisis: Findings from the ESMO Resilience Task Force survey series on how members can be helped and supported – A qualitative analysis**
C. Hardy¹, E. Thorne², M. O'Connor³, M.E. Elez Fernandez⁴, K. Kamposioras⁵, K. Punie⁶, C. Oing⁷, K. Murali⁸, J. Haanen⁹, K.H.J. Lim⁵, S. Banerjee¹⁰, ¹Lancaster University Division of Health Research, Lancaster, GB, ²Lancaster University, Lancaster, GB, ³University Hospital Waterford, Waterford, IE, ⁴Vall d'Hebron University Hospital, Barcelona, ES, ⁵The Christie NHS Foundation Trust, Manchester, GB, ⁶ZAS - Ziekenhuis aan de Stroom, Antwerpen, BE, ⁷Newcastle University, Newcastle upon Tyne, GB, ⁸Austin Health - Austin Hospital, Heidelberg, AU, ⁹NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ¹⁰The Royal Marsden Hospital - Chelsea, London, GB
- 14:50 - 14:55 **1540MO - The patient voice: An analysis of real-world data using the recurrent respiratory papillomatosis foundation/CoRDS patient registry (RRPF/CoRDS)**
S. Pai¹, W. Ochieng², N. Hedlund², A. Martino³, N. Chohan³, M. Pawlak², E. Morais⁴, K. McClellan², ¹Yale University School of Medicine, New Haven, US, ²Recurrent Respiratory Papillomatosis Foundation USA, Lawrenceville, US, ³Merck & Co. Inc., Rahway, US, ⁴MSD France, Puteaux, FR



14:55 - 15:00

1541MO - Leadership roles in oncology: Gender is still a barrier. Results from the new ESMO Women for Oncology Committee authorship and monitoring studies

H. Linardou¹, J. Bajpai², U. Dafni³, N. Battisti⁴, R. Berardi⁵, A. Bosch⁶, F. Cardoso⁷, C.M. De Cerqueira Mathias⁸, S.P. Choo⁹, E. Felip¹⁰, K. Fizazi¹¹, E. Fountzilas¹², G. Dimopoulou¹³, M. Garassino¹⁴, D. Mukherji¹⁵, J. Naidoo¹⁶, J.W.-H. Tsang¹⁷, S. Peters¹⁸, C. Sessa¹⁹, P. Garrido Lopez²⁰, ¹Metropolitan Hospital, Athens, GR, ²Tata Memorial Hospital - Tata Memorial Centre, Mumbai, IN, ³National and Kapodistrian University of Athens, Athens, GR, ⁴The Royal Marsden Hospital (Sutton), Sutton, GB, ⁵AOU - Ospedali Riuniti Umberto I - G.M. Lancisi - G. Salesi, Torrette di Ancona, IT, ⁶Lund University - Faculty of Medicine, Malmo, SE, ⁷Champalimaud Foundation - Champalimaud Clinical Center, Lisbon, PT, ⁸NOB - Nucleo de Oncologia da Bahia - Grupo Oncoclinicas, Salvador, BR, ⁹NCCS - National Cancer Centre Singapore, Singapore, SG, ¹⁰Vall d'Hebron University Hospital, Barcelona, ES, ¹¹Institut Gustave Roussy, Villejuif, Cedex, FR, ¹²Second Department of Medical Oncology, Euromedica General Clinic, Thessaloniki, Greece, Thessaloniki, GR, ¹³FSF-H - Frontier Science Foundation Hellas, Athens, GR, ¹⁴University of Chicago Department of Medicine - Section of Hematology/Oncology, Chicago, US, ¹⁵Clemenceau Medical Center, Dubai, AE, ¹⁶Beaumont Hospital, Dublin, IE, ¹⁷HKBOG - Hong Kong Breast Oncology Group, Hong Kong, HK, ¹⁸CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH, ¹⁹EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, CH, ²⁰Hospital Universitario Ramon y Cajal, Madrid, ES

15:00 - 15:15

Invited Discussant 1539MO, 1540MO and 1541MO

C. Chomienne, Hopital Saint Louis AP-HP, Paris, FR

15:15 - 15:20

1542MO - Mapping the scale of off-label use in oncology: An important step in harmonising access

H. Timmer¹, A. Huisman², L. Fagereng³, H. Gelderblom¹, S. Van Waalwijk Van Doorn-Khosrovani⁴, ¹Leiden University Medical Centre, Leiden, NL, ²Health Insurers The Netherlands, Zeist, NL, ³Oslo University Hospital, Oslo, NO, ⁴Medical Department, CZ Health Insurance, Leiden/Tilburg, NL

15:20 - 15:25

1543MO - Analysis of concordance between trial and target populations for cancer drugs in the US, EU, and Switzerland (2014-2023)

K. Vokinger¹, C. Glaus¹, M. Serra-Burriel², A. Kesselheim³, ¹University of Zurich, Zurich, CH, ²UZH - University of Zurich - Epidemiology, Biostatistics and Prevention Institute (EBPI), Zurich, CH, ³Brigham and Women's Hospital - Pharmacoepidemiology and Pharmacoeconomics Division, Boston, US

15:25 - 15:30

1544MO - Clinical trial design and treatment effects: A meta-analysis of randomized-controlled and single-arm trials supporting 437 FDA approvals of cancer drugs and indications

J.C. Michaeli¹, C. Michaeli², S. Albers³, D. Michaeli⁴, ¹Breast Center and CCC Munich, BZKF, Universitz Hospital Munich, LMU Munich, Munich, DE, ²UMM - Universitaetsklinikum Mannheim, Mannheim, DE, ³Klinikum rechts der Isar, Technische Universität München, München, DE, ⁴German Cancer Research Center - National Center for Tumor Diseases (NCT), Heidelberg, DE



- 15:30 - 15:45 **Invited Discussant 1542MO, 1543MO and 1544MO**
P.G. Casali, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT
- 15:45 - 15:50 **LBA64 - Outcomes of BRCA and in-house homologous recombination deficiency (HRD) testing in women with ovarian and breast cancer: A multicentre registry study**
K. Shohdy¹, L. Kassem², B. Gabriel³, S. Lasheen², H. Elghazawy⁴, E. Barsoum⁵, T. Elnahas², H. Azim², ¹University of Glasgow, Glasgow, GB, ²Cairo University, Giza, EG, ³Nasser Institute for Research and Treatment, Giza, EG, ⁴Ain Shams University, Cairo, EG, ⁵Barsoum Oncology Center, Giza, EG
- 15:50 - 15:55 **1545MO - Personalised cancer prevention programme (Interception): A cost analysis to inform public policy decision-making**
E. Erdogan¹, A. Bayle¹, L. Veron², O. Caron¹, S. Delaloge¹, J. Bonastre¹, ¹Institut Gustave Roussy, Villejuif, Cedex, FR, ²Gustave Roussy - Cancer Campus, Villejuif, FR
- 15:55 - 16:10 **Invited Discussant LBA64 and 1545MO**
J. Balmaña, Vall d'Hebron University Hospital, Barcelona, ES

15:45 - 16:15	Type: EONS session Title: EONS closing session Chair(s): Virpi Sulosaari, FI; Helena Ullgren, SE; Johan De Munter, BE	Ronda Auditorium - Hall 7
----------------------	---	----------------------------------

- 15:45 - 15:50 **Highlights of EONS17**
- 15:50 - 15:55 **Best rated abstract**
H. Ullgren, Karolinska University Hospital-Solna, Solna, SE
- 15:55 - 16:00 **EONS Poster Awards**
J. De Munter, UZ Gent - Universitair Ziekenhuis Gent, Gent, BE
- 16:00 - 16:05 **ECND 2024 winner**
V. Sulosaari, TUAS - Turku University of Applied Sciences, Turku, FI
- 16:05 - 16:15 **Closing remarks and farewell**
V. Sulosaari, TUAS - Turku University of Applied Sciences, Turku, FI

16:00 - 17:00	Type: Young Oncologists session Title: YO Clinical case discussions	Tarragona Auditorium - Hall 7
----------------------	--	--------------------------------------

- 16:00 - 16:00 **Integrating precision medicine / ESCAT in your choice of treatment**
J. Mateo¹, P. Sobczuk², E. Kocakavuk³, ¹Vall d'Hebron University Hospital, Barcelona, ES, ²Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, PL, ³Universitätsklinikum Essen, Essen, DE

- 16:00 - 16:00 **Multiple co-occurring cancers**
E. Garralda¹, E. Mariamidze², D.C. Guven³, ¹Vall d'Hebron University Hospital, Barcelona, ES, ²Todua Clinic, Tbilisi, GE, ³Hacettepe University Oncology Hospital, Ankara, TR
- 16:00 - 16:00 **Use of ablative therapies in patients with oligometastatic disease**
I. Meattini¹, E. Connolly², ¹AOUC - Azienda Ospedaliero-Universitaria Careggi, Firenze, IT, ²Chris O'Brien Lifehouse, Sydney, AU
- 16:00 - 16:00 **Cell therapy in solid tumours**
J. Haanen¹, A. Starzer², ¹NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ²Medizinische Universitaet Wien, Vienna, AT
- 16:00 - 16:00 **Fertility and pregnancy in patients with gynaecological cancer**
I. Colombo¹, M. Kfoury², R. Sanchez Bayona³, ¹EOC - Ospedale Regionale di Bellinzona e Valli, San Giovanni, Bellinzona, CH, ²IPC - Institut Paoli-Calmettes, Marseille, Cedex 09, FR, ³Hospital Universitario 12 de Octubre, Madrid, ES

16:30 - 18:15 **Type: Proffered Paper session** **Barcelona Auditorium - Hall 2**
Title: Presidential Symposium III: Eyes to the future
 Chair(s): Fabrice André, FR; Nadia Harbeck, DE

- 16:30 - 16:42 **LBA7 - The Rome trial from histology to target: The road to personalize targeted therapy and immunotherapy**
A. Botticelli¹, S. Scagnoli¹, P. Conte², C. Cremolini³, P. Ascierto⁴, F. Cappuzzo⁵, M. Aglietta⁶, F. Mazza⁷, E. Capoluongo⁸, G. Blandino⁵, U. Malapelle⁹, M. Nuti¹⁰, G. D'Amati¹, B. Cerbelli¹, G. Pruner¹¹, M. Biffoni¹², G. Giannini¹³, F. Cognetti¹⁴, G. Curigliano¹⁵, P. Marchetti¹⁶, ¹Sapienza Università di Roma, AOU Policlinico Umberto I, Rome, IT, ²S. Camillo Hospital IRCCS, Lido di Venezia, IT, ³University of Pisa, Pisa, IT, ⁴Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT, ⁵IRCCS Istituto Nazionale Tumori Regina Elena (IRE), Rome, IT, ⁶IRCCS - Istituto di Candiolo - FPO, Candiolo, IT, ⁷Sapienza University of Rome, Oncology Unit, Sant' Andrea Hospital, Rome, IT, ⁸UOC PATOLOGIA CLINICA - Ospedale San Giovanni Addolorata, Roma, IT, ⁹Azienda Ospedaliera Universitaria Federico II, Napoli, IT, ¹⁰Sapienza Università di Roma - Dip. di Medicina Sperimentale, Rome, IT, ¹¹Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ¹²Istituto Superiore di Sanità (ISS), Rome, IT, ¹³Sapienza - Università di Roma, Rome, IT, ¹⁴Confederazione Oncologi Cardiologi Ematologi (FOCE), ROMA, IT, ¹⁵European Institute of Oncology, IRCCS; University of Milano, Milan, IT, ¹⁶IDI-IRCCS, Rome, IT
- 16:42 - 16:54 **19420 - Application of GigaPath: An open-weight billion-parameter AI foundation model based on a novel vision transformer architecture for cancer mutation prediction and TME analysis**
C. Bifulco¹, H. Poon², N. Usuyama³, H. Xu⁴, S. Wang⁴, B. Piening⁵, R. Leidner⁶, ¹Providence Cancer Institute, Southfield, US, ²Microsoft Research, Redmond, US, ³Microsoft, Redmond, US, ⁴University of Washington, Seattle, US, ⁵Earle A. Chiles Research Institute at the Robert W. Franz Cancer Center, Portland, US, ⁶Providence Cancer Institute Franz Clinic, Portland, US



- 16:54 - 17:04 **Invited Discussant LBA7 and 19420: Moving towards molecular and AI-driven oncology**
F. Di Nicolantonio, IRCCS - Istituto di Candiolo - FPO, Candiolo, IT
- 17:04 - 17:16 **5090 - Total neoadjuvant treatment (TNT) with non-operative management (NOM) for proficient mismatch repair locally advanced rectal cancer (pMMR LARC): First results of NO-CUT trial**
A. Amatu¹, M.G. Zampino², F. Bergamo³, S. Mosconi⁴, D. Sibio¹, M. Gerardi², A. Prete³, F.R. Filippone⁴, G. Ferrari¹, S. Borin², S. Galuppo³, S. Mariano¹, F. Tosi¹, E. Bonazzina¹, G. Patelli⁵, S. Ghezzi¹, L. Lazzari⁶, K. Bencardino¹, A. Sartore Bianchi⁵, S. Siena⁵, ¹ASST Grande Ospedale Metropolitano Niguarda, Milan, IT, ²IEO - Istituto Europeo di Oncologia, Milan, IT, ³IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, ⁴ASST Papa Giovanni XXIII, Bergamo, IT, ⁵Università degli Studi di Milano, Milan, IT, ⁶IFOM ETS - The AIRC Institute of Molecular Oncology, Milan, IT
- 17:16 - 17:24 **Invited Discussant 5090: Systemic therapy for organ preservation**
D. Sebag-Montefiore, St. James's University Hospital, Leeds, GB
- 17:24 - 17:36 **LBA8 - Precision immuno-oncology for advanced non-small cell lung cancer (NSCLC) patients with PD-(L)1 inhibitors resistance (PIONeer): A phase Ib/IIa clinical trial targeting identified resistance pathways**
P. Tomasini¹, C. Cropet², A. Jeanson¹, M. Pérol², J. Mazieres³, C. Fontaine¹, A. Rabeau³, M. Meurer¹, L. Greillier¹, M. Le Ray¹, L. Laborde⁴, A. Cohen⁵, V. Martin⁴, M. Roumieux⁶, F. Monville⁷, E. Vivier⁸, D. Perol², S. Chabaud², F. Barlesi⁹, ¹Assistance Publique Hôpitaux de Marseille, Marseille, FR, ²Centre Léon Bérard, Lyon, FR, ³Centre Hospitalier Universitaire de Toulouse - Hopital Larrey, Toulouse, FR, ⁴IPC - Institut Paoli-Calmettes, Marseille, Cedex, FR, ⁵Assistance Publique-Hopitaux de Marseille, Aix-Marseille University, Marseille, France., Marseille, FR, ⁶Aix-Marseille University, Marseille, FR, ⁷Veracyte, Inc., Marseille, Cedex, FR, ⁸Innate Pharma, Marseille, FR, ⁹Gustave Roussy & Paris Saclay University, Villejuif, FR
- 17:36 - 17:44 **Invited Discussant LBA8: Discovering mechanisms of resistance to standard therapy**
B. Ricciuti, Dana Farber Cancer Institute, Boston, US



17:44 - 17:56	6040 - Phase I dose escalation and initial dose expansion results of AMG 193: A MTA-cooperative PRMT5 inhibitor, in patients (pts) with MTAP-deleted solid tumors <u>A. Sacher</u>¹, M. Villalona-Calero², B. O'neil³, J. Rodon⁴, T. Doi⁵, S. Postel-Vinay⁶, F. Ghiringhelli⁷, N. Yamamoto⁸, S. Wahlroos⁹, L. Villaruz¹⁰, A. El-Helali¹¹, Y. Fujiwara¹², A. Addeo¹³, C.-C. Lin¹⁴, E. Fontana¹⁵, C.-H. Chuang¹⁶, C. Liu¹⁶, T. Eggert¹⁶, N. Penel¹⁷, H. Prenen¹⁸, ¹UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA, ²City of Hope National Medical Center, Duarte, US, ³Community Health Network, Indianapolis, US, ⁴MD Anderson Cancer Center, Houston, US, ⁵National Cancer Center Hospital East, Kashiwa, JP, ⁶Institut Gustave Roussy, Villejuif, FR, ⁷Platform of Transfer in Cancer Biology, Centre Georges François Leclerc, INSERM LNC UMR1231, University of Bourgogne Franche-Comté, Dijon, FR, ⁸National Cancer Center Hospital, Tokyo, JP, ⁹Chris O'Brien Lifehouse, Camperdown, AU, ¹⁰UPMC Hillman Cancer Center, Pittsburgh, US, ¹¹HKU - The University of Hong Kong, Hong Kong, HK, ¹²Aichi Cancer Center Hospital, Nagoya, JP, ¹³HUG - Hopitaux Universitaires de Geneve, Geneva, CH, ¹⁴National Taiwan University Hospital, Taipei, TW, ¹⁵Sarah Cannon Research Institute SCRI UK, London, GB, ¹⁶AMGEN (Headquarters) - USA, Thousand Oaks, US, ¹⁷Centre Oscar Lambret, Lille, FR, ¹⁸UZA - University Hospital Antwerp, Edegem, BE
17:56 - 18:04	Invited Discussant 6040: Epigenetic modulation of the tumour and its microenvironment <u>C. Kadoch</u>, Dana Farber Cancer Institute, Boston, US
18:04 - 18:15	Q&A and discussion
16:30 - 18:00	Type: Educational session Title: Promises and pitfalls in earlier stage NSCLC Chair(s): Isabelle Schmitt-Opitz, CH; Laura Mezquita, ES
16:30 - 16:50	To resect or not to resect, and how? Advancing surgical management in early stage NSCLC <u>I. Schmitt-Opitz</u>, USZ - University Hospital Zürich, Zurich, CH
16:50 - 17:10	Incorporating systemic therapy in the perioperative setting <u>S. Peters</u>, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH
17:10 - 17:30	Oncogene-addicted earlier stage NSCLC: Current standards, debates, and open questions <u>L. Mezquita</u>, Hospital Clinic y Provincial de Barcelona, Barcelona, ES
17:30 - 17:50	The role of radiotherapy in earlier stage NSCLC <u>S. Senan</u>, Amsterdam UMC - Vrije University Medical Centre (VUmc), Amsterdam, NL
17:50 - 18:00	Q&A and discussion



16:30 - 17:45 **Type: Multidisciplinary session** **Salamanca Auditorium - Hall 5**
Title: Controversies in the management and follow up of small localised neuroendocrine tumours
 Chair(s): Els Nieveen van Dijkum, NL; Chris Verslype, BE

16:30 - 16:35 **Presentation of case/condition**
C. Verslype, UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE

16:35 - 16:55 **Appendiceal NEN: When to recommend radical surgery?**
E. Nieveen Van Dijkum, Amsterdam University Medical Center (UMC) - locatie Academic Medical Center (AMC), Amsterdam, NL

16:55 - 17:15 **Gastric NEN: When to recommend radical surgery?**
J. Díaz Tasende, UCM - Universidad Complutense de Madrid, Madrid, ES

17:15 - 17:35 **Pancreatic NEN: Watchful wait vs radical surgery**
M. Falconi, IRCCS Ospedale San Raffaele, Milan, IT

17:35 - 17:45 **Discussion**

16:30 - 18:00 **Type: Special symposium** **Valencia Auditorium - Hall 5**
Title: New therapeutic approaches in concomitant chemoradiotherapy
 Chair(s): Jean Bourhis, CH; Anna Spreafico, CA

16:30 - 16:35 **Introduction and scientific background**
A. Spreafico, UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA

16:35 - 16:50 **Targeting cell death pathways**
J. Bourhis, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH

16:50 - 17:05 **Targeting the DNA damage response**
M. Dillon, ICR - Institute of Cancer Research - Chester Beatty Laboratories, London, GB

17:05 - 17:20 **Targeting innate immune signalling pathways**
S. Pai, Yale University School of Medicine, New Haven, US

17:20 - 17:35 **How to select patients? Models to predict response**
I. Tinhofer-Keilholz, Charité - Universitätsmedizin Berlin, Berlin, DE

17:35 - 17:55 **Q&A and discussion**

17:55 - 18:00 **Conclusions and perspectives**
J. Bourhis, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH



17:00 - 17:45	Type: Challenge your Expert Title: Management of advanced urothelial carcinoma: Does chemotherapy hold or lose its position? Chair(s): Michiel van der Heijden, NL	Santander Auditorium - Hall 5
17:00 - 17:20	Presentation by Expert <u>P. Giannatempo</u> , Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT	
17:20 - 17:45	Discussion led by Chair <u>M. Van Der Heijden</u> , Netherlands Cancer Institute, Amsterdam, NL	
18:30 - 20:00	Type: Industry Satellite Symposium Title: Pierre Fabre Laboratories - Precision oncology for BRAF mutant cancers Chair(s): Josep Tabernero, ES	Salamanca Auditorium - Hall 5
18:30 - 18:35	Welcome and Introductions <u>J. Tabernero</u> , Vall d'Hebron University Hospital, Barcelona, ES	
18:35 - 18:45	Targeting oncogenic BRAF <u>R. Dummer</u> , USZ - University Hospital Zürich, Zurich, CH	
18:45 - 18:55	BRAF as a breakthrough in the treatment of BRAFV600-mutant metastatic melanoma <u>A. Hauschild</u> , UK-SH, Campus Kiel, Kiel, DE	
18:55 - 19:10	Same strategy, different challenge: Managing BRAFV600 disease in advanced NSCLC <u>G. Riely</u> , Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US	
19:10 - 19:25	Different strategy, same target: Managing BRAFV600E-mutant metastatic colorectal cancer <u>C. Cremolini</u> , AOU Pisana - Stabilimento di Santa Chiara, Pisa, IT	
19:25 - 19:55	Interactive, case-based panel discussion: Optimal care of patients receiving treatment with BRAF-targeted agents <u>J. Tabernero</u> ¹ , <u>R. Dummer</u> ² , <u>A. Hauschild</u> ³ , <u>C. Cremolini</u> ⁴ , <u>G. Riely</u> ⁵ , ¹ Vall d'Hebron University Hospital, Barcelona, ES, ² USZ - University Hospital Zürich, Zurich, CH, ³ UK-SH, Campus Kiel, Kiel, DE, ⁴ AOU Pisana - Stabilimento di Santa Chiara, Pisa, IT, ⁵ Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US	
19:55 - 20:00	What's next for this target? <u>J. Tabernero</u> , Vall d'Hebron University Hospital, Barcelona, ES	



18:30 - 20:00	Type: Industry Satellite Symposium Title: Daiichi Sankyo, Inc. - Transforming Precision Lung Cancer Care: Expert Guidance on HER2-, HER3-, TROP2-, and B7-H3-Targeted ADCs Chair(s): David Planchard, FR	Santander Auditorium - Hall 5
18:30 - 18:35	Welcome, Introduction, and Baseline Assessment <u>D. Planchard</u>, Institut Gustave Roussy, Villejuif, Cedex, FR	
18:35 - 18:55	Brief Anatomical Review of ADCs: An Exploration of ADC Structure and Mechanism of Action & ADCs in HER2-mutated NSCLC <u>E. Smit</u>, LUMC-Leiden University Medical Center, Leiden, NL	
18:55 - 19:00	Panel Discussion: HER2-Targeted ADCs <u>D. Planchard</u>¹, <u>H.A. Yu</u>², <u>E. Smit</u>³, ¹Institut Gustave Roussy, Villejuif, Cedex, FR, ²MSKCC - Memorial Sloan Kettering Cancer Center, New York, US, ³LUMC-Leiden University Medical Center, Leiden, NL	
19:00 - 19:15	ADCs in EGFR-mutated NSCLC <u>H.A. Yu</u>, MSKCC - Memorial Sloan Kettering Cancer Center, New York, US	
19:15 - 19:20	Panel Discussion: HER3-Targeted ADCs <u>D. Planchard</u>¹, <u>H.A. Yu</u>², <u>E. Smit</u>³, ¹Institut Gustave Roussy, Villejuif, Cedex, FR, ²MSKCC - Memorial Sloan Kettering Cancer Center, New York, US, ³LUMC-Leiden University Medical Center, Leiden, NL	
19:20 - 19:40	Expanding the Applicability Beyond HER2m and EGFRm: TROP2-Targeted ADCs <u>D. Planchard</u>, Institut Gustave Roussy, Villejuif, Cedex, FR	
19:40 - 19:45	The Potential of ADCs to Transform Lung Cancer Care in Patients with SCLC <u>D. Planchard</u>, Institut Gustave Roussy, Villejuif, Cedex, FR	
19:45 - 19:50	Panel Discussion: TROP2-, and B7-H3-Targeted ADCs <u>D. Planchard</u>¹, <u>H.A. Yu</u>², <u>E. Smit</u>³, ¹Institut Gustave Roussy, Villejuif, Cedex, FR, ²MSKCC - Memorial Sloan Kettering Cancer Center, New York, US, ³LUMC-Leiden University Medical Center, Leiden, NL	
19:50 - 19:59	Question & Answer Session <u>D. Planchard</u>¹, <u>H.A. Yu</u>², <u>E. Smit</u>³, ¹Institut Gustave Roussy, Villejuif, Cedex, FR, ²MSKCC - Memorial Sloan Kettering Cancer Center, New York, US, ³LUMC-Leiden University Medical Center, Leiden, NL	
19:59 - 20:00	Closing Remarks <u>D. Planchard</u>, Institut Gustave Roussy, Villejuif, Cedex, FR	



18:30 - 20:00 **Type: Industry Satellite Symposium** **Valencia Auditorium - Hall 5**
Title: Medscape Global Oncology - Redefining Care for HR-Positive Metastatic Breast Cancer: How to Navigate Critical Decision Points
 Chair(s): Javier Cortés, ES

18:30 - 18:40 **Welcome and Introduction**

J. Cortés, INTERNATIONAL BREAST CANCER CENTER, IBCC, Barcelona, ES

18:40 - 18:50 **New Frontiers in Estrogen Receptor Inhibition**

S. Loibl, German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE

18:50 - 19:05 **Novel Approaches to Targeting the PI3K/AKT/mTOR Pathway**

J. Cortés, INTERNATIONAL BREAST CANCER CENTER, IBCC, Barcelona, ES

19:05 - 19:20 **Latest Insights on ADCs for HR-Positive/HER2-Negative Metastatic Breast Cancer**

A. Bardia, UCLA - David Geffen School of Medicine, Los Angeles, US

19:20 - 19:35 **Latest Insights on ADCs for HR-Positive, HER2-Low Metastatic Breast Cancer**

P. Tarantino, Dana Farber Cancer Institute, Boston, US

19:35 - 19:45 **Hot Topics and Common Clinical Queries With ADCs**

J. Cortés¹, A. Bardia², P. Tarantino³, S. Loibl⁴, ¹INTERNATIONAL BREAST CANCER CENTER, IBCC, Barcelona, ES, ²UCLA - David Geffen School of Medicine, Los Angeles, US, ³Dana Farber Cancer Institute, Boston, US, ⁴German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE

19:45 - 19:50 **Experts' Key Takeaways From ESMO 2024**

J. Cortés¹, A. Bardia², P. Tarantino³, S. Loibl⁴, ¹INTERNATIONAL BREAST CANCER CENTER, IBCC, Barcelona, ES, ²UCLA - David Geffen School of Medicine, Los Angeles, US, ³Dana Farber Cancer Institute, Boston, US, ⁴German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE

19:50 - 20:00 **Audience Q&A and Close**

J. Cortés, INTERNATIONAL BREAST CANCER CENTER, IBCC, Barcelona, ES

18:30 - 20:00 **Type: Industry Satellite Symposium** **Alicante Auditorium - Hall 3**
Title: F. Hoffmann - La Roche Ltd - Pioneering GI cancer treatments and maximising outcomes for patients with HCC
 Chair(s): Richard Finn, US

18:30 - 18:35 **Welcome and introduction**

R. Finn, UCLA - David Geffen School of Medicine, Los Angeles, US

18:35 - 18:50 **Innovating to address unmet needs**

R. Finn¹, P. Chow², ¹UCLA - David Geffen School of Medicine, Los Angeles, US, ²NCCS - National Cancer Centre Singapore, Singapore, SG



18:50 - 19:10	Current therapeutic approaches in HCC <u>P. Chow</u>¹, <u>M. Allaire</u>², ¹NCCS - National Cancer Centre Singapore, Singapore, SG, ²Hopital Pitié Salpetrière AP-HP, Paris, FR
19:10 - 19:30	The importance of surveillance and diagnosis <u>A. Saborowski</u>¹, <u>A. Yopp</u>², ¹MHH - Medizinische Hochschule Hannover, Hannover, DE, ²UT Southwestern Medical Center, Dallas, US
19:30 - 19:40	Experiences from the clinic: a dynamic case study discussion <u>R. Finn</u>¹, <u>A. Yopp</u>², <u>A. Saborowski</u>³, <u>M. Allaire</u>⁴, <u>P. Chow</u>⁵, ¹UCLA - David Geffen School of Medicine, Los Angeles, US, ²UT Southwestern Medical Center, Dallas, US, ³MHH - Medizinische Hochschule Hannover, Hannover, DE, ⁴Hopital Pitié Salpetrière AP-HP, Paris, FR, ⁵NCCS - National Cancer Centre Singapore, Singapore, SG
19:40 - 19:55	Audience Q&A and panel discussion <u>R. Finn</u>¹, <u>A. Yopp</u>², <u>A. Saborowski</u>³, <u>P. Chow</u>⁴, <u>M. Allaire</u>⁵, ¹UCLA - David Geffen School of Medicine, Los Angeles, US, ²UT Southwestern Medical Center, Dallas, US, ³MHH - Medizinische Hochschule Hannover, Hannover, DE, ⁴NCCS - National Cancer Centre Singapore, Singapore, SG, ⁵Hopital Pitié Salpetrière AP-HP, Paris, FR
19:55 - 20:00	Close <u>R. Finn</u>, UCLA - David Geffen School of Medicine, Los Angeles, US
18:30 - 20:00	Type: Industry Satellite Symposium Oviedo Auditorium - Hall 3 Title: Pfizer Inc. - Cancer Patients with Cachexia: the Unmet Needs and Evolving Therapeutic Landscape Chair(s): Jeffrey Crawford, US; Paula Jimenez Fonseca, ES
18:30 - 18:35	The Cancer Patient with Cachexia <u>J. Crawford</u>¹, <u>P. Jimenez Fonseca</u>², ¹Duke Cancer Institute, Durham, US, ²Hospital Universitario Central de Asturias, Oviedo, ES
18:35 - 18:55	Overview of Cachexia in Cancer Patients: Epidemiology and Therapeutic Approaches <u>P. Bossi</u>, IRCCS Humanitas Research Hospital, Rozzano, IT
18:55 - 19:15	Biological Basis of Potential Therapeutic Options for Cancer Patients with Cachexia <u>D. Breen</u>, Pfizer Inc, San Diego, US
19:15 - 19:35	Clinical Trials in Cancer Patients with Cachexia <u>J. Crawford</u>, Duke Cancer Institute, Durham, US

19:35 - 19:55	Questions from Audience/Panel Discussion <u>P. Jimenez Fonseca</u> , Hospital Universitario Central de Asturias, Oviedo, ES
19:55 - 20:00	Concluding Remarks <u>J. Crawford</u> ¹ , <u>P. Jimenez Fonseca</u> ² , ¹ Duke Cancer Institute, Durham, US, ² Hospital Universitario Central de Asturias, Oviedo, ES
18:30 - 20:00	Type: Industry Satellite Symposium Title: Astellas - The Evolving Landscape of LA/mUC, from Data to Clinical Practice Chair(s): Jose Pablo Maroto Rey, ES Toledo Auditorium - Hall 3
18:30 - 18:35	Welcome and introductions <u>J.P. Maroto Rey</u> , Hospital de la Santa Creu i Sant Pau, Barcelona, ES
18:35 - 18:50	Transforming the management of LA/mUC patients <u>M. Van Der Heijden</u> , Netherlands Cancer Institute, Amsterdam, NL
18:50 - 19:10	Changes in treatment paradigm, what is the optimal choice for my patients? <u>R. Jones</u> ¹ , <u>M. Van Der Heijden</u> ² , ¹ MVLS - Medical, Veterinary and Life Sciences College - University of Glasgow, Glasgow, GB, ² Netherlands Cancer Institute, Amsterdam, NL
19:10 - 19:20	Management of potential skin toxicities associated with recent therapies for LA/mUC <u>E. Carmona Rocha</u> , Hospital de la Santa Creu i Sant Pau, Barcelona, ES
19:20 - 19:50	Clinical pearls: LA/mUC, treatment and AE management <u>J.P. Maroto Rey</u> ¹ , <u>M. Van Der Heijden</u> ² , <u>R. Jones</u> ³ , <u>E. Carmona Rocha</u> ¹ , ¹ Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ² Netherlands Cancer Institute, Amsterdam, NL, ³ MVLS - Medical, Veterinary and Life Sciences College - University of Glasgow, Glasgow, GB
19:50 - 19:58	Q&A <u>J.P. Maroto Rey</u> ¹ , <u>M. Van Der Heijden</u> ² , <u>R. Jones</u> ³ , <u>E. Carmona Rocha</u> ¹ , ¹ Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ² Netherlands Cancer Institute, Amsterdam, NL, ³ MVLS - Medical, Veterinary and Life Sciences College - University of Glasgow, Glasgow, GB
19:58 - 20:00	Summary and Close <u>J.P. Maroto Rey</u> , Hospital de la Santa Creu i Sant Pau, Barcelona, ES



17.09.2024

09:00 - 13:00	Type: Scientific Congress highlights Title: Scientific Congress highlights 1 Chair(s): Rebecca Dent, SG; Fabrice André, FR	Madrid Auditorium - Hall 2
09:00 - 09:20	Basic science & TR <u>P. Bedard</u> , UHN - University Health Network - Princess Margaret Cancer Centre, Toronto, CA	
09:20 - 09:40	Breast cancer, early stage <u>F.C. Bidard</u> , Institut Curie, Paris, FR	
09:40 - 10:00	Breast cancer, metastatic <u>G. Bianchini</u> , IRCCS Ospedale San Raffaele, Milan, IT	
10:00 - 10:20	Gynaecological cancers <u>L. Mileskin</u> , Peter MacCallum Cancer Center, Melbourne, AU	
10:20 - 10:40	Policy and preventive strategies <u>S. Delaloge</u> , Institut Gustave Roussy, Villejuif, Cedex, FR	
10:40 - 11:00	Break	
11:00 - 11:20	CNS tumours <u>A. Darlix</u> , ICM Regional Cancer Institute of Montpellier, Montpellier, FR	
11:20 - 11:40	Investigational immunotherapy <u>H.C. Toh</u> , NCCS - National Cancer Centre Singapore, Singapore, SG	
11:40 - 12:00	Developmental therapeutics <u>A. Stathis</u> , EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, CH	
12:00 - 12:20	Genitourinary tumours, prostate <u>U. Vogl</u> , IOSI - Istituto Oncologico della Svizzera Italiana, Bellinzona, CH	
12:20 - 12:40	Genitourinary tumours, non-prostate <u>I. Duran</u> , HUMV - Hospital Universitario Marques de Valdecilla, Santander, ES	
12:40 - 13:00	Close	



09:00 - 13:00	Type: Scientific Congress highlights Title: Scientific Congress highlights 2 Chair(s): Andres Cervantes, ES; Solange Peters, CH	Sevilla Auditorium - Hall 2
09:00 - 09:20	Melanoma and other skin tumours <u>K. Suijkerbuijk</u> , UMC-University Medical Center Utrecht, Utrecht, NL	
09:20 - 09:40	Sarcoma <u>Z. Papai</u> , MH Honvedkorhaz - Hungarian Army Health Center, Budapest, HU	
09:40 - 10:00	Head and neck cancer, excluding thyroid <u>I. Braña</u> , Vall d'Hebron University Hospital, Barcelona, ES	
10:00 - 10:20	Gastrointestinal tumours, lower digestive <u>D. Arnold</u> , Asklepios Klinik Altona - Hämatologie, internistische Onkologie, Palliativmedizin und Rheumatologie, Hamburg, DE	
10:20 - 10:40	Gastrointestinal tumours, upper digestive <u>S. Derks</u> , VU University Medical Centre, Amsterdam, NL	
10:40 - 11:00	Break	
11:00 - 11:20	Supportive and palliative care <u>I. Vaz Luis</u> , Institut Gustave Roussy, Villejuif, Cedex, FR	
11:20 - 11:40	Haematological malignancies <u>M. Gomes Da Silva</u> , Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E. (IPO Lisboa), Lisbon, PT	
11:40 - 12:00	NETs and endocrine tumours <u>C. Verslype</u> , UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE	
12:00 - 12:20	Non-metastatic NSCLC and other thoracic malignancies <u>A. Addeo</u> , HUG - Hopitaux Universitaires de Geneve, Geneva, CH	
12:20 - 12:40	NSCLC, metastatic <u>A. Zer</u> , Rambam Health Care Campus, Haifa, IL	
12:40 - 13:00	Close	